510 Kardiac Devices (Atlanta, GA; no SBIR) medical tech startup that designs cardiovascular devices cardiologists can use to perform procedures to targeted locations within the structures of the heart, raised nearly $3 million of a $3.5 million round, according to a filing with the SEC. [Madison Hogan, AtlantaInno, Oct 1, 19]
10X Genomics (Pleasanton CA; no SBIR, founded 2012) up 35% [Sep 12, 19] after $390M IPO. prior funding $242M [crunchbase.com]
Eight months after gene sequencing company10x Genomics (Pleasanton, CA; SBIR) raised $125 million in debt and equity financing, the company now has an additional infusion of cash. ... announced that the equity portion of last year’s funding, a $50 million Series D round, has been extended by $35 million. [Frank Vinluan, xconomy.com, Jan 7,19]
10x Genomics (Pleasanton, CA; no SBIR) reeled in $50 million in series D cash. The round moves 10x’s VC haul up past the $180 million mark, setting it up to introduce a range of add-ons to its long-read sequencing and single cell analysis technology in the coming months. 10x first made waves early in 2015, when it exited stealth with a $55 million series B and technology for constructing long DNA sequences from the output of Illumina’s dominant short-read machines. A deal with Illumina and another $55 million financing followed, putting 10x on a path that led to 150% year-on-year sales growth. [Nick Paul Taylor, Fierce Biotech, Apr 27, 18]
10X Genomics (Pleasanton, CA; no SBIR) raised $55 million in a Series C venture round to push ahead with its sequencer upgrade technology. The company makes a box that connects to Illumina machines and provides a better way to interpret short-read sequencing data, its officials say. The round adds to the $80 million in funding 10x announced at its debut last year. [Alex Lash, xconomy.com, Mar 18, 16]
When scientists sequence a complete human genome today, some information gets lost in the shuffle. Now a San Francisco Bay Area startup called 10X Genomics (no SBIR) has raised more than $55 million to start selling a new technology that is supposed to provide a more richly detailed picture ... one of the oldest, and toughest [problems], in genomics [Luke Timmerman, Forbes, Jan 12, 15]
10X Genomics (Pleasanton, CA; no SBIR), a DNA sequencing technology whose board is led by Illumina Inc. co-founder John Stuelpnagel, said Monday that it raised $55.5 million in a Series B round .... has raised more than $80 million as founder and CEO Serge Saxonov and his team try to roll out a new genomics platform that they say will "change the definition" of DNA sequencing. [Ron Leuty, San Francisco Business Times, Jan 12, 15]
1366 Technologies raises $9M to grow solar wafer business [Boston Business Journal, Nov 1, 17] has raised about $96M to date [crunchbase.com]
Solar power components maker 1366 Technologies (Bedford, MA; no SBIR) snagged $15 million in yet another extension of its Series C round, which now stands at $47.5 million. ... raised $10 million in early May. It has raised $95 million from investors to date. [Jeff Engel, xconomy.com, Jul 5, 16]
1366 Technologies (Bedford, MA; no SBIR) developer and manufacturer of solar power components, has tacked $10 million on to its Series C funding round, which now stands at $32.5 million. The company has raised $80 million from investors to date, a spokeswoman says. .... makes less expensive silicon wafers, the cells that are the building blocks of photovoltaic solar panels that make up solar power systems [Jeff Engel, xconomy.com, May 6, 16]
The proposed 1366 Technologies plant in the Town of Alabama [NY] has received a $5 million grant from Empire State Development. The ESD grant is one of several public-sector incentives being offered to 1366 Technologies to help finance its proposed $700 million, 100,000-square-foot plant in the Western New York Science and Technology Advanced Manufacturing Park. The company is the first to commit to the fledgling development park. [James Fink, Buffalo Business First, Dec 28, 15]
Solar wafer maker 1366 Technologies has survived the carnage in the U.S. solar manufacturing industry over the last five years. Now the company, which uses a novel technology for making the silicon wafers used in most solar cells, is embarking on its next phase, building a large manufacturing plant in upstate New York [Richard Martin, technologyreview.com, Oct 14, 15]
1366 Technologies (New Bedford, MA; no SBIR) will be building a 100,000-square-foot plant at the Western New York Science and Technology Advanced Manufacturing Park. ... produces solar wafers commonly used in the production of solar panels. [James Fink, Buffalo Business First, Oct 8, 15]
1366 Technologies said that it raised $22.5 million in Series C funding and will more than triple its workforce over the next year as it explores a potential IPO. ... led by the China-based venture capital firm Haiyin Capital and will be used for the construction of 1366’s 130,000-square-foot 250 megawatt manufacturing facility, which will produce silicon wafers [David Harris, Boston Business Journal, Apr 10, 15]
1366 Technologies, a producer of low-cost solar wafers, said it has added $2.5 million to its Series C round of funding. The money is allotted to the construction of a full-scale manufacturing facility [Kyle Alspach,, Mass High Tech, Dec 12, 13]
1366 Technologies raised $15 million this month to bring total investments to $100 million (including government grants), on the promise that its technology could cut the cost of the silicon wafers—the most expensive part of silicon solar cells—in half. .... plans to reduce the cost of silicon wafers from roughly 20 cents per watt to about 8 cents per watt. [Kevin Bullis, technologyreview.com, Nov 1, 13]
1366 Technologies (Bedford, MA; no SBIR), a producer of low-cost solar wafers, said it has raised a $15 million Series C round for the construction of a full-scale manufacturing facility. ... new funding was led by an existing partner, major Japanese silicon producer Tokuyama. [Kyle Alspach, Boston Business Journal, Oct 15, 13]
1366 Technologies opened a 42,000-square-foot plant in Bedford that will be the proving ground for a one-step manufacturing process that significantly cuts the cost of the silicon wafers used in solar panels. The $6 million plant is the first step in an investor- and government-financed growth plan for 1366 Technologies that, if successful, could make the company a major player in a fiercely competitive solar industry that has already sunk several promising firms such as Evergreen Solar of Marlborough. [Erin Ailworth, Boston Globe, Jan 30, 13]
Solar technology developer 1366 Technologies (Lexington, MA; no SBIR) announced it has received a $150 million loan commitment from the U.S. Department of Energy for the construction of a commercial production facility in Massachusetts along with a second larger plant in the U.S. [Mass High Tech, Jun 17, 11]
to its Series B round, solar-power technology developer 1366 Technologies has added another $2.4 million, bringing it to $28.4 million, according to a regulatory filing [Kyle Alspach, Mass High Tech, Jan 14, 11]
1366 Technologies boosted its Series B financing round by $6 million, bringing it to a total of $26 million, according to a regulatory filing. .... developing a process for creating low-cost solar wafers [Mass High Tech, Dec 16, 10]
1366 Technologies, (Lexington, MA; no SBIR) focused on solar manufacturing, announced the close of a $20 million Series B financing that brings the total amount that the company has raised to $37.55 million [Boston Globe, Oct 19, 10]
Solar-power technology developer 1366 Technologies has landed $5.1 million of a planned $6.2 million round of venture capital. [Craig Douglas, Mass High Tech, Feb 4, 10]
several Massachusetts projects will receive a total of $33.2 million in federal funding for energy research. 1366 Technologies (Lexington) $4 million; , Agrivida (Medford; $300K SBIR) $4.6 million for efforts to cut the costs of cellulosic biofuels and chemicals; MIT $7 million on all-liquid metal grid-scale batteries; FastCAP Systems (Cambridge) $5.3 million to reduce the cost of hybrid and electric vehicles and of grid-scale storage; FloDesign Wind Turbine (Wilbraham) on new high efficiency shrouded wind turbines that could reduce noise and safety concerns $8.3 million ; Sun Catalytix (Cambridge) $4 million for a novel catalyst to enhance the efficiency of splitting water into hydrogen and oxygen. [Boston Globe, Oct 27, 09]
Private companies to watch on electricity as picked by MIT Tech Review (Sep/Oct09): Nanosolar ($1.7M SBIR) founded 2002, raised $400M; A123 Systems IPO Sep 24; Brightsource Energy; Tendril; 1366 Technologies; Deepwater Wind; Solyndra; Silver Spring Networks; AltaRock; Stirling Energy Systems.
1st Detect (Austin, TX, no SBIR) which is developing a portable chemical detection device, said that it has received a $1.8 million grant from the Texas Emerging Technology Fund. .... formed by Astrotech (Austin, TX; no SBIR) satellite and space research company. It is commercializing miniature mass spectrometer technology first developed for the International Space Station. [Austin American-Statesman, Mar 4, 10]
Seventeen [Texas Emerging Technology Fund]’s startups spawned by public money have gone bust.... were awarded commercialization grants worth nearly $23.5 million. ..... the ETF has been dogged by allegations of impropriety and political influence in its application process, and many question whether the state should be funding startups. .... the largest grant amount awarded was 21-Century Silicon (Richardson, TX; no SBIR) that was awarded a $3.5 million grant in 2009 [Christopher Calnan, Austin Business Journal, Feb 3] With politics poisoning the well, it is hard to say whether the failure rate is from expected tech risk or pure political handouts to supporters. It's also hard to find a reason to believe that the guv acted cleanly in picking winners.
Whom You Know. [Sen Ben] Nelson's current $7.5 million earmark for software helps 21st Century Systems (21CSI) (Omaha, NE; $3M+ SBIR), which employs the senator's son, Patrick Nelson, as its marketing director. The company gets 80% of its funds from federal grants, mostly through earmarks. With nine offices scattered among states represented by appropriators in Congress, the company has in recent years spent $1.1M to lobby Congress and $160K in congressional campaign contributions. "As of April," the Omaha World-Herald reported, "only one piece of [the company's] software has been used -- to help guard a single Marine camp in Iraq -- and it was no longer in use." [Robert Novak, Washington Post, Jul 23]
Genetic testing company 23and Me is laying off about 14 percent of its staff amid slowing consumer demand for DNA tests. [xconomy.com, Jan 23, 20]
23andMe's test is approved to detect 33 variants of multiple genes to provide information about how a person metabolizes some medications. [Amirah Al Idrus, Fierce Biotech, Nov 1, 2018]
Glaxo SmithKline makes $300M investment in 23andMe, forms 50-50 R&D pact [Fierce Biotech, Jul 26, 18]
A 23andMe genetic test for cancer risk received FDA approval, allowing the company to sell directly to consumers. The test screens for genetic mutations associated with higher risks for breast, ovarian, and prostate cancers. [Ben Fidler, xconomy.com, Mar 9, 18]
Genetic testing powerhouse 23andMe announced today that it’s officially received the FDA go-ahead to launch a direct-to-consumer testing kit for genes linked to various forms of cancer. The forthcoming kit, which will be made available without a prescription, tests for BRCA1 and BRCA2, which are linked to higher risk of ovarian, break and prostate cancer. [Brian Heater, TechCrunch, Mar 7, 18]
23andMe, following a banner Christmas season for sales of its personal DNA-testing kits, has just announced a large-scale study intended to uncover the genetic reasons why diet and exercise have different effects on different people. The company, whose testing kits were top sellers on Amazon this season, has just announced it will recruit for the study 100,000 of its customers who are overweight, but in otherwise good health. [Ethan Baron, San Jose Mercury News, Dec 31, 17]
23andMe (Mountain View, CA; no SBIR) reeled in a new $250 million round of private funding [Frank Vinluan, xconomy.xom, Sep 12, 17]
23andMe seen raising $200M from Sequoia, others, rather than IPO.Add 23andMe Inc. to the growing list of venture-backed unicorns that are raising IPO-sized rounds from private investors instead of going public. [Cromwell Schubarth, Silicon Valley Business Journal, Sep 6, 17]
DIY genomics[FDA] recently approved 10 of the personal-genomics company 23andMe’s screening tests for genetic health risks, including one for Alzheimer’s and one for a rare blood disorder. The decision represents a turning point in the democratization of personalized medicine. It’s also a turnaround for the FDA, which had pulled the tests from the market in 2013 ... For the first time, patients don’t have to go through a physician to learn about potential risks related to their genetic makeup [Peter Huber and Paul Howard, Wall Street Journal, Apr 30, 17]
More than three years after federal regulators stripped it from marketing its "spit kits" as a way to probe for the genetic likelihood of getting Alzheimer's, Parkinson's or a host of other diseases, 23andMe Inc. won [FDA] approval for its tests. [Ron Leuty, San Francisco Business Times, Apr 6, 17]
[FDA] approved the first-ever direct-to-consumer genetic testing for people’s personal risk of contracting 10 potentially serious conditions including late-onset Alzheimer’s, Parkinson’s disease, celiac disease and a hereditary blood-clot condition called thrombophilia. The product is offered by the closely held Silicon Valley genetics-testing company 23andMe (no SBIR), which was initially stymied by the FDA in 2013 when it sought to offer such saliva-analysis tests to the general public. [Thomas Burton, Wall Street Journal, Apr 6, 17]
Genetic analysis of over 450,000 people has been performed by 23andMe and Pfizer to identify 15 regions of the human genome linked to a higher risk of struggling with serious depression. [MIT Tech Review, Aug 2, 16]
Direct-to-consumer genomics firm 23andMe is offering its spit-to-sequence kits to researchers for $199. Study volunteers can then join the company’s ancestry database and receive information on carrier status for diseases. [Jenny Grens, The Scientist, Jul 15, 16]
nine years after its introduction, the only one of its kind sold directly to consumers. 23andMe has managed to amass a collection of DNA information about 1.2 million people, which last year began to prove its value when the company revealed it had sold access to the data to more than 13 drug companies. [Antonio Regalado, technologyreview.com, June 21, 2016]
consumer genetics company 23andMe plans to let its customers use their iPhones to share their genetic data with researchers carrying out medical studies. The plan will allow university researchers to access DNA profiles collected by the Google-backed company and pair them with health-related data currently being collected on participants’ phones. [Antonio Regalado, technologyreview.com, Mar 21, 16]
Genetic information company 23andMe's "spit kits" will be available at Walgreens stores, a company leader said. But the company officially said no deal is imminent. The deal, if it actually is finalized, would demonstrate how far Mountain View-based 23andMe has come since the [FDA] two years ago spanked it for not getting the agency's approval before marketing its kit to consumers as a way to uncover disease-signaling gene mutations. [Ron Leuty, San Francisco Business Times, Feb 26, 16]
Have you ever been diagnosed with brain cancer? Mail off your spit for a $99 genetic analysis from 23andMe, and you will get information about your ancestry, served up on a web account. You will also encounter a list of optional survey questions. [Kelly Servick, Science, Sep 25, 15]
after nearly two years [FDA directed suspension], 23andMe is announcing that it will begin providing customers with health information again, though much less than before and with F.D.A. approval. [ANDREW POLLACK, New York Times, OCT. 21, 2015]
genetic-testing company 23andMe raised $115 million in [VC Series E] financing as it prepares to introduce a new consumer product and expands its drug-discovery arm. ... has popularized a $99 DNA test that analyzes consumers' spit for genetic information [Caroline Chen, Bloomberg News, Oct 14, 15]
DNA testing startup 23andMe has apparently nudged its way into the growing venture-backed crowd whose valuation has hit at least $1 billion. ... The new valuation is nearly three times what 23andMe was figured to be worth when it last raised funds in 2012, before the Food and Drug Administration warned that the company needed its approval before its tests could be marketed. [Cromwell Schubarth, Silicon Valley Business Journal, Jul 9]
DNA testing startup 23andMe raised $79 million according to a new regulatory filing. ... to create a kit to provide customers with information about their genealogical and biological makeup. The kits cost $99 and can use a person’s saliva to test for 254 markers for disease [Gina Hall, Silicon Valley Business Journal, Jul 6, 15]
Dr Ellenberg points out that services like 23andMe, which provide ancestral and medical interpretations of individuals’ genetic information, have not yet delivered the revolution in health that many had expected. In the early days of genomics, excited mathematicians thought they had discovered thousands of correlations, most of which were chance findings. [The Economist, Mar 7, 15]
23andMe, the Google-backed genetic-testing startup that popularized a $99 DNA spit test, will expand from screening people for diseases to inventing new medicine to cure them. ... went from a seller of novelty ancestry kits to one of the world’s biggest repositories of genetic data, doing business with major pharmaceutical companies like Pfizer and Genentech. Now it may compete with those giants. ... The company has raised $126 million in four previous rounds of funding since its founding in 2006. [Caroline Chen, Seattle Times, Mar 12, 15]
Nearly a year after the FDA blocked sales of its personal genetic testing service, 23andMe has gotten approval to use the direct-to-consumer test again — but only for a single, rare genetic condition [carriers of a gene variant that could lead to their offspring inheriting Bloom syndrome, a serious disorder that causes short stature, sun sensitivity and increased mortality]. ... FDA blocked its sales last year. But it appears that attitude may be thawing, albeit in a minor way. [Eric Van Susteren, Silicon Valley Business Journal, Feb 20, 15]
Direct-to-consumer genetic analysis company 23andMe has announced the first two of a string of anticipated deals to share its data with drug developers. Through the sale of $99 saliva testing kits, the company has built a coveted genetic database of 800,000 people, more than 80% of whom have agreed to participate in research. Last week, 23andMe announced that it will share 3000 whole genomes with biotech company Genentech to help identify new drug targets for Parkinson's disease—in return for an upfront $10 million, plus more to come, depending on the project's progress. And on 12 January, it revealed another agreement with pharma giant Pfizer, for a lupus research effort that will involve enrolling 5000 patients in a longitudinal study. The company has said that it plans to roll out 10 such deals this year. [Science, Jan 16, 15]
Genetic information provider 23andMe inked a deal with Roche’s Genentech division to provide whole-genome sequencing data from 3,000 Parkinson’s disease patients. Genentech will use the data for drug R&D, and pay 23andMe up to $60 million, according to media reports. It’s the second collaboration between the two parties. [Alex Lash, xconomy.com, Jan 8, 15]
If not here, there. A controversial personal DNA testing kit from Google-backed genetics business 23andme (no SBIR) was launched in Britain. It offers users a chance to see if they are at risk from certain diseases and has a green light to go on sale, after securing a so-called "CE" mark of European quality assurance. Last year, 23andme agreed to stop selling its DNA test in the United States after the Food and Drug Administration said false positive or false negative results could prompt patients to take "morbidity inducing" actions, like unnecessary surgery. It is now seeking regulatory approval for the U.S. market. [Ben Hirschler, Reuters, Dec 1, 14]
Pfizer is teaming up with DNA testing company 23andMe to study the possible genetic underpinnings of inflammatory bowel disease, a hard-to-treat ailment that affects an estimated 1.4 million Americans. Under the agreement, 23andMe will map the DNA of 10,000 patients who have forms of the disease, which include Crohn's disease and ulcerative colitis. [Matthew Perrone, AP, Aug 12, 14]
Anne Wojcicki, chief executive of 23andMe, is determined to overturn the way traditional health care works in the U.S. It hasn't been easy. Last year, the [FDA] shut down sales of her genetics company's personalized health reports—one of its main sources of revenue. .... Her company is working with the FDA on getting its reports approved for direct delivery to consumers. Before the FDA's warning letter, 23andMe had 550,000 customers. Now it has 700,000 ....The field is starting to change, as evidenced by the rise of personal health trackers like Fitbit. Still, Ms. Wojcicki worries that patients don't realize that they own their own data. "You own your tumor," she says. [Alexandra Wolfe, Wall Street Journal, Jun 27, 14] SBIR not needed when your husband is co-founder of Google. Besides, federal agencies not likely interested in empowering individual citizens.
Genetic testing company 23andMe is facing a class action lawsuit alleging that the Silicon Valley startup misled customers about its test kit. [Matthew Perrone, AP, Dec 3, 13]
"personal genetics" startup 23andMe released another conciliatory statement in its unusual war of words with the [FDA], which has demanded the company stop marketing its signature DNA tests. ... "We stand behind the data that we return to customers -- but we recognize that the FDA needs to be convinced of the quality of our data as well," co-founder and Chief Executive Anne Wojcicki wrote in a blog post. .... The startup would seem to be financially well-positioned for a legal fight with the feds. 23andMe has raised more than $125 million from backers including Google (GOOG) co-founder Sergey Brin [Peter Delevett, San Jose Mercury News, Nov 27, 13]
23andMe (Mountain View, CA; no SBIR, founded 2006) said it is seeking federal approval of its genetic tests, which it claims help consumers understand their chances of getting various ailments. The company already legally sells the tests, which cost $299 per person. But it is believed to be the first direct-to-consumer genetic testing firm to seek U.S. Food and Drug Administration certification of its products. [Steve Johnson, San Jose Mercury News, Jul 30, 12]
Anne Wojcicki is a Stanford-educated geneticist is the founder of 23andMe (no SBIR) which develops tests to identify gene markers for susceptibility to particular diseases. After spending 10 years managing investments in biotech companies, Wojcicki founded 23andMe in 2006. She is also married to another global innovator, Google’s Sergey Brin. [cnbc.com, Aug 5, 10] One of CNBC's fifteen leading innovators for the next decade. Mr Brin can surely spare all the needed seed capital for such a company.
24M Technologies (Cambridge, MA; no SBIR, founded 2010) announced it has raised a $21.8 million Series D to accelerate the deployment of its simple, capital-efficient, low-cost manufacturing process and the development of differentiated, high energy density lithium-ion cells for the EV market. ... financing was led by advanced ceramics manufacturer Kyocera Group and leading global trading company, ITOCHU Corporation. [company press release, Dec 17, 18] prior funding $16M [crunchbase.com]
24M Technologies (Cambridge, MA; no SBIR) maker of a new,semisolid lithium-ion battery, raised $21.8M in an equity offering (Sri Kalyanaraman, BostInno, Dec 3, 18]
MIT-based scientist Yet-Ming Chian [one of the founders of A123] publicly unveiled his latest startup, 24M (Cambridge, MA; no SBIR). ... uses a novel battery composition based on a semi-solid material that eliminates much of the bulk of conventional lithium-ion batteries—which are typically made up mostly of inactive, non-energy-storing materials—while dramatically increasing the energy density. Chiang and 24M CEO Throop Wilder also say that they can reduce the time needed to make a battery by 80 percent and the cost by 30 to 50 percent. ... has raised $50 million in funding along with a $4.5 million grant from the U.S. Department of Energy. It has strategic partnerships with the Japanese [Richard Martin, technologyreview.com, Jun 22, 15]
Battery startup 24M Technologies (Wellesley, MA) has received $10 million in Series A financing and will share in $6 million of federal funding to develop its technology, the company announced today. The company’s technology is spun out of research at MIT and lithium ion battery company A123 Systems. [Kyle Alspach, Mass High Tech, Aug 16, 10]
Two Austin startups, 30 Second Software Inc. and Phurnace Software Inc., have received venture capital infusions. 30 Second Software, founded by Austin entrepreneur Dave Sikora, has raised $2.9 million from two corporate investors, to develop mobile commerce technology and services. Phurnace, which won the 2006 University of Texas MOOT Corp business-plan competition, received $1.3 million [from] a Texas-based venture fund affiliated with Draper Fisher Jurvetson. [Austin American-Statesman, Sep 3, 07]
Austin software industry veteran Dave Sikora has launched a startup focused on mobile commerce technology and services. The company, 30 Second Software Inc., offers a free e-commerce service for making purchases using BlackBerry devices. ... Sikora was formerly CEO of Austin-based Pervasive Software Inc. Prior to that he led three Austin software startups: Ventix Systems Inc., Question.com Inc. and Powered Inc. [Austin American-Statesman, Jan 29, 07]
360fly (Pittsburgh, PA; no SBIR) creator of 360-degree cameras based on robotics technology developed at Carnegie Mellon University, said it has raised $40 million [Series C]. [ Patty Tascarella, Pittsburgh Business Times, May 5, 16] 360fly captures your life in immersive, interactive 360° video that can be shared instantly on social media and relived fully in virtual reality via our mobile and desktop apps. It’s the 360° camera that misses nothing. And changes everything. [company website]
3Bar Biologics (Columbus, OH; at least $600K SBIR) provider of a beneficial microbe delivery system, announced it has secured $2M in funding from an impressive group of investors, ... Building on over 15 years of research at The Ohio State University, Bio-Yield® uses living microbes that are sourced and discovered in local fields and activated on-site [company press release, Aug 16, 17]
3Bar Biologics (Columbus, OH; no SBIR), a TechColumbus tenant, is headed into its second season since launching its system for growing and distributing concentrated supplies of beneficial bacteria around seeds at planting, aiming to increase yields 5 percent. The Ohio State University spinoff relies on advanced DNA sequencing techniques. [Carrie Ghose, Columbus Business First, Jan 16, 15]
New CEO at 3C 3C Semiconductor (Portland, OR) announced Don Hagge, a veteran founder of tech companies, as first President and CEO. 3C got a BMDO Phase 2 SBIR recently to pursue heat resistant contacts to 3C silicon carbide devices. Having an business scarred CEO comforts the VCs who don't particularly like a scientist trying to do both science and business. Founder-scientist Jim Parsons and his investors from an Oregon VC firm apparently agreed a solution.
h3>3DBio Therapeutics (NYC, NY)3DBio Therapeutics (NYC, NY; no SBIR) and the Microtia-Congenital Ear Deformity Institute announced they have conducted a human ear reconstruction using the AuriNovo™ implant, an investigational, patient-matched, 3D-bioprinted living tissue ear implant. [compsany press release, Jun 2, 2022]
3DEO (Gardena, CA; $1M SBIR, founded 2016), a metal 3D printing company that manufactures parts for medical and other industries, raised $14 million, according to [SEC] filing. [Dana Bartholomew, LA Business Journal, Feb 8, 19]
3D Glass Solutions (Albuquerque, NM; no SBIR, founded 2006), a leading innovator of glass-based, three-dimensional (3D) passive RF devices, announced it has closed $12 million in series B equity funding, bringing the company’s total equity funding to more than $19 million. [company press release, Jul 9, 19]
3D Glass Solutions (Albuquerque, NM; no SBIR, founded 2006, 15 employees) startup that created a new type of proprietary glass ceramic, dubbed APEXGlass, to make advanced semiconducting chips, is gearing up for launch next year of its first standard product line. ... expects to triple its workforce in the next year [Kevin Robinson-Avila / Albuquerque Journal, Nov 17,15]
Maryland Technology Development Corp approved awards of $8.5 million to 29 new stem cell research projects. The for-profit firms each receiving over $1M are: TissueGene (Rockville, MD; $100K SBIR), Longeveron LLC (Miami, FL; no SBIR), MaxCyte (Gaithersburg, MD; $1M SBIR), Propagenix (Rockville, MD; no SBIR), Seraxis (Germantown, MD; no SBIR), and 3Dnamics (Germantown, MD; no SBIR). [Morgan Eichensehr, Baltimore Business Journal, May 16, 17]
3D Robotics (Berkeley, CA; no SBIR) the drone maker that began life in Tijuana and San Diego, has been consolidating its operations after stumbling in its bid to go head-to-head against China’s DJI, the world’s biggest maker of consumer drones. .. is closing its San Diego facility, with three years still remaining on its lease [Bruce Bigelow, xconomy.com, Mar 24, 16]
Rockwell Medical (Wixom, MI; no SBIR) biopharma startup targeting end-stage renal and chronic kidney diseases, has received approval from the China Food and Drug Administration for the submission of its lead product. ... the first step in getting Triferic to market in China. Triferic is Rockwell’s proprietary iron replacement and hemoglobin maintenance drug for treating anemia in dialysis patients. [Sarah Schmid, xconomy.com, Mar 24. 16]CyPhy Works (Danvers, MA; $700K SBIR) announced a $22 million Series B round ... [FAA] decision to green-light commercial drone use earlier this year appears to be spurring the deployment of even more capital into the fledgling sector. ... founded by iRobot co-founder Helen Greiner. ... Other [VC recipients] in this sector include 3D Robotics (Berkeley, CA; no SBIR), which has raised more than $90 million, and Airware (San Francisco, CA; no SBIR), which has snagged more than $40 million. [Jeff Engel, xconomy.com, Oct 13, 15]
3D Robotics (Berkeley, CA; no SBIR) reportedly has raised $50 million in a record funding for a U.S.-based personal drone startup. ... has raised $85 million to date [Gina Hall, Silicon Valley Business Journal, Feb 26, 15]
Commercial drone maker 3D Robotics (Berkeley, CA; no SBIR) [ 200 employees in North America and more than 30,000 customers worldwide. ... previously raised $30 million in mid-2013] said that it has raised $50 million in additional venture capital, led by Qualcomm. [Mike Freeman, utsandiego, Feb 27, 15]
[CEO] Chris Anderson is building [3D Robotics] (San Diego, CA and Tijuana; no SBIR) based on the idea that drones can be a big benefit at home – doing things such as climate research to daily crop monitoring. .... now sell more drones every six months than the entire drone fleet of the U.S. military, which numbers about 7,000 aircraft. [Mike Freeman, utsandiego.com, Apr 12, 13]
3D Systems down 21% [Aug 3, 17]
United
Therapeutics (Silver Spring, MD; no SBIR) has
ambitions to build an unlimited supply of certain transplantable
organs. ... said the company's new multiyear
collaboration
—
specifically with United Therapeutics' transplantation-focused
subsidiary, Lung
Biotechnology
PBC — will use patient-specific
biological material, including re-differentiated stem cells, to create
materials for the transplants. The project will be based out of 3D Systems (San
Diego, CA; no SBIR) new
bioprinting lab. ... United
Therapeutics additionally invested $100 million in two rounds, in 2014
and 2016, in Synthetic
Genomics
(La Jolla, CA), a
company started by
scientist J. Craig Venter, to further its own research and development
in its North Carolina facility. The local company also invested $41.8
million in TransMedics
(Andover, MA; no SBIR) that
develops
ex vivo perfusion systems for donor lungs, hearts and kidneys.
[Tina Reed, Washington Business Journal, May 2, 17]
3D Systems up 25% [Mar 14,16] after quarterly results
3-D printers can produce even junk food these days. Appropriate, as the firms making them have given investors a sharp case of indigestion. The share price of Stratasys (no SBIR) has collapsed 50% in the past 12 months, while close rival 3D Systems (no SBIR) is down more than 60% in that time. That has erased the huge gains those stocks enjoyed during a run-up in 2013. Smaller 3-D printer plays such as ExOne (no SBIR)and voxeljet (no SBIR) have charted a similar course. ExOne shares are actually 10% below their IPO price from February 2013. [Dan Gallagher, Wall Street Journal, Feb 22, 15]
3D Printing Money. Shares of Voxeljet AG (Germany) more than doubled after the 3-D printing company raised $84.5 million in its initial public offering. Voxeljet's 3-D printers can make anything from vehicle parts to chairs to artwork. [AP, Oct 18]..... Stocks of 3-D printing companies have soared over the last year as 3-D printing grows in popularity. Shares of The ExOne (North Huntingdon, PA; no SBIR) have tripled since the company went public in February. Stratasys Ltd.'s (Eden Prairie, MN; no SBIR) shares have jumped 73 percent over the last year. And 3D Systems (Rock Hill, SC, no SBIR) shares have more than doubled from a year ago. [Paul Ausick, 24/7 Wall Street, Oct 18]
Big funding round being announced this morning by Formlabs (Somerville, MA; no SBIR, founded in 2011 by a trio of engineers and researchers from MIT's Media Lab) startup that ran a wildly-successful Kickstarter campaign last fall for a new 3D printer— and was promptly sued for patent infringement by 3D Systems (no SBIR), the industry's biggest player. After collecting almost $3 million in pre-orders for its Form1 printer on Kickstarter, Formlabs is banking $19 million in new funding from investors [Scott Kirsner, Boston Globe, Oct 24, 13]
True 3D Display (May 5) Elizabeth Downing had a continuous flow of lookers at Photonics West 97 at her 3D pictures in a cube. She should get a larger flow after the John Drake's friendly article in MIT Technology Review May/Jun97. The BMDO SBIR-supported idea makes an image in 3D, not a 2D representation of a 3D image as on Hollywood's best silver screen or even Reveo's Vrex projector. Downing has now attracted VC to build a 6-inch cube display at her 3D Technology Laboratories (Mountain View, CA).
Thirteen NC companies will split $1 M from a new state fund intended to help businesses create environmentally friendly technologies. In the Triangle area: Ecocurrent of Raleigh received $100,000 to convert hog manure into electric power; Kyma Technologies of Raleigh received $60,000 to work with N.C. State University on a more efficient, cheaper electric switch.; 3F LLC of Raleigh received $100,000 to develop a natural fiber-reinforced concrete formula.; Piedmont Biofuels of Pittsboro received $75,000 to work on a reactor that more efficiently creates biodiesel.; Nextreme Thermal Solutions of Durham received $57,319 to manufacture a generator that converts waste heat into electricity.; Rain Water Solutions of Raleigh received $18,000 to develop a new rain barrel manufacturing process. [Raleigh News & Observer, Jul 1]
3iNanotech (Greensboro, NC; no SBIR, founded 2018) emerges out of Gateway University Research Park ... develops point-of-care devices for disease diagnostics and protein detection. [NC Biotech Center]
Spawned by Yale University, 3PrimiR (Westport, CT; no SBIR), which is focused on applying microRNA discoveries to cancer diagnostics, has raised $2 million in a planned $4 million equity financing, according to federal documents. [Mass High Tech, Sep 16, 09]
Biotech startup 3Scan (San Francisco, CA; no SBIR, founded 2011) raised $14 million to improve its robotic microscope and build out its software. [Gina Hall, Silicon Valley Business Journal, Jul 11, 16]
3-V Biosciences Menlo Park, CA; no SBIR) said that it lined up $20 million .... has raised $85 million over its six-year history ... Much of the cash historically has gone into 3-V's antiviral drug research [Ron Leuty, San Francisco Business Times, Jun 24, 13]
Video analytics firm 3VR Security of San Francisco raised $15 million in a third round of venture led by DAG Ventures. Also participating with follow-on investments were In-Q-Tel,the strategic venture firm funded by the Central Intelligence Agency, VantagePoint Venture Partners, and Kleiner Perkins Caulfield & Buyers. [San Jose Mercury News, Oct 11]
NCBiotech announced last week that it had awarded $1,060,352 through 17 grants and loans in the first quarter of its 2016-17 fiscal year. In total, four Triangle firms snagged funding. InnAVasc Medical (Durham, NC; no SBIR), 410 Medical Innovation (Durham, NC; no SBIR), UVision360 (Research Triangle Park, NC; no SBIR), and EpiCypher (Research Triangle Park, NC; no SBIR) each received a $250,000 small business research loan for applied research, NCBiotech said. [Jennifer Henderson, Triangle Business Journal, Oct 20, 16]
454 Life Sciences (no SBIR) was founded by Jonathan Rothberg originally as 454 Corporation, a subsidiary of CuraGen (while a graduate student at Yale, Jonathan founded CuraGen). For their method for low-cost gene sequencing, 454 Life Sciences were awarded the Wall Street Journal's Gold Medal for Innovation in the Biotech-Medical category in 2005. ... In late March 2007, Roche Diagnostics announced an agreement to purchase 454 Life Sciences for $155 million.[3] Roche announced that it will shut down 454, and stop supporting the platform by mid-2016 ... In 2007 founded Ion Torrent that also commercialized technologies for DNA sequencing that have significantly reduced the cost of sequencing a genome.[wikipedia] sold Ion Torrent it for $500M which allowed him to ply the ocean on a 130-foot yacht and to indulge high-concept hobbies like sequencng the DNA of math geniuses ... also founded an incubator 4Combinator to finance companies that combine medical sensors with a branch of AI called deep learning [Anthony Regalado, MIT Technology Review]
4C Medical Technologies (Minneapolis,MN; no SBIR, founded 2015) focused on the development of minimally invasive therapies for structural heart disease, announced a private placement ..with total gross proceeds of approximately $17 million. [company press release, Sep 10, 18] total funding $27M [crunchbase.com]
4C Medical Technologies (Brooklyn, MN; no SBIR) recieved $8M equity funding on July 19, 17 ... focused on heart disease.The company's implant is the first MR therapy with supra-annular positioning and atrial-only fixation. It preserves the native mitral valve and left ventricle, eliminating known issues associated with transcatheter mitral valve replacement technologies which rely on placement and fixation in the native mitral annulus and left ventricle. [crunchbase.com]
4D Molecular Therapeutics (Emeryville, CA; no SBIR, founded 2013) is already working with several large pharmaceutical companies to help them develop new gene therapies. Now, as its own gene therapy candidate approaches clinical trials, the company has raised $90 million. [Frank Vinluan, xconomy.com, Sep 5, 18] total funding $100M [crunchbase.com]
4s3 Bioscience (Boston, MA; no SBIR) focused on developing genetic disease therapies for orphan neuromuscular disorders, has raised $20 million ... to support the continued development of a proprietary antibody technology that provides targeted and active intracellular delivery of active proteins, enzymes and other macromolecules to skeletal muscle. [DC Denison, Boston Globe, Mar 5, 12]
5D Robotics (Carlsbad, CA; no SBIR) said this week that it has raised $5.5 million in seed funding to support its efforts to expand its autonomous navigation technology from military uses to commercial markets. ... said its technology has been tested on over 30 robots and vehicles in military applications. [Mike Freeman, San Diego Union Tribune, Feb 5, 16]
biotech startup 65Bio (Wellesley. MA; no SBIR) raised $1.8M in equity in a $4M funding round, according to an SEC filing. [Bost Inno, Aug 17, 20]
Department of Energy has selected 20 companies to receive Bipartisan Infrastructure Law funds totaling $2.8 billion to grow the battery supply chain for the power grid, as well as electric vehicles and associated components. Three companies had SBIR: 6K (North Andover, MA; $3.5M SBIR); Lillac Solutions (Middletown, RI; one SBIR); Sila Nanotechnologies (Atlanta, GA; $3.6M SBIR) [govconwire, Oct 20, 2022]
high-efficiency air conditioner company 7AC Technologies (Woburn, MA; no SBIR) has received an unspecified Series B investment from the venture capital investment arm of manufacturing giant 3M, which also has a line of air conditioners. .... plans to introduce a commercial prototype in coming months using its liquid desiccant technology to remove humidity from the air. The process lowers air temperature and dries the air in a building in one step rather than two, like traditional air conditioners — saving half the electricity [Don Seiffert, Mass High Tech, Jul 20, 12]
7AC Technologies (Woburn, MA; no SBIR) bumped up a debt financing last week to $460,000 from a previous offering of $300,000 filed in September ... Founded in 2009 and known until September as 7Solar Technologies ... developed a combination photovoltaic and thermal module technology to heat and cool buildings. It now is described as providing net-zero energy retrofits using the waste heat driven air conditioning system that integrates to a desiccant chiller for winter heating and summer cooling. [Michelle Lang, Mass High Tech, Dec 13, 11]
89bio up 17% [Nov 15, 19]
89bio (San Francisco, CA and Israel; no SBIR) up 30% [Nov 11, 19] after IPO to raise $89M
89Bio (San Francisco and Israel; no SBIR), a clinical-stage biopharmaceutical company focused on nonalcoholic steatohepatitis (NASH) and other liver and metabolic disorders, announced it has closed a $60 million Series A financing ... to advance the company's pipeline of biologic and small molecule drug candidates acquired from Teva Pharmaceutical Industries, Ltd. [company press release, Oct 25, 18]
908 Devices (Boston, MA; no SBIR) up 145% [Dec 18 20] after $130M IPO
working to make tiny mass spectrometry tools, 908 Devices (Boston, MA; no SBIR, founded 2012), announced a collaboration with, as well as recent funding from, one of the world’s biggest oilfield services company. [$7M in equity from Schlumberger] [Don Seiffert, Boston Business Journal, Sep 10, 12]
stealthy startup 908 Devices (Boston, MA; no SBIR) that’s working on security-related applications for a range of potential uses has raised $8.1 million in Series A funding .... [VP] said it plans to have a product ready to launch by the end of 2013. [Don Seiffert, Mass High Tech, Sep 5, 12]
9Mile Labs,
the new Seattle
area startup accelerator for business-to-business companies, delivered
nine new companies to potential investors .... [A]
network
of dozens of mentors, along with work space at the SURF
Incubator
and a $20,000 investment, are the main benefits the startups receive in
exchange for giving 4 to 8 percent equity stakes to 9Mile
Labs.
[Benjamin Romano, xcononmy.com, Sep 10] The collection of
startups are not good SBIR candidates because the uncertainties are
only about business prospects of ready-to-go technology.
A10 Networks [San Jose, CA; no SBIR, stealth SBIR not allowed) came out of stealth this week with plans to raise up to $100 million in an IPO. ... used new rules to file plans confidentially around Thanksgiving .... It has raised about $120 million since it was founded in 2004 [Cromwell Schubarth, Silicon Valley Business Journal, Feb 19, 14]
A sexy electric roadster is parked outside A123 Systems, a battery firm in Michigan. It is made by Fisker Automotive, a failed American firm acquired by Wanxiang, and it is meant to inspire. Jason Forcier, A123’s boss, says his firm would not be there except for Mr Lu’s dream about solving China’s pollution problem. Wanxiang bought the company at a bankruptcy auction in 2012 for about $250m and imposed strategic focus and cost discipline on the free-spending startup. Mr Forcier expects a profit this year. [The Economist, Sep 12]
MIT-based scientist Yet-Ming Chian [one of the founders of A123] publicly unveiled his latest startup, 24M (Cambridge, MA; no SBIR). ... uses a novel battery composition based on a semi-solid material that eliminates much of the bulk of conventional lithium-ion batteries—which are typically made up mostly of inactive, non-energy-storing materials—while dramatically increasing the energy density. Chiang and 24M CEO Throop Wilder also say that they can reduce the time needed to make a battery by 80 percent and the cost by 30 to 50 percent. ... has raised $50 million in funding along with a $4.5 million grant from the U.S. Department of Energy. It has strategic partnerships with the Japanese [Richard Martin, technologyreview.com, Jun 22, 15]
A123 Systems is suing Apple Inc. for what it alleges is an “aggressive campaign to poach employees.” The complaint names five employees that have either defected to Apple or appear to be in the process of recruiting others to join Apple. A123 believes Apple aims to build a competing battery business, partially relying on expertise from former A123 employees to help it succeed. Apple declined to comment. [Wall Street Journal, Feb 19, 15]
Japan's NEC Corp. announced that it had acquired a unit of battery maker A123 Systems, a division of Wanxiang Group based in Westborough, Mass., for $100 million. [Boston Business Jiurnall, Mar 25, 14]
A123 Energy Solutions (Westborough, MA; lots of SBIR as A123 Systems), a division of (Chinese) Wanxiang Group, said that a major grid battery project in Spain has been commissioned. [Kyle Alspach, Boston Business Journal, Jan 13, 14]
Three months after bankrupt battery maker A123 Systems was cleared for sale to a Chinese firm, the Waltham-based company has announced a plan to use its remaining assets to help foster a new generation of energy-storage startups. Now a wholly owned subsidiary of Wanxiang America Corporation — the U.S. arm of Chinese auto parts maker Wanxiang — A123 said it has launched a new technology incubation division, dubbed A123 Venture Technologies. [Kyle Alspach, Boston Business Journal, May 1, 13]
What follows A123? changing the company’s name to B456 Systems [Patricia Resende, Boston Business Journal, Mar 29, 13]
China's largest auto parts maker won U.S. government approval to buy A123 Systems, a maker of electric car batteries, despite warnings by some lawmakers that the deal would transfer sensitive technology developed with U.S. government money. [San Jose Mercury, Jan 29, 13]
Chinese-owned auto-parts manufacturer Wanxiang America won the bidding for A123 Systems the government-backed battery maker that has yet to turn a profit, at a bankruptcy auction that ended early Saturday morning. Wanxiang's winning bid of $256.6 million topped a combined offer from Milwaukee-based auto-parts manufacturer Johnson Controls and electronics maker NEC of Japan, the company said .... At least two dozen members of Congress have written to CFIUS warning that a sale to Wanxiang requires careful scrutiny. A123 has a number of contracts to provide high-power batteries and other services to the U.S. military. [Patrick Fitzgerald, Wall Street Journal, Dec 10, 12]
Fingers pointing and waggingA bankrupt battery manufacturer that was a cornerstone of President Obama’s effort to make the United States a global leader in clean-energy technology could end up in the hands of a Chinese company when it goes on the auction block Thursday. Congressional Republicans call the company, A123 Systems, which received $133 million in federal stimulus grants, a textbook case of how the Obama administration wasted taxpayer money trying to nurture new industries. Administration officials say the stimulus money was used to build a new manufacturing facility in Michigan that could remain open under new owners, even if they turn out to be foreign. [Washington Post, Dec 6, 12] Sensible people should ask what the Michigan Republicans thought when the administration sent the big money to Michigan.
Bidding war for a dead battery. Lawyers for A123 System ’s one-time Chinese partner appeared in bankruptcy court Thursday to reaffirm Wanxiang Groups’ interest in buying the Waltham battery company, potentially setting up a bidding war for the firm. [Erin Ailworth, Boston Globe, Oct 19, 12]
Out of volts. A123 Systems filed for Chapter 11 bankruptcy .... said it will sell off its automotive business assets to Johnson Controls in a deal valued at $125 million. The agreement comes just two months after A123 said it struck a deal with China-based auto parts maker Wanxiang Group to provide the battery maker with $465 million. ... “We determined not to move forward with the previously announced Wanxiang agreement as a result of unanticipated and significant challenges to its completion, Said CEO Vieau [Patricia Resende, Mass High Tech, Oct 16, 12] received nearly $250 million in federal-government grants and $358 million in start-up funding [Wall Street Journal, Oct 17].
A123 Systems has been warned that the struggling firm’s low share price could get it removed from the Nasdaq stock market or moved to a smaller exchange, the company said in a regulatory filing [Erin Ailworth, Boston Globe, Aug 22, 12]
A123 Systems will receive a $25 million injection after signing a binding agreement with a Chinese conglomerate that could ultimately to invest up to $465 million in the struggling battery maker and gain control of the firm, the companies said [Erin Ailworth, Boston Globe, Aug 16, 12]
A Chinese firm will invest up to $450 million to stabilize battery maker A123 Systems, the company announced ... Wanxiang Group Corp. is China's largest automotive components maker and one of the country's largest non-government-owned companies, according to the news release ... The announcement came hours after Boston battery tech competitor Boston-Power announced a deal with state-owned Beijing Automotive Industry Holding to supply parts for a new electric vehicle the company is making. [Galen Moore, Boston Business Journal, Aug 8, 12]
A123 Systems announced an agreement with BAE Systems to supply the company with additional battery packs for a propulsion system designed for city bus systems around the world. A123 has been supplying BAE with battery packs for about five years. Currently, about 3,000 buses using BAE’s propulsion system are in operation in various cities around the world [Chris Reidy, Boston Globe, Jul 19, 12]
A123 Systems that is struggling to stay in business, said that it plans to sell stock and warrants to raise about $9 million in proceeds after expenses. [AP, Jul 6, 12]
Mid-Continent Instrument Co. said that it has signed a distribution and supply agreement with A123 Systems Inc. under which Mid-Continent will offer A123’s advanced Nanophosphate lithium-ion battery technology for aviation applications. With operations in Kansas, Mid-Continent manufactures and repairs aircraft instruments, avionics, and power solutions for the general aviation industry. [Chris Reidy, Boston Globe, Jun 27, 12]
A123 up 52% [Jun 12, 12] said it has developed a new technology that allows lithium ion batteries to function in extreme temperatures, eliminating the need for separate heating and cooling systems and potentially making electric vehicles (EVs) cheaper. [Reuters]
A123 Systems has raised $50 million in funding, according to [SEC] filing .... after two lawsuits were filed against A123 Systems over its recall of defective battery packs, which the company said could cause electric vehicle batteries to fail prematurely. [Patricia Resende, Mass High Tech, Jun 7, 12]
A123 Systems fell the most in more than three months after saying it expects “significant” losses and is pursuing options to raise cash. [Bloomberg News, May 31, 12]
A123 Systems supported by grants from the Obama administration, reported a significant loss and drop in revenue as a result of quality problems and slower-than-expected demand for electric cars.The company also said it plans to raise $50 million through a private offering of convertible notes [Wall Street Journal, May 14, 12]
A123 Systems rose the most in three weeks after the US Army introduced a prototype vehicle that uses its products. [Bloomberg News, Apr 27, 12]
A123 fell 12%; said it will recall defective battery packs developed for auto makers that were made at its Livonia, Mich., plant. [Wall Street Journal, Mar 26, 12]
A123 Systems
said that it will supply
its battery packs
to Tata Motors, a large automaker in India. Tata plans to use A123’s
battery packs in Tata’s hybrid electric systems for commercial vehicles
such as city buses. [Chris Reidy, Boston Globe, Mar 1, 21]
A123 bought a South Korean manufacturer as a way to begin developing the expertise it needed to make the flat cells required for electric-car batteries. When A123 decided it needed to be closer to its potential automotive customers in Detroit, it cloned the Korean plant in Livonia, Michigan, and the Chinese factory a few miles away in Romulus, aided by a $249 million grant from the federal government. As a result of this strategy, A123 was able to become a major manufacturer in a remarkably short time, building the Livonia plant in just over a year and the Romulus plant in nine months. [David Rotman, Technology Review, J/F12]
A123 Systems said it found a “potential safety issue” in batteries it supplies to Fisker Automotive Inc. A123, which also sells batteries to automakers such as General Motors Co. and Daimler AG, said hose clamps that are part of the internal cooling system of its batteries supplied to Fisker were “misaligned” and may cause coolant to leak. Such a leak could lead to an electrical short circuit. [Craig Trudell, Bloomberg, Dec 23, 11]
Global competition. Over the past few years, domestic companies have entered a global competition to supply the advanced batteries that power electric vehicles. The start-ups came into the game with big backers and high hopes behind them: Venture capitalists saw a booming market ahead, and Washington saw a chance to spur a domestic green-manufacturing industry. So far, the results have been disappointing. Some high-profile battery makers have stumbled, burdened by high manufacturing costs, strong competition from Asian rivals and a slower-than-expected rollout of electric vehicles. Now the companies are responding by cutting costs, scaling back production and trying to tap other markets, such as large-scale storage for the electricity grid. ... Another prominent U.S. battery maker, A123 Systems Inc., has had to scale back production plans because one of its biggest customers, Fisker Automotive Holdings Inc., delayed battery purchases. A123 also missed out on some big contracts. The company lost a bid to provide batteries for General Motors Corp.'s Chevrolet Volt plug-in electric vehicle to LG Chem Ltd. of South Korea. Meanwhile, a joint venture between South Korea's Samsung SDI Co., part of Samsung Group, and Germany's Robert Bosch GmbH pushed A123 out of the bidding for a Chrysler Group LLC vehicle program. [Wall Street Journal, Dec 5, 11]
A123 Systems up 14% [Nov 30, 11]
A123 Systems up 11% [Nov 9, 11] has formed a licensing partnership with Japanese industrial equipment manufacturer IHI Corp., which will make IHI the sole provider of A123 battery systems in Japan’s transportation market. The deal will bring a $25 million payment from IHI to A123, the companies reported in a news release [Michelle Lang, Mass High Tech, Nov 9, 11]
A123 Systems down 10% [Nov 4, 11]
A123 Systems up 11% [Oct 27, 11]
A123 Systems up 27% [Oct 12, 11] will supply battery packs for the Chevrolet Spark EV mini-car, which will be sold in limited quantities in select US and global markets starting in 2013, General Motors Corp. said. [Chris Reidy, Boston Globe, Oct 12]
A123 Systems up 16% [Oct 4, 11]
A123 Systems down 12% [Oct 3, 11]
A123 up 15% [Sep 7, 11]
A123 Systems down 10% [Aug 12, 11]
A123 Systems up 45% [Aug 11, 11] after a new contract with General Motorsto supply battery technology for GM as it expands production of electric vehicles.
[CNBC, Aug 11]A123 Systems up 12% [Aug 9, 11]
A123 Systems down 23% [Aug 8, 11]
A123 Systems down 12% [Aug 4, 11]
A123 Systems up 11% [Jun 13, 11]
A123 Systems down 10% [Jun 8, 11] when the company announced it had received an order for 24,000 electric vehicles from Wuxi Hao Jie Vehicle. [Motley Fool.com, Jun 8]
A123 Systems up 11% [Apr 18, 11]
A123 down 13% [Mar 29, 11]
A123 down 11% [Mar 1, 11]
A123 Systems has been chosen to produce battery packs for a pure-electric vehicle by a “major” North American automaker, which is expected to hit the market in 2013, CEO David Vieau said ... said its annual net loss widened by 78 percent in 2010 as the company laid a foundation to support rapid growth in coming years. [Kyle Alspach, , Mass High Tech, Mar 1, 11]
A123 Systems said its energy storage technology will be used by a power grid facility in Northern Chile. [Boston Globe, Feb 7, 11]
A123 Systems said that its battery packs will be used in electric cars made by one of China’s largest automakers. The lithium-ion batteries will be used by Shanghai Automotive Industry Corp. in a new 2012 electric passenger car for the Chinese market [Mass High Tech, Nov 10, 10]
A123 Systems down 14% [Nov 10, 10]
Battery startup 24M Technologies (Wellesley, MA) has received $10 million in Series A financing and will share in $6 million of federal funding to develop its technology, the company announced today. The company’s technology is spun out of research at MIT and lithium ion battery company A123 Systems. [Kyle Alspach, Mass High Tech, Aug 16, 10]
A123 Systemsthat was awarded $249 million in federal stimulus funds a year ago, will not supply batteries for Chrysler’s electric Fiat 500. In an earnings call earlier this week, A123 chief executive David Vieau said his company had withdrawn from a Chrysler production program after a rival vendor said it could provide batteries at below market cost. [Boston Globe, Aug 12, 10] Can't compete with below-cost vendor. When does predatory pricing law take effect?
A123 Systems down 18% [Aug 11, 10] said its net loss widened, to $34.2 million, in the second quarter as the company invested ahead of major projects in the automotive and electric grid sectors [Mass High Tech, Aug 11, 10]
A123 Systems up 14% [Jul 26, 10]
A123 Systems up 11% [May 26, 10]
ARPA-E Awards. The administration announced $106M in ARPA-E stimulus awards. Small biz winners: Ginkgo BioWorks (Boston, MA; one SBIR) $6M primary; OPX Biotech (no SBIR) $6M primary; Logos Tech (Arlington, VA; $2M SBIR) secondary; Sion Power (Tucson, AZ; $250K SBIR) $5M primary; ReVolt Tech (no SBIR) $5M primary; PolyPlus Battery (Berkeley, CA; one SBIR) $5M; Pellion Tech (no SBIR) $3.2M primary; A123 Systems secondary, twice; Planar Energy Devices (no SBIR) $4M; Maxpower (Harleysville, PA; $9M SBIR) secondary; NanoLab (Newton, MA; $5M SBIR) secondary; Codexis (no SBIR) $4.6M; Nexant (no SBIR) secondary.
A123 Systems up 11% [May 14, 10]
A123 Systems down 11% [May 6, 10]
Subsidy. Massachusetts is giving A123 Systems a $5 million forgivable loan in return for creating 250 jobs and expanding operations for making large batteries that connect to the electricity grid. [Boston Globe, Apr 22, 10] Companies with jobs exploit inter-state competition to pull in government subsidies.
A123 Systemsis still producing on a small scale but appears to be positioned well in both the U.S. and Asia. Although it has great potential, A123 has to wait for the production of electric cars and hybrids to really rev up in the next few years. And while it is one of the few U.S. battery companies already in Asia and vying for its vast market, it must battle regional heavyweights with years of experience in making batteries. [Cassandra Sweet, Wall Street Journal, Mar 24, 10]
Companies to Watch in personalized medicine. Affymetrix, Life Tech, Illumina, Helicos Biosciences, Metabolon. Among the fifty most innovative: A123 Systems, American Superconductor, Alnylam, Illumina, iRobot, Novomer, BIND Biosciences. [MIT Tech Review, M/A10]
A123 Systemswill be making its lithium ion battery systems for electric vehicles for truck company Navistar International Corp. under a new deal that will provide the batteries to a joint venture between Illinois-based Navistar and Japanese company Modec Inc. [Mass High Tech, Mar 11, 10]
A123 Systems said it is expanding capacity at its facility in Michigan and also announced a battery supply agreement with Fisker Automotive, a new American automaker building premium green vehicles. [Boston Globe, Jan 14, 10]
Army's venture venture. The Army's VC (OnPoint Tech) current investment portfolio : A123 Systems (Boston, MA; $750K SBIR, IPO 2009) advanced Lithium-Ion based cells for rechargeable battery packs; Atraverda (UK) advanced bi-polar battery electrodes for rechargeable batteries; Integrated Fuel Cell Technologies (Burlington MA; no SBIR) next generation fuel cell systems for portable devices; Nanosolar (Palo Alto, CA; $1.7M SBIR) thin-film solar technology for roll-to-roll printing of solar cells on flexible substrates, PowerGenix (San Diego, CA; no SBIR) next-generation rechargeable batteries; Power Precise (Herndon, VA; no SBIR) a fabless semiconductor company specializing in battery management devices; Ultra Cell (Livermore, CA; no SBIR) integrated fuel cell systems; Zinc Matrix Power (Santa Barbara, CA; no SBIR) high-performance rechargeable alkaline battery technology for commercial and military markets; Akermin (St Louis, MO; no SBIR) portable fuel cells based on its proprietary “Stabilized Enzyme Biofuel Cell” SEBC™ technology; Superprotonic (Pasadena CA; $200K SBIR) solid acid fuel cell. [defense-ventures.com] No surprise that a VC, even one doing it for the government, sees tech opportunity much different than does Army SBIR. I note that the three outside trustees (of five trustees) of OnPoint are a DOD political appointee, and entrepreneur/attorney, and Paul Gompers from Harvard Business School who with Josh Lerner publish a lot of venture research. Lerner did a lot of SBIR study until, I presume, he gave up on SBIR's ever being anything but a political handout.
A123 SystemsRomelke caseand General Motors Co. partner SAIC Motor Corp. said that they plan a joint venture in China to supply batteries for electric and hybrid vehicles. [AP, Dec 17, 09]
A123 Systems up 18% [Nov 24, 09]
Factories Cost. Not even three months after it netted $249 million in stimulus dollars to build a manufacturing facility in Michigan, A123Systems is finalizing a deal with the U.S. Department of Energy for another $250 million, this time in loans for that facility’s construction, according to a report from Reuters. [Mass High Tech, Oct 22, 09]
A123 Systems down 10% [Oct 5, 09]
A123 Systems up 14% [Oct 2, 09]
Private companies to watch on electricity as picked by MIT Tech Review (Sep/Oct09): Nanosolar ($1.7M SBIR) founded 2002, raised $400M; A123 Systems IPO Sep 24; Brightsource Energy; Tendril; 1366 Technologies; Deepwater Wind; Solyndra; Silver Spring Networks; AltaRock; Stirling Energy Systems.
A123Systems went public at $13.50 to collect $378 million; stock trades as AONE. [Mass High Tech, Sep 24, 09] First day trading ended up 50%.
A123 Systemshopes to raise some $225 million through an IPO the week of Sept. 21. The event, the first venture-backed cleantech company to go public this year [Mass High Tech, Sep 18, 09]
A123 Systemsappears to be on its way to filing an [IPO], given the company’s move today to set terms of the offering. [Mass High Tech, Sep 9, 09]
Money Talks. A post on Scott Kirsner's Innovation Economy blog on Boston.com notes that A123Systems spent far more [$500K] on lobbying than Boston-Power did [$30K]. [Boston Globe, Aug, 7, 09] Boston-Power apparently still could win future federal funding. It is in the running for a $100 million grant from the Department of Defense, to be announced later this year. [Innovation Economy blog]
A123Systemsyesterday was awarded $249 million in federal stimulus funds, which the company said will go to build factories to manufacture high-tech lithium-ion batteries. A123 previously received $100 million in economic incentives from the Michigan Economic Development Corporation to build a factory in Livonia, Mich [Boston Globe, Aug 6, 09]
The Obama administration plans to announce Wednesday the winners of $1.2 billion in federal stimulus funds for makers of advanced automotive batteries, part of an effort to make sure that electric cars sold in the U.S. run on American-made power sources. One of the winners in a competition that drew applications from more than 100 companies is A123 Systems [Wall Street Journal, Aug 5, 09]
In the interstate competition for federal battery money, Michigan is giving as much as $400 million in state support for four companies: Johnson Controls-Saft Advanced Power Solutions LLC, LG Chem-Compact Power Inc., KD Advanced Battery Group LLC and A123 Systems ... DOE said 122 companies submitted applications in May seeking to share $2 billion in stimulus funds that were earmarked for advanced-battery efforts. The DOE said it will divide $1.2 billion of that sum among seven or eight manufacturing companies, part of an effort to develop quickly a U.S. capability to produce millions of batteries for electric cars [Rebecca Smith, Wall Street Journal, Jul 9, 09]
A123Systems, that just yesterday said it had raised $69 million in its latest financing round, announced today that it has secured more than $100 million in refundable tax credits from the state of Michigan. [Boston Globe, Apr 14]
Chrysler chose A123 Systems[for batteries] in part because the company was looking for a supplier based in the United States, says Lou Rhodes, the vice president of advanced vehicle engineering at Chrysler. A123 is based in Watertown, MA, and is building factories in Michigan. The company's battery cells met Chrysler's performance and safety specifications, and the company was developing battery modules that could be easily adapted to fit different vehicles. This was important, Rhodes says, because the automaker plans to start selling several different electric vehicles at around the same time. [Kevin Bullis, MIT Tech Review, Apr 10]
Chrysler says A123Systems will supply the lithium-ion batteries for the company's extended-range gas-electric cars and its all-electric cars. [Boston Globe, Apr 7, 09]
A123 Systems announced a $15 million investment from GE Energy Financial Services and GE Capital Equity to expand the company’s lithium ion battery manufacturing and smart grid capabilities in the U.S. The investment brings GE’s total of seven funding events in A123 to about $70 million [Mass High Tech, Apr 13, 09]
A123Systems said it is seeking $1.84 billion in direct federal loans ... from DOE's Advanced Technology Vehicles Manufacturing Incentive Program (love those multi-syllables) ... to support the construction of new world-class lithium ion battery manufacturing facilities in the United States, with the first construction location in southeast Michigan, the company said in a press release. [Chris Reidy, Boston Globe, Jan 7, 09]
General Electric invested an additional $30 million in A123Systems, a maker of lithium-ion batteries that aims to power plug-in cars from General Motors and Chrysler. The investment raises GE's stake to 9 percent, making it the start-up's biggest cash investor. [Washington Post, Oct 23, 08]
A123 Systems (Watertown, MA; $750K SBIR) filed for IPO. A radically modified version of the lithium-ion batteries used in portable electronics, the technology could jump-start the long-sputtering electric-vehicle market, which today represents a tiny fraction of 1 percent of vehicle sales in the United States. A123 Systems's batteries in particular have attracted the interest of General Motors, which is testing them as a way to power the Volt, an electric car with a gasoline generator; the vehicle is expected to go into mass production as early as 2010. [MIT Tech Review, Apr 30, 08]
A123 Systems publicly launched its Hymotion product line, which can convert Toyota Prius hybrid vehicles into 100 mpg, electric-powered plug-in hybrids to consumers. [Mass High Tech, Apr 29
Of the 15 game-changing startups likely to upend existing industries - and spawn new entrepreneurial opportunities, two used SBIR - Cree and A123 Systems. Business 2.0 also named One Laptop Per Child, Desktop Factory, Renewable Energy Group, Zink, Vanu, Bloom Energy, PatientstLikeMe, Virgin Charter, MFG.com, Zipcar, Expensr, Raydiance,and Blinkx.
A123 Systems (Watertown, MA) Inc. has cut a new deal with a Norwegian electric car manufacturer that puts its nanophosphate power plants at the heart of a five-seat "crossover" style vehicle. [Mass High Tech, Mar 6, 08]
Nanotech battery maker A123Systems has been granted a new patent for its "nanophosphate" lithium ion batteries [Mass High Tech, Mar 4, 08]
A123Systems, which makes nanotechnology-based lithium-ion batteries, has completed a $30 million round of funding from GE Energy Financial Services, bringing the total raised by the company to $132 million. [Mass High Tech, Oct 24]
A123Systems has cut a new deal to supply nanophosphate lithium ion battery technology to Cessna Aircraft. [Mass High Tech, Sep 19, 07]
A123Systems (Watertown, MA) reports that, starting in early 2008, BAE Systems plans to offer A123Systems' lithium ion battery technology as part of its HybriDrive propulsion system, available on the DaimlerChrysler Orion VII hybrid transit bus. [Mass High Tech, May 17]
A123Systems (Watertown, MA; one Phase 2 SBIR) claims a powerful, safe, long-lived battery. “The problem came down to usability,” said Nick Zelenski, G.M.’s chief vehicle engineer. “You had to plan your life around when you were going to charge the EV1.” ... When Professor Chiang and two others founded the company in 2002, it was devoted to a radical business proposition: it hoped to develop a technique where component materials would “self assemble” into a practical lithium battery. ... Nice idea, too bad. By late 2003, the company had abandoned self-assembly for another, less alchemical but still dramatic technology. In place of cobalt oxide, it used a commonplace substance, iron phosphate, but assembled it in a novel, nano-structure .... [It] has raised more than $102 M from a variety of investors and a deal with GM to develop a battery for a new GM hybrid model [Jason Pontin, New York Times, Mar 11]
A4 Pharmaup 22% [Apr 23, 19]
Aadi Bioscience (Pacific Palisades, CA; SBIR), a clinical-stage biotechnology company announced the finish of a $23 million series A funding round [May 8, 81]... developing the a potentially best-in-class mTOR inhibitor for targeted patient populations in oncology and cardiovascular diseases. [crunchbase..com]
Fifteen university research teams from Maryland will receive a total of $4.1 million to work with local companies to turn their research into products that could one day be sold on the commercial market. .... MIPS will contribute $1.8 million and private companies will contribute $2.8 million. The companies: A&G Pharmaceutical (Columbia, MD; no SBIR), Rehabtics LLC (Baltimore, MD; no SBIR) High Impact Environmental (Church Hill, MD; no SBIR), Birich Technologies (Towson, MD; no SBIR), Earth Networks (Germantown, MD; no SBIR), Fiberight (Halethorpe, MD; no SBIR), CoolCAD Electronics (College Park,MD $1.6M SBIR), XChanger Companies (Annapolis, MD; no SBIR), Remedium Technologies (College Park, MD; no SBIR), Pothole Pros LLC (Waldorf, MD; no SBIR), Hoopers Island Oyster Aquaculture (Fishers Creek, MD; no SBIR), Metompkin Seafood (Crisfield, MD; no SBIR) GreatGrow Maryland LLC (Rock Hall, MD; no SBIR), vCalc (Hagerstown, MD; SBIR), Shore Thing Shellfish (Tall Timbers, MD; no SBIR). ($114,094) [Sarah Gantz, Baltimore Business Journal, Feb 26, 14]
Aastrom Biosciences up 15% [Jan 10, 11]
Aastrom Biosciences down 23% [Dec 10, 10]
Aastrom Biosciences up 12% [Dec 6, 10]
Aastrom Biosciences down 16% [Nov 15, 10]
Aastrom Biosciences up 13% [Nov 9, 10]
Aastrom Bioscience, a quite volatile stock up 12% [Oct 30,06]
A massive U.S. Air Force contract has been awarded to a group of five small businesses that will share in the $851 million worth of work, according to Washington Technology ... sharing the contract: Abacus Technology (Chevy Chase, MD); EIS (Vienna, VA); Odyssey Systems Consulting Group(Wakefield, MA); P3I (Hopkinton, MA); and SpectrumS4 (Burlington, MA). [Dayton Business Journal, Nov 1, 12] No SBIR to any.
every commercial revolution is born out of pain and controversy. Abaxis (no SBIR) has often been a clumsy midwife to its own baby. For 18 months the company missed out on 100 to 200 unit sales per quarter because it couldn't fill orders; one-third of its machines had defective components and were returned. Salesmen had good leads but were distracted dealing with unhappy customers. ... Piling promise on top of unfulfilled promise, Abaxis has spent $100 million to develop its exceptional machine. Lawsuits, firings, cash shortages and operational mishaps ... founded in 1989 by a trio of ambitious scientists ... a machine that could take a drop of blood and within a few minutes give readings on 80 tests used by physicians. ... Entrepreneur of the Year CEO Severson thinks the worst is behind. His aim is to double earnings per share over the next couple of years and move closer to a 10% slice of the market for blood chemistry. [Forbes, Oct 29]
Abcombi Biosciences (Buffalo, NY; no SBIR, U Buffalo spinoff) has been accepted into JLABS @ Toronto, a prestigious new biomedical research incubator spearheaded by Johnson & Johnson [wnypapers.com, May 12, 16]
Abcombi Sciences (Buffalo, NY; no SBIR, founded 2015 by PhD Candidate Charles Jones) is licensing UB-created biotechnology to develop products that enhance vaccine efficacy and global accessibility. [buffalo.edu, Dec 19, 15]
Abcuro (Newton, MA; one , a biotech firm focused on autoimmune diseases and cancer, closed a $42M Series A-1 round [BostInno, Jan 7, 21]
Abeona Thera down 18% [Nov 12, 18]
A biotechnology company seeking to bring to market a genetic therapy from Nationwide Children’s Hospital has proposed a Cleveland headquarters and research lab after merging with a Texas company. ... Abeona Therapeutics ; no SBIR) said it would create 20 new jobs in three years in Cleveland – averaging $120,000 annual pay – under an incentive approved Monday by the Ohio Tax Credit Authority ... went public in May when it was acquired by Plasmatech Biopharmaceuticals (formerly Access Pharmaceuticals, Dallas, TX; no SBIR) with the combined company keeping Abeona’s name. It has raised a total of $40 million from investors and acquisition proceeds [Carrie Ghose,Columbus Business First, Jul 27, 15]
AbGenomics International (Los Altos, CA; no SBIR) disclosed that it raised about $8 million in new funding to be used for working capital in its efforts to develop drugs to treat autoimmune diseases and cancer. .... previously raised $52 million since it was founded in 2000. In addition to its Los Altos office, it has operations in Taiwan and the Netherlands. [Cromwell Schubarth, Silicon Valley Business Journal, Jun 10, 13]
Medical device company Abilitech Medical (Minneapolis, MN; $240K SBIR) won the Minnesota Cup’s Grand Prize on Monday night, securing $50,000 to grow its business. Abilitech landed an additional $25,000 as the competition’ top women-led startup. Prior to Monday night’s finale, Abilitech received $30,000 for winning the Cup’s Life Sciences/Health IT division. This brings the company’s total MN Cup winnings to more than $100,000. Abilitech is creating a device that helps restore mobility to people with upper-limb and neuromuscular conditions. The wearable device fits to the arm, and like a vehicle’s power steering, requires a small percentage of power from the patient to enable a functional range of motion. Abilitech says the device itself is lightweight, easy to use and comfortable. [Maddy Kennedy, MinneInno, Oct 15, 2019]
Johnson & Johnson, the world’s largest, most diversified healthcare products company, and Abiomed (Danvers, MA; $17M SBIR), a world leader in breakthrough heart, lung and kidney support technologies, today announced that they have entered into a definitive agreement under which Johnson & Johnson will acquire through a tender offer all outstanding shares of Abiomed, for an upfront payment of $380.00 per share in cash, corresponding to an enterprise value of approximately $16.6 billion which includes cash acquired. [joint companies press release, Nov 1, 2022]
Abiomed (Danvers, MA; $17M SBIR) claimed it doubled its revenue over five years. [Boston Business Journal, Sep 26, 2022]
Abiomed (Danvers, MA; $16M SBIR) announced it has acquired Breethe, developer of an extracorporeal membrane oxygenation system, in an effort to better support patients with cardiogenic shock or other conditions which produce insufficient oxygen to the lungs. [healio.com, May 2, 20]
Abiomed (Danvers, MA; $17M SBIR) down 20% [Nov 18, 19]
Abiomed (Danvers, MA; $17M SBIR) down 26% [Aug 1,19] after the company reported mixed quarterly results and lowered full-year guidance.[Yahoo Finance, Aug 1, 19]
Abiomed down 13% [Feb 8, 16]
Abiomed down 11% [Feb 5, 16]
Abiomed (Danvers, MA; $15M SBIR, market cap $4B) down 29% [Oct 29, 15] after announcing quarterly results
Abiomed (Danvers, MA; $15M SBIR) up 17% [Aug 4,15] Announces Q1 FY 2016 Revenue of $73.4Million, Up 50% Over Prior Year [company press release]
Abiomed up 16% [May 5,15]
Abiomed (Danvers,MA; $15M SBIR) up 18% [Mar 24,15]
Abiomed up 29% [Jan 28, 15] top percentage gainer
Medical device maker Abiomed up ??% [Jan 27, 15] raised its full-year revenue forecast and said the [FDA] had approved its heart pump, sending its stock up about 30 percent in extended trading. [Reuters, Jan 17, 15]
Abiomed ($14.5M SBIR) up 24% [Oct 30, 14] on strong quarter revenue
Abiomed (Danvers, MA; $14M SBIR) down 10% [Mar 13, 14]
Abiomed up 11% [Oct 31, 13]
Abiomed down 12% [Sep 23, 13]
Abiomed down 31% [Nov 1, 12]after announcing that the US Attorney’s Office was investigating the company’s marketing and labeling of the Impella 2.5 circulatory support device. [Larry Huston, Forbes, Nov 1, 12]
Abiomedup 10% [Sep 7, 12]
ABIOMED up 22% [Nov 3, 11]
ABIOMED up 10% [Oct 27, 11]
Abiomed up 10% [Oct 4, 11]
ABIOMED down 21% [Aug 4, 11]
Abiomed up 12% [Apr 15, 11]
The FDA has alerted health care providers to an ongoing recall launched by Abiomed for a device that supplies power to a blood pump used on failing hearts. [Mass High Tech, Mar 16, 10]
The man who underwent the first commercial implantation of a self-contained heart - a device made by a Danvers company - has died. Abiomed Inc. and Robert Wood Johnson University Hospital in Brunswick, N.J., yesterday acknowledged the death of the 76-year-old patient, who was not identified to protect his privacy. [Boston Globe, Sep 3, 09]
Abiomed up 11% [Apr 9, 09]
Abiomed up 10% [Mar 25, 09]
Abiomed down 11% [Mar 5, 09]
Abiomed down 12% [Mar 2, 09]
Abiomed down 23% [Feb 5, 09] biggest NASDAQ percentage decliner
Abiomed up 10% [Nov 24, 08]
Abiomed up 19% [Oct 30, 08]
Abiomed down 10% [Oct 27, 08]
Abiomed announced $20 million in shipments for fiscal year 2009 second-quarter shipments -- a record for the billed products and services. The amount signifies a 75 percent increase over fiscal year 2008’s second-quarter [Mass High Tech, Oct 17, 08]
Medical device maker Abiomed completed a public stock offering that raised nearly $42 million. [Boston Globe, Aug 22, 08]
Abiomedis expanding into Ireland, ... signed a long-term operating lease for a manufacturing facility in Athlone, Ireland, and expects its Impella blood pump production line to be operational there in about 18 months. [Elizabeth Campbell, Boston Globe, Jul 31, 08]
Abiomed reports it has agreed to convert a $5 million loan it received from World Heart Corp. into World Heart common stock -- part of World Heart’s plan to recapitalize itself for a total purchase price of at least $30 million. [Mass High Tech, Jun 24]
Abiomed jumped 16%, ...said the FDA approved its Impella 2.5 Cardiac Assist Device .... .threaded into the body through an artery to improve blood flow in the sickest of patients. ... about 150,000 patients in the U.S. each year are candidates for the pump, which will cost $20,000. [Wall Street Journal, Jun 3, 08]
Abiomed (Danvers, MA; much SBIR) said that it has gotten the approval of European Union regulators to market a power-pack (right) for one of its heart pumps in EU countries and countries that recognize EU approval. [Chris Reidy, Boston Globe, Mar 28]
Jewish Hospital in Louisville is citing the expense of the AbioCor implants as a reason for not partnering with the device's maker, Abiomed. [Boston Globe, Jan 25, 08]
FDA approved system upgrades for Abiomed’s AbioCor implantable replacement heart. The device replaces severely damaged hearts in patients who are not eligible for a transplant or other treatments. [AP, Jan 23]
Abiomed wins FDA OK for iPulse system. [Mass High Tech, Dec 19, 07]
Abiomed (Danvers MA) agreed to invest in World Heart Corp. through $5M convertible loans. [Mass High Tech, Dec 12, 07]
Abiomed up 12% [Aug 16,07]
OK for Canada which approved Abiomed's Impella devices for heart failure patients. [Jul 18, 07] Not yet OK for USA.
Abiomed up 11% [Mar 20, 07]
Abiomed plans to raise $60M+ in a public stock sale. [Mar 07]
Abiomed signed a $16M five-year distribution agreement with a Japanese distributor of cardiac assist devices to sell Abiomed's AB5000 and Impella products. [AP, Nov 13, 06]
complicated Leon relationship concerns Abiomed, . In 2005, Leon's incubator, Accelerated Technologies, sold a small company called Impella to Abiomed for $42.2 M in stock. Impella had invented a tiny pump that helps the heart do its job and can be implanted in minutes. Three versions of it are on sale in Europe, and the company is conducting clinical trials in the U.S. Leon received stock then worth nearly $1 million, plus the opportunity to receive a small share of up to $16.75 million in milestone payments, based in part on Abiomed's regulatory approvals and units sold. Six months later, Impella was featured in two live cases at TCT. At the same conference, Abiomed co-sponsored an evening event featuring doctors talking about heart pumps. Leon, who was the keynote speaker, noted briefly in the disclosure booklet and on a slide that preceded the presentation that he was a "major shareholder" of Impella-Abiomed. He retains the opportunity to collect milestone payments from the company. Abiomed CEO Michael Minogue says Leon's involvement isn't problematic. "He doesn't own that high a percentage of the company, and he's not involved in the trials," Minogue says. "What he has brought to the company is that he helped make the product more user-friendly." This year's TCT promises the event's first-ever panel on conflicts of interest.
Abiomed gap-opened down 10% on projection of lower than expected revenues. [Oct 13, 06] It has had at least 15 Phase 2 SBIRs over the two decades of SBIR and a volatile stock price (between 3 and 60, now 13) over the last decade. Its cardiovascular business is medical products to assist or replace the pumping function of the failing heart.
Ablative Solutions (Kalamazoo, MI; no SBIR, founded 2011) medical device company raised a $77 million Series D [Will Flanagan, MinnieInno, Feb 5, 19] offers an alternative to surgical renal denervation for treating hypertension; total prior funding $63M [crunchbase.com]
biotech firm Ablexis LLC (San Francisco, CA; no SBIR) announced a $12 million round of Series A funding [San Francisco Business Times, Jun 3, 10] ... to advance AlivaMab, its transgenic mouse method for discovering human therapeutic antibodies....Ablexis was formed in December and is based on technology from Aliva Biopharmaceuticals (Pasadena, CA; $200K SBIR), which now is a subsidiary of Ablexis. [Ron Leuty, [San Francisco Business Times, Jun 2, 10]
Eight Wisconsin biotech companies have been selected as winners of the BioForward 2013 Emerging Company Showcase: LLC (Greenfield, WI; no SBIR); Co-D Therapeutics (Madison, WI; no SBIR); Imbed Biosciences (Madison, WI; no SBIR) medical device company developing novel and patent-pending technologies for imbedding bioactive molecules in wound dressings and surgical implants [company website]; Insert MRI (no SBIR) developing a platform technology for encapsulating workflow 'apps' to interactively guide magnetic resonance (MR) image-guided surgical procedures [company website]; Microscopy Innovations (Marshfield, WI; no SBIR) New Capsule-based System for preparing Microscopy Specimens [company website]; Regenerative Medical Solutions (Chicago/Madison; no SBIR) develop a protocol to grow healthy and resilient pancreatic stem cells [company website]; Stealth Therapeutics (Madison, WI; no SBIR) less invasive medical devices [company website]; and XenoGen Biosystems ( Madison, WI; no SBIR) Mathematical Modeling and Computing for the Life Sciences [company website]. ... represent "a cross section of emerging companies in our industry sector that we feel are going to make an impact down the road," said Bryan Renk, BioForward's executive director. [Kathleen Gallagher, Milwaukee Journal Sentinel, Sep 4, 13]
Preclinical-stage biotech Abpro Therapeutics (Woburn, MA; no SBIR, founded 2004) filed a $69 million IPO [to] fund clinical trials of its lead antibody drugs for cancer and vascular eye disease due to start next year. [Amirah Al Idrus, Fierce Biotech, Apr 12,18] total funding $22M [crunchbase.com]
AbSci (Vancouver, WA; no SBIR), a global leader in biomanufacturing technologies, announced the completion of an over-subscribed $12 million Series C financing. .... will enable AbSci to expand its R&D and to scale up capacity in order to meet the growing demand from its large pharma and biosimilar partners. [company press release, May 30, 18] total funding $17M [crunchbase.com]
Absorbent Materials (Wooster, OH; no SBIR; 7 people) is looking for $2.4 million in funding. ... using organically modified chemicals called silanes, resulting in reactive, swelling glass materials. The materials are hydrophobic — repelled by water — but can absorb nearly any volatile organic compound, according to the company. [Mass High Tech, Aug 28, 09]
Citing a shrinking labor force and a growing worldwide demand for food, Abundant Robotics (Hayward, CA; no SBIR) is off to a good start in the apple-picking business. The company has designed intelligent robots capable of determining whether apples are ready to pick, day or night, and carefully picking them using a gentle vacuum technology rather than a standard claw- or hand-like mechanism. Abundant Robotics recently raised $10 million in an investment round led by GV (formerly Google Ventures), which will help the company develop robots that can harvest other foods. [cybertrend.com, Jun 1, 17]
GV (formerly Google Ventures) is leading a $10 million investment in Abundant Robotics (Hayward, CA; no SBIR), a company building apple-picking robots that could eventually be adapted to harvest other fruits. [Lora Kolodny, techcrunch.com, May 3, 17]
Juno Therapeutics focused on re-engaging the body's immune system to revolutionize the treatment of cancer, announced that it has acquired AbVitro (Boston, MA; no SBIR). The acquisition provides Juno with a leading next-generation single cell sequencing platform that will augment Juno’s capabilities to create best-in-class engineered T cells against a broad array of cancer targets. Juno and Celgene Corporation have agreed in principle to enter into an agreement to license Celgene a subset of the acquired technology and to grant Celgene options to certain related potential product rights emanating from the acquired technology. [company press release, Jan 11, 16]
Juno Therapeutics has agreed to acquire AbVitro (Boston, MA; no SBIR) biotechnology firm for more than $120 million in cash and stock, the company announced. Juno said the deal brings “a leading next-generation single cell sequencing platform that will augment Juno’s capabilities to create best-in-class engineered T cells against a broad array of cancer targets.” [Seattle Times, Jan 11, 16]
AbVitro (Boston, MA, no SBIR,founded in 2010) received $745,000 in equity out of a $3 million offering ... working on a next-generation antibody discovery platform [Don Seiffert, Mass High Tech, Apr 2, 12]
ACADIA Pharmaceuticals (San Diego, CA; $1.7M SBIR) up 34% [Dec 13, 2023] announced that the U.S. District Court for the District of Delaware has issued a Claim Construction Order in favor of Acadia regarding its ‘721 formulation patent for NUPLAZID® (pimavanserin), Acadia’s drug for the treatment of Parkinson’s Disease Psychosis. In today’s Order, the Court ruled in favor of Acadia on all of the disputed claim construction points. [company press release, Dec 13, 2023]
ACADIA Pharmaceuticals (San Diego, CA; $1.5M SBIR) up 25% [Jul 14, 2023] Acquires Ex-North American Rights to Trofinetide and Global Rights to Neuren’s NNZ-2591 in Rett Syndrome and Fragile X Syndrome [company press release, Jul 13, 2023]
ACADIA Pharmaceuticals down 33% [Jun 21, 22]
ACADIA Pharmaceuticals (San Diego, CA; $1.6M SBIR) down 20% [Dec 21, 21] announced that it plans to resubmit its supplemental New Drug Application (sNDA) for pimavanserin for the treatment of hallucinations and delusions associated with dementia focused on Alzheimer's disease psychosis (ADP). Resubmission of the sNDA to [FDA] is planned for the first quarter of 2022. [company press release, Dec 21, 21]
ACADIA Pharmaceuticals down 17% [Apr 5, 21]
By 2050 output of cobalt, graphite and lithium, for instance, would have to be more than 450% higher than in 2018 to meet battery demand. [The Economist. Apr 3, 21]
ACADIA Pharmaceuticals down 45% [Mar 9, 21] with the news that the [FDA] had “identified deficiencies” in the company’s application to expand the label of its drug pimavanserin. [Josh Nathan-Kazis, Barron's, Mar 9, 21]
ACADIA Pharmaceuticals (San Diego, CA; $1.6M SBIR) announced the acquisition of CerSci Therapeutics (Ft Worth, TX; $2.2M SBIR), a clinical-stage biotechnology company with worldwide rights to a portfolio of novel compounds for neurological conditions, including non-opioid therapies for acute and chronic pain. ... ACADIA acquired all of the outstanding shares of CerSci for $52.5 million, primarily in ACADIA stock. CerSci shareholders may also receive up to $887 million in development, commercialization, and sales milestones in addition to tiered royalties in the mid-single digits based on annual net sales. [joint companies press release, Aug 25, 20]
ACADIA Pharma up 63% [Sep 9, 19] announced that its Phase 3 HARMONY study, a double-blind, placebo-controlled relapse prevention trial evaluating pimavanserin for the treatment of dementia-related psychosis, met its primary endpoint, demonstrating a highly statistically significant longer time to relapse of psychosis with pimavanserin compared to placebo in a planned interim efficacy analysis. [company press release, Sep 9, 19]
Acadia Pharma up 17% [Aug 1,19] reported that its revenue in the second quarter increased 46% year over year to $83.2 million, fueled by continued momentum for antipsychotic drug Nuplazid. This easily topped the consensus Wall Street estimate of a little over $72 million in revenue. [Yahoo Finance, Aug 1, 19]
Acadia Pharmaceuticals’ treatment for Parkinson’s disease-related psychosis failed a Phase 3 trial that was studying use of the drug for schizophrenia patients who haven’t fully responded to existing therapies. [Sarah de Crescenzo, xconomy.ccom, Jul 22, 19]
Acadia Pharma reported a [quarterly] net loss of $85.3 million. [company press release, May 1, 19]
ACADIA Pharma up 27% [Sep 20, 18] announced that the FDA has completed a postmarketing review and issued a clear statement reaffirming the positive benefit-risk profile of NUPLAZID (pimavanserin) for patients with Parkinson's disease psychosis. [company press release, Sep 20, 18]
Acadia Pharma up 11% [May 4, 18]
Acadia Pharma down 22% [Apr 25, 18]
ACADIA Pharma down 23% [Apr 9, 18]
ACADIA Pharma down 20% [Feb 28, 18]
ACADIA Pharma up 12% [Aug 9, 17]
ACADIA Pharma down 10% [May 10,17]
ACADIA Pharma up 12% [Dec 20, 16]
Acadia Pharma up 17% [Nov 8, 16]
ACADIA Pharmaceuticals focused on the development and commercialization of innovative medicines to address unmet medical needs in central nervous system disorders, announced that it intends to sell $200,000,000 of its common stock in an underwritten public offering. [company press release, Aug 8, 16]
ACADIA Pharma up 13% [Jun 6, 16]
Acadia Pharmaceuticals slumped after the biotech reported a wider-than-expected loss of 45 cents per share in the first quarter of 2016. [Bruce Bigelow, xconomy.com, May 6, 16]
The FDA said it has approved Acadia Pharma pimavanserin (Nuplazid), a treatment for psychosis associated with Parkinson’s disease. Acadia stumbled badly last year, [with] internal missteps that caused a delay in Acadia submitting its marketing application to the FDA. [Alex Lash, xconomy.com, Apr 29, 16]
ACADIA Pharma up 10% [Apr 6, 16]
ACADIA Pharma up 17% [Mar 28,16]
ACADIA Pharma down 11% [Mar 23,16]
Acadia Pharma down 14% [Jan 13, 16]
Acadia Pharma down 15% [Jan 6, 16] announced a secondary offering to raise $300M [Wall St Journal]
ACADIA Pharma down 12% [Nov 6, 15]
Acadia Pharma down 10% [Sep 21, 15]
Acadia Pharma down 13% [Aug 7, 15]
ACADIA Pharma down 22% [Mar 11, 15] as multiple law firms announce investigation of claims against the board of directors concerning possible violations of federal securities laws.
Acadia Pharma up 18% [Mar 10, 15]
Acadia Pharmaceuticals (one SBIR in Y2K) has become one of the most highly valued biomedical companies in San Diego largely on the promise of an experimental drug for psychosis. Next year, the 21-year-old company expects to begin delivering on that promise. Sometime in the first quarter of 2015, Acadia plans to submit a marketing application for its medication Nuplazid. The drug, also known by its generic name of pimavanserin, has successfully completed Phase 3 testing for Parkinson’s disease psychosis. It’s in Phase 2 clinical trials for schizophrenia and Alzheimer’s disease psychosis. [Bradley Fikes, utsandiego.com, Dec 29, 14]
Acadia Pharma up 11% [Oct 15, 14]
Acadia Pharmaceuticals plans to sell $150 million of stock in a secondary offering .... is in Phase 3 testing of pimavanserin, a drug for Parkinson's disease psychosis. [Bradley Fikes, utsandiego.com, Mar 3, 14]
ACADIA Pharma
up 17% [Feb 21,
14]
ACADIA Pharma up
12%
[Oct 24, 13] amid
general enthusiasm
for biomedical stocks [Mike Freeman, utsandiego.com, Oct
24, 13]
ACADIA Pharma up 16% [Oct 10, 13]
ACADIA Pharma down 15% [Oct 9, 13]
ACADIA Pharma down 15% [Oct 8, 13]
Acadia Pharmaceuticals shares are up 328 percent so far in 2013, more than quadrupling its value. This puts Acadia's market cap above $1.5 billion, rarified territory for a San Diego biomedical company. ... has received favorable clinical trial news about pimavanserin, its drug for Parkinson's disease psychosis. [Bradley Fikes, utsandiego.com, Jul 16, 13]
ACADIA Pharma up 10% [Jul 15, 13]
ACADIA Pharma up 15% [Jun 10, 13]
ACADIA Pharma up 13% [Jun 6, 13]
Acadia Pharmaceuticals said it has raised $115 million in gross proceeds from its secondary public offering. [Bradley Fikes, utsandiego.com, May 20, 13]
ACADIA Pharma up 64% [Apr 11, 13] announcement that it will not have to run a second late-stage trial of its drug pimavanserin represents a "major positive" for the stock, according to a Jefferies analyst
ACADIA Pharma up 10% [Mar 25, 13]
ACADIA Pharma up 24% [Mar 21, 13] after Positive Phase 3 results for Parkinson's psychosis drug .... holds worldwide rights to the drug. [Bradley Fikes, utsandiego.com, Mar 21]
ACADIA Pharma up 12% [Jan 14, 13]
Acadia pharmaceuticals is raising an expected $86.4 million from a private placement of company stock. [Bradley Fikes, utsandiego.com, Dec 13,12]
ACADIA Pharma up 13%[12/12/12]
ACADIA Pharma (one SBIR in Y2K) up 136% [Nov 27, 12] after the company’s experimental treatment helped Parkinson’s disease patients with psychosis in a study. [Bloomberg]
Acadia Pharmaceuticals focused on central nervous system disorders. ... says it is selling nearly 12.6 million shares expected to generate gross proceeds of $15 million. [signonsandiego, Jan 10, 11]
Acadia Pharma down 66% [Sep 1, 09] after the company said its drug candidate pimavanserin failed to meet key treatment goals in a late-stage study focusing on patients with Parkinson's disease psychosis. [AP, Sep 1]
Acadia Pharma up 16% [Aug 13, 09]
Acadia Pharna up 16% [Aug 10, 09]
Acadia Pharma up 15% [Aug 3, 09]
Acadia Pharma up 29% [Jul 27, 09]
Acadia Pharma up 31% [Jul 24, 09]
Cash-strapped Acadia Pharmaceuticals said yesterday that it will receive $30 million in upfront cash in a deal with a Canadian company to commercialize its experimental drug to treat Parkinson's disease psychosis. [Penni Crabtree, San Diego Union Tribune, May 5, 09]
Acadia Pharma up 130% [May 4, 09]
Acadia Pharma up 61% [Oct 13, 08]
Acadia Pharma up 16% [Sep 18, 08 ]
Acadia Pharma down 14% [Sep 17, 08]
Acadia Pharma up 14% [Sep 16, 08]
Acadia Pharmaceuticals were beaten down 43% after the company reported a complete failure of its Phase II-b trial of a schizophrenia drug. The study didn't meet any of its primary or secondary goals at two separate doses. [Wall Street Journal, Jun 17, 08]
Acadia Pharmaceuticals down 43% [Jun 16, 08]
ACADIA Pharmaceuticals down 12% [Feb 5, 08]
Acadia Pharmaceuticals up 11% [Jan 31, 08]
Acadia Pharmaceuticals down 11% on downgrade to Sell. [Nov 6, 07]
Acadia Pharmaceuticals up 12% on news of selling another tranche of shares. [Apr 3, 07]
The Trials Giveth, ... Acadia Pharmaceuticals doubled on good news from the trials of its schizophrenia drug. [Mar 19, 07]
Acambis (the two Cambridges; one Phase 1 SBIR)reports beginning clinical trials of its West Nile virus vaccine. [Mass High Tech, Mar 21]
startup Accel Diagnostics (Pittsburgh, PA; no SBIR) is making plans for a clinical trial by the end of the year for an at-home test that could help avoid hospitalizations for many people with heart disease. .... looking for funding for a disposable, credit-card size device that tests a blood sample for signs that a patient needs medical attention. The test is designed for people with congestive heart failure [Kris B. Mamula, Pittsburgh Business Times, May 17, 14]
Acceleron Pharma (CAMBRIDGE, MA; no SBIR)up 50% [Jan 28, 20] announced that the PULSAR Phase 2 trial of sotatercept met its primary and key secondary endpoints in patients with pulmonary arterial hypertension (PAH). [company press release, Jan 27, 20]
Acceleron Pharma is paying Fulcrum Therapeutics (no SBIR) $10 million up front to kick off a partnership aiming to identify small molecule drugs to treat pulmonary disease. [xconomy.com, Jan 3, 19]
A drug that Celgene and Acceleron Pharma developed to treat low red blood cell levels in patients who have a rare blood disorder now has regulatory clearance to enter the market. The FDA on Friday approved luspatercept (Rebloyzl) for patients who have beta thalassemia, an inherited disorder that leads to anemia, or low levels of oxygen-carrying red blood cells. [Frank Vinluan, xconomy.com, Nov 8, 19]
ACE-083, anexperimental drug from Acceleron Pharma failed a Phase 2 study in facioscapulohumeral muscular dystrophy. With the beta thalassemia drug luspatercept, Acceleron could notch its first drug approval next year. [Alex Lash, xconomy.com, Sep 19,19]
ACE-083, an experimental drug from Acceleron Pharma failed a Phase 2 study in facioscapulohumeral muscular dystrophy. With the beta thalassemia drug luspatercept, Acceleron could notch its first drug approval next year. [Alex Lash, xconomy.com, Sep 19,19]
A drug [luspatercept, as a treatment for beta-thalassemia] from Celgene and Acceleron Pharma (Cambridge, MA; no SBIR) has met the main goals of a late-stage test as a treatment for a rare blood disorder, the second set of positive results that the partners have released for the drug in as many weeks. [Frank Vinluan, xconomy.com, Jul 9, 18]
Acceleron Pharma (Cambridge MA; no SBIR, founded 2004, 139 employees) up 43% [Jun 28, 18] Celgene and Acceleron Pharma announced results from a phase III, randomized, double-blind, multi-center clinical study (MEDALIST). Luspatercept achieved a highly statistically significant improvement in the primary endpoint of red blood cell (RBC) transfusion independence of at least 8 consecutive weeks during the first 24 weeks compared to placebo. [company press release, Jun 28, 18] total funding $145M [crunchbase.com]
Acceleron Pharma up 13% [Apr 2, 14]
Acceleron Pharma down 11% [Nov 7, 13]
Acceleron Pharma down 14% [Oct 9, 13]
Acceleron Pharma up 10% [Oct 3, 13]
Acceleron Pharma said that the Food and Drug Administration granted orphan drug designation for ACE-536 as a potential treatment for two rare blood disorders. The disorders are beta-thalassemia and myelodysplastic syndromes, the company said in a press release. Orphan designation is granted to advance the evaluation and development of therapies for the treatment of rare diseases or conditions affecting fewer than 200,000 people in the US. [Boston Globe, Mar 26, 13]
The Wall Street Journal's third annual ranking of the top 50 venture-capital-backed companies shows a crop of contenders that overall are focused less on online consumers than in years past. .... Unlike in years past, none of the companies on this year's list are in the energy sector, underscoring the challenges faced by that industry. This year was also the first time that a health-care company didn't top the ranking. [Zoran Basich and Emily Maltby, Wall Street Journal, Sep 27] Companies with tech that might fit SBIR: 7. Glaukos (Laguna Hills, CA; $200K SBIRs) $126M; 8. NeuroPace (Mountain View, CA; no SBIR) $180M; 35. Achaogen (South San Francisco, CA; no SBIR) $103M; 48. Acceleron Pharma (Cambridge, MA; no SBIR) $307M. The other 46 took VC to reduce business risk, a job not appropriate for government technology subsidy.
Acceleron Pharma’s (no SBIR) development and commercialization collaboration with New Jersey partner Celgene continues to pay off in the form of funding for the Cambridge biomedical company. ... co-founded in 2004 by Christoph Westphal, life sciences-focused serial entrepreneur [Michelle Lang, , Mass High Tech, Dec 23, 11]
Acceleron Pharma said it has launched a Phase 1 clinical trial of its ACE-536 anemia treatment candidate, which will trigger a $7.5 million milestone payment from collaborator Celgene of New Jersey. [Lori Valigra, Mass High Tech, Sep 14, 11]
Acceleron Pharma and Celgene said today that they have entered into a joint development and commercialization agreement for a potential anemia treatment called ACE-536. As part of the agreement, New Jersey-based Celgene will make an upfront payment of $25 million to Acceleron, which is headquartered in Cambridge. Acceleron is eligible to receive development, regulatory, and commercial milestones of up to $217 million for the ACE-536 program. [Boston Globe, Aug 3, 11]
Acceleron Pharma told the state it cut 57 employees, or roughly 40 percent of its workforce, late last month. [Boston Globe, Nov 2, 10]
Acceleron Pharma (Cambridge, MA; no SBIR, founded 2004) has raised $8.4 million of a planned $11.5 million securities offering, according to [SEC filing] ... develops novel therapeutics that modulate the growth of cells and tissues, including muscle, bone, fat, red blood cells and the vasculature. ... raised $11 million in equity financing in December. The financing was preceded by a $31 million Series C round in 2007. [Mass High Tech, Jun 25, 10]
Acceleron Pharma (Cambridge, MA; no SBIR) has raised $8.4 million of a planned $11.5 million securities offering, according to [SEC filing] .... develops novel therapeutics that modulate the growth of cells and tissues, including muscle, bone, fat, red blood cells and the vasculature.... raised $11 million in equity financing in December. The financing was preceded by a $31 million Series C round in 2007 [Mass High Tech, Jun 23, 10]
Acceleron Pharma (Cambridge, MA; no SBIR) landed $10.9 million in equity financing, ... develops preclinical protein treatments to combat bone loss, grow blood vessels and block fat growth. ... co-founded in 2004 [Mass High Tech, Dec 16, 09]
Alkermes said it will invest $10 million to license the rights to a drug technology developed by Acceleron Pharma (Cambridge, MA; no SBIR), and also take an equity stake. [Boston Globe, Dec 4, 09]
Acceleron Pharma (Cambridge, MA; no SBIR) said that preliminary test results were encouraging for its drug candidate designed to help people with neuromuscular diseases such as muscular dystrophy and amyotrophic lateral sclerosis, or ALS. [Boston Globe, Sep 3, 09]
Acceleron Pharma (Cambridge, MA; no SBIR) said that it has signed a lease on a third facility in Cambridge, further expanding its laboratory and office space by an additional 19,700 square feet ... biopharmaceutical company focused on discovering, developing, manufacturing, and commercializing biotherapeutics that modulate the growth of bone, muscle, red blood cells, fat, and the vasculature to treat musculoskeletal, metabolic, and cancer-related diseases. ... "has grown by more than 50 percent in each year since the company was founded in 2004, and we expect this rate of growth to continue throughout 2009," company founder and chief executive John Knopf said in a statement. [Chris Reidy, Boston Globe, May 1, 09]
Accelrys (San Diego,CA; no SBIR) life sciences software company, said that it has completed the purchase of Symyx Technologies in an all-stock deal valued at about $180 million. [signonsandiego.com, Jul 1, 10]
life science software maker Accelrys (formerly Biosym Technologies; San Diego, CA; founded in 1984, $1.6M SBIR 1985-1991, employs about 750 people) has been sold for about $750 million to 3D software vendor Dassault Systèmes (France), the companies said [Bradley Fikes, utsandiego.com, Jan 31, 14] Sounds like a good case for SBIR that funds early technology development that the firm then takes to the capital markets for its future. This firm expanded, weaned itself from government support, grew handsomely, and expanded its reach by joining a global firm with more market power. Government's role, SBIR or other, should belimited to reducing the technical risk of the new technology to the level of a mere business risk, and then leave the company to the markets. It should not keep handing out SBIR contracts to the company for just ordinary government R&D, like it does for so many companies. It should not be SBIR's objective to provide employment for families nor save the company from bankruptcy nor keep a firm in its political locality. All those home-cooking objectives are mere political niceties.
Biotechnology companies in the United States are raising less cash than they have in a decade, in part because of the global economic crisis. The reductions have led to bankruptcies and threaten development of drugs based on biomedical breakthroughs. ... Twenty-five percent of the 370 public U.S. biotechnology companies have less than six months of cash, according to data compiled by the Biotechnology Industry Organization, a trade group in Washington. .... Among others, Peptimmune (Cambridge, MA; one SBIR), a 6-year-old firm, said it is struggling to pay for clinical trials of its multiple sclerosis drug. ... cut its staff more than half, to 22 people; moved to smaller offices to conserve the $6.5 million it has on hand; and is delaying research on drugs for Alzheimer's disease and Parkinson's disease, chief executive Thomas Mathers said. .... On Nov. 10, MicroIslet (San Diego, CA; $1.8M SBIR) developer of diabetes treatments, and Accentia BioPharmaceuticals (Tampa, FL; no SBIR) sought bankruptcy protection to reorganize, each citing an inability to raise money. [David Olmos and Rob Waters, Bloomberg News, Dec 1, 08]
Accent Therapeutics (Cambridge, MA; no SBIR), developing breakthrough treatments for cancer patients, announced today that it has completed a $63 million Series B financing [to] advance the development of Accent’s novel therapies targeting RNA-modifying proteins (RMPs), including its lead programs METTL3 and ADAR1, and to continue to expand its pipeline in the rich target space of RNA modification. [company press release, Apr 23, 20]
Accent Therapeutics (Cambridge, MA; no SBIR) announced a $40 million Series A financing [for] the earliest stages of drug discovery, and is betting on some really new science. Only in the last five years or so have scientists started learning the details of yet another method of gene regulation—chemical changes at the RNA level. RNA, in particular messenger RNA (mRNA), is important because these molecules are made based on the DNA code and provide the instructions for making proteins to the cell’s protein-making machinery [Corie Lok, xconomy.com, May 18, 18]
Accera (Boulder, CO; no SBIR), a leading CNS therapeutics company, announced results of the AC-1204 Phase 3 study for the treatment of mild-to-moderate Alzheimer’s disease. Patients treated with AC-1204 did not demonstrate a statistically significant difference at 26 weeks compared with patients treated with placebo. ... AC-1204 was shown to be safe and demonstrated high levels of tolerability with the most prevalent adverse event being only mild, transient gastrointestinal disturbance. [company press release, Feb 28, 17] The potential of the therapeutic approach has enabled Accera to pull in more than $150 million from backers including Nestlé, according to SEC filings. [Nick Paul Taylor, Fierce Biotech, Mar 1, 17]
A biotechnology company seeking to bring to market a genetic therapy from Nationwide Children’s Hospital has proposed a Cleveland headquarters and research lab after merging with a Texas company. ... Abeona Therapeutics (Cleveland, OH; no SBIR) said it would create 20 new jobs in three years in Cleveland – averaging $120,000 annual pay – under an incentive approved Monday by the Ohio Tax Credit Authority ... went public in May when it was acquired by Plasmatech Biopharmaceuticals (formerly Access Pharmaceuticals, Dallas, TX; no SBIR) with the combined company keeping Abeona’s name. It has raised a total of $40 million from investors and acquisition proceeds [Carrie Ghose,Columbus Business First, Jul 27, 15]
As major pharmaceuticals seek companies with a pipeline of promising drugs to augment their own depleting inventories, some pros bet that one target will be Access Pharmaceuticals ($200K SBIR), now at 2.85 a share. It hit a high of 17 in 2005. Its drug MuGard, approved by the FDA in 2007, treats oral mucositis, a debilitating side effect of chemotherapy and radiation treatment. It's now sold in Europe, with a global market potential of $5 billion, says Access. [Gene Marcial, Business Week, Oct 12, 09]
Access Scientific (San Diego, CA; no SBIR) which raised more than $2.6 million five months ago, has raised an additional $2 million, according to a regulatory filing yesterday. The company has begun the launch of its first new product, the “PICC Wand,” an all-in-one device intended to simplify the process of deploying a peripherally inserted central catheter line, a type of intravenous line that can remain in a patient for an extended period of time. [Bruce Bigelow, signonsandiego.com, Nov 24, 10]
Access Vascular (Bedford, MA; no SBIR, fouded 2015), a medical device company developing the next generation of intravenous devices from novel biomaterials designed to minimize the risk of bloodstream infection, catheter thrombosis, and vein trauma, announced $6M in new funding. [company press release, Sep 26, 19] prior funding $9M [crunchbase.com]
Accion Systems (Charlestown, MA; no SBIR, founded 2014) developer of satellite propulsion systems for the space industry, announced it raised a $3 million round led by Boeing [Lucia Maffei, BostonInno, Oct 10, 18] developed TILE (tiled ionic liquid electrospray) that aims to increase the lifespan and maneuverability of satellites and other vehicles in space [spacenews.com] total funding $15M [crunchbase.com]
Accion Systems (Boston, MA; no SBIR, 10-employees) startup that makes satellite propulsion systems. ... has so far raised $10.5 million in venture capital and $6.5 million in government funds to commercialize its technology, [CEO] Brikner says. [Jeff Engel, xconomy,com, Jun 17, 16]
Accion Systems (Boston, MA; no SBIR), a space-technology startup led by MIT graduates, has raised $7.5 million in Series A funding....has developed a miniature space propulsion system for small satellites. It may sound like a niche application, but small satellites are a multibillion-dollar annual market and growing [Gregory Huang, xconomy.com, May 14, 16]
Accion Systems (Cambridge, MA; no SBIR) maker of electric propulsion systems for satellites, has raised $2 million in seed funding to accelerate product development and employee hiring. ... developing liquid ion sources for micro-propulsion systems in satellites. The propulsion systems could one day be used in small satellites to provide constant earth imagery, track the growth of corn crops to better predict their yields, to better monitor natural disasters, or to provide global Internet coverage, said founder and CEO Natalya Brikner ... began accepting pre-orders last year, and so far has two customers [Sara Castellanos, Boston Business Journal, Jan 5, 15]
Accumetrics (San Diego, CA; no SBIR) develops, manufactures, and markets the VerifyNow® System, a comprehensive suite of tests for the assessment of platelet response to antiplatelet therapies. ... signed an agreement with Portola Pharmaceuticals, (South San Francisco, CA; $500K SBIR) to develop and supply the VerifyNow System and VerifyNow Tests for use in clinical trials. [Accumetrics company press release] has raised $24 million from investors since 2009 .. employs 70 people [signonsandiego.com, Mar 2, 11]
AccuraGen (Menlo Park, CA and Shanghai, China; no SBIR) startup working on liquid biopsy technology, has raised $40 million in new funding. [Cromwell Schubarth Silicon Valley Business Journal, Jun 2, 16] developed a high-sensitivity next-generation sequencing-based system for the detection of cancer mutations in miniscule concentrations of circulating cell-free DNA (cfDNA) in blood. [company website]
Business Waverider The LoFlyte Mach 5 Waverider of Accurate Automation Corp (Chattanooga, TN) got national business coverage in Business Week (Aug26). Now to see if AAC can make a business of it and not be swallowed by the aerospace giants if and when the idea proves itself. Founder Bob Pap may well have enough of his spirit committed to the dream to resist all but the sweetest offers.
Bird? UFO? Plane? Waverider? The LoFlyte waverider aircraft of Accurate Automation Corp (Chattanooga, TN) made the front page (above the fold) of yesterday's Sunday Times (Aug 11) in London. The news angle is explaining UFO sightings (give people a reason to read your stuff) over Europe. But since AAC has just started serious building plans, the sightings will need a different explanation. Or maybe DOD has been doing waverider for years and using AAC as a convenient innocent distraction. On the other hand, UFO sightings do attract attention. (A neighbor once told the newspapers of one right over our block; I saw it too - a C-135 on final approach at night to a rarely used Army military airfield.) AACs' strengths, nurtured with lots of Navy SBIR money for neural nets, are the neural control system and the entrepreneurial spirit of founder and CEO Bob Pap
LoFLYTE Rollout 750,000 people in Oshkosh watched the rollout of the first neural network piloted , SBIR powered, jet, the pride of Accurate Automation Inc (Chattanooga, TN). LoFLYTE is a high-lift, low drag, Mach 5 autonomous aircraft that rides the hypersonic shock and thus earns its waverider nomenclature. The PR Newswire story said that the "program represents a coordinated approach to SBIR contracts attempted by NASA Langley Research Center and the US Air Force to realize a complex objective". Which raises a complex question for SBIR - "What is SBIR really for?". Why would agencies fund it exclusively with SBIR if it has such high value? Did Congress intend such concentration of funding? Are the agencies just thereby avoiding the normal appropriations oversight of large projects? Even though the company has some decent claim to be commercially minded, does such a project pass a competitive investment efficiency test of commercial impact per marginal dollar invested? Did, indeed, the agencies even consider the investment competitiveness as viewed from the market sector? Why would anyone rain on a small business victory parade? Now that SBIR has proven the principle, will the normal agency R&D assume responsibility for the development under competitive bidding practices? And if so, can the company compete well outside the SBIR shelter since the technology belongs to the government for government use? Will success in such a maneuver now embolden the agencies to abandon the infant, diversified, market-minded, investment approach to invest a lot more money in a lot fewer companies with the objective of "a coordinated approach to SBIR contracts"? Does DOD hereby announce that Fast Track will be Second Track?
Accuray up 31% [Oct 31, 18]
Accuray (Sunnyvale, CA; $1.3M SBIR) up 15% [Sep 27, 18]
Accurayup 10% [Aug 17, 18]
Accuray (Sunnyvale, CA; $1.2M SBIR) up 11% [Oct 25, 17] "Our 11 percent year-over-year gross orders growth during the first quarter was highlighted by Radixact system wins primarily in new and competitor bunkers," said Joshua H. Levine, president and chief executive officer. [company press release, Oct 24, 17]
Accuray (Sunnyvale, CA; $1.2M SBIR) up 15% [Feb 1, 16]
Accuray (Sunnyvale, CA; $1.1M SBIR) up 12% [Oct 30, 15]
Accuray ($1.2M SBIR) down 16% [May 1,15]
Accuray up 15% [Jan 31, 14]
Accuray up 13% [Nov 8, 13]
Accuray (Sunnyvale, CA; $1.2M SBIR) up 11% [May 8, 13]
Accuray ($1.2M SBIR) down 12% [Feb 7, 13]
Accuray (Sunnyvale, CA; $1.2M SBIR) said it will buy TomoTherapy (Madison, WI; $1M SBIR) for $277 million ( a 30% premium) in a deal that unites two companies that make radiation therapy systems. [Marley Seaman, AP, Mar 7, 11] Tomo rose 25%; Accuray fell 10%
Accuray (one SBIR) shed 12.5% after the maker of robotic surgery systems projected sales for the first quarter and the fiscal 2010 below analysts' expectations. [Wall Street Journal, Aug 26, 09]
Since CyberKnife was first approved in 1999 for tumor treatment, it has been used in some 40,000 cases, and demand is growing. ... from Accuray (Sunnyvale CA; one SBIR) ... allows doctors to treat tumors using a noninvasive, outpatient procedure that helps patients avoid the side effects of surgery, chemotherapy or other forms of radiation. It uses software and robotics to home in on cancerous tissue and deliver large doses of radiation while sparing surrounding healthy tissue. [Time, Dec 17, 07]
Accuray (Sunnyvale CA; one SBIR) entered a partnership with Still River Systems which makes proton bean radiotherapy products. [Silicon Valley Business Journal, Oct 30]
Accuray (one SBIR a decade ago) was up 62% from its IPO price the day before. [Feb 9, 07]
Accuri Cytometers (Ann Arbor, MI; no SBIR) got $13 M Series C Financing ... Spun out of the University Of Michigan in 2002, ... developed revolutionary high performance cell analysis systems. .... "We are a state-supported start-up company," says CEO Jennifer Baird, "and we've been making decisions of how to manufacture our product. We've decided to do it in the state of Michigan." [MetroMode, Jul 9, 08]
Fannin Innovation Studio (Houston, TX), an early-stage life sciences commercialization group, today announced it has signed an agreement with Rice University to form new portfolio company Acelerox, LLC (Houston, TX; no SBIR) . ... developing a novel nanoparticle-based antioxidant therapy for a range of patient indications. Renowned synthetic organic chemist and Rice University professor James M. Tour, Ph.D. developed the molecules. [Fannin press release, Feb 12, 15]
Acelity LP (San Antonio, TX; no SBIR) is again expanding its product portfolio. The advanced wound care and regenerative medicine company is rolling out its BIOSORB Gelling Fiber Dressing in the U.S. [W. Scott Bailey, San Antonio Business Journal, Jul 28, 16] a global advanced wound care and regenerative medicine company created by uniting the strengths of three companies, Kinetic Concepts, LifeCell. and Systagenix Wound Management, Limited. [company website]
AcelRx Pharmaceuticals (Redwood City, CA; no SBIR), a specialty pharmaceutical company, announced that it received a Complete [FDA] Response Letter (CRL) regarding its New Drug Application (NDA) for DSUVIA™ (sufentanil sublingual tablet), 30 mcg [which] states that the FDA determined it cannot approve the NDA in its present form and provides recommendations needed for resubmission. [company press release, Oct 16, 17]
AcelRx Pharmaceuticals which late last week had to tamp down investor enthusiasm after a leak that its pain drug system was approved by regulators, lost more than 30 percent in pre-market trading Monday after the Food and Drug Administration rejected the drug-device. [Ron Leuty, San Francisco Business Times, Jul 28, 14]
DesignMedix (Portland, OR; $1.4M SBIR), a biotech startup that is manufacturing an anti-malarial drug, has closed a sizable funding round. has ties to Portland State University, collected a second round of angel funding worth $1.5 million. ... housed in the PSU Business Accelerator. It recently secured a $3 million grant to test the drug in human clinical trials. [Elizabeth Hayes, Portland Business Journal, Jul 18, 14]
Pain management company AcelRx Pharmaceuticals (Redwood City, CA; no SBIR) has filed for an IPO that could raise up to $86 million. ... founded in 2005 and has not yet generated product revenue [Silicon Valley / San Jose Business Journal, Nov 15, 10]
Acera Surgical (St Louis, MO; no SBIR) raised $5.1 million in equity financing, according to a recently posted SEC filing. ... is developing an implantable nanomedical scaffold intended for medical applications including soft tissue repair, according to a St. Louis Business Journal report. Acera also produces a protective wound cover called Restrata. [Fink Densford, massdevice.com, Oct 30, 18]
Acera Surgical (Creve Coeur, MO; no SBIR), a medical device startup born out of Washington University, has reported raising [$600K] of a $4 million debt and option offering. [Brian Feldt, St. Louis Business Journal , Jun 5, 17] commercializing a portfolio of fully synthetic electrospun scaffolds for regenerative medical applications. [company website]
Acera Surgical
(St Louis,
MO; no SBIR), a medical
device
startup, plans to seek [FDA] approval this fall, which would put the
startup on track to bring its surgical mesh technology to market
sometime in 2015. .... developing a surgical mesh called a
CeraFix Dural Substitute, an implantable surgical mesh aimed at
improving neurosurgical procedures. .... To date,
the
company has raised $1.3 million from investors, including the Missouri
Technology Corporation, which provided $250,000 in matching funds
through its Seed Capital Co-Investment program.
[Brian Feldt, St. Louis Business Journal, Apr 30, 14]
Acera Surgical (St. Louis, MO; no SBIR) medical device startup, said it closed on a $600,000 funding round .... to finance further development of surgical mesh Acera makes called a CeraFix Dural Substitute, an implantable surgical mesh aimed at improving neurosurgical procedures. [Brian Felft, St Louis BusinessJournal, Aug 8, 13]
Acera Surgical (St. Louis, MO; no SBIR) medical device startup, has sold $500,000 worth of debt. ... looking to raise up to $1.5 million, according [SEC] filing ... developing a line of implantable electrospun neurosurgical meshes and related tools and accessories for use by surgeons. .... in the Innovative Technology Enterprises, a University of Missouri - St. Louis incubator [Matthew Hibbard, St Louis Business Journal, Jun 6, 13]
Acer Thrapeutics (Newton, MA; no SBIR) down 79% [Jun 25, 19] focused on the acquisition, development and commercialization of therapies for serious rare and life-threatening diseases with significant unmet medical needs, announced it has received a Complete Response Letter (CRL) from [FDA] regarding its New Drug Application (NDA) for EDSIVO(TM) for the treatment of vascular Ehlers-Danlos syndrome (vEDS). The CRL states that it will be necessary to conduct an adequate and well-controlled trial to determine whether celiprolol reduces the risk of clinical events in patients with vEDS. Acer plans to request a meeting to discuss the FDA's response. [company press release, Jun 25, 19]
Celgene paid Acetylon (Boston, MA; no SBIR, founded 2008) $100 million in 2013 for an option to buy the company outright, but the deal recently expired without an acquisition, leaving Acetylon to chart a new course. Celgene remains an Acetylon investor, however, and the two are testing drugs together in a variety of trials. [Ben Fidler, xconomy.com, Aug 11, 16] developing next-generation selective small molecule histone deacetylase (HDAC) inhibitors [company website]
Presage Biosciences (Seattle, WA; no SBIR) has been named one of FierceBiotech ’s “Fierce 15” of 2013. ... a spinoff company of the Fred Hutchinson Cancer Research Center .... patented a novel method for simultaneously analyzing multiple cancer drug candidates and drug combinations within a single tumor while that tumor is still in a patient. .... FierceBiotech evaluates hundreds of private companies from around the world each year before selecting the 15 it considers the most innovative, creative and promising. The other Fierce 14 are: Acetylon Pharmaceuticals; AnaptysBio; CytomX (Santa Barbara, CA; $500K SBIR); FibroGen (South San Francisco, CA; $1.3M SBIR); Immunocore; Jounce Therapeutics; Kala Pharmaceuticals; MacroGenics (Rockville, MD; $2.6M SBIR) ; Moderna Therapeutics; Nimbus Discovery; Scioderm; Ultragenyx; UniQure; and Visterra. [Valerie Bauman, Puget Sound Business Journal , Sep 24]
Acetylon Pharmaceuticals (no SBIR) has taken in $15 million in a strategic investment from Celgene, a potential partner or competitor in the treatment of blood cancers. [Rodney Brown, Mass High Tech, Feb 9, 12]
Acetylon Pharmaceuticals (Boston, MA; no SBIR) said today that it has completed a $27 million Series B preferred equity investment round of financing. ... has raised a total of $40 million, said Walter C. Ogier, a company co-founder as well as its president and chief executive. ... focused on developing small molecule drugs to treat cancer, auto-immune diseases, and other diseases. Much of the company’s work is based on technology initially developed at the Dana-Farber Cancer Institute and at Harvard University. The company’s lead drug candidate is a potential treatment for relapsed and relapsed-refractory multiple myeloma. [Chis Reidy, Boston Globe, Jum 29, 11]
Acetylon Pharmaceuticals (Boston, MA; no SBIR) has raised $12.4 million of a planned $30 million Series B financing round, according to a filing with the U.S. Securities and Exchange Commission. ....founded in 2008, is focused on commercializing Histone Deacetylase inhibitors and pharmaceutical technology coming out of Harvard University and Dana-Farber Cancer Institute. [Michelle Lang, Mass High Tech, Feb 23, 11]
Therapeutics startup Acetylon Pharmaceuticals (Boston, MA; no SBIR) has pulled in $2 million in funding, bringing the total investment in the company to $9.25 million. [Mass High Tech, Jan 8, 10] ... formed in late 2008 to commercialize promising pharmaceutical technology emerging from collaborative research at Harvard University and the Dana-Farber Cancer Institute. Acetylon is focused on development and commercialization of next generation, selective, small-molecule Histone Deacetylase (HDAC) inhibitors with enhanced therapeutic efficacy and tolerability versus current alternatives. [mattcenter.mediaroom.com]
A handful of local life sciences companies have sprung to life over the past several months, in spite of a venture capital landscape that has sometimes looked windswept and barren. ... Companies that have successfully launched in this environment have powerful allies and a frugal mindset. Several are going after a platform that could target several diseases. Analysts say this approach gives the company several shots at profitability, making them more attractive to investors. ... Last week, Acetylon Pharmaceuticals (Cambridge, MA; no SBIR) announced its official launch with $7.25 million from private investors ... One company that did raise money from a traditional venture firm is Targ-Anox (Boston, MA; no SBIR). The company coalesced around technology discovered by Brigham and Women’s Hospital chief of medicine Joseph Loscalzo. [Mass High Tech, Aug 14, 09]
HDAC therapeutics startup Acetylon Pharmaceuticals (Cambridge, MA; no SBIR) has pulled in $7.25 million in a Series A funding round [Mass High Tech, Aug 7, 09]
Aciex Therapeutics (Westborough, MA; no SBIR) developer of eye-focused treatments, has raised $8 million in an equity offering ... gained a worldwide licensing deal for an Aciex over-the-counter eye care product and a manufacturing deal for another of Aciex’s ophthalmic products. .... seeking partners to co-develop, in-license and out-license treatments for dry eye, allergies, inflammation, glaucoma, infectious diseases and ocular pain [Michelle Lang, Mass High Tech, Aug 12, 11]
ACIST Medical Systems (Eden Prairie, MN; no SBIR) announced the first successful human case to use its RXi Rapid Exchange FFR System [to detect and assess blockages in coronary arteries that could require angioplasty] in the United States. .... received FDA clearance for the RXi system in January. ... conducted a clinical trial in New Zealand and is currently performing an additional study in Europe. [James Walsh, Minneapolis Star Tribune, Feb 19, 14]
Aclaris (FALCON HEIGHTS, MN; $1.6M SBIR) reducing its headcount by around 46% ... CEO Douglas Manion, M.D., linked the decision to the reduction of zunsemetinib’s prospects after the drug failed to match placebo on any primary or secondary endpoints in a phase 2 rheumatoid arthritis trial last month. [James Waldron, Fierce Biotech, Dec 20, 2023[
Aclaris (SAINT PAUL, MN; $1.6M SBIR) has dropped zunsemetinib after the latest fail saw the MK2 inhibitor unable to match placebo on any endpoints in a rheumatoid arthritis trial. [James Waldron, Fierce Biotech, Nov 13, 2023]
Aclaris Therapeutics (Wayne, PA; no SBIR) up 220% [Jan 19, 21] , a clinical-stage biopharmaceutical company focused on developing novel drug candidates for immuno-inflammatory diseases, announced positive preliminary topline results from a 12-week, Phase 2a, multicenter, randomized, investigator and patient-blind, sponsor-unblinded, parallel group, placebo-controlled clinical trial to investigate the safety, tolerability, pharmacokinetics and pharmacodynamics of ATI-450, an investigational oral MK2 inhibitor, in subjects with moderate to severe rheumatoid arthritis (RA) (ATI-450-RA-201). ATI-450 was developed internally utilizing Aclaris' proprietary KINect(TM) drug discovery platform. [company press release, Jan 19, 21]
Aclaris Therapeutics (Malvern, PA; no SBIR, founded 2012, IPO 2015), a dermatologist-led, biopharmaceutical company focused on identifying, developing and commercializing innovative and differentiated therapies to address significant unmet needs in medical and aesthetic dermatology announced that it has acquired Confluence Life Sciences (St. Louis MO; at least $300K SBIR), biotechnology company focused on the discovery and development of kinase inhibitors to treat inflammatory and immunological disorders and cancer. At the closing, Aclaris paid approximately $10 million in cash and issued approximately 350,000 shares of its common stock, with a value of approximately $10 million on the closing date, to the former equityholders of Confluence. [Aclaris press release, Aug 8, 17]
Aclaris Therapeutics (Malvern, PA; no SBIR) announced that it has submitted an Investigational New Drug Application (IND) to [FDA] for its drug candidate ATI-50001 for the treatment of alopecia universalis and alopecia totalis. Aclaris plans to conduct a human pharmacokinetic/pharmacodynamic (pK/pD) study to evaluate the safety of ATI-50001 in healthy volunteers. [company press release, Oct 31, 16]
Aclaris Therapeutics (Malvern, PA; no SBIR) entered into a $20 million stock purchase agreement Friday with a group of institutional accredited investors [for R&D], including its new JAK inhibitor programs for androgenetic alopecia — better known as male or female pattern baldness — and vitiligo, a disorder in which the cells that make pigment in the skin are destroyed causing patches of skin to appear on different parts of the body. [John George, Philadelphia Business Journal, May 27, 16]
Aclaris Therapeutics (Malvern, PA; no SBIR), a clinical-stage specialty pharmaceutical company focused on identifying, developing, and commercializing novel drugs to address unmet needs in dermatology, received 38M in VC and $56 in IPO funds in 3Q 2015. [Philadelphia Business Journal and company website, Nov 20, 15]
Aclaris Therapeutics (Malvern, PA; no SBIR, founded 2012) [last month filed plans to go public in an $86.25 million IPO] competed a $40 million series C venture capital financing ... is attempting to develop new treatments for skin disorders. ... Along with the completion of the $40 million financing, Aclaris said its wholly own subsidiary, Aclaris Therapeutics International Ltd., entered into a deal to acquire an exclusive, worldwide license for a set of compounds being developed to treat alopecia areata and other dermatological conditions. Under the terms of the agreement, Aclaris Therapeutics International agreed to make an upfront payment of $8 million to Rigel Pharmaceuticals (San Francisco, CA; no SBIR) is also eligible to receive undisclosed future milestone payments and tiered royalties on any future sales of the compounds, should they become approved therapies. [John George, Philadelphia Business Journal, Sep 14, 15]
Aclaris Therapeutics (Malvern, PA; no SBIR) raised $21 million ... series B venture capital financing .... developing new therapies to treat skin disorders, has now raised $42 million since its formation in August of 2012. ... follows the company’s completion of a phase-II clinical trial that yielded positive results for its lead product candidate, A-101, which is being developed as treatment for a common type of skin tumor known as seborrheic keratoses. [John George, Philadelphia Business Journal, Oct 2, 14]
Aclaris Therapeutics (Malvern, PA; no SBIR, founded 2012) raised $20.9 million in private stock sale this week, according to [SEC] documents .... led by President and CEO Neal Walker who was previously the chief executive of another local biopharmaceutical company, Vicept, which was acquired by Allergan last year in a deal valued at up to $275 million. ... specializing in developing new treatments for skin disorders. [John George, Philadelphia Business Journal, Sep 12, 12] Sounds like an eyes-on-the-prize leader who knows what investment is for and can attract confidence of serious investors. Not interested in consuming tens of millions of dollars in SBIR funding with a 6% profit margin to produce shelfloads of technical reports that make government smarter.
Acorda Therapeutics (NYC, NY; $2.3M SBIR) up 17%
Acorda Thera up 19% Jan 19, 21]
Acorda Therapeutics (Ardsley, NY; [email protected] SBIR around 2005) up 44% [Jan 13, 21] announced that it has entered into a definitive agreement to sell its INBRIJA manufacturing operations to Catalent for $80 million in cash. In connection with the sale, Acorda and Catalent have entered into a long-term global supply agreement under which Catalent will manufacture and package INBRIJA for Acorda, ensuring an uninterrupted drug supply for Acorda's patients and continued adherence to best-in-class manufacturing quality and safety standards. [company press release, Jan 12, 21]
Acorda Thera up 27% [Sep 10, 19]
Acorda Thera down 49% [Aug 2,19] reported quarterly financials [company press release, Aug 1, 19]
Acorda Thera down 15% [Dec 11, 18]
Acorda Thera down 25% [Sep 10, 18]
Acorda Thera up 12% [Jan 5, 18]
Acorda Thera (Ardsley, NY; $2M SBIR, market cap $910M) up 10% [Nov 20, 17] is scrapping its Parkinson’s disease drug tozadenant following patient deaths in its phase 3 trial. The action marks the end for an oral adenosine A2a receptor antagonist Acorda paid $363 million in cash for last year. [Nick Paul Taylor, Fierce Biotech, Nov 20, 17]
TransEnterix, pioneering robotics to improve minimally invasive surgery, announced that Florida Hospital entered into an agreement to purchase the Company's Senhance™ Surgical Robotic System. ... the first commercial unit of the Senhance Surgical System to be installed in the United States. [company press release, Nov 13, 17]
Acorda Therapeutics down 40% [Nov 15, 17] said that it has seen troubling safety problems in a Phase 3 trial of its experimental Parkinson’s disease drug tozadenant. Acorda reported cases of arangulocytosis, dangerously low levels of infection-fighting white blood cells, and some of them have led to sepsis and death. Acorda said some of these incidents could be related to tozadenant treatment. [Ben Fidler, xconomy.com,Nov 15, 17]
Acorda Thera up 10% [Oct 2, 17]
Acorda Thera down 24% [Aug 29, 17]
Months after Acorda Pharma lost a key group of patents, the FDA has declined to review, at least for now, an experimental Parkinson’s disease drug that is critical to the company’s future. Acorda said that the FDA has sent the company a “refusal to file” letter for the Parkinson’s drug it hopes to sell as Inbrija. [Ben Fidler, xconomy.com, Aug 29, 17]
Acorda Thera down 12% [Apr 3, 17]
Acorda Thera down 21% [Mar 31, 17] announced that the United States District Court for the District of Delaware upheld U.S. Patent No. 5,540,938 which pertains to the formulation of AMPYRA(R) (dalfampridine) Extended Release Tablets, 10 mg and is set to expire in July 2018. [company press release, Mar 31, 17]
The Patent Trials and Appeal Board upheld four patents covering Acorda Therapeutics’s multiple sclerosis drug dalfampridine (Ampyra) that had been challenged by hedge fund manager Kyle Bass. [Ben Fidler, xconomy.com, Mar 10, 17]
Acorda Thera up 10% [Feb 27,17]
Acorda Thera up 21% [Feb 9, 17]
Acorda Therapeutics said it will no longer test dalfampridine (Ampyra) in stroke patients who are having trouble walking. A phase 2 study in those patients didn’t show what the firm called “sufficient efficacy” to warrant further development. .... will now turn its attention to its two experimental Parkinson’s drugs: CVT-301 and tozadenant (now known as SYN115). Acorda bought Civitas Therapeutics in 2014 for $525 million to get its hands on CVT-301, an inhalable version of the decades-old Parkinson’s drug, levodopa. And in January, Acorda bought Biotie Therapies for $363 million to get SYN115, which, like CVT-301, is meant to help Parkinsons’ patients during their “off” episodes, when their medications stop working. [Ben Fidler, xconomy.com,Nov 21, 16]
Acorda Thera down 16% [Sep 26, 16]
Back in 2012, Acorda Therapeutics bought Neuronex (Morrisville, NC; no SBIR) as part of a plan to branch out beyond its flagship multiple sclerosis drug dalfampridine (Ampyra). Unfortunately, the drug, a nasal spray form of the old seizure control drug diazepam, never lived up to expectations, leading Acorda today to shelve it altogether. [Ben Fidler, xconomy.com, May 20, 16]
Acorda Therapeutics (Ardsley, NY; $2M SBIR) paid $363 million in cash for Finland’s Biotie Therapies, the second deal the company has made for a Parkinson’s disease drug developer in less than two years. Acorda paid $525 million for Civitas Therapeutics in September 2014. [Ben Fidler, xconomy.com, Jan 22, 16]
Acorda Thera up 10% [Oct 22,15]
Acorda Thera up 12% [Oct 5,15]
Acorda Thera down 10% [Feb 10, 15]
Acorda Thera up 28% [Sep 24, 14] On the eve of a planned $75 million [IPO], biotech Civitas Therapeutics (Chelsea, MA; no SBIR, 44 employees) has been acquired by Acorda Therapeutics (Ardsley, NY; $2M SBIR) for $525 million. Acorda, which is developing treatments for multiple sclerosis and spinal cord injury treatments, will be buying worldwide rights to CVT-301, a Phase 3 inhaled drug delivery technology for controlling episodes of Parkinson’s disease. Acorda estimates the market for the drug to be more than $500 million, which explains the high premium it's willing to pay despite the fact that CVT-301 won't begin late-stage trials until next year, with an approval application expected in 2016. [Don Seiffert, Boston Business Journal, Sep 24, 14]
Acorda Pharma down 10% [May 2, 14]
Acorda Thera up 10% [Feb 13, 14]
Salix Pharmaceuticals took a big step toward bringing another drug to market when it announced that [FDA] had accepted its new drug [called budesonide] application. ....Through Sept. 30, 2013, Salix had spent $38 million developing budesonide [Jason deBruyn, Triangle Business Journal, Jan 30, 14]
Jazz Pharmaceuticals plc (Ireland) and Aerial BioPharma, LLC (Morrisville, NC; no SBIR) announced that the companies have signed a definitive agreement under which Jazz Pharmaceuticals has acquired rights to ADX-N05, a novel compound in clinical development for the treatment of excessive daytime sleepiness in patients with narcolepsy. [Jazz website, Jan 13, 14]founded in January of 2011 by the management team from Neuronex and Addrenex Pharmaceuticals, both successful start-ups based in the Research Triangle Park area. Neuronex was acquired by Acorda Therapeutics in 2012 and Addrenex Pharmaceuticals was acquired by Shionogi Pharma in November of 2009 [Aerial website] a deal that could be worth up to nearly $400 million. Jazz paid $125 million up front [Jason deBruyn, Triangle Business Journal, Jan 17, 14]
Acorda Therapeutics completed a previously announced buyout of certain rights to struggling NeurogesX’s post-shingles nerve pain treatment made from the active ingredient in chili peppers, capsaicin (Qutenza), as well as a late-stage product for diabetic neuropathy known as NP-1998. [Ben Fidler, xconomy.com, Jul 12, 13]
Acorda Thera up 12% [Apr 16, 13]
Acorda Thera (Hawthorne, NY; $2M SBIR) up 12% [Apr 15,13] on a bloodbath day
Accorda Thera up 13% [Nov 4, 11]
Acorda
Thera up 14% [May 20, 11]
Acorda Thera down 12% [May 5, 11]
Acorda Thera up 26% [Apr 14, 11] on a report that it may receive additional patent protection for its top- selling drug, an RBC Capital Markets analyst said. [Bloomberg, Apr 14]
Acorda Thera down 14% [Jan 21, 11]
Acorda Thera up 10% [Jan 22, 10]
Acorda Therapeutics up 47% after the company got a positive FDA panel vote Wednesday for fampridine-SR to improve walking in multiple-sclerosis patients. The FDA is set to decide on the drug's approval next week. [Wall Street Journal, Oct 16, 09]
Acorda Thera down 21% [Oct 9, 09]
Acorda Thera
down 15%
[Jul 1, 09] after
the
biotechnology company announced a licensing and collaboration agreement
with Biogen
Idec -->.
[Wall Street Journal,
Jul 2]
Acorda
Therapeutics up 17%
[May 6, 09] after the
FDA
assigned the company's multiple-sclerosis drug priority review and an
October approval decision date. [Wall Street Journal, May
7] Acorda Thera
up 19%
[Apr 23, 09] Acorda Thera down 20%%
[Mar 31, 09] Acorda Thera
up 11%
[Mar 6, 09] Acorda Thera
up 19% [Feb 24,
09] Acorda Thera up 13% [Dec 18,
08] Acorda Thera down 15%
[Dec 1, 08] On a stock
bloodbath day Acorda Thera up 12% [Oct 28,
08] Acorda Thera down
10% [Oct
6, 08] Acorda Thera down
10% [Oct
6, 08] Acorda Therapeutics
(Hawthorne, NY; $1.8M SBIR) rose 31% [Jun
2, 08] ... company
said a
second late-stage trial showed that
its multiple-sclerosis drug improved mobility in some patients with the
debilitating disease. Acorda plans to file for licensing to market the
drug, being developed with Elan,
in the first quarter [WSJ] Acorda Therapeutics up 15%
[Feb 13, 08] Acorda
Therapeutics
down
11% [Feb 6, 08] on announcing
higher R&D spending. Acorda
Therapeutics
(Hawthorne, NY; $1.6M SBIR) up 25% [Jan
28, 08] after it said its
multiple
sclerosis drug Fampridine-SR
does not raise the risk of heart-related side effects anymore than a
placebo in a so-called QT cardiac safety study required by the FDA
[Forbes.com] Acorda Therapeutics up 12%[Jan
10, 08] Acorda
Therapeutics up 10%
on
no news. [Nov 20, 06]
Start-up Acorn Cardiovascular (no SBIR) went out of business late last year after spending $50 million on the main trial for its heart device and then conducted two more studies the FDA requested, former president Steve Anderson says. The FDA kept changing the terms of a third extra trial it sought, he says. The FDA says Acorn repeatedly ignored its advice and failed to address the problems it raised. we can't be responsible for bad decisions by company,spokeswoman says. [Jonathan Rockoff, Wall Street Journal, Feb 18, 11]
one of Massachusetts’ fastest-growing tech firms, Acquia (no SBIR), became the latest to ditch noncompetes as the push against the measures in the tech community picks up steam. [Kyle Alspach, boston.com, May 6]
Life
Technologies up 8% as
Thermo
Fisher agreed to buy diagnostics equipment maker Life
Technologies in a $13.6 billion deal that will significantly
expand Thermo Fisher and establish it as a major force in the emerging
personalized medicine market. [Robert Weisman, Boston
Globe, Apr
15,
13] formed in 2008 by the merger of Invitrogen ($4M
SBIR) and
Applied Biosystems
(no SBIR);
acquired AcroMetrix (one
SBIR) in
2010; acquired Ion
Torrent (no SBIR) in 2010; won a $45 million Army contract
in
2012.
said it acquired the Bay Area company AcroMetrix(Benicia, CA; one SBIR) for an undisclosed amount. AcroMetrix makes diagnostic quality control products for laboratories, blood screening centers and diagnostic manufacturers. [Thomas Kupper, San Diego Union Tribune, Jan 13, 10]
I-Flow Corp. of Lake Forest, Calif., agreed to pay $25M in cash to acquire AcryMed(Beaverton, OR; $1.5M SBIR) ... focused on wound dressings since its beginning in 1993. [The Oregonian, Jan 3, 08]
battery startup ActaCell (Austin, TX; no SBIR, nine employees) has merged with California battery maker Contour Energy Systems (Azusa, CA; one SBIR). [Brian Gaar, Austin American Statesman, Sep 7, 12]
ActaCell (Austin, TX; no SBIR) . has been awarded a $6.2 million research grant from the U.S. Commerce Department's National Institute of Standards and Technology. ... plans to use the grant to develop technology to increase production of the company's nanocomposite material for lithium batteries, a news release said. ... founded in 2007, licenses lithium-ion battery technologies that were developed at the University of Texas, according to the company's website. [Austin American Statesman, Dec 28, 10]
ActaCell (Austin, TX; no SBIR) won a grant from a national battery consortium to evaluate its high-powered lithium-ion cells. The $179,015 grant is from the United States Advanced Battery Coalition, a collaboration of the three major U.S.-based automakers. .... to evaluate its cells against the coalition's goals for cycle and storage life in hybrid-electric vehicles. Two weeks ago, ActaCell won a $3 million grant from the federal National Institute of Standards and Technology. That money will be used to advance the development of ActaCell's technology. [Austin American Statesman, Dec 23, 10]
NIST TIP winners $22 million in funding for nine research projects targeting innovative manufacturing technologies in fields ranging from biopharmaceuticals and electronics to renewable energy sources and energy storage: Isogenis (Aurora, CO; $4.8M SBIR); ActaCell, (Austin, TX; no SBIR); Engineered BioPharmaceuticals (Manchester, CT; no SBIR); Arsenal Medical (Watertown, MA; no SBIR); Kent Displays (Kent, OH; $2.6M SBIR); Precision BioSciences (Research Triangle Park, NC; $340K SBIR); Ginkgo BioWorks (Boston, MA; one SBIR); Sinmat (Gainesville, FL; $4.4M SBIR); Polyera (Skokie, IL; no SBIR). http://www.nist.gov/tip/tip_121510.cfm
ActaCell (Austin, TX; no SBIR) which is developing advanced battery cells, has received a grant worth as much as $1 million from the Texas Emerging Technology Fund. The company, which was founded in 2007 to commercialize some of the University of Texas' lithium-ion battery research, will get an initial $250,000, with more money to follow as the company meets certain benchmarks. .. previously raised $5.8 million from investors including Google.org, [Lori Hawkins, Austin American Statesman, Nov 11, 09]
ActaCell (Austin, TX; no SBIR) is hardly alone. [CEO] Ott estimates that a dozen companies, many of them startups, are chasing the same goal. Most them are trying to modify the lithium-ion technology now used in many laptop computers and cell phones. One Austin company, Valence Technology already is making batteries for a variety of vehicles, including the Segway Personal Transporter. ... and $2 billion in federal funds for advanced battery development just passed by Congress — has sparked a rush of investment in startup battery companies and a surge of interest in promoting more manufacturing of advanced batteries in the U.S. [Kirk Ladendorf, Austin American-Statesman, Mar 9, 08]
ActaCell (Austin, TX; no SBIR), A small battery company spun out of the University of Texas and nurtured by the Austin Technology Incubator has raised $5.8 million in a first round of venture capital, including a grant from the philanthropic arm of Google. ... formed to commercialize some of UT's lithium-ion battery research [Austin American Statesman, Jul 23, 08]
Actasys (Troy, NY; no SBIR), a start-up company developed at Rensselaer Polytechnic Institute, will use a $500,000 state grant to create a prototype for a device that increases the fuel efficiency of tractor-trailer trucks. ... funding from the New York State Energy Research and Development Authority to develop energy efficient transportation models. .... Once it develops a prototype, Actasys will test its device on trucks operated by the Price Chopper Supermarket chain ... wants to raise an additional $500,000 for product development. [Megan Rogers, Albany Business Review, Apr 18, 14]
ACTBiotech (San Francisco, CA; no SBIR), a tiny 7-person operation led by executives from Onyx Pharmaceuticals ($800K SBIR) and Proteolix (no SBIR), showed off the data for its lead drug against stomach cancer. When given in combination with standard chemotherapy, the ACT Biotech drug was able to shrink tumors by at least 30 percent or more in about two-thirds of all patients (25 of 39) in a mid-stage clinical trial. [Luke Timmerman, m.xconomy.com, Jun 6, 11]
(New York, NY; $400K SBIR) up 34% [Oct 31, 2022] announced positive top-line results from the pivotal Phase 3 trial for its lead product candidate Iomab-B. [company press release, Oct 31, 2022]
ActivBiotics (Lexington, MA; no SBIR) developer of antibiotics, reports plans to liquidate all of its assets following the failure of its lead drug in clinical trials. [Mass High Tech, Dec 19, 07]
Smart new wheels. The government giveth to technology companies, and the government maketh life really difficult for them. Last week, I had the chance to ride in a souped-up, artificially intelligent motorized wheelchair. It was developed by ActivMedia Robotics of Peterborough NH., under a $100K NIH grant, and was shown publicly for the first time ... The chair uses a digital map of the room it is in to navigate autonomously. Click a point on the map and it will take you there, avoiding obstacles and people along the way. Eventually, it could be driven by touching icons on the screen or by speaking voice commands, like ''Go to the dining room.'' ... If not for the NIH grant, the chair wouldn't exist, and it won't have much hope of making it to the market without a further $750K NIH infusion. After that, there's the FDA approval process [who] must certify that the chair won't endanger the lives of its users by, for example, autonomously pitching them down a flight of stairs.... How large is the market for an intelligent wheelchair? And will prospective users and their caretakers trust the chair's driving ability enough to buy it? No one knows. Dietsch estimates that the chair, if made in small quantities, would cost about $30,000. If manufactured in large volume, $20,000. That's about the same price at which Johnson & Johnson is expected to sell its Independence 3000 Ibot Transporter, the robotic wheelchair developed by Dean Kamen that climbs stairs, handles all kinds of rough terrain, and balances on two wheels. ... Both the Ibot and ActivMedia's Independence-Enhancing Wheelchair are entirely new kinds of products, and they both will require that new tests be developed before they can be deemed safe for use. But how safe is safe enough? A human wheelchair operator is responsible if she drives the chair into a wall, and that happens often enough: Dietsch says that wheelchair accidents send 35,000 people to the hospital each year. Should ActivMedia's artificially intelligent chair be required to perform more reliably than a human and prevent 100 percent of all possible wheelchair accidents? The FDA's guidelines say that the benefits of a new medical device must outweigh the risks. But the agency can be slow in figuring that out. Clinical trials for the Ibot began in mid-1999. Kamen initially thought it would be on the market by early 2001, but the revised projection is later this year. [ Red glare, black ink. [Scott Kirsner, Boston Globe, July 1,02]
Active Power (Austin, TX; no SBIR) is rolling out a stock offering to raise more than $9 million for working capital and general corporate purposes, according to [SEC] documents ... founded in 1992, develops backup power systems. It employs 220 workers [Michael Theis, Austin Business Journal, Feb 27, 14]
Power system manufacturer Active Power (Austin, TX; no SBIR) has priced a 13.2 million common stock offering at 75 cents per share that could raise an expected $9 million for the company. ... founded 1997, 150 employees [Austin Business Journal, Feb 22, 10]
Active Power (Austin, TX; no SBIR), which makes battery-free, flywheel-based backup power systems, agreed to a $3 million private placement of its shares. [Austin American-Statesman, Jun 2, 09]
Shares of Active Power shot up 40.5 percent after the company reported a 58.7 percent increase in fourth-quarter revenue and a dramatically smaller loss. [Austin American-Statesman, Jan 31]
Active Power (Austin, TX)received two multimillion-dollar orders from Caterpillar. [Austin Business Journal, Nov 24, 08]
Active Power (Austin, TX; no SBIR) said sales grew 34% in 2007, and the company narrowed its full-year ...makes battery-free backup power systems for facilities that need uninterrupted power. [Austin American-Statesman, Feb 2]
Active Power (Austin, TX; no SBIR), inventor and manufacturer of the most energy-efficient critical power systems in the world, announced today it completed a private placement of approximately $14 M of common stock to institutional investors. .. flywheel-based UPS systems protect critical operations in data centers, healthcare facilities, manufacturing plants, broadcast stations and governmental agencies in more than 40 countries. [company news release, Aug 16]]
Backup power systems company Active Power reported a 27% gain in revenue ... specializes in battery-free, flywheel-based power systems ...still it lost $4.9M [Austin American-Statesman, Oct 27, 06]
Protective nanocoating company actnano (Boston, MA; no SBIR, founded 2012) announced that it has raised $12M in a Series A funding round. ...is setting a new standard for electronics protection with its commercialized water and environmental resistant coating technology, Advanced nanoGuard™ (ANG). [company press release, Oct 13, 20] More nano-wonder products adding to a potential serious health hazard, although the company claims human-safe, non-toxic and environmentally sustainable.
Nano coating startup actnano (Cambridge, MA; no SBIR) raised $10M in equity in an $11.8M funding round, according to an SEC filing. [BostInno, Aug 14, 20] prior funding $850K [crunchbase.com]
Drug developer Acton Pharmaceuticals (Marlborough, MA; founded 2008) has closed a $500,000 tranche in a planned $10 million preferred-stock sale, according to a regulatory filing.... engaged in the acquisition, development and commercialization of potential therapies to treat respiratory illnesses, according to the company’s website. [Mass High Tech, Dec 16, 09]
Actuality Systems Founded in 1997, develops the world's first Spatial 3D visualization systems, which have been proven to provide faster and more accurate outcomes in critical defense, medical, and security operations. Organizations evaluating Perspecta include the National Institutes of Health, Centacor (J&J), Kyoto University, Nissho International, Purdue University, the US Army, University of Toronto $1.7 million grant from ATP for work to commercialize low-cost scalable 3D holographic video.sale of its PerspectaTM 3D system to the NASA Ames Research Center in California. The unique 360-degree display will be used as part of the center's work in 3D imaging of scientific data in the fields of earth science and astronomy. .. Apache Corp. has invested $1.2 million in the company. Houston-based Apache's investment is part of $6.5 million raised to expand business development, and add engineering staff.
Actuate Therapeutics (Ft Worth, TX; no SBIR, founded 2015) raised $21.7 million to take its lead oncology asset deeper into the clinic. The series B round comes shortly after Actuate dosed the first patient in a phase 1/2 trial of glycogen synthase kinase‐3 beta (GSK-3β) 9-ING-41. [Nick Paul Taylor, Fierce Biotech, May 20, 19]
The board majority at Acucela (Seattle, WA; $200K SBIR) was voted out and replaced by a slate supporting founder Ryo Kubota, who was promptly restored to the CEO post he’d lost in December. ... Kubota is the largest single shareholder, and with a proxy from Japanese investment firm SBI Holdings he controlled more than 50 percent of the vote. [Seattle Times, May 1, 15]
Acrimony. A struggle for control of the early-stage company has erupted into public acrimony. Acucela (Seattle, WA; $200K SBIR), whose stock is publicly traded in Japan, told shareholders its founder and board chairman Ryo Kubota was replaced as chief executive in December because he proved “unable to make the transition from founding visionary to public company CEO.” Kubota, who is the largest single owner of Acucela stock and is backed by a big institutional stockholder, wants to oust the current board members who pushed him out. [Rami Grunbaum, Seattle Times, Mar 6, 15]
Acucela (Seattle, WA; $200K SBIR) will raise $162.4 million in total proceeds in an IPO on the Tokyo Stock Exchange, according to a regulatory filing. ... to develop eye drugs [Luke Timmerman, xconomy.com, Feb 4, 14]
Acucela (Bothell, WA; $200K SBIR, founded 2002), biotechnology company developing treatments for eye diseases, plans an [IPO] of up to $125 million on the Tokyo Stock Exchange, a rare move for a U.S.-based company. ... has no marketable products yet ..... had revenue of nearly $42 million in the nine months ended Sept. 30, all from collaborations with Japanese pharmaceutical company Otsuka that began in 2008. Otsuka also owns a 13 percent stake. [Seattle Times, Dec 17, 13]
things are looking better: the research-oriented startups seem poised to survive the downturn, and long-awaited clinical results could propel larger companies like Dendreon to stardom. ... despite the financial crisis, the Accelerator, a local incubator based in Seattle's Eastlake neighborhood, created three firms last year - Recodagen, GPC-Rx and Mirina (none had SBIR) ... "Seattle is really a town of development-stage biotechs," Miller said. ... Light Sciences Oncology (no SBIR), a firm that canceled its initial public offering last February, managed to raise $10 million from venture capitalists in July. Private investors provided Redmond-based Healionics (no SBIR) — which manufactures material for implants — with a $2.6 million boost in December. In a deal that could yield big results, Bothell-based Acucela (no SBIR), which is developing therapies to treat blindness, signed a partnership deal in September with Japanese firm Otsuka Pharmaceutical that could potentially bring it $258 million. [Angel Gonzalez, Seattle Times, Jan 25, 09]
Medtronic has joined in a $21 million round of funding for AcuFocus (Irvine, CA; no SBIR), which makes an implant for treating near-vision loss. .... to expand further into Europe ... makes a tiny, ring-shaped implant that treats presbyopia, a condition that reduces the eye’s ability to focus on nearby objects. ... Medtronic also participated in a $65 million round of funding for the company three years ago. [Katharine Grayson, Minneapolis / St. Paul Business Journal, Sep 5, 14]
A Lockheed Martin, Aculight (Bothell, WA; $40M SBIR) subsidiary has won a $220.8 million other transaction agreement to build a prototype of high-energy laser technology for the U.S. Army’s ground-based Indirect Fire Protection Capability weapon system. [Jamie Bennett, govconwire.com, Jul 20, 2023]
Laser technology company Aculight (Bothell, WA; $22M SBIR, 90 employees) is being purchased by Lockheed Martin for an undisclosed sum. [Puget Sound Business Journal, Jul 28, 08] Thanks to Duane Zieg, MDA Tech Applications group; MDA furnished a small fragment of the SBIR haul.
Acumen Pharmaceuticals (CHARLOTTESVILLE, VA; $800K SBIR) up 55% [Jul 17, 2023] announced that it has commenced an underwritten public offering of $100 million of shares of its common stock [company press release, Jul 17, 2023]
Acumen Pharmaceuticals (Charlottesville, VA; $800K SBIR) up 23% [Jan 31, 2023]
Acumen Pharmaceuticals (Charlottesville VA; $800K SBIR) up 104% [Sep 28, 2022] after Biogen Inc and Eisai Co announced that the Phase 3 clarity study of lecanemab met its primary endpoint. [Adam Eckert, Benzinga, Sep 28, 2022]
Acumen Pharmaceuticals (Livermore, CA; $800K SBIR) is filing for a $100 million [IPO] hot on the heels of the FDA’s conditional approval of Biogen's controversial Alzheimer's disease drug Aduhelm (aducanumab). [Kyle LaHucik, Jun 10, 2021, Fierce Biotech]
Think triage. Despite the ending of the war in Iraq, and the winding down of one in Afghanistan, provider of electrical power supply products for military uses Acumentrics Holding (Westwood, MA; $1.7M SBIR) is not only confident of the future market for its product, it just launched a new product and is looking for a new space to expand manufacturing. ..... in order to double the production of its UPS systems. [Don Seiffert, Mass High Tech, Oct 1, 12] Beware, private sector predictions of military behavior in budget cutting times run a big risk of disappointment. The military well understands triage.
Acumentrics (Westwood, MA; one SBIR) has developed and introduced a rugged uninterruptible power supply system able to provide simultaneous DC and AC outputs ... for solid oxide fuel cells. [Boston Globe, Sep 11]
Acumentrics (Westwood, MA; one SBIR) got a 3 1/2-year, $15.6 M grant to continue the development of the company's tubular solid oxide fuel cell technology, courtesy of the DOE's Office of Energy Efficiency and Renewable Energy [Mass High Tech, Jun 5, 08]
Acumentrics (Westwood MA) got its first recorded SBIR Phase 2 from DOE to develop optimized manufacturing techniques and to build pre-commercial prototypes of a hybrid ceramic-metallic heat exchanger for solid oxide fuel cells (SOFCs) [press release Oct 11, 07]
AcuraStem (Monrovia, CA; no prior SBIR, founded 2016) received a $3.7 million fast-track [NIH SBIR] grant to develop a treatment for Lou Gehrig’s disease. [By Dana Bartholomew, LA Business Journal, June 19, 18]
Acutus Medical (Carlsbad, CA; no SBIR, founded 2011) announced a $170 million financing, including a $100 million Series D equity financing and a $70 million credit facility. The funding is intended to accelerate commercialization and facilitate global business development activities as the company continues to transform arrhythmia care through distinct, innovative technologies designed to provide physicians and patients with improved results. [company press release, Jun 20, 19] prior funding $208M [crunchbase.om]
Acutus Medical, (Carlsbad, CA; no SBIR) medical device maker with new technology for diagnosing and treating irregular heartbeats, said it has closed on $75 million in Series C funding. ... says its AcQMap technology provides a 3-D, high-resolution image of the heart’s interior, and maps its electrical activity. Acutus creates this computerized map by threading a sensor-laden “basket” catheter through a major blood vessel and into the heart. ... Boston Scientific, St. Jude Medical, Abbott, and others are developing competing technologies. [Bruce Bigelow, xconomy,com, Mar 21, 16]
Acutus Medical (Rancho Bernardo, CA; no SBIR) raised $28 million in venture funding, the medical device company said .... developing a minimally invasive cardiac catheter to treat irregular heart rhythms. ..... will fund product development, clinical trials and speed commercialization .... first announced its funding on June 26, stating it had raised $21 million in the round. The financing announced Tuesday marks the round's closing. [Bradley Fikes, utsandiego.com, Aug 20, 13]
In its second round of venture funding, heart device maker Acutus Medical (San Diego, CA; no SBIR, founded 2011) raised $21 million. ... develops technology for imaging inside the heart, something useful in treatment of atrial fibrillation and other types of cardiac arrhythmia. [Stephen EF Brown, San Francisco Business Times, Jun 25, 13]
Adagio Therapeutics (Waltham, MA; no SBIR) launched with the closing of a $50 million Series A financing, to advance its portfolio of coronavirus antibodies as both therapeutics and prophylactics against SARS-CoV-2 as well as future coronavirus outbreaks. [company press release, Jul 16, 20]
M/div>Adamas Pharmaceuticals (Emeryville, CA; no SBIR) joined the parade of health and bio IPOs, raising $48 million in an offering that priced at the low end of its target range. .... reports posted about $50 million of net income in 2013 ... had raised over $40 million in VC funding. Its biggest stakeoholders before the offering [Cromwell Schubarth, Silicon Valley Business Journal, Apr 10, 14]
Adamas Pharmaceuticals (Emeryville, CA; SBIR) will offer nearly 3.5 million shares at $16 to $18 in an IPO, raising more than $62 million, the company said .... zeroes in on central nervous system drugs like those to treat Alzheimer's-related dementia and Parkinson's disease, is in a long queue of Bay Area life sciences companies waiting to go public. [Ron Leuty, San Francisco Business Times, Mar 26, 14]
Adamas Pharmaceuticals (Emeryville, CA; SBIR) will offer nearly 3.5 million shares at $16 to $18 in an IPO, raising more than $62 million, the company said .... zeroes in on central nervous system drugs like those to treat Alzheimer's-related dementia and Parkinson's disease, is in a long queue of Bay Area life sciences companies waiting to go public. [Ron Leuty, San Francisco Business Times, Mar 26, 14]
La Jolla Pharmaceutical (LaJolla, CA; no SBIR) announced a merger deal with another small biotechnology company. The deal between La Jolla Pharmaceutical and Adamis Pharmaceuticals (DelMar, CA; no SBIR) will give La Jolla shareholders as much as 30 percent ownership of the combined company, while Adamis gets $2.5 million to $3 million in cash expected to be left over from La Jolla’s operations. [Thomas Kupper, San Diego Union Tribune, Dec 8, 09]
A year ago, startup Adapteva (Lexington, MA; no SBIR) scraped up nearly $900,000 through an Internet crowdfunding campaign. [Now] $3.6 million, from Israeli venture capital firm, and the Swedish telecommunications giant Ericsson ... to contine development of a high-powered chip for next-generation cell phones. The company’s Epiphany [low power] processor contains as many as 64 computing cores, compared to the two- or four-core chips found in today’s smartphones. [Hiawatha Bray, Boston Globe, Jan 16, 14]
Adaptimmune (Philadelphia, PA and Oxford UK), a leader in T-cell therapy to treat cancer, announced that it has entered into a definitive agreement with Matrix Capital Management to purchase an aggregate of approximately US$42,000,000 of its American Depositary Shares [company press relese, Apr 5, 17]
T-cell therapy developer Adaptimmune Therapeutics (Philadelphia, PA and Oxford UK) raised $66 million through an underwritten public offering of American depositary shares. ... focused on the development of novel cancer immunotherapy products. The Company’s unique SPEAR (Specific Peptide Enhanced Affinity Receptor) T‑cell platform enables the engineering of T-cells to target and destroy cancer, including solid tumors. ... also developing its NY-ESO SPEAR T-cell program under a strategic collaboration and licensing agreement with GlaxoSmithKline [company press release, Mar 29, 17]
Adaptive BioTech down 17% [Sep 5, 19]
Adaptive Bio down 17% [Jul 1, 19]
Adaptive Bio up 20% [Jun 28, 19]
Boom and bust 1990s redux. Adaptive Biotechnologies (Seattle) [up 102% [Jun 27, 19] just raised $300 million. BridgeBio Pharma (Palo Alto, CA) has topped it, raising $348.5 million. .... BUT SVB Leerink analyst Geoffrey Porges sees a few warning signs, like a drop in financing across the biotech sector. He also notes that just over half (53 percent) of the biotechs that have gone public during this super-cycle have disappointed investors, with annualized eturns of negative 10 percent or worse. [Alex Lash, xconomy.com, Jun 27, 19]
Ten years after spinning out from Fred Hutch, Adaptive Biotechnologies (Seattle, WA; $4.5M SBIR) is planning a $200 million IPO to help power its diagnostic sequencing tests aimed at the body’s immune system and the scores of related therapies. [Conor Hale, Fierce Biotech, Jun 17, 19]
Adaptive Biotech (Seattle, WA; at least $2.5M SBIR, founded 2009, 300+ employees) a high-flying startup that makes technology to read the human immune system, has officially filed to go public to raise $230 million [James Thorne, geekwire.com, May 30, 19] total funding $400M [crunchbase.com]
Chad and Harlan Robins spun their startup Adaptive Biotechnologies (Seattle, WA; no SBIR) out of Fred Hutch 7 years ago. Now it’s worth $1 billion. [Casey Coombs, Puget Sound Business Journal, Dec 16, 16] at the forefront of immune-based discoveries, combining high-throughput sequencing and expert bioinformatics to profile T-cell and B-cell receptors. [company website]
A Boston Globe story [Sep 5] outlined how hard it might be to make precision medicine a standard in cancer care, mostly because of how this approach may address one cell mutation that seems to be at the center of the disease, when another could easily emerge later. .... In the , numerous life sciences companies and institutions are trying to reap the medical and financial rewards of precision medicine. Adaptive Biotechnologies (Seattle, WA; no SBIR), for example, creates technologies that sequence a patient's immune system to determine which treatments will work best to treat that patient's cancer. ... Investors have poured their money into this [Puget Sound] region to fund what could be some of the most promising precision medicine cancer treatments in years, but the Globe's reporting calls into question how well these types of treatments will perform in the long run. [Annie Zak,Puget Sound Business Journal, Aug 31, 15]
Juno Therapeutics CEO Hans Bishop sang the praises of another local rising star: Adaptive Biotechnologies (Seattle, WA; no SBIR) [which] recently raised an astonishing $195 million venture capital round, bringing the biotech's total VC funding to about $394 million — all within one year. .... develops immunosequencing tools used to help pharmaceutical companies and researchers understand how a drug treatment works on an individual person. [Annie Zak, Puget Sound Business Journal, May 28, 15]
Adaptive Biotechnologies (Seattle, WA; no SBIR), a leader and pioneer in next generation sequencing (NGS) of T-cell and B-cell receptors in the immune system, announced today the completion of Adaptive’s Series F financing round with a $195 million investment to support several strategic growth initiatives. ... Adaptive is also backed by industry-leading strategic investors Illumina, Celgene, BD Biosciences and LabCorp. [company website, May, 6, 15]
Adaptive Biotechnologies (Seattle, WA; no SBIR), which was spun out of Fred Hutch and raised $105 million last year, this morning announced it acquired Sequenta (San Francisco, CA; no SBIR) ... did not disclose the acquisition price, but Adaptive raised $94 million in private equity to buy Sequenta ... Both companies use immunosequencing to profile immune systems and help pharmaceutical companies and researchers understand how a drug treatment works for an individual person. [Annie Zak, Puget Sound Business Journal, Jan 7, 15]
research company Adaptive Biotechnologies (Seattle, WA; no SBIR), which was spun off from the Fred Hutchison Cancer Research Center, said it's raised $105 million ... "to expand globally its preeminent immunosequencing research platform and downstream validated clinical diagnostic products." [Ben Miller, Puget Sound Business Journal, Apr 8, 14]
Adaptive Biotechnologies (Seattle, WA; no SBIR), which was spun off from the Fred Hutchison Cancer Research Center, said it's received a $2.53 million [NIH SBIR] award .... to "commercialize a test to measure the ability of a cancer patient's adaptive immune system to fight infection after a cord blood transplant [Ben Miller, Puget Sound Business Journal , Sep 16, 13]
Intel Capital said it's investing more than $30 million in four technology startups... Adaptive Computing (Provo, UT) developer of software for data centers and cloud computing; Ciranova, (Santa Clara, CA) maker of chip design software; Joyent, (San Francisco, CA) provider of cloud-computing infrastructure; Nexant a (San Francisco, CA) developer of energy-efficiency software and clean-energy services. [FM Russell, San Jose Mercury News, Sep 15, 10] None had SBIR.
Adaptive Phage Therapeutics {Gaithersburg, MA; $300K SBIR) announced that the AMR Action Fund has joined an existing $41 million Series B round as a co-investor. [company press release, Apr 4, 22]
We told you a couple weeks ago that biotech Adaptive Phage Therapeutics (Gaithersburg, MD; no SBIR) had administered its therapy to select patients in Texas with antibiotic-resistant bacterial infections from Covid-19. Now, it’s armed with a game-changing allowance from regulators — clearing its expanded access investigational new drug application for coronavirus patients infected with certain types of bacteria that cause pneumonia, as well as bacteremia or septicemia, or bacteria in the bloodstream. [Sara Gilgore, DCInno, Nov 19, 20]
Adaptive Phage Therapeutics ( Gaithersburg, MD; no SBIR) landed $7M in fresh capital as it looks to protect people from superbugs. The investment was led by Alexandria Venture Investments and an undisclosed public life sciences company and health care provider. The fresh capital is earmarked for APT's phase 2 clinical trials for PhageBank, its therapy that uses viruses to kill antibiotic-resistant bacteria. [Kieran McQuilkin, DCInno, Oct 9, 19]
The Maryland Technology Development Corp.(TEDCO), has made a total of $600K in seed investments in five different local startups [that] must be based in Maryland, be in the seed stage and create a tech-based product addressing a need in a growing market. TEDCO added these five companies to its 137-active investment portfolio. [Sam Sabin, DCInno, Feb 7, 18] including Adaptive Phage Therapeutics (Bethesda, MD; no SBIR, founded 2016) develops clinical and therapeutic technology that matches phages to patient-specific bacterial infections, enabling medical researchers to develop drugs that can detect and eliminate multi-drug resistant bacteria. [company website] seed round Apr 2017 $765K. [pitchbook.com]
Adaptive TCR (Seattle, WA; no SBIR), a startup that grew out of immune-system profiling work at the Fred Hutchinson Cancer Research Center, has raised $5.8 million in an equity investment round that could be worth as much as $7.5 million over time. [Luke Timmerman, m.xconomy.com, Jun 6, 11]
In Washington state’s biotech cluster, 83 local biotech companies were awarded grants worth a combined $34 million, Adaptive TCR, AVI Biopharma, Omeros, Proteotech, and Trubion Pharmaceuticals and 78 others. [Luke Timmerman, Seattle Times, Nov 3] Most were $245K, a little money for almost everyone. Too little money to make a big swing in effect. Just politics.
Adarza BioSystems (St Louis, MO; $2.5M SBIR) announced that it has raised $25 million in a Series D round [to]support full commercialization of ZIVA, its automated biological testing platform for academic and clinical research. [company press release, Feb 4, 20]
Adarza BioSystems (O’Fallon, MO; $2.2M SBIR in New York state) announced that it has put in place the leadership, new manufacturing center and branding to begin selling its technology to researchers in the second quarter of 2019. [company press release, May 23, 18] .... based on research at the University of Rochester, the diagnostic technology firm came to St. Louis in 2013 in search of funding, facilities and expertise. [David Nicklaus, St Louis Post Dispatch, Feb 23, 17]
Adarza BioSystems (Henrietta, NY; $1.8M SBIR) raised $17 million in its Series C financing round, officials said. .... develops and manufactures immunoassay technology, in the form of microchips, that can identify proteins and genetic markers in medical samples such as blood, officials said. The funding will help the firm expand production capacity in St. Peters, Mo., where its manufacturing facility is based. [Kerry Feltner, Rochester Business Journal, Jan 20, 17] If Trump really wanted to grow good US jobs, he could see that the federal agencies steer SBIR to companies like Adarza instead of sheltering companies that just service government R&D. The mission agencies might go along if the amount of money were substantially cut so the programs didn't feel like they had to have a fair share of it for what theycould do better anyway in open competition. Unfortunately for his "deplorables", they won't qualify for the new good jobs, but then Trump's dream of satisfying them with good jobs is a fantasy anyway.
Cultivation Capital has invested just short of $11 million of the $20 million tech fund it created in 2012. ... started out as a tech fund, created its life sciences fund in 2013 with plans to invest some $30 million over five years. .... its portfolio: Immunophotonics (Columbia, MO; no SBIR) developed a cancer vaccine; Molecular Sensing (Nashville, TN; no SBIR) commercializing a label-free molecular interaction assay system based on Back-Scattering Interferometry; Adarza BioSystems (WEST HENRIETTA, NY; $1.8M SBIR) early stage medical diagnostics; Cardialen (Minneapolis, MN; no SBIR) developed a treatment to keep the heart in a normal rhythm for people suffering from atrial fibrillation (AF) ; Euclises Pharmaceuticals (St Louis, MO; no SBIR) developing pain and cancer medications; Mobius Therapeutics (St Louis, MO; no SBIR) commercial stage venture focused on ophthalmic surgery solutions; Pulse Therapeutics (St. Louis, MO; no SBIR) developed a new approach to accelerate the concentration and delivery of physician-selected agents within the vasculature; Galera Therapeutics (Malvern, PA; no SBIR) focused on the development of breakthrough drugs targeting the oxygen metabolic pathways. [Brian Feldt, St. Louis Business Journal, Oct 27, 14]
Addiction Therapeutix (Wauwatosa, WI; no SBIR) start-up that is developing therapies for people who can't kick alcohol, painkiller and nicotine habits, has licensed several compounds from the University of Wisconsin-Milwaukee. [Kathleen Gallagher, Milwaukee Journal Sentinel, Jan 20]
Jazz Pharmaceuticals plc (Ireland) and Aerial BioPharma, LLC (Morrisville, NC; no SBIR) announced that the companies have signed a definitive agreement under which Jazz Pharmaceuticals has acquired rights to ADX-N05, a novel compound in clinical development for the treatment of excessive daytime sleepiness in patients with narcolepsy. [Jazz website, Jan 13, 14]founded in January of 2011 by the management team from Neuronex and Addrenex Pharmaceuticals, both successful start-ups based in the Research Triangle Park area. Neuronex was acquired by Acorda Therapeutics in 2012 and Addrenex Pharmaceuticals was acquired by Shionogi Pharma in November of 2009 [Aerial website] a deal that could be worth up to nearly $400 million. Jazz paid $125 million up front [Jason deBruyn, Triangle Business Journal, Jan 17, 14]
Addrenex Pharmaceuticals (Durham, NC; no SBIR) has been acquired for $29 million by Sciele Pharma , an Atlanta pharmaceutical company that has already licensed three of Addrenex’s products and is one of its current investors. [Triangle Business Journal, Nov 16, 09]
Adenosine Therapeutics (Charlottesville VA; $7.5M SBIR) got $14M financings from Novartis Option Fund [company press release, Jun 27, 07]
Echelon (Santa Clara, CA; one SBIR, 74 employees) up 98% [Jun 29, 18] Adesto Technologies (Sunnyvale, CA; $800K SBIR), a leading provider of innovative application-specific semiconductors for the IoT era, and Echelon Corporation announced a definitive agreement under which Adesto will acquire Echelon for [a total equity value of approximately $45 million] Echelon is a pioneer in the development of open-standard networking platforms for connecting, monitoring and controlling devices in commercial and industrial applications. [Echelon press release, Jun 29, 18]
Adesto Technologies (Sunnyvale, CA; $700K SBIR) up 18% [Oct 27, 15]
Adesto Technologies (Sunnyvale, CA; $700K SBIR) modest IPO plans got smaller after the chipmaker said it plans to sell its shares well below its target range..... raising about $48 million. ... raised about $56 million since it was founded in 2006 [Cromwell Schubarth, Silicon Valley Business Journal, Oct 15, 15]
Adeza Biomedical shot up by half on news that it was being bought by Cytyc rose 2%. [Feb 12, 07]
Adherex Technologies (Durham, NC) has a deal with a Canadian investment bank for $25M in stock to work on new cancer therapies. Adherex recently regained the rights to develop its most advanced cancer therapy when GlaxoSmithKline decided not to continue assisting in its development., [Raleigh News and Observer, Jan 23] No SBIRs yet.
Adhesys Medical (Houston, TX; no SBIR), maker of a new surgical adhesive, announced a commercialization partnership with Grünenthal (Germany), which is where Adhesys—then known as Medical Adhesive Revolution—was founded. Adheysys won the Rice Business Plan Competition in 2014, receiving investment from Houston investors ... Adhesys’ surgical adhesive is made of polyurethane, a material already used in a variety of commercial applications in construction and automobiles. The issue has been turning that into a medical-grade product for use on and in the body. [Angela Shah, xconomy.com, May 11, 16]
biotech Adial Pharmaceuticals (Charlottesville, VA; no SBIR, founded 2007) set the terms for its IPO. .... plans to earn $14M from its IPO. ..... aimed at treating alcohol-use disorders. [DCInnoBeat, Sep 8, 17] Total Equity Funding $6.73M in 2 Rounds ... research pipeline includes AD04, a compound that completed Phase IIb study for the treatment of alcohol use disorders; and AD01, which completed Phase I clinical stage for treating addictive behaviors. [crunchbase.com, Sep 10, 17]
Adicet Bio down 25% [Sep 22, 20] Determines Not to Proceed with Public Offering of Common Stock [company press release, Sep 22, 20]
Adicet Bio down 37% [Sep 21, 20] announced sale of oommon stock
Adicet Bio (Menlo Park, CA; no SBIR) focused on the development of allogeneic cell therapies for cancer using innovative gamma delta T cells, announced the completion of an $80 million Series B financing [to] continue to develop our proprietary technology, to enter the clinic in Non-Hodgkin’s Lymphoma and to advance our solid tumor programs. [company press release, Oct 2, 19]
Adicet Bio (Menlo Park, CA; no SBIR), a biopharmaceutical company focused on the development of next-generation cell immunotherapies, announced today that it closed a $51 million Series A financing. Adicet also announced the acquisition of Applied Immune Technologies (Israel) that develops immunotherapies directed to the intracellular proteome. ... pioneered and advanced the generation and development of TCRLs for therapeutic and diagnostic applications in cancer, inflammation, autoimmune, and infectious diseases. [company press release, Jan 27, 16]
Five Prime Therapeutics (South San Francisco, CA; no SBIR) closed its second collaboration since it went public [for $62M] in September, bagging a deal around antibodies that could stimulate the immune system to attack cancer cells. .... Terms of the deal with Adimab LLC (Lebanon, NH; no SBIR) were not disclosed, but Adimab will use its antibody discovery technology to identify fully human antibodies for Five Prime. [Ron Leuty, San Francisco Business Times, Jan 9, 14]
Adimab (Lebanon, NH; no SBIR) has found two new partners to come in and test out its antibody drug discovery technology. Celgene and China-based Innovent Biologics will each identify one or more biological targets for Adimab to discover antibodies against, and then license them from Adimab or split their commercialization rights with the company. Adimab, which has done several deals like this in the past, didn’t disclose how much each transaction is worth. [Ben Fidler, xconomy.com, Aug 23, 13]
Adimab (Lebanon, NH; no SBIR) has raised $4 million, reports in a regulatory filing. ... [founder] Gerngross, an engineering professor at Dartmouth College, previously founded the biotech company GlycoFi ($2.2m SBIR)., which he sold to Merck & Co. Inc. for over $400 million. [Mass High Tech, Dec 1, 10]
AdiMab (Lebanon, NH; no SBIR) a biotech focused on antibody discovery technology, has closed a Series B round of venture capital to fuel growth and hire more workers, company officials said. ... $6.2 million Series A round last summer. Gerngross said the value of his biotech has increased by 300 percent from the time of the Series A to the Series B, based on investor valuations [Mass High Tech, Mar 26]
Most Promising Technology ... at the 10th Annual SmartStart UNYTECH Venture Forum– ADispell (Rochester, NY; no SBIR) biotech that develops new treatments for Alzheimer’s patients [Business Review (Albany), May 19, 10]
The BioMaryland
Center has awarded
nearly $1 million in grants to five life sciences firms. The companies
received up to $200,000 each and will use the funding for research.
... part of the Maryland Department of Business and Economic
Development. The recipients:
ADMA Biologics (Ramsey, NJ; no SBIR) up 21% [Feb 12, 19] biopharmaceutical and specialty immunoglobulin company that manufactures, markets and develops specialty plasma-derived biologics for the treatment of immune deficiencies and the prevention of certain infectious diseases, announces that it has entered into a senior secured term loan facility for up to $72.5 million. [company press release, Feb 12, 19]
Admittance Technologies (Austin, TX; no SBIR) raised $3.8 million [Austin Business Journal, Jun 29, 15] the application of CardioVol™, which can interrogate the heart with electric fields, and in real-time provide ventricular volume data including relative stroke volume. [company wbsite]
CardioVol [by Admittance Technologies (San Antonio, TX; no SBIR)] turns pacemakers into heart monitors .... the potential to save lives through the early detection of heart attack symptoms. .... developed by Dr. Marc Feldman, at the Health Science Center, who has accomplished a rare feat by having two of his companies receive funding from the Texas Emerging Technology Fund (ETF). [Mike Thomas, San Antonio Business Journal, Jan 18, 13] The sometimes blatantly political Texas Emerging Tech Fund gave $1.99M for the commercialization of CardioVol™. [company website]
Novartis (Swiss giant) said it broadened its immuno-oncology pipeline with the acquisition of Admune Therapeutics (Danvers, MA; no SBIR) and licensing agreements with Xoma and Palobiofarma (Spanish) [Reuters, Oct 21, 15]
Bristol-Myers Squibb said yesterday that it would pay $430M for Adnexus Therapeutics (Waltham, MA; no SBIR), a privately held biotechnology company whose lead product is a cancer drug in the earliest stages of human trials. ... is owned by a handful of venture capital companies [Reuters, Sep 25]
Adolor up 143% [Oct 24, 11] Cubist Pharmaceuticals agreed to buy all outstanding shares of Adolor Corp. with an up-front payment of $190 million. Adolor can qualify for additional payments if its drugs achieve regulatory and commercialization milestones; the total transaction is valued at up to $415 million,... Adolor markets a drug designed to accelerate recovery time for patients who have had bowel resection surgery, and it has another promising drug candidate in its pipeline. [Chris Reidy, Boston Globe, Ocr 25, 11]
Adolor said it is laying off 30 workers, or nearly 30 percent of its work force. [Philadelphia Business Journal, Jul 15, 10]
Adolor fell 8.7% after the company's Phase II trials of two possible treatments for osteoarthritis failed to meet the goals of the study. [Wall Street Journal, Jun 19, 10]
Adolor said it is eliminating 45 jobs, or 285 of its work force, and implementing other cost-saving moves to reduce its operating cash burn rate. [Philadelphia Business Journal, Jun 3, 09]
Adolor up 17% [Feb 3, 09]
Adolor up 10% [Oct 20, 08]
Adolor up 18% [Oct 16, 08]
Adolor down 12% [Sep 17, 08]
Adolor down 11% [Jul 7, 08]
Adelor down 10% [Mar 14, 08]
Adelor up 19% [Dec 5, 07] after a deal with Pfizer.
Adolor up 13% [AP, Nov 28, 07] after it and GlaxoSmithKline PLC said that a U.S. Food and Drug Administration committee will review Adolor's application for experimental drug Entereg, which treats stomach-related side effects after surgery.
Adolor up 12% [Aug 7, 07]
Adolor's stock free-fell 60% after the company announced it had suspended for safety reasons clinical testing of its lead new drug candidate as a potential treatment for opioid-induced bowel dysfunction. [bizjournals.com] [Apr 10, 07]
Adelor up 26% [Mar 12, 07] on news that Glaxo will expand the testing of Adelor's bowel drug.
Avalon Ventures and UK-based drug giant GSK said they have formed another San Diego biotech startup. ... PDI Therapeutics (named for the enzyme protein disulfide isomerase, La Jolla, CA) , will develop immunotherapies for cancer. Like all other companies formed under the three-year-old partnership, PDI will be housed at Avalon's COI Pharmaceuticals, an incubator that provides shared facilities and management. Meanwhile, Avalon said the first two companies created under the collaboration, Sitari Pharmaceuticals and Silarus Therapetics, have identified a clear path to potential drugs, thus meeting their first milestones, said Jay Lichter, an Avalon managing director and also COI's president and CEO. Sitari and Silarus are respectively developing drugs for celiac disease and iron overload disorders. ... GSK and Avalon established their partnership in April 2013, with up to $465 million from GSK and up to $30 million from Avalon to form up to 10 companies in San Diego. Up to $10 million in Series A funding is to be invested in each company to get it off the ground. ... The five other companies founded by the Avalon/GSK collaboration are Thyritope Biosciences, Adrenergics, CadheRx Therapeutics, Calporta Therapeutics, and Iron Horse Therapeutics. [Bradley Fikes, San Diego Union Tribune, May 20, 16]
Crossing the halfway point in their alliance to form up to 10 biotech companies in San Diego, La Jolla's Avalon Ventures and UK-based GlaxoSmithKline they have added three new companies to their portfolio. Adrenergics (no SBIR), CadheRx Therapeutics (La Jolla, CA; no SBIR), and Calporta Therapeutics (no SBIR), will each receive up to $10 million, along with research and development support from the partners. Previously announced companies include Sitari Pharmaceuticals (San Diego, CA; no SBIR) , Silarus Therapeutics (La Jolla, CA; no SBIR) , and Thyritope Biosciences (San Diego, CA; no SBIR). [Bradley Fikes, utsandiego.com, Jun 15, 15]
Rocket Ventures, a pre-seed, early-stage venture fund for technology-based [Ohio] companies, has awarded Ignite! grants to three Toledo firms - ADS Biotechnology, TechTol Imaging, and DoX Systems. These grants are given to help the companies develop and use technology to create new products or improve processes that have an impact on jobs and revenues in Northwest Ohio. [Toledo Free Press, Jun 13, 08] No SBIR.
Chinook Therapeutics (Canada) is set to merge with fallen Big Pharma darling Aduro Biotech (Berkeley, CA; $700K SBIR) to create a kidney disease player with $180 million in cash. [Nick Paul Taylor, Fierce Biotech, Jun 3, 2020]
Aduro Biotech (Berkeley, CA; $600K SBIR, founded Y2K) is laying off nearly 60 percent of its workforce and closing its European office in a cash-saving move. The corporate shakeup comes one month after Novartis (NYSE: NVS) removed a clinical-stage Aduro cancer drug from its portfolio and nearly one year after a restructuring that cut the biotech’s workforce by 37 percent to focus on its cancer drug pipeline. [xconomy.com, Jan 10, 20] total funding $178M [crunchbase.com]
Aduro Biotech down 40% [Jun 2, 19] announced the presentation of data from an ongoing Phase 1b clinical trial in collaboration with Novartis. [company press release, Jun 2, 19]
Aduro Biotech down 21% [May 8, 19]
Aduro Biotech down 29% [Oct 22, 18]
Aduro Biotech up 11% [Sep 28, 18]
Aduro Biotech up 10% [Sep 27, 18]
Aduro Bioech down 10% [Sep 7, 18]
Aduro Biotech up 10% [Aug 31, 18]
Aduro Biotech down 10% [Jul 30, 18]
Aduro Biotech down 15% [Jun 4, 18]
Aduro Biotech up 11% [Mar 9, 18]
Adoro Biotech down 11% [Jan 24,18]
DNA-encoded library technology expert HitGen just inked a multiyear, multitarget drug discovery deal with Aduro Biotech. [Fierce Biotech, Aug 15, 17]
Aduro Biotech down 10% [Nov 28, 16]
Aduro Biotech up 14% [Nov 9, 16]
Aduro Biotech up 10% [Nov 7, 16]
Aduro Biotech up 11% [Nov 4, 16]
Aduro Biotech reported bad news about its combination immunotherapy treatment for advanced pancreatic cancer. In a Phase 2 trial, patients taking the treatment, based in part on Aduro’s engineered Listeria bacteria, did not fare as well as patients who were on chemotherapy. [Ben Fidler, xconomy.com, May 20, 16]
Aduro Biotech down 17% [May 16, 16] Trading of Aduro was halted earlier as the drug maker said patients with advanced pancreatic cancer taking a combination of its immunotherapies in a clinical trial did not fare as well than those on standard chemotherapy. Due to the disappointing results, Aduro will shelve its work on third-line pancreatic cancer—that is, in patients who haven’t responded to at least two other kinds of treatment for what is one of the deadliest forms of cancer. [Alex Lash, xconomy.com, May 16, 16]
Aduro Biotech up 10% [Apr 6, 16]
Aduro Biotech down 12% [Mar 10,16]
Aduro Biotech up 10% [Mar 1,16]
Aduro Pharma down 12% [Feb 8, 16]
Aduro Biotech down 16% [Nov 24, 15]
Aduro Bio up 12% [Nov 23, 15]
Aduro Biotech (Berkeley, CA; $300K SBIR) added antibody technology expertise by acquiring Dutch firm BioNovion for $32.4 million with possible future payments as well. ... the deal adds to Aduro’s preclinical pipeline; its lead program is in Phase 2b trials for pancreatic cancer. [Bruce V. Bigelow, xconomy.com, Sep 25, 15]
Fast-growing Aduro Biotech [Berkeley, CA; $300K SBIR) will take little more than half of a new Wareham Development building in Berkeley's Aquatic Park with an option for the remainder of the four-story structure. ... main drugs focus on revving up the immune system to fight off cancer, zeroing in on some of the toughest-to-fight tumors. It is in a Phase II trial, for example, in metastatic pancreatic cancer and it plans to start a late-stage trial in mesothelioma. [Ron Leuty, San Francisco Business Times, Sep 18, 15]
Aduro Biotech up 12% [May 4,15]
Aduro Biotech down 13% [Apr 28,15]
Aduro Biotech down 11% [Apr 27,15]
Aduro Bio down 10% [Apr 21,15]
Aduro Biotech (Berkeley, CA; $300K SBIR) up 147% [Apr 15,15] following its $119M IPO in biotech bubbleland, putting its market cap at $2B. In March it planned an $86M IPO. A competitor, Advaxis ($1.5M SBIR) [down 12% [Apr 15,15], is developing similar cancer immunotherapy drugs that also involve re-engineering listeria to stimulate a patient's immune system. [Adam Feuerstein, the street.com]
Aduro Biotech (Berkeley, CA; $300K SBIR) filed to raise up to $86 million [IPO] ... has raised $143.4 million to date in eight rounds ... founded in 2000 to develop early-stage cancer therapies. [Ben Soriano, Silicon Valley Business Journal, Mar 13, 15]
Aduro BioTech (Berkeley, CA; $300K SBIR), said it has raised a $51 million Series D round from investors ... the kind that often signal a try for an IPO is coming soon. The cash helps Aduro push ahead with its cancer immunotherapy programs, one of which employs a highly unusual approach, as Xconomy San Francisco editor Bernadette Tansey explained in this story from last summer. [Alex Lash, xconomy.com, Jan 8, 15]
Tiny Aduro BioTech (Berkeley, CA; $300K SBIR) experimental cancer vaccine has come up big again, landing a potential $817 million deal with Johnson & Johnson’s Janssen Biotech unit around lung cancer, the companies said ... Aduro and Janssen in May signed a potential $365 million deal centered on the same technology to treat prostate cancer. .... This latest deal gives Aduro $30 million upfront and the ability to receive more if the lung cancer treatment, called ADU-214, hits certain development, regulatory and commercial milestones. [Ron Leuty, San Francisco Business Times, Oct 16, 14] If you have a big deal innovation, someone big has a big deal for you.
Aduro BioTech (Berkeley, CA; one SBIR) recently has raised a $55 million venture round and licensed its genetically engineered version of the food-borne bacterium Listeria to Johnson & Johnson, which wants to use it to develop treatments for prostate cancer. Aduro is pursuing its own program in pancreatic cancer. [Alex Lash, xconomy.com, Jun 19, 14]
tiny Aduro BioTech (Berkeley, CA; $300K SBIR) is making news with results from a mid-stage study in one of the toughest cancers to beat. Pancreatic cancer patients on the company’s therapy — a combination of two “cancer vaccines” that Aduro picked up on the cheap after they were dubbed failures on their own — lived a median of 6.1 months, according to results of a 93-patient Phase II study delivered by Dr. Dung Le, an assistant professor of oncology at the Johns Hopkins Sidney Kimmel Comprehensive Cancer Center..... has raised about $40 million total [Ron Leuty, San Francisco Business Times, Jan 14, 14]
Advanced Animal Diagnostics (Morrisville, NC; one SBIR) raised $1.5 million, half of a $3 million debt offering that has yet to close. [Jennifer Henderson, Triangle Business Journal , Oct 28, 16]
VC awards in the [NC] Triangle: G1 Therapeutics (Research Triangle Park, NC; no SBIR) an oncology drug developer raised $47 million in Series C funding in May; Spyryx Biosciences, (Durham, NC; no SBIR) a lung disease therapy developer $4.5 million; T3D Therapeutics (Research Triangle Park, NC; $1.8M SBIR), an Alzheimer’s disease therapy developer $3 million; and Advanced Animal Diagnostics, (Morrisville, NC; one SBIR) livestock farming diagnostics company $1.8 million. [John Murawski, Raleigh News & Observer, Jul 15, 16]
Advanced Animal Diagnostics (Durham, NC; one SBIR 2004, founded 2001) raised nearly $15 million in a private placement round. ... develops products to help farmers detect and diagnose diseases in livestock. [Jason deBruyn, Triangle Business Journal, Dec 3, 14]
Advanced Animal Diagnostics (Durham, NC; one SBIR in 2004, founded 2001) raised $2.5 million in a private placement round. ... develops products to help farmers detect and diagnose diseases in livestock. ... Most recently, the company raised $6 million in venture money [Jason deBruyn, Triangle Business Journal, Sep 10, 14]
[Irish] Pharmaceuticals Shire has agreed to sell its Dermagraft treatment to U.S. group Organogenesis (Cambridge, MA; $300K SBIR a decade ago), taking a $650 million hit on the loss-making bio-engineered skin substitute it bought less than three years ago. Shire had hoped that Dermagraft would be the foundation of a regenerative medicine franchise when its acquired owner Advanced BioHealing (Westport, CT; no SBIR) for $750 million, but it received a setback when the treatment for diabetic foot ulcers failed to be approved for leg ulcers months after the deal in June 2011. The company said on Friday that Dermagraft's prospects had also reduced significantly after changes in U.S. federal reimbursement payments for wound-care products. Shire said it will receive no upfront payment from Organogenesis but it would be entitled to up to $300 million cash in milestone payments if it meet sales targets up to 2018. [Paul Sandle, Reuters, Jan 17, 14]
Advanced BioHealing (Westport, CT; no SBIR), a developer of cell-based regenerative skin therapy, has filed terms of an initial public offering, for which it plans to raise about $200 million. ... makes and sells its Dermagraft product, an FDA-approved skin substitute developed to treat diabetic foot ulcers. ... employs about 150 people and maintains a manufacturing facility in La Jolla , CA [Michelle Lang, Mass High Tech, May 6, 11] founded in 2003 to develop and commercialize bioengineered tissue products. By 2005, two rounds of venture financing totaling $10.4 million had been raised [company website]
Bioventus (Durham, NC; no SBIR,spun out of Smith & Nephew and has been a stand alone entity since May 2012) acquired BioStructures (Newport Beach, CA; no SBIR), a maker of bioresorbable bone graft products. ... In 2014, Bioventus acquired the OsteoAMP product line, intellectual property and commercial business from Advanced Biologics (no SBIR). [Jason deBruyn, Triangle Business Journal, Nov 30, 15]
Back to SBIR. Advanced Bionics ($500K SBIR) will become an independent company again, with businesses in cochlear implants and its development program in drug pumps as Boston Scientific unwinds its 2004 acquisition ... Boston Scientific will be left with Advanced Bionics' pain-management business, including a spinal-cord stimulator for chronic pain, and the Bion, which is in development to treat migraine headaches. [Keith Winstein, Wall Street Journal, Aug 10]
Bio-Techne (Minneapolis, MN; no SBIR) maker of biotech research supplies is acquiring Advanced Cell Diagnostics (Newark, CA; $4.2M SBIR, 100 employees) biotech firm for $250 million, marking a step into new territory, the company announced this week. [Covey Son, Minneapolis Star Tribune, Jul 8, 16]
Biotech startup Advanced Cell Diagnostics (Hayward, CA; $4.2M SBIR in one Phase 2, founded 2007) raised $22 million in Series C funding to accelerate research. ... uses “in situ” (on site) RNA detection with a platform called “RNAscope” technology. The technology can profile single gene expression by studying the targeted molecular structure of each cell in a sample. ... capable of detect every gene in the human transcriptome. [Gina Hall, Silicon Valley Business Journal, Jun 19, 15]
Advanced Cell Diagnostics Closes $12M Series B Funding Round. a Larta NIH-Commercialization Assistance Program alumnus, develops cell- and tissue-based diagnostic tests for personalized medicine, which promise greater efficacy at lower cost, as they will allow customized treatments based on the profile of a disease in individual patients. ACD's ongoing efforts include developing proprietary diagnostic tests for cancer management. ... will support the commercial expansion of its proprietary technology and accelerate the entry into the clinical diagnostics market. [LARTA, Dec 19, 12]
Advanced Cell Diagnostics (Fremont, CA;$1.2M SBIR) has been awarded a three-year, $3 million grant from the National Cancer Institute ... developing its tumor-detection system for circulating tumor cells [San Francisco Business Times, Oct 8, 10]
Advanced Cell Technology (Marlborough, MA; $500K SBIR) said it expects as early as Friday to start the process for regulatory approval of what experts said would be the first human trial involving stem cells created by reprogramming adult cells back to an embryonic-like state. [Johnathan Rockoff, Wall Street Journal, Dec 14, 12]
Advanced Cell Technology (Worcester, MA; $400K SBIR) has landed a $25 million financing and been cleared by the U.S. Food and Drug Administration for its Investigational New Drug application to use human embryonic stem cells (hESC) in treating Dry Age-Related Macular Degeneration. [Mass High Tech, Jan 3, 11]
Advanced Cell Technology said that its is closing its research facility and Charlestown and won’t be renewing its lease on its headquarters in Alameda. Calif., in an effort to cut operating expenses. [Mass High Tech, Sep 9]
Advanced Cell Technology ($200K SBIR), the biotechnology company that recently announced it was having financial troubles, may find relief from its latest accomplishment. The firm announced that its scientists have used human embryonic stem cells to generate billions of blood cells. Though the technique is still preliminary and has not been proven safe in animals, the hope is that it could eventually lead to a new supply of blood for patients. The research appears online (pre-published ahead of print) in the journal Blood. [AAAS, Aug 27, 08]
Advanced Cell Technology a developer of stem cell treatments, has granted an exclusive license, potentially worth up to $1.25 million, to Embryome Sciences Inc. [Mass High Tech, Aug 11, 08]
For the past decade, Advanced Cell Technology (Worcester, MA; $300K SBIR) has claimed one spectacular success after another. ... the first to clone an endangered species ... cloned the first human embryo ... Now, ACT could be on the verge of shutting down. ... the company warned that it doesn't have cash to continue operating after July 31 without raising additional money or drastically slashing operations. [Todd Wallack, Boston Globe, Jul 17, 08]
Advanced Cell Technology (one SBIR) reports that, along with colleagues from the University of California, San Francisco and embryo bank StemLifeLine, the company has developed five human embryonic stem cell lines without having to destroy any embryos. [Mass High Tech, Jan 11, 08]
A Los Angeles-based developer of stem cell treatments with research facilities in Worcester [MA] is on the hunt for corporate partners to develop recently acquired products and therapies. Advanced Cell Technology (one SBIR) took ownership of a stem cell treatment for heart failure through a $5M acquisition of Boston's Mytogen (no SBIR), completed in September. [Mass High Tech, Dec 7]
Eyes Are Watching. Advanced Ceramics Research got some notoriety from the investigation of Congressman Curt Weldon (a huge friend of Defense) for its payments to lobbyists: paid Grimes $60,000 as its registered lobbyist in 2003 and 2004. An affiliate of Advanced Ceramics paid her an additional $40,000 during that time, according to her lobbying registration documents. Weldon gave testimonials on behalf of Advanced Ceramics Research in two separate hearings of the House Armed Services subcommittee on tactical air and land forces, which he chairs. Weldon had invited the Arizona company's CEO to testify in 2004 and 2005 about what he characterized as its "very interesting work in developing state of the art composites that have increased performance while significantly reducing component cost." ... Some watchdog organizations [like Taxpayers for Common Sense] previously noted Weldon's support for companies that had little to do with his constituents in Delaware County and that paid fees to the firm operated by his daughter and Sexton, or to a close friend of Weldon's, lobbyist Cecilia Grimes. [Jeffery Smith and Carol Loennig, Washington Post, Oct 18] Advanced Ceramics, and its apparent manufacturing spinoff (same address), have had $20M of SBIR.
Business Week (June 23) reports that Advanced Ceramics Research (Tucson) makes plastic bones that can be tailored to the exact shape needed for compound fractures. It says that ONR "pioneered" such rapid prototyping and indeed ONR gave ACR two Phase 2 SBIRs for such osteoinductive material work. ACR has been blessed with many SBIRs (29 DOD Phase 1s since 1992 leading to five Phase 2s so far, and three NASA Phase 2s). FDA approval could come in 3-4 years.
Advanced Circulatory Systems (Eden Prairie, MN; $7M SBIR) has received FDA clearance to sell its ResQCPR device, which helps paramedics and first-responders give more effective CPR to patients. ... in December agreed to be sold to Zoll Medical Group ; it'll keep its Minnesota headquarters. ... received more than $17 million in federal grants through the National Institutes of Health and the Department of Defense in recent years. [Mark Reilly, Minneapolis / St. Paul Business Journal, Mar 10, 15]
Advanced Circulatory Systems (Roseville, MN; $7M SBIR) has reached a deal to be sold to Zoll Medical for an undisclosed amount. ... develops technology that prevents heart and brain damage by boosting blood flow to critical organs. [Katharine Grayson, Minneapolis / St. Paul Business Journal, Dec 22, 14]
Advanced Circulatory (Roseville, MN; $7.2M SBIR) received $2 million in bridge financing to fund the launch of a device that treats cardiac arrest. .... seeking regulatory approval to sell its ResQCPR system, which helps keep blood flowing to a trauma patient's heart and brain during cardiac arrest. .... has received more than $17 million in federal grants through the National Institutes of Health and the Department of Defense in recent years [Katherine Grayson, Minneapolis / St Paul Business Journal, Jul 31, 13]
The Department of Energy has awarded $53 million [of SBIR] to multiple small businesses to develop clean energy materials and systems in support of the Biden administration’s net-zero emission goals. Proposals include a lithium-ion electric vehicle battery from Bioenno Tech (Santa Ana, CA; $4M prior SBIR), a bio-based composite material from Z&STech (no apparent SBIR) and a direct air capture system from Advanced Cooling Technologies (Lancaster, PA; $80M prior SBIR; competitor in same city,Thermacore; $32M prior SBIR). ... Charles River Analytics (Cambridge, MA; $270M SBIR) proposed a method to detect an attack on critical infrastructure assets such as power grid, while Cornerstone Research Group (Miamisburg, OH; $127M prior SBIR) offered a predictive health monitoring tool to maintain electric grid systems. [Mary-Louise Hoffman, govconwire.com, May 19, 2022] prior SBIR data from SBA
Air Force (USAF) selected Sierra Nevada (Sparks, NV; $1M SBIR, founded 1963, 2500 employees) and its partner Embraer (Brazil) Defense and Security for its Light Air Support (LAS) program. ... deemed the A-29 Super Tucano aircraft, and the overall solution offered by SNC, to be the superior choice for this critical mission. The initial $427.5 million delivery order is to supply the USAF with 20 A-29 Super Tucano aircraft. ... for. light air support, reconnaissance and training capabilities to the Afghanistan military. As such, it is a vital element of the United States’ Afghan withdrawal strategy .. work will be in Jacksonville, FL [company press release Feb 27, 13] over the years it has gathered up companies: Space Dev (Poway, CA; $5M SBIR) ; MicroSat Systems (Littleton, CA; $11M SBIR) ; Straight Flight (Denver, CO; no SBIR) ; Waveband (Torrance, CA; $17M SBIR); Aviation Resources Delaware (no SBIR); Inter-4 (San Francisco, CA; no SBIR); Turtle Mountain Communications (no SBIR) ; Plano Microwave (Plano, TX; no SBIR) ; Spectral Systems (Beavercreek, OH; no SBIR) ; Advanced Countermeasure Systems (Sacramento, CA; no SBIR) .
Wisconsin investors also participated in a $3.5 million funding round for an Illinois company, Advanced Diamond Technologies (Romeoville, IL; $700K SBIR) firm turns natural gas into diamond for a variety of industrial, electronic and medical applications. [Kathleen Gallagher, Milwaukee Journal Sentinel, Sep 30, 09]
Advanced Electron Beams (Wilmington, MA; no SBIR) said it has closed a $14.2 million Series C financing, bringing its total amount raised to more than $50 million since October 2005. [Boston Globe, Aug 4, 09]
| A Party, A Party (Apr 21) On-Line Technologies is having a grand opening party for its manufacturing line. The Governor will remark. On-Line is a spin-off of Advanced Fuel Research (East Hartford, CT) which has consumed tons of SBIR money (and recently ATP $2.8M) for its FT-IR technology. AFR's WebPage on SBIR is still under construction (it takes a long time to make a credible rationale for so much investment). Because AFR and On-Line are private companies, they don't have to tell the public nuttin'; only the federal agencies who have supplied all the money can demand an accounting and they don't seem so inclined. The agencies don't mind the ton of kerosene to light a fire in whose glow they (and the local politicians) would then bask. They believe you can do great things as long as you don't mind how much money it takes. And On-Line's Website pretty much adopts that strategy with the usual stuff about our wonderful products. Nevertheless, a manufacturing line merits a some celebration in SBIR companies. | Is there any harm in pouring all that kerosene into AFR? Depends on your view. If you're a federal agency who has committed itself to a technology, more money is good, not bad, and the competent R&D companies feed well on that. If you are a startup or an existing commercializer with a new idea, you often get shut out as the money goes to the established SBIR companies. Never-had-SBIR companies like startup Actify (San Francisco) and commercializer TM Electronics (Worcester) get not even a Phase 1 to even show their new technologies. Consider the calculus: every Phase 2 to an established company for struggling technology cuts out ten Phase 1 awards to new ideas (whenever the agency caps its SBIR). |
So, you have an interesting concept for an instrument that you think industry will want because it lets them monitor gas temperatures at a distance? You soon find that industry is not as enthusiastic as you are and so you try the government to get R&D money to develop something that industry will surely buy. You tell that story to government, who really doesn't know all that much about industry economics. Lo, and behold, government gives you a cool half-million to develop it. But industry still won't buy it. Maybe you, too, don't understand the industry economics. Why not try government again with the same story? Nah, they can't be that dumb! Oh, really? Consider the case of FT-IR technology at Advanced Fuel Research (East Hartford, CT).
| |
Advanced Fuel Research Phase II SBIRs for FT-IR | ||
|---|---|---|---|
| NASA | 85 | In-Situ Characterization of the Size and Composition of Atmospheric Aerosols by FT-IR | |
| Energy | 86 | Measurement and Observation of Combustion Performance and Coal Water Fuels | |
| USAF | 88 | Materials High Temperature Measuring Instr Emissivity Spectral Emissometers | |
| SDIO | 90 | In Situ Diagnostics for deposition of High T Superconducting Films | |
| NSF | 91 | Temperature Modulation Method for In-Situ Measurement of Surface Treatment & Emissivity | |
| NSF | 92 | Temperature Modulation Instrument for Glass Manufacturing | |
| USAF | 92 | Novel Test Method for Fuel Thermal Stability | |
| Army | 92 | High Temperature Oxygen Index Apparatus Stability | |
| NSF | 92 | A New Method of Time-Temperature Modeling of Sedimentary Basins | |
| NSF | 92 | Measurements and Modeling of the Behavior of Charring Polymers in Fires | |
| USAF | 93 | Process Monitoring and Control During Plasma Processing of Semiconductors | |
| BMDO | 93 | Miniaturized FT-IR Sensor for Infrared Measurement | |
| NSF | 93 | In-Situ Measurement of Sub-Micron Particles during Synthesis from Gaseous Pre-Cursors | |
| NASA | 94 | Blackbody reference for Infrared Imaging Systems | |
| Energy | 94 | On-Chip IR Spectral Sensors by Superconducting Detector Arrays | |
| Energy | 94 | An In-Situ Particle Sensor for Metal Forming Processes | |
| USAF | 95 | Real-Time FT-IR Diagnostics and Control of Semiconductor Fabrication | |
| NSF | 95 | Fourier Transform Infrared Diagnostics | |
| NASA | 95 | Process Control for Plasma Spray Coating | |
| DARPA | 96 | Rapid Thermal Annealing Process with Real-Time Monitoring for SiO2 Layer | |
| Army | 96 | Fiber Optic Raman Probe for Real-Time Monitoring of Composite Viscosity and Intelligent Process Control of Autoclave Cure | |
| NSF | 96 | On-Line Control of Particulate and Volatile Air Toxic Emissions from Thermal Treatment Systems | |
| NSF | 96 | NonIntrusive Diagnostics for Sooting Combustion Systems | |
| Energy | 97 | Sensors for Performance Monitoring of Advanced Gas Turbines | |
| NSF | 97 | In-Line Process Monitoring & Control for Poly-Silicon Formation Inside Cluster Tools | |
| If there's a problem, who's responsible and what's the solution? Whatever, don't blame AFR which merely proposed what it would like to do. The government apparently accepted the promise of a bright future over and over. Could these proposals simply have been the best of a bad lot? Who would believe that with all the government and small firm blather about "a highly competitive" program? 'Nuf Said? Now, if you want the Complete History, dig into what was funded before 1993 by all the agencies whose Websites don't report earlier SBIRs (wonder why?). But then you don't need a longer history to get the message that government's view of history circumnavigates the present. | |||
Advanced Ionics (Milwaukee, WI; $500K SBIR) closed a $12.5 million Series A financing ... a pioneer in scalable, sustainable green hydrogen production [company press release, Aug 15, 2023]
AdvancedLife Sciences led all downers 19% [Jul 2, 07] after bad news on the trials for its pneumonia drug.
Advanced Life Sciences down 10%. [Jun 25, 07]
Investors who stuck with Advanced Life Sciences even after it delayed completion of Phase 3 clinical trials on cethromycin felt rewarded when the Food & Drug Administration granted it "Orphan Drug" designation. ... The U.S. Army Medical Research Institute of Infectious Diseases is collaborating with Advanced Life on cethromycin [Gene Marcial, Business Week, Apr 2, 07]
Defense giant Lockheed Martin has acquired Deposition Sciences (Santa Rosa, CA; $500K SBIR, 85 employees, a subsidiary of Advanced Lighting Technologies (Solon, OH; no SBIR)) that provides thin film coatings [Emily Mekinc, Washington Business Journal, Jun 19, 14]
Baebies (Durham, NC; no SBIR) raised $13 million to develop technologies to advance newborn screening worldwide. ... Pamula and CEO Richard West founded Baebies after the sale of Advanced Liquid Logic (Research Triangle Park, NC; $10M SBIR) to Illumina (in 2013 for undisclosed amount) and licensed its core technology, digital microfluidics, from Illumina. In addition to a technology license in newborn screening that does not include sequencing, Baebies also received equipment, contracts, and other consideration in exchange for a share of ownership in the new company. [Jason deBruyn, Triangle Business Journal, Jul 28, 15]
The N.C. Biotechnology Center, a nonprofit whose state funding is in jeopardy, is hoping its track record as a “a catalyst” for the state’s life science companies will enable it to survive. ... is in essence a support group for the state’s life science industry. .... Entrepreneur Richard West, who has co-founded four life science companies,talked up the benefits of the biotech center. He said his third company, Advanced Liquid Logic (RTP, NC; $10M SBIR, sold for $96 million in 2013 ), parlayed $500,000 in loans from the biotech center into $60 million in additional funding. ... was created in 1984, when Hunt, a Democrat, was governor. Today, Gov. Pat McCrory is a Republican and the GOP holds a majority in both the House and Senate. [David Ranii, Raleigh News & Observer, Jul 21, 15] Republicans are allergic to public subsidy of anything except tax breaks for existing business. R&D subsidy programs are equally allergic to ROI accounting.
Advanced Liquid Logic (Morrisville, NC; $10M SBIR) startup creating “Lab on a Chip” diagnostics, has been acquired by Illumina .... Its microfluidics technology will enable Illumina to advance more efficient next-generation sequencing (NGS). Financial terms were not disclosed. .... the North Carolina Biotechnology Center, responding to a 25 percent budget cut, counts ALL among its portfolio companies, having granted the startup four loans totaling $468,100. N.C. Biotechnology Center spokesperson Robin Deacle confirms that the loans have been repaid. ALL has nabbed other investments over the past few years, including $6 million from angel investors, $30 million in federal research grants and $20 million in strategic partner funding, she notes. [Lauren Ohnesorge, Triangle Business Journal, Jul 23, 13]
Advanced Liquid Logic (RTP, NC: three Phase 1 SBIRs) won a runner-up award in the Semiconductor field for Technology Innovation 2007 by the Wall Street Journal.
Advanced Magnetics says it will sell common stock in a public offering to raise $130-150M. [May 07]
Advanced Magnetics settled its suit with Cytogen by paying $4M cash and releasing 50,000 shares of Cytogen stock to regain rights to two experimental products for use in detecting cancer. [Mass High Tech, Feb 16]
Revenue has dwindled, down nearly 80 percent from 16 years ago, and losses have gotten steeper. But then there is this: Advanced Magnetics shares have soared 430 percent, from $11.08 to $59.54 so far this year, making it the most successful Massachusetts stock of 2006. [Steven Syre, Boston Globe, Dec 28, 06]
Advanced Magnetics will sell another piece of itself for $132M which will more than cover the $25M loss in 2006 by its 36 workers. [facts from Mass High Tech, Dec 8, 06].
It Works! The Phase III clinical trial of Advanced Magnetics's ferumoxytol for blood iron was so good that the stock jumped 30%. Or as a sciencecrat said demonstrated a statistically significant achievement of all the primary and secondary endpoints. [Nov 17, 06]
Advanced Photonix up 10% [Oct 23, 07] after announcing that its subsidiary, Picometrix, has received a follow-on $750K AF Phase II SBIR for further non-destructive testing (NDT) application development involving the testing of radomes for defects such as delaminations and water intrusion utilizing the T-Ray 4000 terahertz system platform. [company press release] Picometrix started life in 1992 with an SDIO SBIR when Steve Williamson got fed up with his university's handling of patenting his work.
We own the night! Advanced Photonix jumped 26% when it said it had booked a $520K Army buy of its (LED) Arrays used for night vision displays in the Army that claims to own the night. API is most notably a vendor of avalanche photodiodes. It had one Phase 2 SBIR, from BMDO, in 1993 for single-chip photodetector arrays when it had 65 employees and a market cap around $50M. Now it has 50 employees and a market cap of only $16M.
Ultra Electronics Advanced Tactical Systems has been awarded a $14.3 million contract from the U.S. Navy as Advanced Programming Concepts (one SBIR in 1990), develops tactical command and control systems. [Christopher Calnan, Austin Business Journal, Dec 1, 10]
Fourteen startups that received a total of more than $17 million from [Texas Emerging Technology Fund managed by Gov. Rick Perry’s office... which has backed 143 startups] have failed or gone bankrupt. .... [ MIT professor Bill Aulet, who is managing director of the Martin Trust Center for MIT Entrepreneurship] said the number of failed ETF companies would be higher if state officials took the chances they needed when investing in startups. "They really haven't taken any risk," he said. "Governments aren't good at being venture capitalists because governments aren't good at risk." .... a partial list of the ETF-backed startups in Texas that have since closed, followed by the grant amounts they received: • NanoTailor, $250,000; • Star Vision Technologies, $750,000; • Terrabon, $2.7 million; • Thrombo Vision, $1.5 million; • Nanocoolers, $3 million; • Advanced Receiver Technologies, $250,000; • Bauhaus Software, $500,000; • Net Watch Solutions, $500,000; • Sunrise Ridge Algae, $250,000; • SeprOx, $750,000; • Speer Medical, $2.5 million [Christopher Calnan, Austin Business Journal, Jan 9, 14] None of these had SBIR.
Advanced Scanners (Austin, TX; no SBIR) making a 3D optical vision platform to track brain movements during brain surgery, announced it has raised a $1.5 million seed round. [AustinInno, Oct 7, 19] Surgical navigation systems rely on the patient’s preoperative MRI to guide the surgeon during surgery. BUT the brain is continuously changing shape during the procedure. The FDA recently warned surgeons that errors in surgical navigation systems are causing patient deaths, serious or life-threatening injuries, failed, aborted or prolonged medical procedures. [company website]
Continental AG, the German auto-parts supplier, acquired a division of Advanced Scientific Concepts (Santa Barbara, CA; $38M SBIR, founded 1987) that makes an imaging sensor used in autonomous vehicles. ... As auto makers hurtle toward offering cars that can drive themselves, researchers believe that lidar—for light detection and ranging—will be a requirement. ASC’s sensor has no moving parts, a feature car makers prefer to avoid breakdowns. ... Nissan Motor Co.’s autonomous Leaf electric car uses several ASC’s sensors located around a vehicle, to construct a nearly 360-degree field of vision. [Mike Ramsey, Wall Street Journal, Mar 3, 16]
National Cancer Institute awarded $3 million to Advanced Targeting Systems (San Diego, CA; $5.2M SBIR) ... develops and provides products for neuroscience researchers, and has developed technology for targeting specific types of cells [Bruce Bigelow, signonsandiego.com, Oct 13, 10]
Medtronic announced that it has acquired Advanced Uro-Solutions (Elizabethton, TN; no SBIR, founded 2009), a developer of neurostimulation products for the treatment of bladder control issues. Terms of the acquisition agreement, which closed in December 2014, were not disclosed. ... develops and manufactures the NURO(TM) percutaneous tibial nerve stimulation system, which consists of a small external stimulator and a single, reusable lead to provide temporary stimulation to the tibial nerve. [streetinsider.com, Feb 23, 15]
AdvanDx (Woburn, MA; no SBIR) maker of medical diagnostics, has raised $8 million, part of a Series C funding round [Mass High Tech, Aug 18, 09]
Cornerstone Research Group (Beavercreek, OH; $32M SBIR, 80 employees) is looking to start a $2 million manufacturing operation that could create up to 50 new jobs. .... to make Metagraphite, a composite material it developed, for sale to the residential and civil construction market. .... Cornerstone has started to see success with some of its subsidiary companies. That includes: NONA Composites LLC, a process engineering company for composite tooling and parts manufacturers. It provides a no-oven, no-autoclave composite fabrication solution to significantly reduce time and capital equipment investments; Advantic LLC, which provides an engineering service and product that acts as a lightweight alternative to pre-cast concrete, allowing customers to bid projects more competitively and eliminate heavy installation issues; and Spintech LLC, which markets a forming system that allows composite structures to be built with a quickly removable and reusable mold. [Joe Cogliano, Dayton Business Journal, Dec 3, 14]
Advaxis down 31% [Apr 3, 19]
Advaxis executed a 1:15 reverse split. [Mar 27, 19]
For the third time, the FDA has halted testing of an experimental cervical cancer therapy from Advaxis, axalimogene filolisbac. The stoppage is related to manufacturing problems, not safety issues, according to the Princeton, NJ-based firm, which also lost a partnership with Amgen last month. [Alex Lash, xconomy.com, Jan 25, 19]
Advaxis CEO Ken Berlin has launched a search for a partner for its stalled lead axalimogene filolisbac (AXAL) and will scale back trials of the immunotherapy in order to bring earlier stage programs forward. It will also eliminate almost a quarter of its workforce. [Phil Taylor, Fierce Biotech, Jun 8, 18]
FDA has placed a clinical hold on a study of Advaxis’ axalimogene filolisbac and AstraZeneca’s PD-L1 checkpoint inhibitor Imfinzi. Regulatory officials took the action upon learning a cervical cancer patient developed respiratory failure and died after receiving the combination. [Nick Paul Taylor, Fierce Biotech, Mar 13, 18]
Advaxis down 28% [Feb 22, 18] announced the pricing of its public offering of $2.00 per share to raise $20M. [company press release, Feb 22, 18]
Advaxis down 13% [Dec 21, 17]
Advaxis up 15% [Sep 27, 17]
Advaxis down 11% [Sep 13,17]
Advaxis down 11% [Jun 15,17]
Advaxis (Princeton, NJ; $1.5M SBIR 2004-2009) and Sellas Life Sciences Group (no SBIR), two companies that have pursued different ways of prompting the body’s immune system to fight cancer, are now hoping that combining their efforts will lead to a more precise treatment. The agreement between the companies calls for Advaxis to license to Sellas its technology for targeting antigens. If the partnership leads to an FDA-approved treatment, Advaxis stands to gain milestone payments from Sellas that could reach $358 million. Advaxis would also receive royalties on net sales. [Frank Vinluan, xconomy.com, Feb 27, 17]
Advaxis up 12% [Nov 4, 16]
Advaxis up 10% [Oct 4, 16]
Advaxis up 11% [Aug 5, 16]
Advaxis up 24% [Aug 3, 16]
Advaxis up 31% [Aug 2, 16] Amgen and Advaxis announced a global agreement for the development and commercialization of Advaxis' ADXS-NEO, a novel, preclinical investigational cancer immunotherapy treatment that is designed to activate a patient's immune system to respond against the unique mutations, or neoepitopes, contained in and identified from each individual patient's tumor. [companies joint press release, Aug 2, 16]
Advaxis up 15% [Jun 28, 16]
Advaxis down 13% [Mar 23,16]
ADVAXIS (North Brunswick, NJ; $1.5M SBIR) up 12% [Mar 21,16]
Advaxis up 13% [Mar 4,16]
Advaxis up 27% [Mar 2,16]
Advaxis up 13% [Dec 17, 15] after the company said that the Food and Drug Administration had lifted a clinical hold on its cancer drugs, allowing trials to continue. [Austen Hufford, Wall Street Jounral, Dec 17, 15]
Advaxis up 32% [Dec 16, 15] said the [FDA] lifted a clinical hold on three of its experimental cancer therapies. The company said it would resume studies on the three therapies, which belong to a class of treatments that spur the body's immunity system against the disease. [Vidya L Nathan, Reuters, Dec 16, 15]
Advaxis down 12% [Dec 14, 15]
Advaxis up 12% [Nov 2, 15
Advaxis down 10% [Oct 20,15]
Novartis (Swiss giant) said it broadened its immuno-oncology pipeline with the acquisition of Admune Therapeutics (Danvers, MA; no SBIR) and licensing agreements with Xoma and Palobiofarma (Spanish) [Reuters, Oct 21, 15]
Advaxis down 17% [Sep 29,15]
Advaxis down 15% [Sep 21, 15]
Advaxis up 15% [Sep 10, 15]
Advaxis up 16% [Aug 12, 15]
Advaxis down 12% [Aug 6, 15]
Advaxis down 10% [Jul 8, 15]
Advaxis up 18% [Jun 30, 15]
Advaxisdown 14% [Jun 18, 15]
Advaxis udown 10% [Jun 16, 15]
Advaxis down 10% [Jun 9, 15]
Advaxis down 15% [Apr 30,15]
Advaxis up 10% [Apr 21,15]
Aduro Biotech (Berkeley, CA; $300K SBIR) up 147% [Apr 15,15] following its $119M IPO in biotech bubbleland, putting its market cap at $2B. In March it planned an $86M IPO. A competitor, Advaxis ($1.5M SBIR) [down 12% [Apr 15,15], is developing similar cancer immunotherapy drugs that also involve re-engineering listeria to stimulate a patient's immune system. [Adam Feuerstein, the street.com]
Advaxis up 18% [Apr 8,15] Advaxis and Merck announced that enrollment has initiated in the Phase 1/2 clinical trial evaluating the combination of ADXS-PSA (ADXS31-142), an investigational Lm-LLO immunotherapy, and KEYTRUDA(R) (pembrolizumab), the first anti-PD-1 (programmed death receptor-1) therapy approved in the United States, in patients with previously treated, metastatic castration-resistant prostate cancer (mCRPC). [joint press release, Apr 8, 15]
Advaxis up 15% [Feb 18, 15]
Advaxis up 20% [Jan 27, 15]
Advaxis down 11% [Jan 22, 15]
Advaxis down 29% [Jan 21, 15]
Advaxis up 30% [Dec 22, 14]
BioCryst won [FDA] approval to begin selling a new intravenous drug for treating flu. The drug, Peramivir, will be sold in the United States under the brand name Rapivab. Company officials said it’s the first new flu drug to be approved in 15 years ... marked the 28-year-old company’s first full FDA approval for a drug [Jay Price, Raleigh News & Observer, Dec 22, 14]
Advaxis (Princeton NJ; $1.5M SBIR) up 18% [Dec 19, 14]
Advaxis (Princeton NJ; $1.8M SBIR) up 20% [Dec 15, 14] Announces FDA Acceptance of Its Investigational New Drug Application to Commence Clinical Trials of ADXS-HPV in Combination With MedImmune's MEDI4736 for the Treatment of HPV-Associated Cancers [company press release]
Federal regulators rejected a new formulation of a chemotherapy drug made byAdventrx Pharmaceuticals (San Diego, CA; no SBIR), saying they couldn’t be certain the experimental non-small cell lung cancer treatment is as safe and effective as the original therapy, the company said [Keith Darce, signonsandiego.com, Aug 10, 11]
Can't Afford Science. The staff cuts (at Adventrx (San Diego, CA; no SBIR)), including the chief scientific officer, vice president of medical affairs and vice president of research and development, are expected to reduce 2009 payroll expenses by $1.5 million. ... leave the company with enough cash to fund operations until mid-09. [San Diego Union Tribune, Oct 22, 08]
ADVENT TECHNOLOGIES (Madison, AL; one SBIR) an eight-year-old startup developing fuel cell technology as alternative source of energy for transportation, aviation and off-grid power generation, plans to go public via a reverse merger. [Rowan Walrath, BostInno, Oct 14, 20]
Adverum Biotechnologies (Menlo Park, CA; no SBIR) and Editas Medicine (Cambridge, MA; no SBIR) announced a collaboration to explore the delivery of genome editing medicines to treat up to five inherited retinal diseases. This collaboration brings together Adverum’s next-generation adeno-associated viral (AAV) vectors for use with Editas’ leading genome editing technologies to create a series of novel therapies for debilitating eye diseases that have poor therapeutic options. [joint companies press release, Aug 9, 16]
In March, Advion BioServices (Ithaca, NY; no SBIR) announced plans to establish a $6.1 million laboratory at the Purdue Research Park at Ameriplex, likely adding 49 jobs immediately and up to 66 jobs by 2015. [Indianapolis Star, Apr 27, 11]
Advion BioSciences (Ithaca, NY; no SBIR, founded 1993) will open a new lab in an effort with Eli Lilly in a Purdue University park near Indianapolis International Airport.... will research how potential new medicines are absorbed and metabolized in experimental models, collecting data for the preparation of a molecule's entry into clinical testing. ... The Indiana Economic Development Corp., a state agency assisted Advion with its efforts. [Indianapolis Star, Mar 3, 11] A commenter says, Net gain of jobs in Indianapolis -0. Some of the Lilly employees laid off, will get these lower paying jobs. SBIR advocates who tout small biz as a job engine will conveniently ignore the better compensated job loss elsewhere.
Drug developer Adynxx (San Francisco, CA; no SBIR) is trying to address [post-surgical] pain with a new treatment developed to be administered to patients during surgery. ... a new investor in the company led the $16 million Series B round. Domain Associates, which backed Adynxx’s $18 million Series A round in 2010 also participated. ... The idea of preventing post-surgical pain caught the eye of Cubist Pharmaceuticals , which paid $20 million in 2013 for the right to acquire Adynxx pending mid-stage clinical trial results. But after getting a look at those results in 2014, Cubist passed on its option to buy the company, saying that the “magnitude of the clinical response did not meet Cubist’s exercise criteria.” Cubist itself was acquired by Merck later that year. [Frank Vinluan, xconomy.com, Jan 10, 17]
Adynxx (San Francisco, CA; no SBIR) has kept a low profile since its founding five years ago, but is discussing its work publicly today, announcing it has completed enrollment in its initial clinical trial of 30 healthy volunteers. ... supported by a Series A venture financing of $18 million from Domain Associates from 2010, is composed of people who worked together on a series of Domain-backed companies that were acquired, including Peninsula Pharmaceuticals (no SBIR), Cerexa (no SBIR), and Calixa Therapeutics (no SBIR). [Luke Timmerman, xconomy,com, Aug 7, 12]
Aegea Medical(Redwood City, CA; no SBIR) has raised $13.3 million private equity financing ... has developed a minimally invasive treatment for abnormal uterine bleeding. [San Francisco Business Times, Jun 30, 11]
Applied Technology Associates (Albuquerque, NM; $39M SBIR) announced it's joining the formation of BlueHalo, a leading provider of advanced engineering solutions and technology to the national security community. BlueHalo was formed through the combination of AEgis Technologies (Albuquerque, NM; $22M SBIR), including its previously integrated acquisitions Excivity (Birmingham, AL; no SBIR) and EMRC Heli (no SBIR) , and its recently announced acquisition of Brilligent Solutions (Fairborn, OH; one SBIR). [ATA press release, Oct 29, 20]
After a brutal year in which Aegerion Pharmaceuticals (Cambridge, MA; no SBIR) lost 74 percent of its market value amid financial problems and a management overhaul, the company said this morning it’s cutting a quarter of its global workforce, or about 75 employees. ... markets the drug Juxtapid, said the move will “significantly reduce its operating expenses and extend its cash position” as sales of that drug in the U.S. are being hurt by competition. Juxtapid is a treatment for a rare form of high cholesterol called HoFH homozygous familial hypercholesterolemia. [Don Seiffert, Boston Business Journal, Feb 11, 16]
Aegerion Pharmaceuticals (Cambridge, MA; no SBIR, 70 employees) said it has won approval from the Food and Drug Administration to market the Cambridge biotechnology company’s first drug, a treatment for a rare inherited genetic disorder that can raise cholesterol to life-threatening levels. The condition, disordehomozygous familial hypercholesterolemia -- or HoFH -- is resistant to statins and other medications typically used to bring high cholesterol under control. [Callum Borchers, Dec 24, 12]
Aeglea BioTherapeutics (Austin, TX; no SBIR, founded 2013) up 20% [Jul 25, 19] announced that [FDA] granted Breakthrough Therapy Designation (BTD) to the Company's lead investigational therapy, pegzilarginase, for the treatment of Arginase 1 Deficiency (ARG1-D), a rare progressive disease presenting in early childhood that results in severe complications and early mortality. [company press release, Jul 25, 19] total funding $56M [crunchbase.com]
Aeglea BioThera (Austin, TX; no SBIR) down 19% [Feb 6, 19] announced the pricing of an underwritten public offering of of its common stock at $8.00 per share [to] raise $60M [company press release, Feb 6, 19]
Aeglea BioThera down 13% [Sep 4, 18]
Aeglea BioThera down 13% [Sep 4, 18]
Aeglea BioThera up 11% [Apr 27, 18]
Aeglea BioThera down 10% [Apr 18, 18]
Aeglea BioThera up 10% [Apr 10, 18]
Aeglea BioThera up 18% [Mar 16, 18]
Aeglea BioThera up 16% [Mar 8,18]
Shares of Aeglea BioTherapeutics (Austin, TX; no SBIR) made their debut Aug 7 on Wall Street, and finished lower on the day, ending the session down 2.3 percent. [Austin Business Journal, Apr 7, 16]
Aeglea BioTherapeutics (Austin, TX; no SBIR, founded 2013) biotech concentrated in the cancer treatment field filed for IPO. ... Since the beginning of 2014 the company has raised more than $80 million . [Chad Swiatecki, Austin Business Journal, Jun 17, 15] to develop engineered human enzymes invented in the laboratory of George Georgiou, Ph.D. of The University of Texas at Austin. [company website]
Aegela Biotherapeutics (Austin, TX; no SBIR) announced it has raised $44 million in Series B funding to pay for development of enzymes that target diseases at the extreme of abnormal metabolism. ... develops novel treatments for inborn errors of metabolism, including those involving tumors. The funding round was led by Indiana-based Lilly Ventures and Switzerland-based Novartis [Chad Swiatecki, Austin Business Journal, Mar 23, 15] Superconductor Technologies (founded 1987 in the early rush to exploit the breakthrough reserch) has inked a purchase agreement with certain investors to acquire $5 million worth of shares. ... recently laid off one third of its workers to cut costs amid lower quarterly earnings. [Austin Business Journal, Mar 20, 15]
Aeglea BioTherapeutics Holdings (Austin, TX; no SBIR) raised $10.7 million [Christopher Calnan, Austin Business Journal, Aug 5, 14]
Aegela BioTherapeutics Holdings (Austin, TX; no SBIR, four employees) has secured a spot at the Austin Technology Incubator, part of the University of Texas’s IC2 Institute. ... recently raised $12 million ... a three-month old drug development company working on novel cancer treatments. ... being funded through a partnership with a trio of pharmaceutical companies — KBI Biopharma, Eli Lilly and Company and Novartis [Chad Swiatecki, Austin Business Journal, Mar 27, 14]
Aeglea BioTherapeutics Holdings (Austin, TX; no SBIR, two employees) completed a $12 million round of funding to pay for research into engineer enzymes that degrade amino acids present in cancerous tumors. [Chad Swiatecki, Austin Business Journal, Jan 9, 14]
The U.S. Air Force has tentatively selected over 500 companies for contracts worth $550M combined as part of an initiative launched with its AFWERX innovation arm and [SBIR]. The service said the AFVentures effort includes a strategic financing initiative where the firms will get a total of over $200M in government funding as well as $350M in private funds. [Brenda Marie Rivers, govconwire, Mar 16, 20] almost half going to the following 21 companies: Aerial Applications, Analytical Space ($3M prior SBIR), Anduril (one prior SBIR) , Applied Minds ($8M prior SBIR), Elroy Air, Sentient ($3.2M prior SBIR) , Icon, Enview ($700K prior SBIR), Edgybees ($700K prior SBIR) , Falkonry (one prior SBIR), Swarm Technologies ($1M prior SBIR) , Orbital Insight (one prior SBIR), Orbital Sidekick ($800K prior SBIR), Virtualitics (one prior SBIR) , Wickr (one prior SBIR), Tectus Corp (one prior SBIR), Valulytics, Shift.org, Pison ($1M prior SBIR), Revacomm. One other company hasn’t been named yet. These “big bet” companies are slated to receive four-year, fixed-price contracts worth a combined $550+ million through AFVentures’ Strategic Financing (STRATFI) program. This amount includes $100+ million in SBIR funds, $100+ million in Air Force funding and $350+ million in private investment. Roper said he believes future rounds of funding will be bigger. [AF Press release , Mar 13, 20]
A fledgling drug development company whose chief executive previously enjoyed success at Aerial BioPharma (no SBIR) and other startups has raised $49 million in funding to acquire and develop promising drugs. The funding for Arrivo Bioventures (Morrisville, NC; no SBIR so soon) is fully committed over five years and can be drawn down to fund new drug projects as needed, said co-founder and CEO Steve Butts. [Raleigh News & Observer, May 24, 16]
Jazz Pharmaceuticals plc (Ireland) and Aerial BioPharma, LLC (Morrisville, NC; no SBIR) announced that the companies have signed a definitive agreement under which Jazz Pharmaceuticals has acquired rights to ADX-N05, a novel compound in clinical development for the treatment of excessive daytime sleepiness in patients with narcolepsy. [Jazz website, Jan 13, 14] founded in January of 2011 by the management team from Neuronex and Addrenex Pharmaceuticals, both successful start-ups based in the Research Triangle Park area. Neuronex was acquired by Acorda Therapeutics in 2012 and Addrenex Pharmaceuticals was acquired by Shionogi Pharma in November of 2009 [Aerial website] a deal that could be worth up to nearly $400 million. Jazz paid $125 million up front [Jason deBruyn, Triangle Business Journal, Jan 17, 14]
Aerie Pharmaceuticals announced that it has launched Rhopressa® in the United States. Rhopressa® is now in national and regional U.S. pharmaceutical distributors, and patients have access to Rhopressa® through their local pharmacies across the nation. ... the first new drug class in more than two decades for the reduction of intraocular pressure in patients with glaucoma or ocular hypertension. [company press release, Apr 30, 18]
Aerie Pharmaceutical (Irvine, CA and Bednminster, NJ; no SBIR) announced that [FDA] approved Rhopressa® (netarsudil ophthalmic solution) 0.02% for the lowering of elevated intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension. [FDA approval decision was made two months ahead of the scheduled PDUFA (Prescription Drug User Fee Act) goal. [company press release, Dec 18, 17]
Aerie Pharma up 16% [Oct 11, 17]
After a big stock bump from positive trials results, Duke University spinout Aerie Pharmaceuticals announced it’s raised another $125M. [Jennifer Henderson, Triangle Business Journal, May 26, 17]
Aerie Pharma up 34% [May 25,17] a clinical-stage pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with glaucoma and other diseases of the eye, today announced that it has commenced a registered underwritten public offering of $50 million of shares of its common stock. [company press release, May 25, 17]
Aerie Pharma up 13% [Sep 20, 16]
Aerie Pharmaceuticals (Bedminster, NJ, and Irvine, CA; SBIR) up 45% [Sep 15, 16] said its drug known as Roclatan has met its main goal in a 718-patient Phase 3 trial, the first of three late-stage studies. The drug—a combination of the most prescribed PGA, latanoprost (Xalatan), and Aerie’s experimental netarsudil (Rhopressa)—did a better job lowering the eye pressure of glaucoma patients than either latanoprost alone or netarsudil alone, for each of nine different time points measured over a three-month span [Ben Fidler, xconomy.com, Sep 14, 16] surged more than 62 percent, to $34.35 apiece, in post-market trading on Wednesday.
Aerie Pharma up 14% [May 18, 16]
Aerie Pharma up 12% [Mar 18,16]
Duke University spinout drug developer Aerie Pharmaceuticals reported positive safety results from a trial testing its glaucoma treatment ... The trial is named “Rocket 2” and is Aerie’s second Phase 3 registration trial for Rhopressa, a once-daily eye drop being tested for its ability to lower intraocular pressure (IOP) in patients with glaucoma or ocular hypertension. [Jason deBruyn, Triangle Business Journal, Feb 17, 16]
Aerie Pharma down 12% [Oct 8,15]
Aeria Pharma up 12% [Oct 7,15]
Aerie Pharma up 67% [Sep 17, 15] reported the successful results of its second Phase 3 trial for Rhopressa™, a novel once-daily, triple-action eye drop being tested for its ability to lower intraocular pressure (IOP) in patients with glaucoma or ocular hypertension. [company website]
Aerie Pharmaceuticals (Bedminster, NJ; no SBIR), the Duke University spin-out working on experimental treatments for glaucoma, and GrayBug (Baltimore, MD; no SBIR), a venture-stage pharma working toward treatments for ocular diseases including wet age-related macular degeneration (AMD) and glaucoma, finalized a research collaboration and license agreement. ... Initially, the partnership will focus on evaluating the ability of GrayBug’s polymer-based delivery technology to provide a multimonth drug release capability for an Aerie small molecule for wet AMD. [Jason deBruyn, Triangle Business Journal, Aug 7, 15]
Aerie Pharmaceuticals up 17% [May 4,15]
Aerie Pharmaceuticals, a drug developer with roots in Duke University, lost more than $500 million in market value after disappointing trial results, but vowed to push forward. [Jason deBruyn, Triangle Business Journal, May 1, 15]
Duke University spinoff Aerie Pharmaceuticals (Research Triangle Park, NC; no SBIR) saw a 10 percent stock bump on news that it secured $125 million in convertible debt. ... will test a drug called Rhopressa and its ability to lower intraocular pressure (IOP) in patients with glaucoma or ocular hypertension. ... completed a public offering on October 2013 in which it raised $68 million. [Jason deBruyn, Triangle Business Journal, Sep 9, 14]
Duke University spinout Aerie Pharmaceuticals received a “No Objection Letter” to begin testing its glaucoma treatment in Canada. .... the treatment, called Rhopressa, would be the only once-daily product available that specifically targets the trabecular meshwork, the eye's primary fluid drain and the diseased tissue responsible for elevated lower intraocular pressure in glaucoma. [Jason deBruyn, Triangle Business Journal, Jul 24, 14]
Duke University spin-off Aerie Pharmaceuticals (Bedminster, NJ; no SBIR, IPO 2014) what it calls a “blockbuster” therapy, dubbed Roclatan, was tested in 297 patients over 28 days, and beat out the efficacy of the most widely prescribed drug, latanoprost. [Lauren K. Ohnesorge, Triangle Business Journal, Jun 25, 14]
Aerie Pharma up 13% [Dec 4,13]
Aerie Pharmaceuticals (Bedminster, NJ; no SBIR, 22-employees) A small drug-development company co-founded [in 2005] by two Duke University professors is seeking to raise up to $57.5 million in an [IPO]. ... filed plans to go public ... As of June 30, Aerie had raised $71 million in venture capital [David Ranii, Raleigh News & Observer, Sep 18, 13]
Duke spinoff Aerie Pharmaceuticals (no SBIR) is looking for $15 million in debt financing, according to a security filing. ... has been developing a glaucoma treatment and netted positive results last month for a Phase 2a study of its once-daily eye drop treatment. ... netted more than $41 million in an equity round last year [Lauren Ohnesorge, Triangle Business Journal, Dec 19, 12]
Aerie
Pharmaceuticals
(Research Triangle Park, NC; no SBIR) has netted $30 million in
venture capital
funds to continue developing treatments for glaucoma.
...
co-founded in 2005 by Duke medical professor David Epstein and Duke
chemistry professor Eric Toone, will use the money to test its lead
drug on patients in this country and in Europe. ... has
raised
$51 million in several rounds of venture capital funding [Raleigh
News & Observer, Mar 8, 11]
Biotech startup Aerin Medical (Sunnyvale, CA, and Singapore; no SBIR) raised $16.7 million in Series C funding to commercialize in select markets. [Gina Hall, Silicon Valley Business Journal, Mar 22, 16] is developing a new class of non-invasive treatments to improve nasal breathing disorders that collectively account for over 13 million patient visits annually to Ear Nose & Throat (ENT) specialists. [company website]
Aeris Technologies (Redwood City, CA; one SBIR) for $2.5M developed a methane gas monitor for DOE's ARPA-E leak detection system consisting of a sensitive and compact laser sensor and an embedded artificial neural network characterization algorithm for the location and quantification. [arpa-e.energy.gov report, May 7, 18] The 2016 SBIR Phase I was doing the same type development for detecting formaldehyde. The federal mission agencies favor SBIR projects for some technology the company has already demonstrated.
Flirsaid it has bought infrared and laser component makerAerius Photonics (Ventura, CA; $14M SBIR) for $27 million. The seven-year-old company makes infrared detectors, lightweight laser rangefinders and infrared illuminators and pointers. [Brent Hunsberger, Oregonlive.com, Jul 22,11]
Aerodyne Research (Billerica, MA; 199 SBIR Phase Is and something like $80M total SBIR) will receive five $1-million DOEnergy [SBIR Phase II] grants, and Radiation Monitoring Devices (Watertown, MA; 404 SBIR Phase Is and something like $150M SBIR) will receive three $1 million grants, the department said. ... Other local companies in line to receive Energy Department grants: Conispire (Boston, MA: no SBIR) , Aspen Products Group (Marlborough.MA; $5.6M SBIR), Capesym (Natick, MA; $5.3M SBIR); Nova Scientific (Sturbridge, MA; $9M SBIR); Beacon Power (Tyngsborough, MA; $1M SBIR), the department said. [Chris Reidy, Boston Globe, Jun 29, 12]
Aero Farms System (Ithaca, NY; no SBIR) a leader in aeroponic technology, received the prestigious Red Herring North America 100 Award, which recognizes North American startups for their technologies and innovation in their respective industries. [LARTA Vox, Jul 13, 10]
Aerovate Therapeutics (Boston, MA; no SBIR), closed on $72.6 million in Series A funding to advance trials of AV-101, an inhaled, dry powder aerosol version of imatinib to treat pulmonary arterial hypertension (PAH). An oral version of imatinib showed significant efficacy in a phase 3 trial as a disease-modifying therapy for PAH, but it was poorly tolerated by PAH patients because of systemic side effects. [company press release, Aug 6, 20]
Aerovate Therapeutics (Boston, MA) closed on $72.6 million in Series A funding to advance trials of AV-101, an inhaled, dry powder aerosol version of imatinib to treat pulmonary arterial hypertension (PAH). An oral version of imatinib showed significant efficacy in a phase 3 trial as a disease-modifying therapy for PAH, but it was poorly tolerated by PAH patients because of systemic side effects. [company press release, Aug 6, 20]
Aerovate Therapeutics (Boston, MA) closed on $72.6 million in Series A funding to advance trials of AV-101, an inhaled, dry powder aerosol version of imatinib to treat pulmonary arterial hypertension (PAH). An oral version of imatinib showed significant efficacy in a phase 3 trial as a disease-modifying therapy for PAH, but it was poorly tolerated by PAH patients because of systemic side effects. [company press release, Aug 6, 20]
Aerovel (Cook, WA; $1.8M SBIR) partners with AeroVironment to pitch Flexrotor drone for military use [Andrew McIntosh, Puget Sound Business Journal Oct 18, 18] ... Also AeroVironment announced a new strategic relationship with General Dynamics Land Systems (GD), the leader in ground combat vehicles, to produce highly integrated and effective tactical UAS and TMS for armored ground combat vehicles [company press release, Oct 8, 18].... Also Aerovironment announced the ]USAF] awarded the company a $13 million indefinite delivery/indefinite quantity (ID/IQ) contract for RQ-11B Raven® small unmanned aircraft systems (UAS) [company press release, Oct 4, 18] ... Also Aerovironment announced the receipt of a fixed-price contract award valued at $5.94 from NATO Support and Procurement Agency [company press release, Sep 13, 18]
the U.S. Army has chosen AeroEnvironment's Switchblade 600 for the first step in a new program designed to put tank-killing loitering munitions in the hands of average soldiers, following the example seen in Ukraine, Defense One's Sam Skove reported [DefOne, Oct 12, 2023]
AeroVironment (Arlington, VA; $20M SBIR) up 21% [Sep 6, 2023]
AeroVironment (Arlington, VA; $20M SBIR) has agreed to buy Tomahawk Robotics (Melbourne, FL; $1.1M SBIR) , a developer of artificial intelligence-based command and control systems, for $120 million in cash and stock. [Naomi Cooper, govconwire, Aug 23, 2023]
Five companies have secured other transaction agreements ranging from $1 million to $25 million to develop prototypes of the U.S. Army’s Future Tactical Unmanned Aircraft System Increment 2. The OTA awards are part of an industry competition seeking a new UAS platform for brigade combat teams to perform reconnaissance and surveillance work even in areas where GPS signals are corrupted, the service branch said. One company, AeroVironment (Arlington, VA; $20M SBIR) , In August 2022, AeroVironment won an $8 million OTA to manufacture, test and deliver the Jump 20 UAS system to a team of soldiers as part of the FTUAS Increment 1 program. [Jamie Bennet, govconwire, March 1, 2023]
AeroVironment (Arlington,VA; $26M SBIR) will provide operations and maintenance support to the U.S. Army’s Puma long endurance and RQ-20B all environment unmanned aircraft systems under an $86.4 million contract. [Jamie Bennet, govconwire.com, Nov 9, 2022]
AeroVironment (Arlington, VA, formerly Monrovia, CA; $22M SBIR), a global leader in intelligent, multi-domain robotic systems, announced it has acquired Planck Aerosystems (San Diego, CA; $1.2M SBIR), a leading provider of advanced unmanned aircraft navigation solutions. The acquisition will significantly accelerate AeroVironment’s development of advanced autonomy capabilities. [Aero press release, Aug 17, 22] financial terms not disclosed.
Switchblade drones, made by AeroVironment (Monrovia,CA; $25M SBIR), were designed to attack either soldiers or tanks. But the technology is versatile: Larger versions can take out artillery tubes, crater runways and destroy radar installations. Smaller versions can target the drivers of vehicles, or individual officers if they are detected. [Julian E. Barnes, NY Times, Apr 22. 22]
Aerovironment down 27% [Dec 7, 21] reported financial results for its fiscal second quarter ... "While we achieved second quarter and first half results in line with our expectations, headwinds to our business have intensified in recent months, requiring us to reduce our full year outlook," said [CEO] Wahid Nawabi. [company press release, Dec 7, 21]
AeroVironment has acquired the intelligent systems group [ISG] of Progeny Systems (Manassas, VA; $130M SBIR) through a $30 million cash transaction as part of efforts to drive autonomy and artificial intelligence technology development work and expand robotic systems engineering support for defense and commercial clients. AeroVironment said it will merge ISG with its MacCready Works Advanced Solutions team and make an additional payment of up to $6 million to Progeny Systems over three years if the acquired group meets specific performance targets. ISG is headquartered in Manassas, Virginia, and has 40 employee [Jane Edwards, govconwire.com, Feb 25, 21]
AeroVironment up 30% [Jan 14, 21]
AeroVironment (Monrovia, CA; $30M SBIR) a global leader in unmanned aircraft systems, and Arcturus UAV, leading provider of Group 2 and 3 unmanned aircraft systems (UAS) and services, today announced that they have entered into a definitive agreement under which AeroVironment will acquire Arcturus UAV for a total purchase price of $405 million, including $355 million in cash and $50 million in AeroVironment stock [company press release, Jan 13, 21]
AeroVironment (SIMI VALLEY, CA; $24M SBIR) a global leader in unmanned aircraft systems (UAS), announced a teaming agreement with Robotic Skies (Chicago, IL; no SBIR), a global maintenance, repair, and overhaul network for UAS, to provide field maintenance, inspection and repair support for AeroVironment customers. [joint companies press release, Sep 29, 20]
AeroVironment landed a potential three-year, $146M contract to provide loitering missile systems designed to help military users reach targets for operations beyond line of sight. The company said Thursday it will start to deliver the Switchblade miniature aerial missiles to the service branch beginning in September under the sole-source contract with a $75.9M base value awarded by the Army Tactical Aviation and Ground Munitions project office due to "joint urgent operational need." Switchblade can be deployed from a six-pack launch platform and seeks to help warfighters hit a target up to six miles from a fixed or a mobile location. The contract includes two option years that would extend work through April 2023. [Nicholas Martin, govconwire.com, May 14, 20]
C2N Diagnostics (St. Louis, MO; no SBIR) received a $20 million Program-Related Investment from GHR Foundation, an independent global philanthropy. [to] position C2N’s Alzheimer’s blood test for entry into the clinic. [company press release, May14, 20]
AeroVironment purchased Pulse Aerospace (Lawrence, KS; no SBIR) for $25.7M in cash to expand its line of small unmanned aircraft systems. [Jane Edwards, GovConWire, Jun 11, 19]
Aerovironment down 16% [Nov 30, 18]
Aerovel (Cook, WA; $1.8M SBIR) partners with AeroVironment to pitch Flexrotor drone for military use [Andrew McIntosh, Puget Sound Business Journal Oct 18, 18] ... Also AeroVironment announced a new strategic relationship with General Dynamics Land Systems (GD), the leader in ground combat vehicles, to produce highly integrated and effective tactical UAS and TMS for armored ground combat vehicles [company press release, Oct 8, 18].... Also Aerovironment announced the ]USAF] awarded the company a $13 million indefinite delivery/indefinite quantity (ID/IQ) contract for RQ-11B Raven® small unmanned aircraft systems (UAS) [company press release, Oct 4, 18] ... Also Aerovironment announced the receipt of a fixed-price contract award valued at $5.94 from NATO Support and Procurement Agency [company press release, Sep 13, 18]
AeroVironment announced that [USAF] awarded the company a $13 million indefinite delivery/indefinite quantity (ID/IQ) contract for RQ-11B Raven® small unmanned aircraft systems (UAS) to support Latin American and Caribbean nations. [company press release, Oct 4, 18]
Aerovironment up 14% [Sep 6, 18]
Crinetics Pharmaup 11% [Sep 6, 18]
AeroVironment has collaborated with NASA’s Jet Propulsion Laboratory to develop an unmanned helicopter platform as part of the Mars Exploration Program. The company said the two drone development models passed tests in simulated Mars environment and JPL has begun production work on the final Mars Helicopter following the tests. [Jane Edwards, GovConWire, Jul 5, 18]
AeroVironment received a $44.6 million contract modification from the Army to provide hardware and parts for Block 10C Switchblade miniature aerial missile systems. [GovConWire, Apr 23, 18]
Aerovironment up 17% [Apr 11, 18] got a piece of an Army $249M drone buy.
Aerovironment down 15% [Mar 7, 18] reported a small net loss while The AeroVironment team continued to execute our fiscal 2018 plan effectively
Aerovironment up 26% [Dec 6, 17] another solid quarter of financial and operational results driven by robust, global customer demand across our business and continued effective execution," said [CEO] Wahid Nawabi. [company press release, Dec 5, 17]
Aerovironment up 18% [Aug 30, 17]
Aerovironment down 17% [Aug 31, 16]
Aerovironment up 15% [Dec 9, 15]
AeroVironment said DARPA has decided not to go forward with a Phase III contract with the company. Aerovironment said DARPA’s decision came after a competition for the Phase III contract following successful Phase I and II efforts as part of the DARPA Tern (Tactically Exploitative Reconnaissance Node) program. [Los Angeles Business Journal, Sep 23, 15]
AeroVironment up 11% [Jul 1, 15]
Aerovironment up 13% [Jul 9,14]
The Navy is joining DARPA on a project that could ultimately result in military drones taking flight from smaller Navy ships. ... The first two phases of the program focus on preliminary design and risk reduction for the TERN system. Five companies were awarded contracts last fall for the first phase of the program, which focuses on development of a preliminary design: Northrop Grumman ; Aurora Flight Sciences (Manassas, VA; $24M SBIR); AeroVironment (Monrovia, CA; $15M SBIR); Maritime Applied Physics (Baltimore, MD; $7M SBIR); Carter Aviation Technologies (Wichita Falls, TX; one SBIR) [Jill R. Aitoro, Washington Business Journal, Jun 13, 14]
Aerovironment up 21% [Mar 5, 14]
Aerovironment up 11% [Nov 27, 13]
Aerovironment up 14% [Jul 17, 13]
Aerovironment down 10% [Mar 6, 13] after its third-quarter sales plunged 35 percent amid a slowdown in U.S. military orders. [Bloomberg, Mar 6]
Aerovironment up 13% [Dec 5, 12]
AeroVironment
(Monrovia,
CA; $16M SBIR) produces
85 percent of
the unmanned aerial systems used by U.S. forces in Iraq and
Afghanistan, .... Measured by number of units deployed,
America’s
top maker of surveillance drones. The Army is also funding production
of AeroVironment’s newest UAV, called Switchblade. Like the Raven-B and
AeroVironment’s other systems, Switchblade, which is still in
development, will fit in a soldier’s backpack. But rather than merely
spy, this toy-size drone can kill: When its operator spots an enemy,
Switchblade locks on, turns into a missile, and blows up the target. “I
think Switchblade, like our other small UAVs, is going to plug a hole
in [the military’s] arsenal,” says Tim Conver, chief executive of
AeroVironment. founded in 1971
by Paul MacCready, a legend in aerospace engineering and meteorology,
and a 1978 documentary about the project, Flight of the
Gossamer Condor, snagged
an Oscar.
... In the 1990s, AeroVironment was a major supplier of
technology for
Another miniaturization era. big, well-known drones are already outnumbered by small, cheap and capable aircraft. One good example is the RQ-11B Raven, made by AeroVironmentand widely used by America’s armed forces. ... Pilots might dismiss Ravens as radio-controlled toys, but they are popular with soldiers. More are being rushed to Afghanistan. ... The controlling hardware is a tablet computer with buttons on the side, rather like a portable games console, and most people can get the hang of it in a couple of days. Predators, by contrast, were originally flown by real, albeit ground-based, pilots [The Economist, Sep 3,11]
Aerovironment down 12% [Aug 8, 11]
Aerovironment up 21% [Jun 22, 11]
Aerovironment down 12% [Apr 1, 11] after a UAV crashed in test
Aerovironment up 14% [Mar 9, 11] the company's blowout earnings report [Motley Fool, Mar 9]
a pocket-size drone dubbed nanohummingbird from the way it flaps its tiny robotic wings has been developed for [DARPA] as a mini-spy plane capable of maneuvering on the battlefield and in urban areas. The battery-powered drone was built by AeroVironment (Monrovia, CA) as part of a series of experiments in nanotechnology. The little flying machine is built to look like a bird for potential use in spy missions. The Pentagon has awarded about $4 million to AeroVironment since 2006 to develop the drone. [WJ Henningan, LA Times, Feb 18, 11] Although DARPA shows no SBIR for such work the AF shows a $4M SBIR in 2007 as an adoption of a SOCOM Phase 1. SOCOM hasn't got that scale of SBIR money.
Aerovironment up 15% [Dec 8, 10] after posting a tiny gain instead of a tiny loss. and getting a $4.9M contract from Norway.
Aerovironment down 12% [Feb 4, 10] after preliminary federal budget plans, Companies in FBR's coverage space that fared the worst because of the budget were industry leader Lockheed Martin and AeroVironment, the firm said [Reuters]
Aerovironment up 10% [Jan 14, 10]
Forbes's 2009 list of best 200 small companies includes Aerovironment, American Science and Engineering (paying a dividend and with nearly $600M market cap), Argon ST, Hittite Microwave, II-IV, Meridian Bioscience, Neogen, NVE, and Synaptics.
AeroVironment hoped to make its plane, called Helios, into a cheaper version of a telecom satellite. That hasn't panned out yet. So the company instead makes most of its money closer to the ground, selling planes with 4-foot wingspans that fly at 500 feet. Small enough to fit in a soldier's backpack and outfitted with cameras that feed real-time video in color or infrared to a handheld screen, these drones have quickly become cherished equipment to soldiers searching for terrorists in Iraq and Afghanistan. .... had been working on small unmanned planes for a decade, so it was able to offer the military a series of small planes that were quickly adopted by several services. [Jonathan Fahey, Forbes, Jul 13, 09]
coondoggie writes "Unmanned aircraft maker AeroVironment got an additional $5.4 million to further develop a diminutive aircraft that can fly into tight spaces undetected, perch and send live surveillance information to its handlers. Last Fall, AeroVironment, got $4.6 million initial funding from the Defense Advanced Research Projects Agency (DARPA) to develop the Stealthy, Persistent, Perch and Stare Air Vehicle System (SP2S), which is being built on the company's one-pound, 29-inch wingspan battery-powered Wasp unmanned system." [slashdot.org, Jun 4, 09]
Aerovironment up 18% [May 7, 09]
AeroVironment down 33% [Mar 10, 09] maker of unmanned aircraft for the military posted fiscal third-quarter net income that fell short of Wall Street's expectations. ... also cut its fiscal-year revenue projection. [Wall Street Journal, Mar 11]
AeroVironment's fiscal third-quarter net income dropped 24% on lower margins and higher research and development expense. Shares sank 27% to $22.25 in after-hours trading as the results fell far short of Wall Street's expectations, and the aircraft manufacturer cut its fiscal-year revenue guidance, citing economic conditions and the timing of the receipt and shipment of customer orders. [Wall Street Journal, Mar 9]
Aerovironment up 12% [Jan 15, 09]
Aerovironment up 11% [Nov 21, 08]
Aerovironment up 10% [Oct 28, 08]
Aerovironment up 13% [Oct 13, 08]
Aerovironment down 18% [Sep 10, 08] after its fiscal first-quarter net income beat analysts' expectations. [Wall Street Journal, Sep 11]
AeroVironment up 15% [Jun 25, 08] to an all-time high after it posted better-than-expected fiscal fourth-quarter earnings [also up 15%] and predicted next year's sales will rise more than Wall Street has anticipated [AP, Jun 25]
The top street analyst for aerospace defense says His top pick this year is unmanned-aircraft maker AeroVironment ($8M SBIR), which went public in January 2007. It's a "pure play" on the military's adoption of such systems and a "strong acquisition candidate" in the next few years, he says. The company's Raven aircraft are small enough to be launched by hand. [Wall Street Journal, May 19]
AeroVironment ($8M SBIR since 1991) a leader in unmanned aircraft systems and efficient electric energy systems, announced that the U.S. Marine Corps has ordered $19.3M in BATMAV (Battlefield Air Targeting Micro Air Vehicle) systems, each consisting of two Wasp III micro air vehicles plus ancillary pieces. [company press release, Nov 20, 07]
AeroVironment, a leader in unmanned aircraft systems and efficient electric energy systems, has installed its Architectural Wind system on the roof of the new Beloit, Wis., manufacturing facility of Kettle Foods, a Salem, Ore.-based producer of all-natural potato chips and other snack foods. The Beloit installation includes 18 wind turbines. [press release, Oct 25]
Spending on products suited for deployed troops in harm’s way remained the most dominant spending driver for the group. Companies such as FLIR and AeroVironment continued to see strong order flow, deliver strong results, and have exceptionally optimistic outlooks for 2008. [Jeff Saut, minyanville.com, Oct 22]
Unmanned-aircraft maker AeroVironment shot up 41% on its first day of trading after its IPO. Eight Phase 2 SBIRs since the early 1990s. The company had a funded backlog of government contracts totaling $64 million as of Oct. 28 and an unfunded backlog of about $492 million. [Wall Street Journal, Jan 24,07]
Aerpio Thera (one SBIR) down 71% [Mar 18, 19] announced that Administration of AKB-9778 twice daily did not meet the study's primary endpoint of the percentage of patients with an improvement of two or more steps in the study eye diabetic retinopathy severity score (DRSS) compared to placebo. [company press release, Mar 15, 19]
Aerpio Pharmaceuticals (Cincinnati, OH; no SBIR, spun off from Akebia Therapeutics in 2011) announced the consummation of a private placement for gross proceeds of approximately $40.0 million [that] will be used for clinical development activities, including advancement of Aerpio’s lead program, AKB-9778, for the treatment of diabetic retinopathy (DR) [company press release, Mar 16, 17]
clinical-stage biopharmaceutical company Aerpio Therapeutics (Cincinnati, OH; no SBIR) announced it has closed a $22 million round of funding. ... will support the expanded development of a small molecule activator called AKB-9778 used to treat diabetic macular edema. It will also be used to advance another activator, called AKB-4924, into clinical development for inflammatory bowel disease. [Andy Brownfield, Cincinnati Business Courier, Apr 23, 14] created in a [2012] spin-out from Akebia Therapeutics to enable more rapid development of its exciting compounds. [company website]
Aerpio Therapeutics (Cincinnati, OH; no SBIR) announced it had successfully completed a study of a new drug to treat vision loss in diabetics. Aerpio also announced the closing of a $9 million extension to a $27 million round of funding raised in 2012. .... will expand the study of the AKB-9778 inhibitor used to treat diabetic macular edema. [Andy Brownfield, Cincinnati Business Courier, Nov 6, 13]
AesRx (Newton, MA; no SBIR) has boosted its latest financing round by about $125,000 to $1.5 million, according to a federal document. [Mass High Tech, Jil 1, 11] one of Central Texas' least-known business success stories.Thermon (Austin, TX; no SBIR) — which creates, manufactures and services heat tracing technologies for some of the world's biggest oil and chemical companies ... for decades, Thermon has consistently churned out profits and has become one of the biggest players in the worldwide heat tracing market, ... a long way from Thermon's 1954 birth, when founder Richard Burdick created the company with a borrowed $40 ... "Thermon is a really interesting play or investment in a high-growth, niche industrial technology space," [Industry analyst Brian] Drab said. "I'm always looking for high-growth industrial technology companies [Barry Harrell, Austin American Statesman, Jul 4, 11]
The Massachusetts Life Sciences Center, a quasi-public agency, awarded $3.75 million in loans to five early-stage life sciences companies. AesRX (Newton, MA; no SBIR) biopharmaceutical company focused on the development of sickle cell disease and other orphan drugs; MoMelan Technologies (MA; no SBIR) medical device company; Myomo (Cambridge,MA; one SBIR) focused on helping people move again after a neuro-muscular impairment; ECI Biotech (Worcester, MA $1.6M SBIR) developer and manufacturer of affordable diagnostic sensors that can be incorporated into any consumer product or medical device; and Grove Instruments (Worcester, MA; $400K SBIR)developing a painless, noninvasive technology that accurately measures blood sugar. [Boston Globe, Mar 23, 11]
AETC (San Diego, CA), that provides remote sensing systems and related services for the DOD, is being bought by SAIC for an undisclosed sum. [San Diego Union Tribune, Nov 9]. AETC had about $2M in DOD SBIRs
Aethlon Medical (San Diego, CA; $2.7M SBIR) down 26% [Jun 10, 21] announced that it has entered into a definitive agreement with a single institutional investor for the purchase in a registered direct offering of 1,380,555 shares of its common stock, [comapny oress release, Jun 10, 21]
Aethlon Medical (San Diego, CA; $2.7M SBIR) up 388% [Jun 9, 21] after major news emerged from the company last week regarding the fight against the novel coronavirus. [Nick Clarkson, Investor Place, Jun 9, 21]
Aethlon Medical (San Diego CA; $600K SBIR) up 72% [Oct 16, 19] announced a 1-15 reverse stock split [company press release, Oct 16, 19]
Aethlon Medical up 11% [Jan 5, 16]
Aethlon Medical, which has been developing therapeutic blood filtration devices for treating infectious disease and cancer, says the [FDA] has approved the company’s request to export its “Hemopurifier” device to India. [Bruce Bigelow, xconomy.com/sandiego, Mar 10, 11]
February under-the-radar deals. Catadon Systems (Carlsbad, CA; no SBIR) A maker of towers for elevating wind turbines Equity $689,500; Aethlon Medical (San Diego, CA; no SBIR) A developer of a medical device to treat infectious diseases Debt* $600,000 ; Ampla Pharmaceuticals (La Jolla, CA; no SBIR) A stealthy biotech company Equity $295,271; Cibus Global (San Diego, CA; no SBIR) A developer of environmentally friendly technology for producing crop traits Equity* $201,132 *includes some options and warrants [Erin Kutz, signonsandiego.com, Apr 6, 10]
Several life sciences startups in the San Diego area have received funding in recent weeks. Auspex Pharmaceuticals raised $3 million, Aethlon Medical raised $600,000, and Tocagen got $3 million. [Bruce Bigelow, signonsandiego.com, Mar 12, 10]
Innovation Works and the Pittsburgh Life Sciences Greenhouse have spent the past decade as a tag-team source for fledgling companies — ideas even — to find the financial support needed to grow into viable, productive and profitable companies. .... Looking at the 2001-2005 period, firms funded by the two groups during this period include Aethon (no SBIR), Vivisimo ($700K SBIR), ALung Technologies (no SBIR), Plextronics ($300K SBIR), Inc., RedZone Robotics ($1.6M SBIR) and Thorley Industries (no SBIR) (4moms). Other than Vivisimo, which was bought by IBM in 2012, all of those companies are core firms in the portfolios of local venture capital firms [Ethan Lott, Pittsburgh Business Times, Jul 8, 13]
Aevi Genomic Medicin (Philadelphia, PA; no SBIR, founded Y2K) announced an adaptive, 6-week, double-blind parallel-group study in children and adolescents (ages 6-17 years) with ADHD with and without copy number variants (CNVs) in specific genes implicated in glutamatergic signaling and neuronal connectivity. [company press release, Aug 21, 18] total funding $78M [crunchbase.com]
Aevi Genomic Medicine (Philadelphia, PA; no SBIR) announced the completion of a previously announced private placement ... for aggregate proceeds of $28.0 millio. The Children's Hospital of Philadelphia Foundation (the "CHOP Foundation") was the lead investor ... to further the development of its two lead clinical programs, to support its ongoing collaboration with Children's Hospital of Philadelphia, to develop other product candidates and for general corporate purposes. [company press release, Oct 17, 17]
Dr. Picard, is a pioneer in the field, especially in the use of computing to measure and communicate emotions. For years, she and a research scientist at the university, Rana el-Kaliouby, have applied facial-expression analysis software to help young people with autism better recognize the emotional signals from others that they have such a hard time understanding. The two women are the co-founders of Affectiva (Waltham, MA; no SBIR) that is beginning to market its facial-expression analysis software to manufacturers of consumer products, retailers, marketers and movie studios. Its mission is to mine consumers’ emotional responses to improve the designs and marketing campaigns of products. [Steve Lohr, New York Times, Jan 2]
Merck agreed to purchase biotechnology company Afferent Pharmaceuticals (San Mateo, CA; no SBIR, founded 2009), whose lead drug candidate is being evaluated as a treatment for refractory, chronic cough and idiopathic pulmonary fibrosis with cough. The deal will include an upfront payment of $500 million and milestones of up to $750 million. Afferent focuses on targeting the P2X3 receptor for neurogenic conditions. Last month, Afferent reported that its lead candidate, AF-219, significantly reduced cough frequency in the first cohort of a two-cohort, Phase 2b study of chronic cough patients. In July, Afferent said it completed a $55 million Series C financing. Merck's resent acquisitions have included an $8.3 billion deal for antibiotic maker Cubist Pharmaceuticals ($5M SBIR) and the purchase of cancer-focused IOmet Pharma (no SBIR). [Josh Beckerman, Wall Street Journal, Jun 9, 16]
Afferent Pharmaceuticals (San Mateo, CA; no SBIR) raised a $55 million Series C round with an eye toward moving its chronic cough treatment into late-stage trials and going public ... [CEO Kathy] Glaub, who was president of Plexxikon (Berkeley, CA; $300K SBIR) and led it into a May 2013 acquisition by Daiichi Sankyo Group, said the funding gives Afferent "additional optionality" as it preps AF-219 for ptoential Phase III trials in pathologic cough, including in patients with IPF. [Ron Leuty, San Francisco Business Times, Jul 9, 15]
Affigen (St Louis, MO; no SBIR) a biotechnology company that develops therapeutics targeting cell lineage-specific tumor proteins, announced the closing of a $17 million Series A financing ...targeting cell-lineage specific tumor proteins with therapeutics that have direct, potent anti-tumor activity and unrivaled safety,” said [CEO] Santos. [company press release, Feb 21, 17]
Affinia Therapeutics (Waltham, MA; $1.2M SBIR) an innovative gene therapy company with a platform for rationally designed adeno-associated virus (AAV) vectors and gene therapies and a mission to develop transformative medicines for devastating diseases, announced it has closed an oversubscribed $60 million Series A financing [to] to advance the company’s platform and develop transformative gene therapies for people affected by muscle and central nervous system (CNS) diseases with significant unmet need. [company press release, Mar 31, 20]
In all, 52 venture capital deals were struck in Connecticut in 2010, with more than $187 million invested, compared with 39 deals and $157.4 million invested in 2009. In the recent quarter, Helix Therapeutics (New Haven, CT; one SBIR) biopharmaceutical company, received $2.5 million; SeeClickFix (New Haven) firm that develops online and mobile platforms, received $1.3 million; and Affinimark Technologies (New Haven, CT; no SBIR) start-up that develops medical diagnostic products, received more than $1.2 million. A Guilford-based online advertising start-up, uKnow, received $453,000; Interactive Mobile @dvertising LLC in Norwalk received $275,000; Retail Optimization Inc., a New Haven firm that develops merchandising software, received $250,000; Twigtek Inc., a New Haven company that operates a website for selling or recycling used electronic equipment, also received $250,000. And Semantifi Inc., a Stamford software firm, received $50,000 from Connecticut Innovations Inc., the state's venture capital investing arm. [Janice Podsada, Hartford Courant, Jan 21, 11]
Affinimark Technologies (New Haven, CT; no SBIR) that develops point-of-care tests for cerebrospinal leaks has received a $1,359,394 investment by the quasi-public agency Connecticut Innovations and LaunchCapital. ... to complete the clinical and regulatory development of the test technology [James Connolly, Mass High Tech, Oct 13, 10]
Thermo Fisher Scientific reports it has bought Affinity BioReagents (Golden, CO; one SBIR) a provider of life sciences research materials. [Mass High Tech, Jul 17, 08]
Affinium Pharmaceuticals (Austin, TX; no SBIR) has started administering its new antibiotic drug AFN-1720 in a Phase 1 clinical trial. ... company's leading candidate in a class of antibiotics inhibiting the biosynthesis of bacterial fatty acids. ... founded in 2003, develops oral antibiotics and specializes in the treatment of antibiotic resistant staphylococcal infections. ... relocated from Toronto to Austin in 2007. [Chad Swiatecki, Austin Business Journal, Sep 6, 13]
Affinivax (Boston, MA; no SBIR) announced it has closed on a $120 million Series B ... first funding since it raised $2.5 million in initial seed and Series A money from the Bill & Melinda Gates Foundation in February 2016, according to Crunchbase ... currently has a lead pneumococcal vaccine currently in clinical trials. It plans to use part of its fresh capital to continue advancing its Multiple Antigen Presentation System (MAPS) pneumococcal vaccine program, which it is conducting in partnership with Tokyo-based Astellas Pharma. [Mary Ann Azevedo, crunchbasenews, Apr 23, 20]
A new approach to vaccines developed at Boston Children's Hospital which aims to make them both stronger and cheaper to produce is the basis of a Gates Foundation-funded startup Affinivax (Cambridge, MA) being launched today. Steve Brugger, CEO, called , said research developed at Children's Hospital by Dr. Richard Malley has already been licensed to the startup biotech. Malley is scientific founder of Affinivax. [Don Seiffert, Boston Business Journal, Oct 30, 14]
Affomix(Branford, CT; $200K SBIR) has entered into a development deal with Canada’s Kalgene Pharmaceuticals Inc. in which Kalgene will use Affomix’s technology to help identify possible diagnostics and therapies for breast cancer. [Mass High Tech, Dec 31, 09] $7 million Series A Financing in 2008
From FDA approval to dissolution in two years, Affymax (Cupertino, CA; $600 SBIR twenty years ago) said it would wind down operations if shareholders approve. With partner Takeda Pharmaceutical, Affymax won the FDA’s green light in March 2012 for peginesatide (Omontys), an anemia treatment for patients on dialysis for chronic kidney disease. It was soon pulled off the market because of fatal allergic reactions. Affymax, of , said this week that its partner Takeda was not able to pinpoint the cause of the reactions, dealing Affymax what seems to be a final blow [Alex Lash, xcononmy.com, Jun 26, 14]
Affymaxdown 64% [Mar 19, 13] after disclosing that it was slashing its workforce dramatically and reiterating that it was looking at strategic options including ankruptcy.
Affymax said that the company is cutting 230 people from its payroll, about 75 percent of its workforce. [Luke Timmerman, xconomy.com, Mar 18, 13]
Affymax up 54% [Mar 7, 13] a spokeswoman for the company, didn’t return telephone calls seeking comment. [Elizabeth Lopatto, Bloomberg, Mar 7]
Affymax down 85% [Feb 25, 13]
Affymax and Japan's Takeda Pharmaceutical Co said they are voluntarily recalling all lots of anemia treatment Omontys (peginesatide) in the U.S., due to reports of serious hypersensitivity reactions, including some deaths. [Reuters, Feb 23]
Affymax down 13% [Dec 19,12]
Affymax down 11% [Oct 19, 12]
Affymaxup 10% [Oct 10, 12]
Affymax up 16% [Jul 13, 12]
Affymax up 19% [Jul 12, 12]
Affymax up12% [Apr 24, 12]
Affymax
up 14% [Feb2, 12]
Affymax down 12% [Dec 16, 11]
Affymax up 36% [Dec 8, 11] as dialysis treatment found favor with FDA
Affymax said it priced a public offering of 8.5 million shares [for] gross proceeds of $50 million.
Affymaxup 12% [Mar 8, 11]
Affymax up 2% after the company said it received a $30 million milestone payment from a Japanese partner for an investigational drug that treats anemia. The stock had plunged 69% Monday on negative study results for its Hematide treatment of anemia. [Wall Street Journal, Jun 23, 10]
Affymax is looking to go head to head with biotech's biggest player in a multibillion-dollar anemia-treatment market that has proved to be troublesome in recent years. ... developing Hematide in partnership with Japan's Takeda Pharmaceutical Co. as a longer-lasting alternative to Amgen Inc.'s Epogen and Aranesp, which had combined U.S. sales of $3.8 billion last year. Although growth of those drugs has evaporated in recent years due to safety and regulatory issues, they had U.S. sales of $5.3 billion in 2006, and Affymax says an opportunity remains for a new option. [Thomas Gryta, Wall Street Journal, Mar 17]
Affymax said it received a $5 million development milestone payment from Takeda Pharmaceutical Co. ... said the payment is part of the companies’ exclusive global agreement to develop and commercialize Hematide, Affymax’s investigational drug for the treatment of anemia in chronic renal failure patients.
Affymax (Palo Alto CA) going public this week. One Phase 2 SBIR.
Affymetrix down 10% [Mar 21,16] Thermo Fisher Scientific fought back against an 11th hour attempt by a rival firm to derail Thermo's planned $1.3 billion acquisition of [Affymetrix]. Origin Technologies, made up largely of former executives at Affymetrix, attempted to outbid Thermo Fisher with a $1.5 billion offer. ... Affymetrix shareholders are scheduled to vote on the Thermo Fisher deal in coming days. [Don Seiffert, Boston Business Journal, Mar 21, 16]
Affymetrix up 14% [Mar 18,16] some of the company’s former executives.. banded together as Origin Technologies, said on Friday that they had offered $1.5 billion [with the help of a Chinese financial backer] to buy Affymetrix, topping an existing takeover proposal by Thermo Fisher Scientific. [MICHAEL J. de la MERCED, New York Times, Mar 18, 16]
Affymetrix (Santa Clara, CA; $3.3M SBIR) up 52% [Jan 11, 12] after announcement of acquisition by Thermo Fisher
Thermo Fisher Scientific will buy Affymetrix (Santa Clara, CA; $3.3M SBIR) in a roughly $1.3 billion cash deal that would boost its biogenetic analysis portfolio, the company said ... Affymetrix, which carried an accumulated loss of about $500 million as of Sept. 30, has about $350 million in annual revenue [Maria Armental, Wall Street Journal, Jan 8, 16]
Affymetrix down 15% [Feb 6, 14]
Affymetrix up 12% [Jan 7, 14]
Affymetrix up 14% [Aug 1, 13]
Startup Phenomenon Conference in Boulder, November 13 to 15. The Boulder-based Van Heyst Group, which plans conferences for tech companies and global nonprofits, is organizing the event. [Michael Davidson, xconomy.com, Jul 31]
Affymetrix down 10% [Jul 17, 13]
Affymetrix down 14% [Apr 9, 13]
Affymetrix down 14% [Oct 8, 12] after the company provided a third-quarter revenue outlook that was below analysts' projections, saying the tightening of the academic funding environment affected its gene expression and eBioscience units.[Wall Street Journal, Oct 9]
First Solar down 11% [Oct 5, 12]
Affymetrix down 13% [Jun 19, 12]
Roche Holding AG is offering $5.7 billion in cash to buy U.S. gene sequencing company Illumina in a hostile takeover bid that marks a major play by the Swiss drugmaker into the gene technology field. .... Companies such as Illumina, AffymetrixLife Technologies get 20-40 percent of their revenue from U.S. government-backed research and may take a hit from any government funding cut. [Reuters, Jan 25, 12] Illumina enjoyed about $10M SBIR 1999-2010, and a $4.6B market cap before the Roche gambit. Founder David Walt now owns less that 1% of the shares. Employees: 1200.
Affymetrix up 10% [Oct4, 11]
Affymetrix down 13% [Aug 8,11]
Affymetrix down 18% [Jul 7, 11]
Affymetrix up
11% [Jun 2, 11]
Affymetrixup 10%[Mar 25, 11]
Affymetrix up 15% [Jan 12, 11]
Affymetrix down 10% [Aug 11, 10]
Affymetrix up 13% [Jul 28, 10]
Affymetrix down 27% [Jul 7, 10] said it now sees second-quarter revenue coming in at $71 million to $72 million, down from its previous forecast of $80 million to $82 million. [Val Kennedy, MarketWatch, Jul 7]
Affymetrix down 14% [Apr 22, 10]
Companies to Watch in personalized medicine. Affymetrix, Life Tech, Illumina, Helicos Biosciences, Metabolon. Among the fifty most innovative: A123 Systems, American Superconductor, Alnylam, Illumina, iRobot, Novomer, BIND Biosciences. [MIT Tech Review, M/A10] Affymetrix up 29% [Feb 4, 10]posted a surprise quarterly profit and said it expects to be profitable in 2010 after almost two years. [Reuters]
Affymetrix up 10% [Jan 14, 10]
Affymetrix down 14% [Jan 13, 10] The technology that Affymetrix develops is quickly becoming obsolete, or so analysts believe. ... increased pricing pressures from competitors as its technology becomes quickly outdated by new genetic analysis technology such as Illumina’s sequencing technology. [Lisa LaMotta, Minyanville.com, Jan 13, 10]
Affymetrix up 10% [Jan 6, 10]
Affymetrix up 14% [Dec 9, 09]
Affymetrix down 10% [Oct 28, 09]
Affymetrix down 18% [Oct 22, 09] after it reported a wider-than-expected quarterly loss hurt by weak gross margins, and forecast fourth-quarter revenue below market estimates. [Reuters]
Affymetrix up 33% [Jul 23, 09] company's second-quarter earnings topped Wall Street's estimates. [Wall Street Journal, Jul 24]
Affymetrix up 17% [Jul 20, 09]
Affymetrix down 10% [May 13, 09]
Affymetrix up 11% [Apr 28, 09]
Affymetrix up 13% [Apr 24, 09]
Affymetrix down 17% [Apr 23, 09]Affymetrix up 11% [Apr 16, 09]
Affymetrix up 14% [Mar 26, 09]
Affymetrix up 13% [Mar 23, 09]
Affymetrix down 20% [Jan 29, 09]
Affymetrix up 20% [Jan 27, 09]
Affymetrix down 10% [Dec 1, 08] On a stock bloodbath day
Affymetrix agreed to buy Panomics (Fremont, CA; $2.3M SBIR) for $73 million in cash. -... Panomics makes products for genetic, protein and cellular analysis. [San Francisco Business Times, Nov 11, 08]
Affymetrix down 14% [Oct 23, 08]
Affymetrix up 11% [Oct 20, 08]
Against the surge, Affymetrix down 17%, [Oct 13, 08] projected lower-than-expected third-quarter sales amid increased competition for academic research and funding and softness in industrial spending. [Wall Street Journal, Oct 14]
The Wall Street Journal's Patent Scorecard in Biotechnology ranks Invitrogen and Maxygen #2 and 3 in Science Strength (13-week rolling average). Sequenom was #6; Affymetrix #11 of 28 listed. Only Sequenom had an impressive stock price record, up 170% over 52 weeks.
Affymetrix fell 27%a day after the company reported moving from a second-quarter profit to a loss and presented a discouraging forecast. [Sacramento Business Journal, Jul 25, 08]
Affymetrix dropped more than a third after the maker of tools to analyze genes cut its revenue forecast, dragging down the shares of equipment suppliers Illumina and Applied Biosystems Group. [San Jose Mercury News, Apr 15, 08]
Affymetrix will pay $75M cash for USB. (Cleveland, OH; no SBIR), which calls itself a supplier of reliable biochemicals and molecular biology products. [Dec 08]
Affymetrix down 10% [Nov 13, 07] said it will offer $250 M of unsecured senior convertible notes, due 2038.
Affymetrix won a four-year, $10.2M million federal grant to delve deeper into the secrets of human heredity. The grant from the National Human Genome Research Institute was awarded to a team of Affymetrix scientists and will finance the identification of various functional regions found across the human genome. [San Jose Mercury News, Oct 9]
Affymetrix won a patent fight with Illumina over five patents held by Affymetrix and Illumina was ordered to pay Affymetrix $16.7M. [Mar 07]
Affymetrix soared 14% after predicting high fourth-quarter revenue. [Jan 8, 07]
aFraxis, (San Diego, CA; no SBIR) which has completed pre-clinical testing of a promising compound for treating fragile X syndrome, the most common cause of inherited mental impairment, has raised $1.2 million in a venture round targeting $6 million, according to a recent regulatory finding [Bruce Bigelow, xconomy.com, May 22, 10]
Three [Triangle] companies raised $25 million or more [in the recent quarter]: drug-development company Ascletis (China); agricultural biotechnology company AgBiome (Durham, NC; no SBIR) and Spoonflower (Durham, NC; no SBIR, which produces on-demand fabrics. [David Ranii, Raleigh News & Observer, Oct 15, 15]
Agricultural biotechnology company AgBiome (Research Triangle Park, NC; no SBIR, 36 full-time employees) raised $34.5 million from investors that it plans to plow into research and development and the anticipated launch of its first product ... [the product] known internally as Howler, is a natural, or biological, fungicide that can be used by organic farmers. [David Ranii, Raleigh News & Observer, Aug 19, 15]
AgeneBio (Baltimore, MD; no prior SBIR, approx $26M NIH grants, founded 2008) has been awarded nearly $500,000 from the Alzheimer’s Drug Discovery Foundation and has been selected to receive a [NIH] SBIR of up to $2.9 million Both awards go towards the development of a first in class therapeutic in AgeneBio, Inc.’s GABA-A a5 program [company press release, Sep 11, 19] prior funding $10M [crunchbase.com]
The Alzheimer's Drug Discovery Foundation (ADDF) has awarded $500,000 to AgeneBio (Baltimore. MD; at least $3M SBIR) to accelerate the first-in-class therapeutic to the clinical stage $2.9 million over 3.5 years from the National Institute on Aging (NIA), adding to the ~$11M of prior NIH investment in this innovative therapeutic program provided through the NIA's AD Drug Development Program and the NIH Blueprint Neurotherapeutics Program. [company press release,, Sep 11, 19]
AgeneBio (Baltimore, MD; no SBIR), a biotech working on an Alzheimer's drug received $4.1 million [Joanna Sullivan, Baltimore Business Journal, Jan 16, 15] developing innovative therapeutics for unserved patients afflicted with neurological and psychiatric diseases to preserve and restore brain function. ... Our Phase 3-ready asset is intended to treat aMCI and delay progression to Alzheimer’s dementia. We plan to initiate our Phase 3 trial in the second half of 2015. [company website]
AgeneBio (Indianapolis, IN; no SBIR, founded 2008) received a $240,000 grant from the Alzheimer's Drug Discovery Foundation to help develop a new class of compounds that have promise in treating a neurological condition that often progresses to Alzheimer's disease. ... has a therapy in midstage clinical trials for the condition known as amnestic mild cognitive impairment. [Indianapolis Star, Aug 27, 10]
Agennix (Houston, TX; $2.5M SBIR) is banking on the idea that an ingredient in mother's milk can help treat lung cancer. ,,, could become the first federally approved cancer drug to come out of Houston. ... Lung cancer kills more Americans than breast, prostate and colorectal cancers combined [Lynn Cook, Houston Chronicle, Jan 17]
Agenovir (So San Francisco, CA), a company incubated at Johnson & Johnson’s JLABS accelerator in South San Francisco aims to use CRISPR technology to develop antiviral drugs [said] that it’s raised $10.6 million. ... based on the work of scientific founder Stephen Quake, a Stanford University bioengineering professor. Quake used Agenovir’s approach to treat cells infected with Epstein–Barr virus, which can lead to a type of cancer called Burkitt lymphoma (as well as mono), in a study published in PNAS.[David Holley, xconoy.com, May 18, 16]
Agenus Pharma (Lexington, MA; 9$1.6M SBIR) is now in the closing stretch of its multidecade effort to bring a drug to market. With the FDA set to decide whether to approve PD-1 drug balstilimab in December, Agenus has published the phase 2 data it hopes will secure authorization in cervical cancer. [Nick Paul Taylor, Fierce Biotech, Aug 27, 21]
Agenus (Lexington, MA; $1.3M SBIR) up 24% [Sep 10, 20] ahead of a planned oral presentation of clinical trial data at the European Society of Medical Oncology (ESMO) Conference on Sept. 18, 2020. An immuno-oncology biotech company developing compounds to help the immune system fight cancer, Agenus' most advanced drugs in development are the anti-PD-1 targeting therapy, balstilimab, and the anti-CTLA-4 antibody, zalifrelimab. [Motley Fool, Sep 10, 20]
Agenus (Horsham, PA; $1.2M SBIR) up 18% [Nov 18, 19]
Agenus down 12% [Apr 16, 18]
Agenus (Lexington, MA; no SBIR) announced plans to phase out 50 jobs worldwide over the next six months — about 20 percent of its headcount — and close a facility in Switzerland as it reorganizes to focus on two potential cancer treatments and its vaccine in development. [Boston Business Journal, Mar 30, 17]
Agenus
up 10% [May
14, 12]
Agenus up 13% [Mar 29, 12]
Agenus up 19% [Mar 19, 12]
Agenus up 17% [Mar 6, 12]
Agenus up 11% [Feb24,12]
Agenus up 18% [Feb 8,12]
Agere Pharmaceuticals (Bend, OR; no SBIR, 53 employees) was sold to Patheon (Durham, NC; no SBIR, 8000 employees). The acquisition could help Patheon make drugs with better absorption rates. ... Patheon helps drug companies develop and manufacture pills and capsules and says it will now better be able to help its customers – those drug developers – reach an optimal dosage. Most drugs are soluble, but there are certain drugs that present challenges and need some modified delivery technology. This is what Agere brings to the table. [Jason deBruyn, Triangle Business Journal, Mar 11, 15]
AgeX Therapeutics (Alameda, CA; one SBIR) announced that AgeX believes that its cash and cash equivalents and available sources of debt and equity capital would not be sufficient to satisfy AgeX’s anticipated operating and other funding requirements for the twelve months [company press release, Aug 12, 22]
AgeX Therapeutics (Alameda, CA; one SBIR) announced that AgeX believes that its cash and cash equivalents and available sources of debt and equity capital would not be sufficient to satisfy AgeX’s anticipated operating and other funding requirements for the twelve months [company press release, Aug 12, 22]
AgeX Thera up 25% [Dec 13, 18]
AgeX Thera down 16% [Dec 11, 18]
AgeX Theradown 25% [Dec 10, 18]
AgeX Therapeutics up 99% [Nov 30, 18], a subsidiary of BioTime (Alameda, CA; $2.3M SBIR) focused on the development and commercialization of therapeutics targeting human aging, announced that its common stock is now trading on the NYSE American exchange [company press release, Nov 29, 18]
Agile Materials& Technologies (Goleta, CA) got a first VC round of $5.8M and looking for $2-3M by next month. Agile, a spinoff of the UCSB, has had $1M SBIR from the Army, [LARTA, Sept. 23]
From SBIR to Real Money(Jul 30) Agile Materials (Goleta, CA) passed briefly through DARPA and SBIR (Army Phase 1) to VC funding. Prof Robert York and Dr. Chris Elsass spun the company out from UCSB where York did thin film ferroelectrics with BST. [story from LARTA July 29] Agile's website claims that ferro-electric materials can shrink capacitors by 99% (I guess that's what "100X smaller" means) from some baseline; cost reduction claims are more vague. Maybe they could shrink the website too, as it takes several screens to deliver a simple message of the BST material's claims.
Motoman Robotics (Miamisburg, OH; a subsidiary of Yaskawa America of Waukegan, IL) has acquired Agile Planet (Austin, TX; no SBIR), a developer of intelligent robotics software and hardware products engineered to improve the efficiency and functionality of industrial robots. [Joe Cogliano, Dayton Business Journal, Jun 18, 13]
When startup FireFly LED Lighting (Austin, TX; no SBIR) was accepted into the Austin Technology Incubator two years ago, its LED bulbs were still prototypes. Since then, the company has launched its product line, signed customers including Kerbey Lane Cafe and the University of Texas and received $3.4 million from backers including the Central Texas Angel Network and the Texas Emerging Technology Fund..... Since its founding in 1989 by legendary business leader George Kozmetsky, ATI has worked with more than 200 startups, helping them raise nearly $1 billion in investment capital. [Lori Hawkins, Austin American Statesman, Jan 26, 12] Graduates: Agile Planet, Atomometrics, Axelo, Calxeda, Dorsan Biofuels, Famigo, GameSalad, Ideal Power Converters, Itzbig, Nitero, Notice Technologies, Open Algae, Qcue, RFMicron, RRE Solar, Savara Pharmaceuticals, Spredfast, Terapio ($500K SBIR), Unwired Nation, WiMax.com.
A smart drug delivery system and an all-electric, self-driving lawnmower company were among 37 startups that received funding as part of the latest Colorado Advanced Industries Accelerator Grant Program. A total of $7,657,811 was approved for Proof-of-Concept and Early Stage Capital and Retention Grants to fuel the growth of Colorado’s advanced industries, which include things like advanced manufacturing, aerospace, bioscience and electronics. [Nick Greenhalgh, Colorado Inno November 30, 2020] included Agile RF Systems (Bertoud, CO; $3.2M SBIR, $250K; ClearSight (Aurora, CO; $1.8M SBIR, $250K; Menogenix (Aurora, CO; $900K SBIR, $108K
Ben Franklin Technology Partners of Southeastern Pennsylvania announced that nine early-stage companies have been approved to receive $1.55 million in funding. Gatherers include: Telefactor (W Conshocken, PA; $2.7M SBIR) $400K and previous $230K from Ben; AgileSwitch (Philadelphia, PA; no SBIR); Smart Structures (Southhampton, PA; no SBIR) [Peter Key, Philadelphia Business Journal, Jun 6, 13]
A contraceptive patch developed by Agile Therapeutics (Princeton, NJ; no SBIR) was awarded FDA approval, clearing the way for a new birth control option to reach the market. ... the first FDA approved product for the company. [Frank Vinluan, xconomy.com, Feb 14, 20]
Agile Therapeutics (Princeton, NJ; no SBIR), a specialty pharmaceutical company that focuses on women's health products, expects to raise $20 million in private stock sale scheduled to be completed later this week. ... is conducting late-stage testing of Twirla, an experimental once-weekly transdermal contraceptive patch. Agile Therapeutics anticipates completing enrollment in the study early in the second quarter of 2015. [John George, Philadelphia Business Journal, Jan 20, 15]
Oregon State U robotics spinoff Agility Robotics (Albany, OR; no SBIR, founded 2015) that designs and builds walking and running robots for advanced mobility in human environments, raised $8 million in Series A funding to accelerate product, technology, and business development. [company press release, Mar 22, 18]
PTC Therapeutics (South Plainfield, NJ; no SBIR) is looking to gene therapy in a bid to broaden its pipeline, scooping up privately held Agilis Biotherapeutics (Cambridge, MA; no SBIR) in a cash and stock deal..... will pay $50 million up front, plus $150 million in PTC shares, for Agilis. Agilis, based in , could get up to $595 million more depending on the progress of its three most advanced gene therapy programs, which target rare central nervous system disorders. [Frank Vinuan, xconomy.com ,Jul 19, 18]
Agilvax (Albuquerque, NM; $2.6M SBIR, founded 2011) raises millions, names new CEO [Albuquerque Business Journal, Aug 29, 19] prior funding $8M [cruchbase.com]
Agilvax (Albuquerque, NM; no SBIR, founded 2011, total funding $3.1M) announced a significant milestone for its immunotherapy, AX09, for the treatment of triple negative breast cancer (TNBC). The preclinical results are being published in an article in the journal OncoImmunology, entitled “A Virus-Like-Particle immunotherapy targeting Epitope-Specific anti-xCT expressed on cancer stem cell inhibits the progression of metastatic cancer in vivo.” Agilvax is a biotechnology company that develops targeted cancer immunotherapies and vaccines using its proprietary virus-like particle (VLP) discovery and development technology. [Business Wire, Dec 5, 17]
biotech firm Agilvax (Albuquerque, NM; no SBIR) has landed $2 million in Series A funding to develop its virus-like particle technology [technology is licensed from the University of New Mexico] . ... in The BioScience Center, has been developing a new class of vaccines that use particles that are so small that they act like viruses. [Dan Mayfield, Albuquerque Business First, Jul 31, 14]
AgilyxBeaverton, OR; no SBIR) that converts waste plastic into crude oil has landed $25 million in investment, anticipating an expansion and, ultimately, a stock listing. ... "We don't see ourselves needing to do another private round," said Chris Ulum, Agilyx's chief executive [Richard Read, The Oregonian, Dec 19, 11]
Agilyx (Tigard,
OR; no
SBIR) has secured a $22
million
funding boost led by a group of investors that includes Waste
Management, Inc., both companies announced today.
The investment aims to further expand a fast-growing venture that takes
waste plastics and converts them into synthetic crude oil. ... founded
in 2004, and operated under the name Plas2Fuel until last year [Eric
Florip, The Oregonian, Mar 31, 11]
Agiltron (Woburn, MA; $30M SBIR) reports it has landed a Phase 3 Small Business Innovation Research grant from the U.S. Navy for a fiber-optic repair system that would help Navy technicians repair aircraft. [Mass High Tech, Dec 16, 09] Technically Phase 3 is not SBIR, but mainline R&D money. Little matter, this company has a decade-old lifeline to the Navy's purse. Let's guess its strengths: good engineering and snappy salutes.
Agios Pharmaceuticals licensed a group of potential cancer drugs from Aurigene Discovery Technologies for $3 million up front. [Alex Lash, xconomy.com, Apr 28, 17]
Agios Pharma down 11% [Jan 21, 14]
Agios Pharma down 12% [Nov 14, 13]
Agios Pharma down 12% [Nov 7, 13]
Agios Pharma down 13% [Oct 9, 13]
Agios Pharma down 11% [Jul 25, 13]
Agios Pharmaceuticals (no SBIR) shot up 73.8 percent on their first day of trading after the Cambridge company raised $105 million in an initial public offering. .... has been working in the field of cellular metabolism to develop cancer-fighting therapies. But while its approach of starving cancer cells by blocking particular enzymes is considered promising, the company has yet to get a drug into a clinical trial. [Boston Globe, Jul 25, 13]
Agios Pharmaceuticals (Cambridge, MA; no SBIR) set the range for its IPO ... The cancer metabolism specialist plans to sell 5 million shares at between $14 and $16 apiece, which would give it $75 million in proceeds at the middle of its range. Celgene, which both has a broad partnership with Agios and is one of its largest stockholders, has also agreed to buy $12.75 million worth of additional shares at the IPO price through a private placement concurrent with the offering. [Ben Fidler, xconomy.com, Jul 12, 13]
Agios Pharmaceuticals (Cambridge. MA; no SBIR) is exploring an IPO for this year. ... According to an estimate by the Reuters news service, the company could raise up to $86 million .... to use its expertise in cellular metabolism to develop treatments for cancer. [Chris Reidy, Boston Globe, Jun 11, 13]
Agios Pharmaceuticals (Cambridge, MA; no SBIR) has raised $8.8 million in venture capital, according to a regulatory filing. ... follows an April 15 announcement that the Cambridge-based biotech had signed a $130 million agreement to collaborate with New Jersey-based Celgene Corp. in the development of potential cancer-fighting therapies. [Julie Donnelly, Mass High Tech, Apr 26, 10]
Agios Pharmaceuticals, (Cambridge, MA; no SBIR) a biopharmaceutical company that is focused on discovering and developing novel drugs in the field of cancer metabolism, said today that it has received funding from Accelerate Brain Cancer Cure (ABC2), a non-profit organization that supports brain cancer research. [Boston Globe, Dec 22, 09] the first biopharmaceutical company dedicated to drug discovery based on targeting cancer metabolism .. founded 2008 with $33 Million Series A Funding [company website]
Agios Pharmaceuticals (Cambridge, MA; no SBIR) says it has secured $33 M in first round financing, for development of cancer metabolism-regulating drugs. .... The field of cancer metabolism concentrates on cell growth within cancer cells, which rely on more nutrients than normal cells to survive, Agios reports. While the company’s initial plans draw on cell metabolism therapeutics related to cancer, it may also eventually apply to other fields, including diabetes, inflammatory, autoimmune and neurological diseases. .... Aggios Pharmaceuticals was founded by cell metabolism leaders Lewis C. Cantley, director of the Cancer Center at Beth Israel Deaconess Medical Center and professor of systems biology at Harvard Medical School; Tak W. Mak, of The Campbell Family Institute for Cancer Research and The University of Toronto; and Craig B. Thompson, director of the Abramson Cancer Center, University of Pennsylvania. [Mass High Tech, Jul 7, 08]
Invenra (Madison, WI; no SBIR) startup that develops therapeutic antibodies for pharmaceuticals companies and other clients, has raised more than $2.9 million from investors, according to a regulatory filing. .... Invenra’s core business involves discovering antibodies and performing related biology work around targets the startup’s partners have identified in advance. Invenra’s collaborators, which include U.K.-based Oxford BioTherapeutics and AgonOx (Portland, OR; $300K SBIR) , are then responsible for taking the drugs forward into the clinic. [Jeff Buchanan, xconomy.com, Oct 5, 17]
BioConsortia (Davis, CA; no SBIR), the agricultural biotechnology company that raised $15 million in venture capital earlier this year, has opened its headquarters office and laboratory space in Davis. .... CEO Marcus Meadows-Smith is a former CEO of AgraQuest (Davis, CA; $1M SBIR) that was sold to Bayer CropScience for $425 million in 2012. [Mark Anderson, Sacramento Business Journal, Aug 28, 14]
A $50 million venture capital fund is being organized in Davis (CA) to invest in early-stage agriculture and life science technology companies. The AgTech Innovation Fund, structured as a limited partnership, likely would invest $250,000 to $500,000 in initial seed rounds of funding into promising companies ..... AgraQuest (Davis, CA; $1M SBIR) was a biotechnology company founded by Pam Marrone. It was bought by Bayer CropScience for $425 million in 2012. Marrone’s next company, Marrone Bio, last August closed the Sacramento region’s first successful initial public offering in nearly a decade, when it netted $56.4 million for expansion. In April, Davis-based agricultural biotechnology company BioConsortia raised a $15 million round of funding from Khosla Ventures and Otter Capital LLC. [Mark Anderson, Sacramento Business Journal, May 5, 14]
Exelixis (a public firm founded 1994; $200K SBIR to Exelixis Plant Sciences (Portland, OR) raised about $180 million on early data to support this idea back in March, and now more and more public data is rolling in to buttress the argument. ... has shown off results over the past several days from a trial that enrolled 490 patients with nine different tumor types, to see where cabozantinib (XL184) might work best. The latest batch of data for this drug, from 171 patients with prostate cancer, is being presented to doctors today at the American Society of Clinical Oncology (ASCO) meeting in Chicago. Exelixis formed Exelixis Plant Sciences in December 2000, after acquiring Agritope ($600K SBIR) in order to expand its access to plant model system technologies and product development. [Luke Timmerman, xconomy.com/san francisco, Jun 6, 11]
Agritech company Agrivida (Woburn, MA; $300K SBIR) raised $1 million in debt, according to a new Form D filing. Agrivida introduced a technology called Grainzyme, that produces enzymes inside a kernel of corn to create livestock feed. [Srividya Kalyanaraman, BostInno, Nov 1, 18]
Just weeks after announcing a partnership with a national ethanol producer, Agrivida (Medford, MA; $300K SBIR) picked up $15 million of a Series C round to develop genetically-engineered corn that is easier to turn into fuel. .... founded in 2003 to create a type of corn in which the leaves and stalks can be converted into biofuel after the edible part is removed [Don Seiffert, Mass High Tech, Sep 12, 12] Is this industry critically dependent on continued government subsides for ag and energy?
Agrivida (Medford, MA; $300K SBIR) has received a $2 million grant from the USDA to develop genetically engineered feedstocks for biofuels production. [Mass High Tech, Nov 20, 09]
several Massachusetts projects will receive a total of $33.2 million in federal funding for energy research. 1366 Technologies (Lexington) $4 million; , Agrivida (Medford; $300K SBIR) $4.6 million for efforts to cut the costs of cellulosic biofuels and chemicals; MIT $7 million on all-liquid metal grid-scale batteries; FastCAP Systems (Cambridge) $5.3 million to reduce the cost of hybrid and electric vehicles and of grid-scale storage; FloDesign Wind Turbine (Wilbraham) on new high efficiency shrouded wind turbines that could reduce noise and safety concerns $8.3 million ; Sun Catalytix (Cambridge) $4 million for a novel catalyst to enhance the efficiency of splitting water into hydrogen and oxygen. [Boston Globe, Oct 27, 09]
Church & Dwight, the parent company of Arm & Hammer Animal Nutrition, announce it has acquired Agro Biosciences (Wauwatosa, WI; no SBIR). Agro BioSciences is a leading microbial biotechnology company with an innovative platform to provide novel, science-based products for animal and agricultural production. [joint companies press release, May 1, 17] for $75 million plus a contingent payment of up to an additional $25 million based on business performance. Agro BioSciences, Inc. is an innovator and leader in developing custom probiotic products for poultry, cattle and swine. [Church press release, May 4, 17]
Allied Signal did an exclusive agreement with Ormet (Carlsbad, CA) to produce fine-line, micro-via, high-density electronic interconnect products. ... Ormet Corporation is an innovator in leading edge technology produces fine-line interconnect products and engineered material products based on its unique electronic materials. With a strong and growing intellectual property portfolio, Ormet is leveraging (whatever that means) both internal and government-sponsored research to produce commercial fine-line products and to license partners in selected technology areas. Ormet designs, manufactures and markets products and solutions in the high-density electronic market. Ormet's products include semiconductor packaging products, fine line-microvia interconnect products, thermally enhanced wiring boards, active substrate products, and engineered material products (EMI shielding, jumper wire and embedded passives). . [May 7] The founder of Ormet, then called Toranaga Technologies, Al Capote, invented Ormet inks and got $750K from BMDO and about $4 M from Venture Capital. The Allied Signal deal, says Capote, resulted from his idea to incorporate the Ormet conductor in microvias for high density PWBs. Capote these days has a new start-up, Aguila Technologies.
|
||||||
|
||||
| Note: Capote's formula works wonders for product innovation. Another innovator class, visionary pioneers, don't satisfy today's clients; they look to create a new world with discontinuous change where today's customers are irrelevant. That's usually long-term, astronomical risk with a history of the pioneer being eaten by more market-driven entrepreneurs. Visionary government (an oxymoron) will help such pioneers. The ones who don't fare well in government competition are those who come down in the muddled middle - neither credible pioneer nor market-driven entrepreneur - scientists wanting a paid hobby. | ||||
You, too, can follow Capote's formula, at least since DOD has made it easier for newbies to find the levers.
Start-up Starts
Up
Aguila Technologies
(San
Marcos, CA), Al Capote's new start-up, won an open competition $855K
DARPA contract to develop a new flip-chip encapsulant technology. Three
other partner companies - Kester Solder Division of Litton, Avex Electronics,
and a major chip
manufacturer - are co-investing in parallel R&D efforts at
their
own expense. Al founded Toranaga
Technologies (Carlsbad, CA) with the help of four VC
outfits
who stepped into direct company management after Al won an SBIR award
over $1M from BMDO with escalating matching provisions. The flip-chip
technology simplifies attaching chips to silicon in multi-chip modules
with a technology spun out from Al's first BMDO SBIR. Al has also done
what SBIR intended, get a seed stage SBIR and then combine with
strategic partners for further investment for market development. (No,
more SBIR is NOT strategic partnering.) Al and Toranaga struck me as
the kind of entrepreneur and company that SBIR was meant for.
Anti-immigrant shriekers take note: Al came from Cuba and has created
22 jobs so far in California.
One of the VCs who sponsored Toranaga Technologies (Carlsbad, CA) from which Al Capote decamped has also decamped. Jim Morgan or the eponymous Morgan Holland Ventures is now CEO of ADRA Systems. Jim served one term recently as President of the National Venture Capital Association. He also served one year as the elected student body Grand Marshal in the 50s at RPI. I don't remember whether I voted for him.
Thermo Fisher Scientific Inc. has agreed to buy Ahura Scientific (Wilmington, MA, founded 2002; no SBIR) maker of analytical instruments, for $145 million in cash. [Mass High Tech, Jan 19, 10]
Ahura Scientific reports it has partnered with QinetiQ North America’s Technology Solutions Group to add Ahura’s spectrometry technology to QinetiQ’s Talon robots. Under terms of the agreement, the companies will add a compact, laboratory-grade Raman spectrometer to Talon military robots. [Mass High Tech, Sep 29, 09]
a hand-held tool with an extremely sensitive laser that can help detect counterfeit drugs. TruScan, developed by Ahura Scientific (Wilmington, MA; no SBIR) can analyze the composition of raw materials or finished manufactured drugs, in about 30 seconds, and is now gaining interest in the market, company officials say. [Mass High Tech, Aug 21, 09]
The National Guard has ordered $2.6M worth of Ahura Scientific (Wilmington MA; three SBIRs) First Defender instruments and fiber-optic extension probes. Early this year, Ahura closed a $7M financing deal bringing its total funding to $29.5M. [Mass High Tech, Nov 15]
Aiko Biotechnology (Portland, ME; one SBIR) plans to raise $400,000 from unnamed investors. None of the shares has been sold so far. ... an early stage drug discovery company with drug candidates targeting pain, addiction and adverse side effects resulting from prescription opioid pain reliever use. [Mass High Tech, Sep 30, 09]
Protein-focused Aileron Therapeutics (Cambridge, MA; no SBIR) reports it has closed on $40 million in a fourth round of financing ... developing therapies using small pieces of a naturally occurring protein, called Stapled Peptides, that restore programmed cell death in multiple myeloma cells [Mass High Tech, Jun 8]
The Multiple Myeloma Research Foundation reports that it has awarded $500,000 each in grant funding to a pair of Cambridge-based companies, Aileron Therapeutics (no SBIR) and Astex Therapeutics (no SBIR), for cancer therapy research. [Mass High Tech, Mar 2, 09]
Aimmune will use fresh cash [to] help boost the launch of Palforzia, but it’s immediately eyeing the future, spending a mere $10 million upfront, with $385 million in biobucks wedded to it, to license Xencor (Monrovia, CA; $900K SBIR, founded 1997)’s XmAb7195. [Ben Adams, Fierce Biotech, Feb 5, 20]
Aimmune Therapeutics, a biopharmaceutical company developing treatments for potentially life-threatening food allergies, announced that its pivotal Phase 3 PALISADE efficacy trial of AR101 met the primary endpoint. In the United States, AR101 has U.S. Food and Drug Administration (FDA) Breakthrough Therapy Designation for peanut-allergic patients ages 4–17. [company press release, Feb 20, 18]
Aimmune Therapeutics (Brisbane,CA; no SBIR, founded 2011 as Allergen Research) signed a lease for the western half of a 40,000-square-foot building in [Clearwater, FL] to use 20,000 square feet for manufacturing, [SEC] filings said. [Margie Manning, Tampa Bay Business Journal, Aug 11, 15]
Aimmune Therapeutics (formerly Allergen Research, Brisbane, CA)(formerly known as Allergen Research, Brisbane, CA; no SBIR) up 51% [Aug 6, 15] after IPO raised $160M. ... a clinical-stage biopharmaceutical company which engages in the research and development of desensitization treatments for [peanut] allergies. Its portfolio includes the characterized oral desensitization immunotherapy (CODIT) system [Wall Street Journal, Aug 6]
Mast Therapeutics (formerly ADVENTRX, San Diego, CA; no SBIR) biopharma specializing in sickle cell disease and heart failure, said it raised $8 million in a secondary public offering [Alex Lash, xconomy.com, Feb 19, 16] leveraging the MAST (Molecular Adhesion and Sealant Technology) platform, derived from over two decades of clinical, nonclinical and manufacturing experience with purified and non-purified poloxamers, to develop vepoloxamer, our lead product candidate, for serious or life-threatening diseases with significant unmet needs...acquired Aired Pharmaceuticals (San Diego, CA; no SBIR) in 2014 [company website]
Airway Therapeutics (Sharonville, OH; no SBIR, founded 2011) biotech has now raised more than $23 million to launch a protein-replacement therapy that helps premature infants breathe easier. .... raised $11 million in March from new and existing investors, according to a [SEC] filing [Dan Monk, WCPO Cincinnati, Apr 17, 18] total funding $59M [crunchbase.com]
Airway Therapeutics (Sharonville, OH; no SBIR) focused on developing new interventions for acute and chronic lung diseases, beginning with premature infants, secured $6.3 million in bridge financing from new and existing investors [company press release, Mar 6, 17]
biotech startup Airway Therapeutics (Cincinnati, OH; no SBIR) raised $4.6 million in [Series A] funding to advance its work to prevent a lung condition in premature infants. .... works to combat bronchopulmonary dysplasia, a debilitating lung disease that develops in extremely premature infants who require ventilation shortly after birth. ... It has developed a protein that could prevent the disease in tens of thousands of infants each year who are born before their bodies can produce it [Andy Brownfield, Cincinnati Business Courier, Sep 10, 14]
AirXpanders, (Palo Alto, CA; no SBIR) a startup whose medical device helps women recover after breast surgery, disclosed it has raised about $4 million in a planned $9 million round of funding. ... makes a patient-controlled tissue expander system that is implanted into breast surgery patients, eliminating the need for weekly saline injections. [Cromwell Schubarth, Silicon Valley Business Journal, Jun 19, 13]
AirXpanders (Palo Alto, CA; no SBIR) developing technology for breast cancer patients who require tissue expansion for reconstructive surgery, said Wednesday it raised $8 million through two financings. (incl $3M from Australia) [Elizabeth Kim, Silicon Valley / San Jose Business Journal, Mar 2, 11]
Irish Wind. The wind energy company Wind Capital Group LLC is getting a $150 M investment from Ireland-based NTR PLC — a financial boost that [founder] Carnahan says will help transform NTR will provide cash and supply 150 megawatts of wind turbines for delivery in 2010. ... NTR has within the last year sold off its interest in Airtricity, a wind energy developer in the U.S. and Europe, and it has been reinvesting some of the proceeds in startup renewable energy firms. Last week, the company agreed to pay $100 M for a majority stake in Phoenix-based Stirling Energy Systems, which is developing solar power plants. [St Louis Post Dispatch, Apr 25]
Airtricity plans to build enough wind-powered electricity plants here to make Texas the No. 1 wind state next year. [Dallas Morning News, Apr 4] New, more efficient wind technology has a future.
AIT Laboratories(Indianapolis, In; no SBIR) has built a reputation as an independent lab for forensics, clinical and pharmaceutical testing. It has spun off AIT Biosciences. ... health and toxicology-testing company [Daniel Evans] founded in 1990, then turned over to ownership by the employees ... could be a poster child for a successful, futuristic client of financing and advice from the [SBA] ... nearly 500 employees nationwide. [Bruce Smith, Indianapolis Star, Aug 9, 11]
CyPhy Works (Danvers, MA; $700K SBIR) announced a $22 million Series B round ... [FAA] decision to green-light commercial drone use earlier this year appears to be spurring the deployment of even more capital into the fledgling sector. ... founded by iRobot co-founder Helen Greiner. ... Other [VC recipients] in this sector include 3D Robotics (Berkeley, CA; no SBIR), which has raised more than $90 million, and Airware (San Francisco, CA; no SBIR), which has snagged more than $40 million. [Jeff Engel, xconomy.com, Oct 13, 15]
Airway Therapeutics (Sharonville, OH; no SBIR) biotechnology company raised $6.3 million in bridge financing from new and existing investors to help develop a way to prevent and treat lung disease in premature babies. developing a protein replacement therapy called AT-100 [Barrett J. Brunsman, Cincinnati Business Courier, Mar 7, 17]
Akadeum Life Sciences (Ann Arbor, MI; no SBIR, founded 2014), a cell-sorting startup based in has raised nearly $1.5 million in new capital ... has developed a product that incorporates buoyancy-activated cell sorting. Microbubbles, which are tiny spheres made out of silica that are one-tenth the width of human hair, are added to biological samples, where they attach to target cells. [Sarah Schmid Stevenson, xconomy,com, Sep 13, 17]
Akamai Physics (Las Cruces, NM; $800K SBIR) landed a $3.2 million deal to support advanced bioscience research for the [USAF] through the 711th Human Performance Wing at [WPAFB] ....to help “provide radically new military capabilities that improve warfighter performance and combat effectiveness [Joe Cogliano, Dayton Business Journal, Aug 24, 12]
Akarna Therapeutics (San Diego, CA and Cambridge, England; no SBIR), a startup developing small-molecule drugs targeting inflammatory and fibrotic diseases with no approved treatment, said it has raised $15 million in a Series B financing ... is moving its lead candidate through proof-of-concept studies in patients with non-alcoholic steatohepatitis (NASH), a progressive fatty-liver disease associated with diabetes and obesity. [Alex Lash and Bruce Bigelow, xconomy.com, Feb 19, 16]
Akashi Therapeutics (Cambridge, MA; no SBIR, founded 2011 as Dart Therapeutics) has been cleared by the FDA to resume testing an experimental Duchenne muscular dystrophy drug roughly a year after a patient taking the treatment died in a clinical trial. ... Eteplirsen, from Sarepta Therapeutics, is meant to slow the progression of the disease, but for just a 13 percent genetic subset of Duchenne patients. The steroid deflazacort—which has been available for years in other countries—was approved in the U.S. in February for all Duchenne patients, but also only helps temporarily delay the disease’s grim march. (Deflazacort hasn’t launched yet; Marathon Pharmaceuticals sold the drug’s rights to PTC Therapeutics last week). [Ben Fidler, xconomy.com, Mar 22, 17]
Akcea Therapeutics up 61% [Aug 31, 20] Ionis Pharmaceuticals and its affiliate Akcea Therapeutics announced that they have entered into a definitive agreement under which Ionis will acquire all of the outstanding shares of Akcea common stock it does not already own, approximately 24%, for $18.15 per share in cash. ... a total transaction value of approximately $500 million on a fully diluted basis. [joint companies press release, Aug 31, 20]
A phase 2 trial of Akcea Therapeutics’ antisense treatment for cardiovascular and metabolic disease has hit its primary endpoint. The Pfizer-partnered antisense oligonucleotide cut triglyceride levels in people with hypertriglyceridemia,Type 2 diabetes and non-alcoholic fatty liver disease (NAFLD) but failed to reduce liver fat or hemoglobin A1C. [Fierce Biotech, Jan 29, 20]
Akcea Thera (Cambridge, MA; no SBIR) up 31% [Oct 7, 19], a majority-owned affiliate of Ionis Pharmaceuticals. and Pfizer announced that the companies have entered into a worldwide exclusive licensing agreement for AKCEA-ANGPTL3-L(Rx) , an investigational antisense therapy being developed to treat patients with certain cardiovascular and metabolic diseases. Akcea and Ionis will receive a $250 million upfront license fee, which will be split equally between the two companies. Akcea will settle its $125 million obligation to Ionis in Akcea common stock. The companies are also eligible to receive development, regulatory and sales milestone payments of up to $1.3 billion and tiered, double-digit royalties on annual worldwide net sales following marketing approval of AKCEA-ANGPTL3-L(Rx) [joint companies press release, Oct 7, 19]
Akcea Thera down 22% [Sep 23, 19] said that CEO and COO have left the company. [xconomy.com, Sep 23,19]
The FDA approved two oral formulations of the Pfizer drug tafamidis, approved specifically to treat the potentially deadly heart problems faced by patients with both the hereditary and “wild-type” forms of ATTR, the latter of which develops over time. ... In 2018 the FDA approved two drugs Alnylam Pharmaceuticals and Akcea Therapeutics (spinout of Ionis Pharmaceuticals, Boston, MA; no SBIR) for hereditary and wild-type ATTR. [Ben Fidler, xconomy.com, May 6 19]
Akcea Thera up 17% [Feb 25, 19] Novartis [said it] will pay $150 million to license a heart disease medication discovered by Ionis Pharma co-developed by Ionis with its majority-owned subsidiary Akcea Therapeutics. Ionis will get half the money, paid for with Akcea stock.[Bradley Fikes, San Diego Union Tribune, Feb 25, 19]
Akcea Thera down 11% [Oct 5, 18]
For the second time since August, the FDA has approved a new treatment for a rare and deadly disease called hereditary transthyretin amyloidosis (hATTR). The agency’s nod for inotersen (Tegsedi) sets the stage for a market battle between the drug’s developer, Akcea Therapeutics, and rival Alnylam Pharmaceuticals. [Ben Fidler, xconomy.com, Oct 5, 18]
Akcea Thera up 12% [Sep 25, 18]
Akcea Thera up 18% [Sep 24, 18]
Akcea Thera down 25% [Aug 28, 18]
Ionis Pharma down 16% [Aug 28, 18]
Akcea Thera up 14% [Aug 7, 18]
<Akcea Thera up 10% [Aug 2, 18]
Ra Pharma down 13% [Aug 2, 18]
Akcea Thera up 15% [May 11, 18]
Akcea Thera up 16% [Mar 15, 18]
A year after GlaxoSmithKline bailed on a partnership with Ionis Pharmaceuticals for a transthyretin amyloidosis drug, Ionis sent the drug, inotersen, to spinout Akcea Therapeutics. Like a rival drug, patisiran, inotersen is under FDA review. [Frank Vinluan, xconomy.com, Mar 15, 18]
Akcea Therapeutics (an affiliate of Ionis Pharmaceuticals, Cambridge, MA; no SBIR) shares fell 25 percent after executives reported on an earnings call that dangerously low platelet counts were reported in another patient on volanesorsen, its drug for the rare metabolic disease familial chylomicronemia syndrome. An FDA advisory panel will debate the merits of volanesorsen on May 10. [Ben Fidler, xconomy.com, Mar 2, 18]
Akcea Therapeutics (Cambridge, MA; no SBIR) [spinout in July with a $125 million IPO] affiliate of Ionis Pharmaceuticals focused on developing and commercializing drugs to treat patients with serious cardiometabolic diseases caused by lipid disorders, announced the submission of a New Drug Application (NDA) to [FDA] for volanesorsen, an investigational medicine for the treatment of familial chylomicronemia syndrome (FCS). [company press release, Sep 1, 17] .
Akebia Therapeutics down 74% [Sep 3, 20] announced Vadadustat did not meet the primary safety endpoint of the PRO(2) TECT program, defined as non-inferiority of vadadustat versus darbepoetin alfa in time to first occurrence of major adverse cardiovascular events (MACE), which is the composite of all-cause mortality, non-fatal myocardial infarction, and non-fatal stroke across both PRO(2) TECT studies. [company press release, Sep 3, 20]
Akebia Therapeutics (Cambridge, MA; no SBIR, founded 2007) up 38% [May 5,20] announced positive top-line results from INNO(2) VATE, the first of its two global Phase 3 cardiovascular outcomes programs. The two INNO(2) VATE studies evaluated the efficacy and safety of vadadustat, Akebia's investigational oral hypoxia-inducible factor prolyl hydroxylase inhibitor (HIF-PHI), versus darbepoetin alfa for the treatment of anemia due to chronic kidney disease (CKD) in adult patients on dialysis. [company press release, May 5, 20]
Akebia Thera up 35% [Mar 19, 20]
Vifor Pharma made a $50 million equity investment in Akebia Therapeutics at $14 per share. The deal gives Akebia license to sell its anemia pill vadadustat, upon FDA approval, at Fresenius Medical Care dialysis clinics in the U.S. Vadadustat and rival roxadustat from Fibrogen are both in Phase 3 testing. [Ben Fidler, xconomy.com, May 19, 17]
Akebia Therapeutics (Cambridge, MA; no SBIR) won a patent suit against rival Fibrogen in Europe related to drugs the two companies are developing for anemia. CEO John Butler said in a statement that the company will now look for a partner in Europe for its prospective anemia drug, vadadustat, to complement the $350 million deal it has already signed with Mitsubishi Tanabe in various Asian countries. [Ben Fidler, xconomy.com, Mar 10, 16]
Cincinnati startup success story Akebia Therapeutics (no SBIR, founded 2007) completed its [IPO], raising $100 million, one-third more than it first expected. ... developing a drug that treats anemia for people with chronic kidney disease. ... to take its anemia drug through critical [FDA] Phase 3 trials [Steve Watkins, Cincinnati Business Courier, Mar 20, 14]
Akebia Therapeutics (Cambridge, MA originally Blue Ash, OH; no SBIR, founded 2007) has filed plans to raise up to $75 million through [IPO] ... developing a drug that can treat anemia in patients with chronic kidney disease. It says the drug is cheaper, less painful to take and expected to be more effective than current treatments. ... Novartis Bioventures, a unit of Swiss drug company Novartis International, owns 25 percent. [Steve Watkins, Cincinnati Business Courier, Feb 18, 14]
Akebia Therapeutics (Blue Ash, OH; no SBIR) CEO Joseph Gardner says his company’s huge $41 million financing round that it just completed Monday could pave the way for a future [IPO]. .... developing its drug as a treatment for anemia in patients with chronic kidney disease. It will be a pill taken daily as opposed to the injectable, more expensive treatments that are used now to address an $8 billion market, Gardner said. [Steve Watkins, Cincinnati Business Courier, Jun 4, 13]
Biomedical firm Akebia Therapeutics (Cincinnati, OH; no SBIR) has raised $16 million in new funding ... develops small-molecule drugs for the treatment of anemia and vascular disorders. Its first drug, an anemia treatment called AKB-6548, is scheduled to start Phase 1 clinical trials later this year. [Business Courier (Cincinnati), Jul 30, 09]
Clean energy startup Akermin (St. Louis, MO; $250K SBIR, 16 employees) received a $3 million R&D grant from the USDOE to develop technology to remove carbon dioxide from power plants. .... to develop and test Akermin’s second-generation approach that uses its proprietary Biocatalyst Delivery System .... In 2010 the company won a $2.6 million grant from the Department of Energy. It also raised $1.5 million early this year [Matthew Hubbard, St Louis Business Journal, Oct 21, 13]
Army's venture venture. The Army's VC (OnPoint Tech) current investment portfolio : A123 Systems (Boston, MA; $750K SBIR, IPO 2009) advanced Lithium-Ion based cells for rechargeable battery packs; Atraverda (UK) advanced bi-polar battery electrodes for rechargeable batteries; Integrated Fuel Cell Technologies (Burlington MA; no SBIR) next generation fuel cell systems for portable devices; Nanosolar (Palo Alto, CA; $1.7M SBIR) thin-film solar technology for roll-to-roll printing of solar cells on flexible substrates, PowerGenix (San Diego, CA; no SBIR) next-generation rechargeable batteries; Power Precise (Herndon, VA; no SBIR) a fabless semiconductor company specializing in battery management devices; Ultra Cell (Livermore, CA; no SBIR) integrated fuel cell systems; Zinc Matrix Power (Santa Barbara, CA; no SBIR) high-performance rechargeable alkaline battery technology for commercial and military markets; Akermin (St Louis, MO; no SBIR) portable fuel cells based on its proprietary “Stabilized Enzyme Biofuel Cell†SEBC™ technology; Superprotonic (Pasadena CA; $200K SBIR) solid acid fuel cell. [defense-ventures.com] No surprise that a VC, even one doing it for the government, sees tech opportunity much different than does Army SBIR. I note that the three outside trustees (of five trustees) of OnPoint are a DOD political appointee, and entrepreneur/attorney, and Paul Gompers from Harvard Business School who with Josh Lerner publish a lot of venture research. Lerner did a lot of SBIR study until, I presume, he gave up on SBIR's ever being anything but a political handout.
Akero Therapeutics (South San Francisco, CA; no SBIR, founded 2017) set a preliminary $86.2 million [IPO] target among the growing number of biotechs developing drugs to treat nonalcoholic steatohepatitis (NASH), a type of fatty liver disease that has no FDA-approved therapies. Akero acquired its NASH drug, AKR-001, from Amgen, which the IPO filing shows owns a 5 percent stake in the company. [Frank Vinluan, xconomy.com, May 29, 19] total funding $135M [crunchbase.com]
biotech Akero Therapeutics (San Francisco, CA; no SBIR) developing transformational treatments for non-alcohol steatohepatitis (NASH) and other serious metabolic diseases, announced $70 million in new financing. [company press release, Dec 12, 18] prior funding $65M [crunchbase.com]
Akers BioScience (Thorofare, NJ; no SBIR, founded 1989, (UK)market cap $2M), developer of rapid health information technologies, announces the closing of its public offering with gross proceeds of $6.9M [company press release, Dec 21, 17]
North Shore InnoVentures, a technology incubator based in Beverly [MA], said that six startup companies in the clean technology and life sciences sectors have joined its program over the last few months. .... Lariat Biosciences (no SBIR), is developing a non-invasive diagnostic to detect early signs of cancer based on circulating free DNA within the bloodstream. ... Other startups recently joined include Akita Innovations, RAN Biotechnologies, Quad Technologies, and ZS Genetics, none has SBIR. .... A total of 21 companies are now in [residence]. [Chris Reidy, Boston Globe, Jun 5]
Akouos (Boston, MA; one SBIR) up 88% [Oct 18, 22] Eli Lilly Akouos announced a definitive agreement for Lilly to acquire Akouos, a precision genetic medicine company that is developing a portfolio of first-in-class adeno-associated viral gene therapies for the treatment of inner ear conditions, including sensorineural hearing loss. [joint companies press relesase, Oct 18, 22]
Akouos (Brookline, MA; $200K SBIR) up 29% [Jun 26, 20] a precision genetic medicine company dedicated to developing gene therapies with the potential to restore, improve, and preserve high-acuity physiologic hearing for people worldwide who live with disabling hearing loss, announced the pricing of its [IPO] to raise $212.5 million [company press release, Jun 25, 20]
Akouos [Brookline, MA; $200K SBIR) is developing a gene therapy to address [hearing loss caused by genetic defects and it’s planning an IPO [for $100M] to finance the first tests of its approach in humans. [Frank Vinluan, xconomy.com, Jun 9, 20]
hearing loss gene therapy biotech Akouos (Brookline, MA; one SBIR) has grabbed a $105 million series B funding round. [Ben Adams, Fierce Biotech, Mar 4, 20]
Akouos (Brookline, MA; $200K SBIR) raised $50 million in a Series A financing round to support work on a gene therapy for hearing loss that it hopes to advance into human testing within three years. [company press release, Aug 8, 18]
Boston startups ended the first quarter of 2020 with a bang. The disruption caused by COVID-19, the respiratory disease caused by the novel coronavirus, notwithstanding, 60 Beantown startups raised over $1.5B. Chief among those were monster rounds raised by biotech companies: Cambridge-based Sarepta Therapeutics raised $400M; Xilio Therapeutics, formerly known as Akrevia Therapeutics, raised $100.5M in a Series B round; and Cambridge biotech Kymera Therapeutics raised $102M.
Akrevia Therapeutics (Cambridge, MA; no SBIR) announced today a $30 million Series A funding round that will help Clackson and his team develop biologics with engineered “on/off” switches. The immune-stimulating drugs would circulate through the body in an inactivated state. When they arrive at the tumor, they would undergo specific biochemical changes, such as the removal of a key protein group, that flip the drug’s switch to “on.” Then the therapy would go to work. ... The startup’s technology is based on the work of John Williams, a protein engineer and structural biologist at City of Hope in Duarte, CA, who uses sophisticated laboratory and software tools to rapidly and precisely design proteins. [Corie Lok, xconomy.com, Sep 26, 18]
Akros Medical (Durham, NC; no SBIR, founded 2015) raised $610,000 from private investors ... developing a medical device for orthopedic surgery [Jason deBruyn, Triangle Business Journal, Dec 31, 15]
A new book by Antoine van Agtmael, who coined the phrase “emerging markets”, and Fred Bakker, a Dutch journalist, called “The Smartest Places on Earth”, argues that the rust belts of the rich world, especially in America, are becoming hotspots of innovation. ... Bruce Katz of the Brookings Institution, a think-tank, reckons that America’s 50 most research- and technology-intensive industries have added nearly 1m jobs since 2010. ... As Van Agtmael and Bakker note, Akron has capitalised on its heritage as home to America’s four biggest tyremakers by turning itself into America’s capital city of polymers. The University of Akron’s Polymer Training Centre houses 120 academics and 700 graduate students. Companies such as Akron Polymer Systems (Akron, OH; $1M SBIR) and Akron Surface Technologies (Akron, OH; no SBIR) are inventing new ways to commercialise synthetic materials..... In Watervliet, New York, firms such as Cleveland Polymer Technologies (Watervliet, NY; no SBIR, with operations in Israel and India, founded 2004 in Elmira, NY) occupy space in an old US Army arsenal. In Manchester, New Hampshire, the old and once-crumbling riverside mill district now buzzes with knowledge businesses and fancy restaurants. [The Economist, Mar 5, 16]
A new book by Antoine van Agtmael, who coined the phrase “emerging markets”, and Fred Bakker, a Dutch journalist, called “The Smartest Places on Earth”, argues that the rust belts of the rich world, especially in America, are becoming hotspots of innovation. ... Bruce Katz of the Brookings Institution, a think-tank, reckons that America’s 50 most research- and technology-intensive industries have added nearly 1m jobs since 2010. ... As Van Agtmael and Bakker note, Akron has capitalised on its heritage as home to America’s four biggest tyremakers by turning itself into America’s capital city of polymers. The University of Akron’s Polymer Training Centre houses 120 academics and 700 graduate students. Companies such as Akron Polymer Systems (Akron, OH; $1M SBIR) and Akron Surface Technologies (Akron, OH; no SBIR) are inventing new ways to commercialise synthetic materials..... In Watervliet, New York, firms such as Cleveland Polymer Technologies (Watervliet, NY; no SBIR, with operations in Israel and India, founded 2004 in Elmira, NY) occupy space in an old US Army arsenal. In Manchester, New Hampshire, the old and once-crumbling riverside mill district now buzzes with knowledge businesses and fancy restaurants. [The Economist, Mar 5, 16]
|
||||||
Alafair Biosciences (Austin, TX; no SBIR) an emerging medical device company, announced that it received 510(k) clearance from the FDA to market and sell its tendon product, VersaWrap™ Tendon Protector, in the US. VersaWrap™ Tendon Protector is an ultrathin, sutureless, bioresorbable hydrogel that protects tendon gliding by separating injured tendon from surrounding tissues. ... is a significant milestone for Alafair and supports our commitment to develop and launch innovative products [company press release, Jul 15, 16] the co-inventors hold PhD degrees in biomedical and chemical engineering from UT. [company website]
Alafair Biosciences (Austin, TX; no SBIR, founded 2011) collected $984,000 of a planned $2 million funding [Chris Colnan, Austin Business Journal, Nov 2, 15]. specializes in commercialization of biomaterials and biomedical devices to enhance internal wound healing. ... Our initial technology, licensed and developed with The University of Texas at Austin, is a hydrogel membrane that provides support during post-surgical critical wound healing. [company website]
Alafair Biosciences (Austin, TX; no SBIR) biosciences firm is the recipient of $2 million from the Texas Emerging Technology Fund, the governor’s office said.... to assist with the commercialization of a technology it has developed — biological film used to protect wounded tissues and assist with healing. ... patent-pending technology was developed in a laboratory at the University of Texas. It helps prevent post-surgery scarring, which is responsible for $3.45 billion in health care costs each year in the United States, according to the company. .... A total of $205 million has been given to 145 companies so far, Perry’s office said. [Gary Dinges, American-Statesman, May 16, 14]
Alafair Biosciences (Austin, TX; no SBIR) received $525,000 of a planned $650,000 funding. .... from three investors ... founded in 2011 as Alafair Biotechnology, develops cross-linked polysaccharide hydrogel films to address the post-surgical complication of adhesion, or tethering between opposing tissue surfaces. ..... Last year, it received $702,000 of a planned $1.5 million financing from 14 investors [Christopher Calnan, Austin Business Journal, Sep 11, 13]
No story about Albany NanoTech(no SBIR) is without a mention of its leader, Alain Kaloyeros, the UAlbany physics professor who has built the $3.5 B facility on Fuller Road by pulling together hundreds of millions of dollars in funding from IBM, the state of New York, and other semiconductor companies. ... BusinessWeek magazine did an extremely flattering piece on how IBM Corp. drastically changed its semiconductor research and development methods to include a host of partners, including Albany NanoTech and Advanced Micro Devices Inc., to great acclaim. [Albany Times-Union, Sep 9,07]
Albamunity (Boston, MA; no SBIR) raised $5M in equity in a $20M funding round, [SEC filing, Aug 5, 20].
Vaccine Trial Halted. After Patient Becomes Ill. The news about AstraZeneca’s drug came on the same day that the company and others pledged to thoroughly vet any vaccine. [NY Times, Sep 9, 20]
Albamunity (Boston, MA; no SBIR) [pharmeceuticals] raised $5M in equity in a $20M funding round, according to an SEC filing. [Rowan Walrath, BostInno, Aug 7, 20]
Albamunity (Boston, MA; no SBIR) [pharmeceuticals] raised $5M in equity in a $20M funding round, according to an SEC filing. [Rowan Walrath, BostInno, Aug 7, 20]
Albireo Pharma (Boston, MA; no SBIR), a clinical-stage orphan pediatric liver disease company developing novel bile acid modulators, announced that topline results from the PEDFIC 1 Phase 3 clinical trial evaluating the efficacy and safety of lead candidate odevixibat for the treatment of progressive familial intrahepatic cholestasis (PFIC) will be announced September 8, 2020. [company press release, Sep 7, 20] also announced that it has commenced a proposed underwritten public offering of 3,000,000 shares of its common stock. [company press release, Sep 8, 20]
drug developer Envisia Therapeutics (Research Triangle Park, NC; no SBIR, 23 employees) reported positive results for a possible next-generation glaucoma treatment. ... ENV515 showed comparable results to Travatan Z, a once-daily eye drop made by Alcon (no SBIR). Envisia reports these as positive because if its product can show the same results, but must be applied only once every six months, it could become a more desirable treatment. Alcon was founded in 1945 as a small ophthalmic shop in Fort Worth, Texas. Alcon is now the second-largest division of Novartis with sales topping $10 billion. ... Envisia Therapeutics spun out of Liquidia Technologies (one SBIR) in late 2013. ... raised $25 million from Liquidia investors [Jason deBruyn, Triangle Business Journal, Oct 6, 15]
Alcresta(Newton, MA; no SBIR) start-up looking to commercialize enzyme-based nutritional products such as infant formulas, emerged from the stealth mode by announcing a $10 million Series A venture capital financing. [Boston Globe, Apr 17, 12]
Aldagen(Durham, NC; one SBIR) as StemCo Biomedical) whose attempts to go public didn't pan out, has been sold in a deal valued at more than $40 million. The 14-person company is being acquired by Cytomedix (Gaithersburg, MD; no SBIR), a small, publicly traded company that plans to continue development of Aldagen's most promising experimental drug - a treatment for stroke [David Ranii, Raleigh News & Observer, Feb 9, 12]
Aldagen (Durham, NC, fomerly StemCo Biomedical; one SBIR) latest attempt at going public has failed once again. ... has withdrawn its plans to raise about $75 million via an initial public offering of common stock because of "market conditions." Founded in 2000, has been developing experimental drugs using stem cells. [David Ranii, Raleigh News & Observer, Apr 5, 11]
Aldagen (Durham, NC; one SBIR)appears to be pushing ahead with its IPO. ... developing drugs using stem cells, revived plans for an initial public offering of stock in late October. ... scrapped an IPO in the fall of 2008 when the stock market slumped. .. founded in 2000 as StemCo Biomedical , based on technology developed at Duke University. [Alan Wolf, Raleigh News & Observer, Dec 11, 09]
Aldagen (Durham, NC; one SBIR), which employs 18 and develops treatments based on adult stem cells, hopes to raise as much as $80M with an IPO...founded in 2000 as StemCo Biomedical, based on technology developed at Duke University. It has raised about $48M in VC since then. ... testing four products in humans. The most advanced would improve cord blood transplants used to treat metabolic diseases in pediatric patients. [Sabine Vollmer, Raleigh News & Observer, May 13, 08]
Aldagen (Durham, NC;) developing treatments based on stem cells raised $18 M VC... founded in 2000 as StemCo Biomedical based on technology developed at Duke University. [Raleigh News& Observer, Apr 26]
Private investment continues to boost young Triangle companies. Biologics (Raleigh NC; no SBIR) oncology pharmacy, $20M; . Aldagen (Durham, NC; no SBIR) biotech company, $9 M; HyperBranch Medical Technologies (Durham NC; one SBIR) medical device startup, $1.5M. [Sabine Vollmer, Raleigh News & Observer, Sep 15] Those who can, do; those who can't or won't ... go for government handouts.
Aldea Pharmaceuticals (Redwood City,CA; no SBIR) landed $24 million from an international list of investors ... In preclinical studies, Aldea’s drug, called AD-6626, activates an enzyme that accelerates metabolism [Ron Leuty, San Francisco Business Times, Aug 25, 14]
AldeaPharmaceuticals, (Westport,CT; no SBIR, founded 2008) a biotechnology startup developing an emergency treatment for alcohol poisoning, seemed like an attractive investment to venture capitalist David Coats. But he didn't rely on a hunch—he consulted the computer model he'd built. Two weeks and a few phone calls later, he cut the company a $1.25 million check. "A decision like that would have normally taken a minimum of three months," says Tim Shannon, a partner with Canaan Partners, the firm that had led Aldea's $7 million fund-raising round. [Jessica Leber, Technology Review, S/O12]
A migraine drug that Lundbeck added to its pipeline via its nearly $2 billion acquisition of Alder BioPharmaceuticals (Bothell, WA; one SBIR) won FDA approval. The drug, eptinezumab (Vyepti), is part of a new class of antibody therapies developed to prevent migraine attacks before they start. [Frank Vinluan, xconomy.com, Feb 25, 20]
H. Lundbeck A/S (Denmark) and Alder Pharmeuticals (Bothell, WA; one SBIR) up 84% [Sep 16, 19] committed to transforming migraine treatment and prevention announced a definitive agreement for Lundbeck to acquire Alder. ... transaction is valued at up to $1.95 billion (approximately DKK 13 billion) net of cash, on a fully diluted basis. [joint companies press release, Sep 16, 19]
Alder BioPharma down 15% [Mar 21, 18]
Alder Bio down 10% [Jan 29,18]
Alder Therapeutics’ migraine-prevention drug hit its main goal in a late-stage study, and the drug developer these early results keep it on track to file for FDA approval later this year. [Frank Vinluan, xconomy.com, Jan 8, 18]
Alder Bioup up 15% [Jan 9, 18]
Alder Bio (Bothell, WA; one SBIR in 2004) up 17% [Jan 8, 18] announced that it has entered into a definitive preferred stock purchase agreement with investors ... committed to purchase up to $250 million of non-voting Class A Preferred Stock during the three-year term of the agreement, with an initial purchase of $100 million of Class A Preferred Stock [company press release, Jan 8, 18]
Alder BioPharmaceuticals developing its solely-owned pivotal-stage product candidate eptinezumab as the only anti-CGRP monoclonal antibody for the prevention of migraine administered via infusion, announced .. total proceeds to Alder from the [public stick] offering will be approximately $161.5 million ..... to fund the continued development of eptinezumab, including completion of the ongoing infusion pivotal trial program, the planned submission of a Biologics License Application (BLA) to [FDA], establishment of the commercial drug supply chain and other commercialization activities, and for working capital and general corporate purposes. [company presss release, Jul 12, 17]
Alder BioPharma up 18% [Jul 13, 17]
Alder BioPharma down 17% [Jul 12, 17]
Alder Biopharma down 28% [Jun 27,17] after the company released positive results for its late-stage migraine prevention drug. The drug, eptinezumab, met the primary and key secondary endpoints in a phase 3 trial, and the company plans to file with the Food and Drug Administration for approval in the second half of next year. [Dow Jones Newswire]
Alder Bio (Bothell, WA; one SBIR) down 10% [May 8,17]
Alder Bio down 12% [Nov 28, 16]
Alder Biopharma up 10% [Aug 22, 16]
Alder BioPharmaceuticals up 50% [Mar 28,16] said its drug to prevent migraines met the main goal in a mid-stage study, the results of which support a quarterly single injection dosing strategy. [Reuters, Mar 28, 16]
Alder Biopharma up 11% [Jan 14, 16]
Alder Bio up 11% [Sep 30, 15]
As it moves into crucial Phase 3 drug trials for its flagship migraine treatment, Alder Biopharmaceuticals (Bothell, WA; one SBIR) is offering up to $200 million shares of its common stock, according to SEC filings. [Annie Zak, Puget Sound Business Journal, Jun 26, 15]
Alder Bio (one SBIR) up 12% [May 15, 15]
Alder BioPharmaceuticals said the gross proceeds from its sale of stock totaled $203.6 million. ... making drugs targeting migraine headaches and rheumatoid arthritis. [Ben Miller, Puget Sound Business Journal, Jan 23, 15]
Alder Bio up 10% [Jan 22, 15]
Alder Bio down 11% [Jan 21, 15]
Alder Bio up 14% [Jan 7, 15]
Alder Biopharmaceuticals (Bothell, WA; one SBIR) whose [IPO] in May was priced at a disappointing $10 per share, is selling more stock now that its shares trade in the high 20s. ... filed for a secondary stock offering that aims to raise $115 million to $132 million. ... developing therapeutic antibodies, with a phase II clinical trial under way testing preventative treatment of chronic migraines. [Seattle Ti mess, Dec 22, 14]
Alder BioPharma up 16% [Dec 17, 14]
Alder Biopharmaceuticals (one SBIR a decade ago) up 32% [Dec 11, 14]
Alder Biopharma (Bothell WA; one SBIR) up 12% [Dec 5, 14] a clinical-stage biopharmaceutical company, discovers, develops, and commercializes various therapeutic antibodies [wsj.com]
Alder Bio (Bothell, WA; one SBIR) down 10% [Nov 4, 14]
Alder BioPharma (Bothell, WA; one SBIR in 2004) down 13% [Sep 2, 14] said Bristol-Myers Squibb is ending an arthritis-drug collaboration pact under which Alder earned more than $100 million since 2009. ... clinicial trials of its antibody-based treatment called clazakizumab yielded promising phase II results for rheumatoid arthiritis, but the pharmaceutical giant decided it “did not warrant further investment based on other priorities in their pipeline.†[Seattle Times, Sep 2, 14]
Alder BioPharma up 18% [Jun 11, 14]
Alder BioPharma up 11% [Jun 5, 14]
Alder BioPharma up 12% [Jun 2, 14]
Alder BioPharmaceuticals (Bothell, WA; one SBIR) ALDR priced its [IPO] [down] at $10 ... raised $80 million ... is testing two drug candidates it developed — one to prevent migraines and one to treat rheumatoid arthritis and psoriatic arthritis. [Seattle Times, May 8, 14]
Alder BioPharmaceuticals (Bothell, WA; no SBIR) filed for a $115 million [IPO].... in partnership with Bristol-Myers Squibb, makes a drug called Clazakizumab to treat arthritis and ALD403, a drug aimed at preventing migraines. ... has been working closely with Bristol-Myers Squibb since 2009 and has received $103.5 million in upfront and milestone payments [Emily Parkhurst, Puget Sound Business Journal, Mar 19, 14]
Alder Biopharmaceuticals (Bothell, WA; one SBIR) has filed for an IPO to raise up to $115 million. The clinical-stage biotechnology company has two product candidates, both discovered by Alder, in the early testing stage — one to prevent migraines and one to treat rheumatoid arthritis and psoriatic arthritis. Alder is partnered with Bristol-Myers Squibb on developing the arthritis product and so far has received $103 million from the drug giant. [Seattle Times, Mar 19, 14]
Nobody has ever come up with a drug that can stop migraine headaches before they start. This will be the year that Alder Biopharmaceuticals (Bothell, WA; one SBIR) finds out if it can achieve that lofty goal, and change the way patients and physicians think about treating migraines. Alder passed its first 96-patient clinical trial last year, which suggested a single dose of its injectable antibody for migraines was safe, potent, and potentially deliverable as a once-monthly shot. [Luke Timmerman, xconomny.com, Jan 24, 13]
Alder Biopharmaceuticals (Bothell, WA; one SBIR) said it received a $3.5 million milestone payment from Bristol-Myers Squibb. ... in April, Alder raised $38 million in Series D financing. [Puget Sound Business Journal, Aug 24, 12]
Alder BioPharmaceuticals (Bothell, WA; one SBIR) said it's raised $38 million in Series D financing, which it said will support the development of the company’s clinical stage pipeline.[Ben Miller, Puget Sound Business Journal, Apr 20, 12]
Aldevon (Fargo, ND; no SBIR), maker of DNA and protein products is putting a research and sales operation in [Wisconsin] .... founded by two ND State U graduates, has more than 70 employees, and provides products and services to pharmaceutical companies and diagnostic test-makers. ... also welcomed to Wisconsin: RJA Dispersions (no SBIR), VitalMedix (no SBIR) and Rapid Diagnostek (no SBIR), from Minnesota; Flex Biomedical (one SBIR) and Exact Sciences (no SBIR), from Massachusetts; NanoMedex ($1M SBIR), from Florida; and Inviragen ($2M SBIR) from Colorado. Biotechnology is the fastest-growing segment of the Wisconsin economy, with an annualized growth rate of nearly 7%, [Gov] Doyle said in a statement. The sector has 400 companies in the state with 34,000 employees.
Aldeyra Therapeutics (Lexington MA; no SBIR, market cap $200M) up 35% [Sep 26, 18] devoted to development of next-generation medicines to improve the lives of patients with immune-mediated diseases, announced positive results from its Phase 2b clinical trial of topical ocular reproxalap in patients with dry eye disease. [company press release, Sep 26, 18]
Aldeyra Therapeutics (formerly Aldexa Therapeutics, Burlington, MA; no SBIR) completed its IPO but raised just $12 million by selling shares at a scaled-back price. .... is developing treatments for rare skin and eye diseases. [Kyle Alspach, betaboston.com, May 2, 14]
Aldeyra Therapeutics (Burlington, MA; no SBIR) [seeks] $22 million [from an IPO], The clinical-stage biotech said that it has just two full-time employees and $3.3 million in cash as of Dec. 31. ... has spent a total of $19.2 million since it was incorporated in 2004. The company is developing treatments for rare skin and eye diseases, and its lead candidate, an eye drop called NS2, has been tested in a Phase I clinical trial in 48 volunteers in which it was observed to be safe and well tolerated. [Don Seiffert, Boston Business Journal, Apr 8, 14]
AbbVie has severed its ties to the potential Alzheimer’s disease immunotherapy—and the asset has vanished from the Alector (San Francisco, CA; $1.6M SBIR) pipeline. [Nick Paul Taylor Fierce Biotech, Jul 8, 2022]
Alector (South San Francisco CA; $1.5M SBIR) down 24% [Jul 29, 20] a clinical-stage biotechnology company pioneering immuno-neurology, announced preliminary data from its Phase 1b and open-label Phase 2 studies of AL001, for the treatment of people with frontotemporal dementia with a progranulin gene (GRN) mutation (FTD-GRN). AL001 is the company's wholly owned, investigational human monoclonal antibody designed to modulate progranulin, a key regulator of immune activity in the brain. [company press release, Jul 28, 20]
Alector (South San Francisco, CA; no SBIR), taking an immunotherapy approach to Alzheimer’s disease and other brain disorders, raised $176 million in an [IPO].[Frank Vinluan, xconomy.com, Feb 6, 19]
Alector (South San Franciso, CA; $1.5M SBIR, founded 2013) filed to go public [forr $150M] to fund human tests of its experimental therapies for degenerative brain disorders such as Alzheimer’s disease. [xconomy.com, Jan 7, 19] thas raised total of $194.5M in funding over 5 rounds [company website]
Alector (South San Francisco, CA; $1.5M SBIR, founded 2013) announced that it raised $133 million in a Series E round, and unveiled the first three immune system-modulating antibodies in its pipeline that will be tested in clinical trials. .... expects to move its drug development program into the clinic later this year, fundraising total now adds up to $415 million [Bernadette Tansey, xconomy.com, Jul 25, 18]
biotech Alector (San Francisco, CA; no SBIR) developing treatments for Alzheimer’s and other neurological diseases, raised a $29.5 million Series D funding just three months after closing a $32 million Series C round. As Xconomy detailed here, Alector aims to develop drugs that lean upon the growing evidence that the immune system plays a key role in neurodegeration. [Alex Lash, xconomy.com, Jan 8, 16]
Biotech startup Alector (San Francisco, CA; no SBIR, founded 2013) raised $32 million in Series C funding to continue developing therapies for Alzheimer’s disease. ... to broaden its drug pipeline, double its current staff of 12 and advance its most promising drug candidates towards clinical trials [Gina Hall, Silicon Valley Business Journal, Sep 16, 14]
Alexar Therapeutics (Malvern, PA; no SBIR) received $5.4 million in a private stock sale, according to [SEC] documents ... represent the second payment to Alexar under a $21.5 million series A financing ... developing what are called liver X receptors, which target a variety of skin disorders. Its lead compound, ALX-101, is in preclinical testing. .... the most recent company launched by NeXeption, a biopharmaceutical management company also based in Malvern [John George, Philadelphia Business Journal, Apr 30, 15]
Alexion Pharma (Cheshire, CT; $1.8M SBIR), a subsidiary of AstraZeneca, entered into a settlement agreement with Chugai Pharmaceutical Co., Ltd. (Chugai), resolving all patent disputes between the two companies related to Ultomiris (ravulizumab). [AstraZeneca press release, Mar 17, 22]
AstraZeneca and Alexion Pharmaceuticals (Boston, MA, originally 1992 of New Haven, CT; $1.6M SBIR in the 1990s) entered into a definitive agreement for AstraZeneca to acquire Alexion [for] total consideration to Alexion shareholders of $39bn. [joint companies press release, Dec 12, 20]
Alexion Pharmaceuticals (Boston, MA) announced the successful completion of its acquisition of Portola Pharmaceuticals [which] adds Factor Xa inhibitor reversal agent Andexxa® [coagulation factor Xa (recombinant), inactivated-zhzo], marketed as Ondexxya® in Europe, to Alexion’s commercial portfolio. [company press release, Jul 2, 20]
Achillion Pharma up 72% [Oct 16, 19] Alexion Pharmaceuticals reached a deal to acquire Achillion Pharmaceuticals for $930 million, pending Achillion shareholder and regulatory approval.[Connor Smith, Barron's, Oct. 16, 2019]
Alexion Pharmaceuticals and Dicerna Pharmaceuticals (Cambridge, MA; $2.2M SBIR, founded 2007, total funding $295M [crunchbase.com] announced a collaboration to discover and develop RNA interference (RNAi) therapies for complement-mediated diseases. Dicerna will receive an immediate upfront payment of $22 million, with Alexion making a concurrent $15 million equity investment in Dicerna at a premium to market as of the collaboration effective date. [joint companies press release, Oct 24, 18]
Alexion Pharmaceuticals and Syntimmune (Boston, MA; no SBIR, founded 2013, total funsing $78M [crunchbase.con]) announced that they have entered into a definitive agreement for Alexion to acquire Syntimmune, a clinical-stage biotechnology company developing antibody therapeutics targeting the neonatal Fc receptor (FcRn). SYNT001 – a humanized monoclonal antibody that inhibits the interaction of FcRn with Immunoglobulin G (IgG) and IgG immune complexes – has the potential to improve treatment in a number of rare IgG-mediated diseases. SYNT001 is currently being evaluated in Phase 1b/2a studies in patients with warm autoimmune hemolytic anemia (WAIHA) and in patients with pemphigus vulgaris (PV) or pemphigus foliaceus (PF) and has demonstrated proof of mechanism showing rapid IgG reduction. .... for an upfront payment of $400 million, with the potential for additional milestone-dependent payments of up to $800 million, for a total value of up to $1.2 billion. [joint companies press release, Sep 26, 18]
Alexion Pharmaceuticals’ flagship drug has made a strong case it can treat yet another rare disease, and the company is now mapping out plans to file for approval in the U.S. and other regions. ... released preliminary Phase 3 data for eculizumab (Soliris) as a treatment for neuromyelitis optica spectrum disorder (NMOSD), a central nervous system disorder that has no FDA-approved treatment. [Frank Vinluan, xconomy.com, Sep 24, 18]
Alexion Pharma up 15% [Apr 26, 18]
Rallybio (Farmington, CT; no SBIR), a new, early-stage startup from Alexion Pharmaceuticals veterans, announced it raised $37 million in series A financing ... plans to develop antibodies, small molecules and engineered proteins for rare and orphan diseases. [Conor Hale, Fierce Biotech, Apr 25, 18]
Sema4 (Stamford, CT; no SBIR, A 2017 Spinout Company of the Mount Sinai Health System) a health information company providing advanced genomic testing,announced the launch of Sema4 Natalis, a supplemental newborn screening test designed to detect 193 childhood-onset diseases or disorders so parents can gain early insight into their baby’s health. This simple genetic test can be performed at home with a gentle cheek swab. [company press release, Feb 7, 18] Alexion Pharmaceuticals and Sema4 announced a strategic partnership to leverage their shared experience in data science and systems biology to accelerate rare disease diagnosis and therapeutic discovery. [company press release, Aug 10, 17]
Alexion Pharmaceuticals is cutting its workforce by 20%, moving its headquarters to Boston and closing offices and manufacturing sites as it works to cut its overhead and move on from a sales-practices controversy. [Wall Street Journal, Sep 12, 17]
Alexion Pharma
down 10%
[Nov 11, 16] said it
would delay
filing its quarterly [SEC] report because of an internal
investigation into sales practices of Soliris, a treatment for blood
diseases. [Charley Grant, Wall Street Journal,
Nov 10, 16]
Ra Pharmaceuticals (Cambridge, MA; SBIR) raised close to $92 million in [IPO] ... to develop an experimental drug, RA101495, that it hopes can become a threat to Alexion Pharmaceuticals’s eculizumab (Soliris). Alexion’s drug is the only approved therapy for two rare blood diseases—paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome—and brings in more than $2 billion annually. [Ben Fidler, xconomy.com, Oct 25, 16]
Paroxysmal nocturnal hemoglobinuria may be an ultra-rare blood disease, but Alexion Pharmaceuticals makes over $2 billion a year by selling the only approved drug for it, eculizumab (Soliris). Ra Pharmaceuticals (Cambridge, MA; no SBIR) is one of those developing an alternative, and filing for IPO. [xconomy.com, Oct 3, 16]
Alexion Pharma down 11% [Jun 7,16]
Alexion Pharmaceuticals announced that the FDA approved Kanuma™ (sebelipase alfa) for the treatment of patients of all ages with a diagnosis of lysosomal acid lipase deficiency (LAL-D). Kanuma, an innovative enzyme replacement therapy (ERT), is the first therapy approved in the U.S. for the treatment of patients with LAL-D, a genetic and progressive ultra-rare metabolic disease in which patients suffer multi-organ damage and premature death. [company press release, Dec 8, 15]
A new drug to treat a rare inherited bone disorder from Alexion Pharmaceuticals that costs more than $550,000 a year for each patient has been deemed too expensive by Britain's health cost watchdog NICE. The case highlights the sky-high price of some medicines for treating rare diseases and the dilemma this poses for cash-strapped healthcare providers. [Reuters, Dec 2. 15] If you must ail, and need public aid, pick an ailment with a wide audience. If you think life is unfair, specualte on how many rare diseases would even be studied in a purely publicly funded R&R world.
[FDA] approved Alexion Pharmaceuticals's Strensiq, a treatment for a rare kind of metabolic disorder. Strensiq is designed to treat perinatal, infantile and juvenile-onset hypophosphatasia, a genetic and potentially fatal disorder that affects multiple systems of the body, which could lead to severe complications [Samantha Kareen Nair, Reuters, Oct 23, 15]
Alexion (Cheshire, CT), a company whose market value stands at nearly $39 billion on the strength of just one product, will soon be selling three drugs. .... bought Enobia Pharma in 2012 for $610 million and Synageva Biopharma for $8.4 billion a few months ago — and Alexion announced that those two companies' innovations were approved by the European equivalent of the U.S. [FDA]. [Mara Lee, Hartford Courant, Sep 1, 15]
Alexion Pharma (Cheshire, CT; $1.8M SBIR 1995-2005), which has one drug and a market cap of $31 billion, is offering to pay a 124% premium [$8.4 billion] for Synageva BioPharma (Lexington, MA; $800K SBIR 2010), one of the biggest premiums paid for any company since 1995, according to Dealogic. Synageva doesn’t have a product on the market, but it is in late-stage development of a treatment for a genetic disease that afflicts about 3,000 people. [Peter Loftus, Jonathan D. Rockoff, and Maureen Farrell, Wall Street Journal, May 6, 15]
Alexion Hires BioXcel (Banford, CT; no SBIR) for data analysis consulting, ... BioXcel has a database of more than 9,000 rare diseases, associated genes, and suggestions for antibody, protein, RNA, small molecule and gene therapy approaches that could work for these diseases. It has added about 2,000 diseases in just the past six months. ... much of the work is done in Gurgaon in the New Delhi area of India, where more than 50 scientists, software experts, business development professionals and others work. [Mara Lee, Hartford Courant, Jan 28, 15]
Alexion Pharmaceuticals and UConn are collaborating on stem cell research in rare diseases, the university announced ... developed under the Connecticut Regenerative Medicine Research Grants Program, the university said. [Hartford Courant, Dec 10, 14]
Alexion Pharma (Cheshire,CT; $1.8M SBIR), the hugely successful biopharmaceutical company, disclosed to investors that last week's[FDA] inspection of its Rhode Island factory suggest the company still needs to find "the definitive root cause" of prior contamination in vials of Soliris. ... Alexion is receiving tens of millions in state subsidies through the First Five Program for adding jobs at its future headquarters in New Haven. The package includes a $6 million grant from the state, a subsidized $20 million loan that will be made into a gift if Alexion has 650 workers in Connecticut by 2017 and tax credits that could be worth as much as $25 million. [Mara Lee, Hartford Courant, Aug 26, 14]
Alexion Pharma said record increased revenue in 2014 related to an agreement that brings to conclusion discussions with the French government and which positively impacts prospective reimbursement of Soliris. [company website]
Alexion Pharma up 21% [Jan 30, 14] after reporting stronger-than-expected sales guidance this year for its drug Soliris, a treatment to prevent the breakdown of red blood cells. [WSJ] wowed Wall Street traders with its announcement that its new "more efficient global tax structure" would dramatically reduce its income taxes and increase its gross profits from 89 percent in 2013 to 91 percent next year. Because the company bought a plant in Ireland it is able to shift some of its tax obligations to that country. [Mara Lee, Hartford Courant, Jan 30, 14]
Alexion Pharmaceuticals and Moderna Therapeutics (Cambridge, MA; no SBIR) announced an exclusive strategic agreement for the discovery and development of messenger RNA Therapeutics to treat rare diseases. Under the agreement, Alexion will make an upfront payment to Moderna of $100 million to purchase 10 product options to develop and commercialize treatments for rare diseases with Moderna’s mRNA Therapeutics platform, the two companies said in a press release. In addition, Connecticut-based Alexion has made a $25 million preferred equity investment into Moderna. [Chris Reidy, Boston Globe, Jan 13, 14]
David Blech was the initial financial force behind the industry giant Celgene, the rare-disease specialist Alexion Pharmaceuticals ($1.8M SBIR), and the cancer-drug developer Ariad Pharmaceuticals ($600K SBIR), not to mention Icos (no SBIR), which developed the impotence pill Cialis. In the early 1990s, Blech was worth about $300 million and made the Forbes list of 400 wealthiest Americans. Now, however, he is about to begin a four-year prison term, is about $11 million in debt, and is mainly an afterthought to the industry he helped foster. [Andrew Pollack, New York Times, Sep 9, 13]
Alexion Pharma was named #2 on Forbes's list of the world's most innovative companies.
Alexion Pharma up 13% [Jul 12, 13]
Alexion Pharmaceuticals will break ground on its new global headquarters in New Haven, the company said — an 11-story, $100 million building for offices and laboratory space [Brian Dowling, Hartford Courant, Jun 14, 13]
[FDA] fast-tracked development of a drug by a subsidiary of Alexion Pharmaceuticals to treat a rare metabolic bone disease for youths. [Brian Dowling, Hartford Courant, May 29, 13]
Alexion Pharma up 11% [Apr 25, 13] Soliris, launched in 2007 to treat a rare cause of anemia. In 2012 that drug will do more than $1.1 billion in revenue, with Wall Street expecting that figure to double again over the next three years. Its current net margin: 22%. Alexion Pharma shares are up 600% since the drug’s approval .... little-known Alexion hit No. 2 in FORBES’ annual ranking of the most innovative companies. .... Soliris is a blockbuster–and Alexion a juggernaut–because of the drug’s astronomical price: $440,000 per patient per year (though it is sometimes given away for free, in hardship cases). Yet the drug is so effective that private insurers and national health agencies, even sticklers like the UK and Australia, are willing to pay. [Forbes, Sep 24, 12]
Every state does it. In 2011 Connecticut paid Alexion Pharma (Cheshire, CT $1.7M SBIR) $46 million to commit to hiring 200 new employees. At $230,000 per job, this still far exceeds the threshold for a sound investment in the state's economy. .... Oklahoma's Small Business Capital Formation Incentive Act provides a 20% tax credit for investments in Oklahoma small businesses. In 2009, reported the Oklahoma Tax Commission, the program cost the state $17 million but generated only 21 new jobs. .... Politicians want to be re-elected, and a solid record on nominal job growth—regardless of the cost—tends to be more important to officials' re-election prospects than is the prudent management of public funds. That is one reason most such programs are structured to yield job creation immediately while deferring the cost of the incentive into the future—preferably when other politicians will be in office. [Tom Foley and Ben Zimmer, Wall Street Journal, Feb 9] Mr. Foley, the 2010 Republican nominee for governor of Connecticut, is founder of the Connecticut Policy Institute, of which Mr. Zimmer is executive director.
AlexionPharma has become one of the industry’s most valuable companies on the strength of one super-expensive antibody drug for patients with a disease that hardly anybody has ever heard of:Paroxysmal nocturnal hemoglobinuria (PNH). While Genzyme is the company everybody looks to as the trailblazer in the rare disease drug development field, Alexion has also set an example that many rare disease-focused startups want to follow. [Luke Timmerman, xconomy.com, Jul 9 ,12]
Alexion Pharmaceuticals (Cheshire,CT; $1.7M SBIR) that develops treatments for rare disorders, has acquired Enobia Pharma (Canada and Cambrdige, MA; no SBIR) for $1.1 billion. The all-cash deal, which closed Wednesday, was agreed to last December. [Janis Podsada, Hartford Courant, Feb 8, 12]
Alexion Pharmaceuticals (Cheshire, CT; $1.7M SBIR, founded 1992, Phase II SBIR in 1995), the maker of a drug for a rare blood disease, agreed to acquire closely held Enobia Pharma (Montreal, Canada) for as much as $1.08 billion, adding experimental treatments for genetic metabolic disorders. Last May, Enobia announced plans to open a US office in Cambridge. [Bloomberg News, Dec 29, 11] Went public in 1996, traded as low as $1.5, now has $13B market cap at around $70.
Alexion Pharmaceuticals and Alexion Pharma International Sà rl (APIS),announced today that the Paul-Ehrlich-Institut (PEI), Germany’s healthcare regulatory body for biological products, has authorized initiation of an open-label clinical trial to investigate eculizumab (Soliris) as a treatment for patients with Shiga-toxin producing E. coli hemolytic uremic syndrome (STEC-HUS), which has resulted from infections by Enterohemorrhagic Escherichia coli (EHEC) in an unusually wide outbreak in Germany that began in May.
Taligen Therapeutics (Cambridge, MA (formerly Greenwood Village, CO); $1M SBIR) has been acquired by Alexion Pharmaceuticals (Cheshire, CT; $1.6M SBIR) for $111 million in an up front cash payment. [Mass High Tech, Jan 31, 11]
Alexion Pharmaceuticals has resolved an ongoing patent dispute with PDL BioPharma Inc. over Alexion’s Soliris antibody therapy. Alexion announced that it would pay $25 million to PDL BioPharma for rights to use some of PDL’s patent portfolio called the Queen in its Soliris drug. [Mass High Tech, Jan 5, 09]
Alexion Pharmaceuticals (Cheshire, CT; $1.8M SBIR) agreed to pay $10M to the Oklahoma Medical Research Foundation for all rights to certain patents related to technology used to develop Alexion's blood-disorder drug Soliris, ending a legal dispute between the two operations [Mass High Tech, Feb 14,08]
Alexion Pharmaceuticals raised $140M with a public stock offering. Alexion has a drug for a rare blood disorder on fast track for FDA approval. The stock has been rising for about three years on an apparent road to recover its high of five years ago at twice the present price. [Nov 22, 06]
Alexza Pharma up 23% [Oct 27, 14]
Alexza Pharma down 10% [Aug 11, 14]
Alexza Pharma down 17% [Aug 8, 14]
Generic drug maker Teva Pharmaceuticals USA will extend its business into name-brand drugs and Alexza Pharmaceuticals. will get $40 million upfront as part of a marketing deal around Alexza's treatment for agitation related to schizophrenia and bipolar disorder. [Ron Leuty, San Francisco Business Times, May 14, 13]
Alexza Pharma up 22% [May 8, 13]
Alexza Pharma down 14% [Dec 24, 12]
Alexza Pharma up 13% [Dec 20, 12]
Alexza Pharma up 11% [Dec 14, 12]
Alexza Pharma down 12% [Dec 5, 12]
Alexza Pharma up 10% [Nov 20, 12]
Alexza Pharma down 12% [Nov 7, 12]
Alexza Pharma up 10% [Oct 5, 12]
Alexza
Pharma
up 12%
[Aug 28, 12]
Alexza Pharma up39% [Aug 13, 12]
Alexza Pharma down 11% [Jul 6, 12]
Alexza Pharma up 10% [Jun 29, 12]
Alexza Pharma up 16% [Jun 25, 12]
Alexza Pharma up 44% [Jun 22, 12] after the company said it filed a new marketing application for its agitation drug Adasuve. Adasuve is an inhaled drug designed to treat acute agitation caused by schizophrenia or bipolar disorder. [AP, Jun 22]
Alexza Pharma down 54% [Oct 11, 10]
Alexza Pharmaceuticals has agreed to sell common stock and warrants worth $18 million to a group of institutional investors [San Francisco Business Times, Aug 5, 10]
Alexza Pharmaceuticals rose 8% after the FDA accepted the company's drug application for a treatment for agitation in patients with schizophrenia or bipolar disorder. [Wall Street Journal, Feb 12, 10]
Alexza Pharmaceuticals said it plans to raise $19.7 million in a private placement of its common stock. [Silicon Valley/San Jose Business Journal, Sep 30, 09]
Alexza Pharma down 12% [Sep 14, 09] as preliminary results from the company's midstage trial for a migraine treatment failed to meet a goal. [Wall Street Journal, Sep 15, 09]
Alexza Pharma down 13% [Jan 29, 09]
Alexza Pharma up 13% [Jan 21, 09]
Alexza Pharma down 10% [Jan 9, 09]
Alexza Pharma up 15% [Oct 16, 08]
Alexza Pharma down 11% [Aug 29, 08]
Alexza Pharma up 18% [Aug 28, 08]
Alexza Pharmaceuticals down 11% [Aug 21, 08]
Alexza Pharmaceuticals up 13% [Jul 30, 08]
Alexza Pharmaceuticals down 14% [Jun 10, 08] on news of disappointing clinical trials.
Alexza Pharma up 16% [Mar 11, 08]
Alexza Pharmaceuticals up 11% [Feb 26, 08]
Alexza Pharmaceuticals up 10% [Nov 28, 07]
Alexza Pharmaceuticals down 12% on lack of good news. [Aug 14,07]
Alexza Pharmaceuticals up 10%. [Aug 8, 07]
Alexza Pharmaceuticals down 10%. [Aug 3, 07]
Alexza Pharmaceuticals doubled after announcing encouraging results from two studies intended to develop new treatments for migraine victims and schizophrenic patients with acute agitation. [Businessweek.com, Mar 26, 07]
Alfalight (Madison, WI; no SBIR, founded 1998 in association with the University of Wisconsin and the Reed Center for Photonics) announced it has received a [$3.7M] contract to deliver lasers for the Terminal High Altitude Area Defense (THAAD) Laser Initiated Ordnance System built by Pacific Scientific Energetic Materials Company as a subcontractor to THAAD prime contractor Lockheed Martin designs and manufactures reliable, rugged, and efficient laser and electro-optical systems for defense and security applications .... most recently got $49M Marine Corps contract [company website, Sep 24, 14] Originally focused on the optical telecommunications market, back in 2011 Alfalight attracted investment from In-Q-Tel, the venture investment wing of the US Central Intelligence Agency (CIA). [optics.org, May 30, 14]
Alfalight (Madison WI; no SBIR) got a $1.2M Army contract for development of stronger fiber lasers for industrial and defense applications. Alfalight's commitment to innovation is validated by funding from several government branches including DARPA, the Air Force Research Laboratory, and the Army Research Laboratory [company website]
research partnership Dublin-based Biosortia Pharmaceuticals (Dublin, OH; no SBIR) formed this month with British pharmaceutical giant AstraZeneca Plc – but the potential for new drug discoveries in the deal widens to a river from a trickle. .... a subsidiary of Marysville-based Algaeventure Systems (Marysville, OH; no SBIR), has technology to harvest and remove water from huge mats of algae living in inland lakes and other bodies of water, preserving complex communities of warring microorganisms and the compounds they secrete. The resulting concentrated samples are sent to several university and hospital partners to isolate the compounds of interest. [Carrie Ghose, Columbus Business First, Jul 19, 13]
San Diego-based investment firm Kapyon Ventures has raised $5.8 million for two of its agricultural biotechnology companies. The companies are developing microbial and plant technologies under the lean "virtual biotech" model that has become popular in the industry. Algenetix (no SBIR) , a company that's developing biofuels and other products from microbes, has raised $2 million. Investors include Two Oceans, a Sydney, Australia-based investment firm. ZeaKal (no SBIR) a developer of technologies to increase yields from soybeans and rice, has raised $3.8 million [Bradley Fikes, utsandiego.com, Apr 29, 13]
AlgEternal Technologies (Austin, TX; no SBIR) working with the University of Texas, has a technology that it hopes will make it possible to grow algae on a much larger scale and in a much smaller space. ... is near completion of a commercial facility at UT's J.J. Pickle Research Campus. ... The concept, in simplistic terms, is to grow algae vertically, instead of the traditional, horizontal way. That's being done with a proprietary process that uses tall glass tubes — called bioreactors — instead of the traditional open-pond method. [Austin American Statesman, Sep 12, 11]
Algorithmia (Seattle, WA; no SBIR, founded 2013), which runs a public marketplace for algorithms, has just landed a deal to provide a private algorithm-sharing platform for the U.S. intelligence community [in a] deal with In-Q-Tel (the VC arm of CIA). ... Algorithmia took a major step forward with its platform last week when it began hosting and distributing trained deep learning models. [Benjamin Romano, xconomy.com, Jul 18, 16] raised $2.4 million last August to connect academics building powerful algorithms and the app developers who could put them to use [techcrunch.com]
Optimism Not Enough. Wall Street just escaped an attempted alien abduction, spurning a wildly inappropriate initial public stock offering from Alien Technology of Morgan Hill. Alien, struggling to develop a new way of making low-cost radio identification tags for retailing and other applications, is in no way qualified to be a public company. Alien's losses are bigger than its sales, its technology is unproven and the company has missed self-imposed deadlines to make that technology work as claimed. [Mike Langberg, San Jose Mercury News, Aug 26]
Alimera Sciences (Atlanta, GA;no SBIR) linked a securities purchase agreement with a group of institutional investors for a $40 million stock sale. ... a biopharmaceutical company that specializes in research, development and commercialization of prescription ophthalmic pharmaceuticals. .... to fund the development and commercialization of Iluvien and for other working capital purposes. [Atlanta Business Journal, Jul 27, 12]
pSividia (Watertown, MA; noSBIR) has taken a $15 million payment from Alimera Sciences (Alpharetta, GA; no SBIR) to cover licensing of its lead product Iluvien to treat diabetic macular edema (DME). ... pSivida was launched in Australia, and reincorporated as a U.S. company based in Watertown in April of 2008. [Mass High Tech, Apr 29, 10]
Johnson & Johnson will buy Alios BioPharma (South San Francisco, CA; no SBIR) in a $1.75 billion cash deal that will boost the big pharmaceutical company’s profile in hepatitis C and other virus fighters. .... Alios in April said it raised $41 million [Ron Leuty, San Francisco Business Times, Sep 30, 14]
Alios BioPharma (South San Francisco, CA; no SBIR) will spend $41 million from a Series B round of funding on a mid-stage trial of its lead drug against respiratory syncytial virus and a handful of preclinical programs targeting influenza and the common cold. .... lead drug, AL-8176, is in a Phase IIa clinical trial against respiratory syncytial virus, which is a major cause of respiratory illness in children. [Ron Leuty, San Francisco Business Times, Apr 8, 14]
biotech firm Ablexis LLC (San Francisco, CA; no SBIR) announced a $12 million round of Series A funding [San Francisco Business Times, Jun 3, 10] ... to advance AlivaMab, its transgenic mouse method for discovering human therapeutic antibodies....Ablexis was formed in December and is based on technology from Aliva Biopharmaceuticals (Pasadena, CA; $200K SBIR), which now is a subsidiary of Ablexis. [Ron Leuty, San Francisco Business Times, Jun 2, 10]
Biogen has bolted on a couple of early-stage drug candidates for neuromuscular diseases via a $535 million deal with startup AliveGen [Thousand Oaks, CA; no SBIR). [Phil Taylor, Fierce Biotech, Jul 24, 18]
Hours after announcing its newest spinout, a cell therapy-focused startup [Vor BioPharma (Boston, MA), which is focusing on “CAR-T” therapy, a type of cell therapy for cancer that has shown some impressive early results against certain blood cancers], [PureTech Health] says it is launching Alivio Therapeutics (Boston, MA) to develop a therapy for chronic and acute inflammation. Alivio has a hydrogel material that it said is designed to adhere to inflamed tissue and deliver drugs based on the level of inflammation. ... As Fidler reported in March, PureTech unveiled Commense (Boston, MA), which aims to build on research into the human microbiome—the trillions of bacteria and other microbes that live in and on our bodies—to potentially protect babies born via C-section from the future onset of a variety of serious conditions. [David Holley, xconomy.com, May 10, 16]
Mural Oncology, Alkermes (Cambridge, MA; $3M SBIR)s’ cancer spinoff, has landed with $275 million in funding and a mission to develop an IL-2 candidate for solid tumors. [Annalee Armstrong, Fierce Biotech, Nov 15, 2023]
Alkermes ($1.9M SBIR in Cambridge, MA), an international pharmaceutical company, was awarded state tax credits to add [90] more jobs at its Wilmington manufacturing plant where it makes four of its key drugs. [ Kaitlin Schroeder, Dayton Business Journal, Feb 3, 17]
Profit over patriotism. Companies such as Alkermes ($2.7M SBIR), which inverted to Ireland in 2011 and has since tripled its revenue, are natural targets for midsize U.S. drug makers, analysts say. .... shows how eager many U.S. companies are to establish legal residency overseas, putting distance between themselves and tax authorities in Washington. .... U.S. companies say it is becoming more clear that the divided Congress won't overhaul the tax code nor let them return money earned and already taxed abroad back to the U.S. at a discounted rate. [Kate Linebaugh and Liz Hoffman,Wall Street Journal, May 11, 14]
Alkermes touted the addition of three new drugs to its pipeline during an event at its headquarters this week, according to the Boston Business Journal. ... one of which - RDB-1419 - represents the company’s first foray into biologic drugs. RDB-1419 expanded the number of tumor-killing cells in preclinical tests, inhibiting lung metastases in a model of lung cancer. [Dayton Business Journal, Jul 18]
Alkermes released all the details from a mid-stage clinical trial on a drug that attacks depression in a whole new way, giving the company a shot to add a potentially big moneymaker to its portfolio should the results hold up in a bigger study. [Ben Fidler, xconomy.com, May 31, 13]
Alkermes up 16% [Apr 17, 13]
Alkermes said it plans to acquire a division of Irish drug maker Elan Corp. plc in a cash and stock deal valued at $960 million. Elan will receive $500 million plus an equity stake of 25 percent in Alkermes, which will now be known as Alkermes plc, and will be incorporated in Ireland [Julie Donnelly, Dayton Business Journal, May 9, 11] Alkermes had $3M NIH SBIR in the 1990s.
Alkermes Pharma down 11% [Mar 3,11] The diabetes drug being developed by Eli Lilly, Amylin Pharmaceuticals, and Alkermes didn't control the disease better than Novo Nordisk A/S' Victoza in a study, Bloomberg News reported [Indianapolis Star, Mar 3, 11]
Alkermes said today that a clinical trial shows one of its drug candidates can relieve constipation caused by use of opioid pain medications without reducing the effectiveness of the pain drugs. [AP, Feb 15, 11]
Alkermes up 10% [Feb 4, 11]
Analysts and company officials at Alkermes have been taken my surprise by [FDA] decision not to approve a drug candidate to treat type 2 diabetes, Bydureon. [Mass High Tech, Oct 20, 10]
Alkermes up 5% said a [FDA] advisory panel voted 12-to-1 that its drug Vivitrol should be approved for the treatment of opioid dependence. The FDA isn't bound by panel recommendations, but it usually follows them. [Wall Street Journal, Sep 18, 10]
Alkermes has launched an early stage drug trial for a potential treatment for side effects of opiod use for patients will chronic pain. [Mass High Tech, Mar 19, 10]
Amylin Pharmaceuticals rose 16% after the FDA issued a complete response letter that rejected immediate approval of a long-acting version of diabetes treatment Byetta, being developed with Eli Lilly and Alkermes. The FDA's response removed the worst-case scenario—the need for additional clinical trials. Alkermes advanced 15% [Wall Street Journal, Mar 16, 10]
Alkermes up 15% [Mar 15, 10]
Life science firms pitch optimism [CEO] of Alkermes stood before scores of potential investors yesterday and talked about two drugs - for diabetes and opiate dependency - that his Cambridge company expects to get approved in 2010. “This year is going to be a big year,’’ Pops said. ... Henri Termeer defending his leadership at Genzyme as it scrambles to fix production problems, Biogen Idec’s James C. Mullen avoiding any mention of his recent decision to step down from the company’s top post - the mood was generally upbeat. ... companies have been raising more money in follow-on offerings than any time in the past decade, about $6 billion in 2009 ... Another huge market opportunity lies in a drug being developed by Vertex Pharmaceuticals to treat hepatitis C, a largely untreated virus estimated to affect about 3 million Americans and 100 million people globally. “We’re doing a lot to raise awareness of this disease,’’ said new Vertex chief Matthew Emmens. [Robert Weisman, Boston Globe, Jan 14, 10] from the 28th annual J.P. Morgan Healthcare Conference in San Francisco
Alkermes said it will invest $10 million to license the rights to a drug technology developed by Acceleron Pharma (Cambridge, MA; no SBIR), and also take an equity stake. [Boston Globe, Dec 4, 09]
Alkermes up 14% [Nov 17, 09] said a late stage clinical trial shows its drug Vivitrol, which is used to help alcoholics quit drinking, also helped opioid addicts stay off drugs. [AP, Nov 16, 09]
Alkermes said that a drug for addiction and nervous system disorders met its goal in two early stage clinical trials. [Boston Globe, Oct 13, 09]
Alkermes up 11% [May 5, 09]
Alkermes up 13% [Mar 26, 09]
Alkermes up 12% [Mar 12, 09]
FDA is looking for more information about Cambridge-based biotech company Alkermes’s bipolar disorder treatment drug Risperdal Consta before it considers granting permission to expand its usage. [Mass High Tech, Feb 11, 09]
Alkermes up 14% [Dec 11, 08]
Alkermes down 10% [Dec 9, 08]
Alkermes up 22% [Dec 8, 08]
Alkermes said that it has regained from Cephalon full commercialization rights to Vivitrol, once-monthly, extended-release injectable medication for the treatment of alcohol dependence. [Boston Globe, Dec 1, 08]
Alkermes down 12% [Oct 27, 08]
Alkermes down 14% [Oct 15, 08]
Alkermes up 13% [Oct 13, 08]
Alkermes down 12% [Aug 27, 08]
Alkermes down 10% [Aug 18, 08]
Alkermes up 11% [Aug 8, 08]
more and more companies in the pharmaceutical game, including biotech firm Alkermes, think the way to kick that addiction is through a dose of their drugs. Millions of Americans are hooked on everything including booze, cigarettes, cocaine and even cheeseburgers — and drug-makers are filling their research and development pipelines with potential treatments for such addictions. With mixed results, Alkermes and several pharma companies have launched a handful of drugs to help patients quit drinking or smoking. [Mass High Tech, Jul 11]
Alkermes will expand its common stock repurchase program by an additional $40 M. According to biotech firm Alkermes, the $40 million boost in the buyback plan comes after the company received a $40 million payment from Eli Lilly after the drug giant canceled its inhaled insulin program with Alkermes in March.
More insulin innovation, please. Alkermes reports that it expects partner Eli Lilly and Co. to pull the plug on the AIR Inhaled Insulin product, which is being developed by the two companies [Mass High Tech, Mar 7, 08] Indeed, Eli Lilly joined the exodus: abandoned plans to develop inhalable insulin, joining other drug makers that have exited from the field. [Wall Street Journal, Mar 8]
Alkermes plans to continue working with partner Eli Lilly and Co. on an inhalable form of insulin for diabetes patients, even though two other drug makers scrapped work on competing products in the past few months. [Boston Globe, Jan 18]
Alkermes said a unit of Johnson & Johnson has agreed to sell its treatment for alcohol and opioid dependence in Russia and other countries of the Commonwealth of Independent States (CIS). [Mass High Tech, Jan 7, 08]
Alkermes reports it plans to sell its stake in New Jersey-based Reliant Pharmaceuticals Inc. to GlaxoSmithKline for up to $174 M cash. [Mass High Tech, Nov 23, 07]
Alkermes up 13% on good earnings and prospects [Aug 3, 07]
Alkermes gained 13% on reporting doubled profit and a brighter future. [Feb 8, 07]
Virtual biotechs. Biotech startup Alkeus Pharmaceuticals (Cambridge, MA; no SBIR) has a lofty goal—curing childhood blindness—but its operating budget is anything but grand. ... zero full-time employees and no laboratory space. CEO Leonide Saad doesn't draw a salary, and holds meetings in empty classrooms at the Massachusetts Institute of Technology or at an Au Bon Pain down the street. Alkeus is one of a burgeoning new generation of so-called virtual biotechs, born of the need to capitalize on fast-moving science in today's more frugal venture-capital environment. [Jeanne Whalen, Wall Street Journal, Jun 3, 14]
Allakos up 12% [Jul 20, 18]
Allakos (San Carlos, CA; no SBIR, founded 2012) up 33% [Jul 19, 18] after IPO raised $130M; boosting a busy period for health care IPOs. [Investors Business Daily, Jul 19, 18] total funding $#4M [crunchbase.com]
Therapeutic antibody developer Allakos (San Mateo, CA; no SBIR) raised $10 million, lifting the company’s Series A round to a total of $42 million. ... to continue developing its flagship program, an antibody that affects types of cells related to inflammation. [Jason McCormick, Silicon Valley Business Journal, Sep 30, 14]
Drug developer Allakos (San Carlos, CA ; no SBIR) raised $24.5 million toward an upsized goal of a $42 million Series A round. .... developing antibody-based drugs against inflammatory diseases, such as asthma, food allergies and gastrointestinal conditions. ... founded by veterans of KaloBios Pharmaceuticals [Ron Leuty, San Francisco Business Times, Aug 27, 14]
Avid Thermalloy (Laconia, NH; no SBIR, founded 1964) announced it has acquired Nuventix (Austin, Texas, no SBIR, founded 2004) Nuventix designs, manufactures and distributes fanless thermal management solutions, including its patented Synjet technology, for LED lighting applications. ... Aavid designs, manufactures, and distributes thermal management solutions, including heat sinks, heat pipe assemblies, and cold plates for telecommunications, server, consumer electronics, transportation, and industrial applications. .... Avid also announced has acquired Allcast, LLC (Allenton, WI; no SBIR) Allcast designs, manufactures and distributes aluminum die casting products for LED lighting, recreational vehicle, consumer, and industrial applications. [Avid press releases Jul 1, 14] Nuventix was founded by researchers at the Georgia Institute of Technology, including Dr. Raghav Mahalingam who is currently Chief Scientist at Nuventix, with the simple goal of removing more heat with less air. Much of the development was supported by [federal government R&D funding] [company website]
Allegro Diagnostics (Maynard, MA; $2.9M SBIR) developer of medical tests for cancer, has closed a $5.4 million Series A financing round, ... to move the company’s BronchoGen genomic test, used to detect potential lung cancer signs, into commercialization next year. [Michelle Lang, Mass High Tech, Jul 7, 11]
Allegro Diagnostics (Boston, MA; no SBIR) a diagnostics startup with ties to Boston University, has reeled in its first round of venture capital financing to develop its molecular tests, officials said [Mass High Tech, Mar 7, 08] announced the completion of $4M in Series A financing. [Boston Globe, Mar 7]
NIH gave Allegro Diagnostics, (Boston, MA; no SBIR) developer of medical tests for cancer, a $2.8 million Phase 1/2 Fast Track SBIR for a clinical study of its lung cancer diagnostic test, BronchoGen. ... Founded in 2006 by researchers from Boston University, ... received a $4 million Series A round in 2008. [Mass High Tech, Oct 22, 09]
Allegro MicroSystems(Worcester, MA; no SBIR) is pulling its planned IPO, citing negative market conditions.The company filed for its IPO, expecting to raise $115 million [Mass High Tech, Aug 22, 08]
Allegro
MicroSystems
(Worcester,MA)
that makes
semiconductors for the automotive industry and other markets, said
today that it will not go through with its initial public offering
of common stock due to current market conditions.
Allena Biopharma up 26% [Apr 3, 18]
Allena Pharma up 19% [Apr 2, 18]
Allena Pharma up 10% [Mar 16, 18]
Allena Pharma up 14% [Feb 15, 18]
Allena Pharma down 15% [Dec 15, 17]
Allena Pharmaceuticals (Newton, MA; no SBIR)a late-stage clinical biopharmaceutical company dedicated to developing and commercializing first-in-class, oral enzyme therapeutics to treat patients with rare and severe metabolic and kidney disorders, announced the pricing of its [IPO] of approximately $75 million [company press release, Nov 1, 17]
Allena Pharmaceuticals (Newton, MA; no SBIR) files for $92M IPO ... arrives on Wall Street armed with data from two phase 2 flops and a pivotal trial design that has so far failed to win over the FDA. [Nick Paul Taylor, Fierce Biotech, Oct 9, 2017]
Allena Pharmaceuticals (Newton, MA; SBIR) added a $53 million Series C round, becoming another possible Boston-area IPO candidate. New backers Partner Fund Management, Fidelity Management & Research, and Wellington Management joined with Allena’s existing investors to provide the new cash, which will go towards a Phase 3 test of the company’s lead drug for secondary hyperoxaluria [Ben Fidler, xconomy.com, Dec 11, 15]
Allena Pharmaceuticals (Newton, MA; no SBIR) launched three years ago with $15 million VC, is today announcing a second round of $25 million to bring its potential drug to treat recurring kidney stones and other renal disease to late-stage clinical trials. ... to complete a Phase 2 trial, and start a Phase 3 trial, of what could become the first pill to treat hyperoxaluria, a disease that can lead to kidney stones, chronic kidney disease, end-stage renal disease and dialysis. ... in the same offices as Alcresta (no SBIR), a biotech developing enzyme-based nutritional products for acute or chronic diseases that is also headed by Margolin and Gallotto. The pair previously founded Alnara Pharmaceuticals (no SBIR), which sold to Eli Lilly in 2010 for $180 million upfront. The drug for cystic fibrosis developed by Alnara, however, failed to gain FDA approval and Lilly sold it to California-based Anthera earlier this year. [Don Seiffert, Boston Business Journal, Dec 4, 14]
Allena
Pharmaceuticals is launching as a start-up after
securing $15 million in Series A venture capital financing. The company
is looking to develop and commercialize non-systemic protein
therapeutics to treat metabolic and orphan diseases, with a focus on
nephrologic and urologic conditions. The company’s founders are
Alexey
Margolin, founder and former chief executive of Alnara Pharmaceuticals
Inc., and Robert Gallotto, former chief business officer of Alnara.
[Chris Reidy, Boston Globe, Nov 16, 11]
Allergy Amulet (no SBIR), which participated in gener8tor's winter class in Madison, raised $880,000 of equity and options or other rights, according to a filing with the SEC. Allergy Amulet is developing a portable allergen detection device that plugs into a piece of jewelry that helps users test food before eating it. [Kathleen Gallagher, Milwaukee Journal Sentinel, Oct 10, 16]
Sixstart-up technology firms have received grants as part of the state's small-business incubator program, ... administered by the Connecticut Center for Advanced Technology ... $32,000 to $50,000 went to: AllerQuest LLC of West Hartford, Catelectric Corp. of Storrs, Hydrogen Safety of East Hartford, Quadra-Aerrow International of Glastonbury, Revegen Inc. of Farmington and the Center for Network Centric Product Support Research of East Hartford. [Hartford Courant, Dec 12, 08] no SBIR for any
The Texas Medical Center, the largest medical complex in the world, announced the TMC Venture Fund, a $25 million initiative designed to support technologies and early-stage companies to flourish in Houston’s health care ecosystem and further the TMC’s mission to advance health, education and research. Its awardees for 2017: Alleviant Medical (Houston, TX, founded 2017) developing a novel minimally-invasive device to treat congestive heart failure; Briteseed (Chicago, IL; no SBIR, founded 2012) commercializing a new class of smart surgical tools that have artificial-vision assistance; CNSDose (Australia, founded 2015, raised $1M) uses advanced genetic technology to fast-track finding the right antidepressant and dose; Noninvasix (Galveston, TX; no SBIR, founded 2007) developing a patient monitor to directly, accurately and noninvasively measure brain oxygenation in premature babies in the neonatal intensive care unit. [TMC press release, Nov 8, 17]
Allied BioScience (Dallas, TX; no SBIR), which moved its headquarters to Dallas earlier this year, has developed a proprietary antimicrobial surface coating that breaks the chain of infection, CEO Michael Ruley told me in an interview. ... About 80 percent of infection is spread through touch, Ruley said. Allied BioScience's product treats entire environments including room walls, windows, mirrors, bed rails, tray tables, corridor walls and nursing stations, he said. ... [the] product, SurfaceWise, is an invisible coating that binds to surfaces at a molecular level, forming a protective shield that creates a hostile microscopic environment for pathogens, Ruley said. The company has worked on the technology for nine years, he said. [ Bill Hethcock, Dallas Business Journal, Dec 8, 14]
Spin Transfer Technology (Fremont, CA; no SBIR, founded 2007) said it has raised $70 million for a faster new form of chip memory. ... a subsidiary of Allied Minds (Boston, MA; no SBIR) that commercializes technologies developed at leading U.S. universities and federal research institutions. [Cromwell Schubarth, Silicon Valley Business Journal, Oct 9, 14]
Alliqua BioMedical (Langhorne, PA; no SBIR) a provider of advanced wound care products, announced that it has signed a definitive agreement to acquire Celleration (Eden Prairie, MN; no SBIR) for an initial purchase price of approximately $30.4 million, which is comprised of both cash and stock. ... Celleration is focused on developing and commercializing the MIST Therapy® therapeutic ultrasound platform for the treatment of acute and chronic wounds ... Since Celleration's MIST Therapy System was commercialized in 2005, MIST therapy has been performed more than 1.2 million times on over 85,000 patients in the U.S. and the U.K. [Alliqua press release, Feb 2, 15]
Alliqua (Langhorne, PA; no SBIR) completed a series of deals that are bringing $13 million and two new products to the wound-care company. .... [after] a 43.75-for-1 reverse stock split. [John George, Philadelphia Business Journal, Nov 19, 13]
AlloCure
(Burlington, MA; no
SBIR) startup developing
cell therapy
to treat
kidney disease, has taken in $1.5 million in a debt and securities
offering ... focuses its lead program, AC607, as a mesenchymal stem
cell treatment for acute kidney injury. An alternative to dialysis,
AC607 is designed to stimulate organ repair, the AlloCure website
noted, and has been tested in a Phase 1 clinical trial.
[Michelle Lang, Mass High Tech, Oct 14, 11]
Spectrum Pharmaceuticals completed its acquisition of Allos Therapeutics [Greg Avery, Denver Business Journal, Sep 5, 12]
Allos Thera up 16% [Nov 5, 10]
Allos Thera down 15% [Jul 28, 10]
Allos Thera down 11% [May 6, 10]
Allos Thera down 13% [Mar 2, 10]
Allos Thera down 11% [Dec 7, 09]
Allos Therapeutics (Westminster, CO; $400K SBIR a decade ago) finished selling 14 million shares of stock, raising $93 million the biotech drug maker plans to use to market its newly approved drug Folotyn and for general purposes. [Denver Business Journal, Oct 13, 09]
Allos Therapeutics ($0.4M SBIR) priced its underwritten public stock offering ... to raise about $99.4 million from the offering, before underwriting discounts and expenses, to help it commercialize its cancer drug Folotyn and for general corporate purposes. [Denver Business Journal, Oct 7, 09]
Allos Thera down 12%% [Mar 31, 09]
Allos Thera up 13% [Jan 21, 09]
Allos Thera up 11% [Dec 31, 08]
Allos Thera down 21% [Dec 8, 08]/p>
Allos Thera up 15% [Dec 5, 08]
Allos Thera down 19% [Dec 1, 08] On a stock bloodbath day
Allos Thera down 13% [Oct 24, 08]
Allos Thera up 10% [Oct 20, 08]
Allos Thera up 11% [Oct 16, 08]
Allos Therapeutics down 14% [Oct 15, 08]
Allos Thera down 11% [Oct 14, 08]
Allos Thera up 30% [Oct 13, 08]
Allos Therapeutics down 14% [Oct 7, 08]
Allos Threapeutics down 10% [Oct 2, 08]
Allos Therapeutics down 14% [Oct 7, 08]
Allos Threapeutics down 10% [Oct 2, 08]
Allos Thera down 11% [Sep 17, 08]
Allos Thera up 11% [Sep 16, 08]
Allos Thera down 10% [Sep 8, 08]
Allos Therapeutics down 10% [Sep 4, 08]
Allos Therapeutics up 14% [May 22, 08]
Allos Therapeutics up 17% [Mar 24, 08]
Allos Therapeutics up 12% [Oct 26, 07]
Allos Therapeutics down 11% on soggy profits. [Oct 16, 07]
Allos Therapeutics down 15% [Aug 8, 07] on news of a growing loss.
Allos Therapeutics down 14% [Jun 22, 07]>
Allos Therapeutics jumped another 11%. [Feb 6, 07]
Allos Therapeutics jumped 10% even after raising $50M in a stock sale a few days earlier. [Feb 2, 07]
Allos Therapeutics up 10% after being up 20% intra-day. [Nov 14, 06]
AlloVir (formerly VeraCyte, Cambridge, MA; no SBIR) is seeking $100M IPO for its T-cell work, which includes an early-stage attempt at a T-cell therapy against the SARS-CoV-02 outbreak partnered with the Baylor College of Medicine. [Ben Adams, Fierce Biotech, Jul 7, 20]
Alloy Polymers (East Texas; no SBIR) a plastics compounding company recently canceled its state job creation contract, joining other businesses that have quit or changed their pacts under the Texas Enterprise Fund. ... citing "business reasons," said Lucy Nashed , a spokeswoman for Gov. Rick Perry. Nashed said the company paid back with interest the $100,000 in taxpayer money it had received so far under the $200,000 agreement.... was to have created 52 new jobs in Houston County as part of the 2006 agreement. [Kelly Shannon, AP, Sep 1, 10]
the Navy has awarded Alloy Surfaces (Chester Township. PA; two SBIRs two decades ago) a contract worth a little more than $9.25 million to make 86,397 MJU-49/B infrared countermeasures for aircraft. [Peter Key, Philadelphia Business Journal, Dec 19, 12]
Navy awarded Alloy Surfaces (Chester Township, PA; two SBIRs 20 years ago) a contract worth a little more than $9.25 million to make 86,397 MJU-49/B infrared countermeasures for aircraft. [Peter Key, Philadelphia Business Journal, Dec 19, 12]
Alloy Surfaces (Aston, PA; two SBIRs twenty years ago) has been awarded a three-year contract worth $38.3 million to produce MJU-49/B decoy devices for the Navy, ... now a subsidiary of the Chemring Group PLC, which is based in Whiteley, England. [Philadelphia Business Journal, Jul 23, 10]
Allurion (Natick, MA; no SBIR) makers of the Elipse® Balloon – the world’s first and only procedureless gastric balloon for weight loss – announced today that it has secured $27 million in Series C funding. [company press release, Jul 11, 17]
The Massachusetts Life Sciences Center, a quasi-public agency tasked with implementing the state’s ten-year, $1 billion Life Sciences Initiative, today announced the awarding of $2.2 million in loans [$750K each] to three early-stage life sciences companies. Intelligent Bio-Systems, (Waltham, MA; $6.3m SBIR) DNA sequencing company with a patented, higher performance, lower cost, DNA sequencing instrument and consumable system; Allurion Technologies,(Wellesley, MA; no SBIR) company that is developing a novel medical device designed to induce significant weight loss by displacing volume in the stomach. The device can be delivered without surgery and it can be eliminated via an orally available, non-toxic dissolution agent; and Paragonix Technologies,(Cambridge, MA; no SBIR) company that is commercializing first-in-class, single-use and highly portable organ preservation and transport devices called ‘Sherpas.’ Paragonix has begun with a Sherpa for kidney transport, but is planning to expand their ‘Sherpa’ product line for other organs. [DC Dennison, Boston Globe, Dec 28, 11]
biotechnology company Allylix (San Diego, CA; one SBIR in Kentucky) says it has raised $18.2 million in investment capital for the continued development of its specialty chemicals, which are used to do everything from make chewing gum more flavorful to enrich the fragrance of perfumes and colognes. [Gary Robbins, utsandiego.com, Mar 12, 12]
Ally Therapeutics (Cambridge, MA; no SBIR) gene therapy company raised $10M according to an SEC filing. [Rowan Walrath, BostInno, Aug 9, 19] .... is developing a new technology that enables AAV to evade the innate immune response. [massbio.org]
Eli Lilly has completed the purchase of Alnara Pharmaceuticals, a Boston-area biotech startup whose promising lead drug could help people with cystic fibrosis. [Indianapolis Star, Jul 23, 10]
Alnara Pharmaceuticals (Cambridge, MA; no SBIR, founded 2008). has agreed to be acquired by Eli Lilly, bringing the Indianapolis pharmaceutical giant an inroad into enzyme replacement therapy, used to treat diseases such as cystic fibrosis. [Mass High Tech, Jul 2, 10]
Alnara Pharmaceuticals (no SBIR) stands ready to send its drug target to treat cystic fibrosis to the U.S. Food and Drug Administration, a mere 16 months after the company raised its first venture capital round of $20 million. [Julie Donnelly, Mass High Tech, Mar 5, 10]
Alnara Pharmaceuticals (Cambridge, MA; no SBIR) a developer of metabolic disease treatments, has raised $35 million in Series B funding. ... to file a new drug application for liprotamase, its pancreatic enzyme replacement therapy for patients with cystic fibrosis, which has gone through Phase 3 clinical trials with support from the Cystic Fibrosis Foundation Therapeutics Inc. [Mass High Tech, Jan 28, 10]
Alnara Pharmaceuticals, a pharmaceutical startup developing non-systemic protein therapeutics for the treatment of metabolic and inflammatory diseases, has secured $20 million in Series A funding [Mass High Tech, Oct 30]
Alnara Pharmaceuticals, a newly formed life sciences company in Boston, announced today that it has secured $20 million in Series A venture capital financing. [Boston Globe, Oct 30,08]
Alnylam Pharmaceuticals (Cambridge, MA; $700K in 2008 SBIR, $17B market cap] up 49% [Aug 3, 22] announced that the APOLLO-B Phase 3 study of patisiran, an investigational RNAi therapeutic in development for the treatment of transthyretin-mediated (ATTR) amyloidosis with cardiomyopathy, met the primary endpoint of change from baseline in the 6-Minute Walk Test (6-MWT) at 12 months compared to placebo (p-value 0.0162). The study also met the first secondary endpoint of change from baseline in quality of life compared to placebo, as measured by the Kansas City Cardiomyopathy Questionnaire (KCCQ) (p-value 0.0397). [company press release, Aug 3, 2022]
Alnylam Pharmaceuticals and Vir Biotechnology said, after evaluating hundreds of potential drugs for COVID-19, they have selected one to move forward into human testing. In theory, the drug would interfere with the genetic instructions the novel coronavirus uses to replicate. According to Alnylam and Vir, preclinical tests indicated that their drug, even at low concentrations, is highly potent against the virus. (BioPharmaDive) [The Hill, May 5, 20]
Blackstone and Alnylam Pharmaceuticals ($600K SBIR in 2006), the leading RNAi therapeutics company, announced the companies have entered into a broad strategic collaboration under which Blackstone will provide up to $2 billion to support Alnylam's advancement of innovative RNA interference (RNAi) medicines that have the potential to transform the lives of patients suffering from a range of debilitating diseases. The deal is anchored by Blackstone's purchase of 50 percent of the royalties owed to Alnylam on global sales of inclisiran, an investigational RNAi therapeutic for the treatment of hypercholesterolemia, currently under review by [FDA]. [joint companies press release, Apr 13, 20] Alnylam also announced today that [FDA] has granted Fast Track designation to vutrisiran, an investigational therapeutic for the treatment of the polyneuropathy of hereditary transthyretin-mediated (hATTR) amyloidosis in adults. [company press release, Apr 14, 20]
Alnylam Pharmaceuticals and Vir Biotechnology have teamed up to develop RNAi therapeutics against the coronavirus behind the COVID-19 outbreak. The collaboration builds on Alnylam synthesis of siRNAs that target highly conserved regions of coronavirus RNA. [Fierce Biotech, Mar 4, 20]
An Alnylam Pharmaceuticals drug developed to treat a rare, inherited metabolic disorder won FDA approval, the second regulatory nod the company has received for a drug that turns off a gene to prevent it from causing disease. ... Alnylam set a $575,000 annual price for its new drug. [Frank Vinluan, xconomy.com, Nov 20, 19]
The FDA approved two oral formulations of the Pfizer drug tafamidis, approved specifically to treat the potentially deadly heart problems faced by patients with both the hereditary and “wild-type” forms of ATTR, the latter of which develops over time. ... In 2018 the FDA approved two drugs Alnylam Pharmaceuticals and Akcea Therapeutics (spinout of Ionis Pharmaceuticals, Boston, MA; no SBIR) for hereditary and wild-type ATTR. [Ben Fidler, xconomy.com, May 6 19]
Alnylam and Regeneron Pharmaceuticals are announcing a wide-ranging alliance to co-develop treatments for eye and neurological diseases using RNA interference, a method of drugmaking that has recently come of age after years of ups and downs. Regeneron will pay Alnylam $400 million in cash up front and buy $400 million in Alnylam stock—4.44 million shares at $90.01 apiece—to kickstart the deal. Alnylam could get another $200 million in downstream payments from Regeneron if the drugs in the deal progress forward and hit certain development targets. [Ben Fidler, xconomy.com, Apr 8, 19]
Shares of Alnylam Pharmaceuticals fell close to 12 percent as initial revenues for its first approved product, patisiran (Onpattro), fell short of analyst estimates, generating $500,000 in its first seven weeks on the market. [Ben Fidler, xconomy.com, Nov 8, 18]
For the second time since August, the FDA has approved a new treatment for a rare and deadly disease called hereditary transthyretin amyloidosis (hATTR). The agency’s nod for inotersen (Tegsedi) sets the stage for a market battle between the drug’s developer, Akcea Therapeutics, and rival Alnylam Pharmaceuticals. [Ben Fidler, xconomy.com, Oct 5, 18]
Alnylam Pharma up 16% [Aug 27, 18]
The FDA approved the first-ever RNAi medicine, a drug from Alnylam Pharmaceuticals, for the rare disease hereditary transthyretin amyloidosis. Alnylam priced it at $450,000 per year but said the actual price would be tied to its performance, starting with one deal it reached in principle with Harvard Pilgrim Healthcare. [Ben Fidler, xconomy.com, Aug 17, 18]
The FDA has just approved Alnylam (one SBIR)’s patisiran (Onpattro), making it the first medicine specifically cleared to treat a rare and deadly disease called hereditary transthyretin amyloidosis (hATTR). The decision is a scientific milestone too: it marks the first-ever approval for a medicine that uses RNA interference (RNAi), a method cells can use to silence a gene before it makes a harmful protein. [xconomy.com, Aug 10, 18]
Alnylam Pharma is moving forward with plans to double its office and manufacturing space, as well as its staff, by 2020. The FDA will decide on the company's first drug this week. [Allison DeAngelis, Boston Business Journal, Aug 7, 18]
Dicerna Pharma (Cambridge, MA; no SBIR, founded 2007, IPO 2014) up 18% [Apr 20, 18] announced [it] resolved all litigation with Alnylam Pharmaceuticals. ... allows Dicerna to advance all of its key and planned pipeline programs while maintaining a strong balance sheet. [company press release, Apr 19, 18] total funding $295M; develops therapeutic agents in various disease areas based on dicer substrate technology platform. [crunchbase.com]
Alnylam Pharma down 15% [Apr 2, 18]
Sanofi has turned down the chance to opt into Alnylam Pharma’s primary hyperoxaluria type 1 (PH1) drug lumasiran. The French pharma’s decision gives Alnylam control of a phase 3-ready rare disease drug with an FDA breakthrough therapy designation. [Nick Paul Taylor,Fierce Biotech, Mar 12, 18]
The FDA has cleared Alnylam Pharmaceuticals to resume testing of an experimental hemophilia drug after instituting a variety of measures meant to manage the possible risks of taking the therapy, known as fitusiran. [Ben Fidler, xconomy.com, Dec 15, 17]
Alnylam has emerged victorious from its hereditary TTR amyloidosis (hATTR) data face-off against Ionis. Data presented by the RNAi pioneer suggest its patisiran has the edge over Ionis’ inotersen in terms of safety and efficacy, although it remains to be seen whether this translates into market share. The safety and feasibility study took place at Royal Brisbane and Women’s Hospital in Australia. It evaluated the use of new, investigational robotic-assisted system in the lungs and appears in the journal CHEST. [Nick Paul Taylor, Fierce Biotech, Nov 3, 17]
Ionis Pharmaceuticals has shared a closer look at phase 3 data on inotersen in patients with hereditary TTR amyloidosis (hATTR). The antisense drug triggered a 20-point improvement against a score of neuropathy impairment, laying a marker for the upcoming showdown with Alnylam [which] is yet to present a close look at data from its trial. [Nick Paul Taylor, Fierce Biotech, Oct 16, 2017]
For the first time, a medicine using RNA interference is headed for an FDA review. Alnylam Pharmaceuticals reported positive Phase 3 results for patisiran, a drug for the rare disease transthyretin amyloidosis, and will now file for approval in U.S. and Europe. The news marks a turning point in the quest to turn RNAi, a biological process discovered in 1998, into a drug making method. [Ben Fidler, xconomy.com, Sep 22, 17]
Alnylam Pharma up 52% [Sep 20, 17]
Alnylam Pharma down 16% [Sep 7, 17]
Alnylam Pharma up 16% [May 15,17]
Cholesterol-lowering drugs known as PCSK9 blockers have been commercial busts so far, but The Medicines (Parsippany-Troy Hills, NJ; no SBIR) and Alnylam Pharmaceuticals are charging ahead into a big Phase 3 program with their own version. The two outlined the trials, which include a 14,000 patient cardiovascular “outcomes” study, this week. [Alex Lash, xconomy.com, Apr 28, 17]
Alnylam Pharma up 10% [Feb 27,17]
Alnylam Pharmaceuticals up 11% [Feb 9, 17] added $350 million to its market cap after the Cambridge biotech posted better-than-expected earnings and provided a rosy outlook for its pipeline in 2017. [Max Stendahl, Boston Business Journal, Feb 9, 17]
Alnylam Pharma up 16% [Nov 9, 16]
Alnylam Pharma down 13%[Nov 3, 16]
Alnylam Pharmaceuticals down 48% [Oct 6, 16] said that it has discontinued development of a drug called revusiran, one of the two most advanced RNAi drugs in the company’s pipeline [due to] safety concerns ... has gone through more than a decade of twists and turns, trying to become the first company to bring an RNA interference drug, a method of “silencing” disease-causing genes, to market. [company press release, Oct 5, 16]
Alnylam Pharmaceuticals just opened a 100-employee commercial hub in the U.K. [Alex Lash, xconomy.com, Sep 23, 16]
Alnylam Pharma up 10% [Aug 5, 16]
Alnylam Pharma up 11% [Jul 1, 16] results from the study showed some improvement for Alnylam’s most advanced candidate, patisiran. Alnylam (NASDAQ: ALNY) reports that patisiran, which must be infused at a hospital, improved the neurological function of most of a small group of 27 patients who took the drug for 24 months, even more than it did after 12 months. [David Holley, xconomy.com, Jul 1, 16]
Alnylam Pharma up 11% [May 26, 16]
Alnylam Pharma up 10% [May 23, 16]
Alnylam Pharma down 12% [May 3, 16]
Massachusetts Gov. Charlie Baker announced $20 million in tax incentives for 28 life sciences companies in the Bay State through a series of awards that are expected to create 1,325 new jobs this year. Some of the recipients are Alnylam Pharmaceuticals —which just opened a new facility in Norton, MA—Enanta Pharmaceuticals (no SBIR), and Moderna Therapeutics (no SBIR). [Ben Fidler, xconomy.com, Apr 28, 16] That's a subsidy of $15K per speculative job, and don't expect any post analysis of actual return since government is good ony at input numbers in the present.
In 2006 Merck paid $1.1 billion for Sirna Therapeutics (no SBIR), a biotechnology firm reckoned to be a leader in the field. Roche and Novartis also made big investments around the same time. RNAi, it seemed, was going to take the pharmaceutical world by storm. But siRNAs, so attractive in theory, proved impossible to tame in practice. Roche ended its work in 2010. Novartis and Merck followed suit in 2014. Nevertheless, a clutch of biotechnology companies are still working on the idea, and some of them now think they have cracked it. Chief among them are Alnylam and Dicerna (Cambridge, MA; no SBIR). These firms have, they believe, overcome one of the problems that caused RNAi to fall so deep into the trough of disillusionment—getting siRNA molecules across cell membranes to where they are needed. [The Economist, Oct 17, 15]
Genzyme opted into rights to an experimental RNA interference drug called ALN-AT3 that Alnylam Pharmaceuticals is developing as a treatment for hemophilia. Genzyme was given the option as part of the wide-ranging alliance the two forged in 2014. ALN-AT3 is currently in Phase 1 testing. ... In other Alnylam news,the company won a long-standing suit against University of Utah professor Brenda Bass over RNAi patents known as “Tuschl II” that it licensed several years ago. [Ben Fidler, xconomy.com, Oct 2, 15]
A new drug in early development cuts cholesterol as much as two potent injections recently cleared for sale but lasts much longer, meaning it may need to be given only every three to six months, initial findings suggest. Results with Alnylam Pharmaceuticals and Medicines Co's experimental product ALN-PCSsc highlight the competition for a market tipped to generate billions of dollars in sales. Unlike rival antibody-based PCSK9 medicines that work in the blood, the new under-the-skin injection is a first-in-class treatment that stops synthesis of the protein which is linked to "bad" LDL cholesterol in the liver. [Ben Hirschler, Reuters, Aug 30, 15]
Alnylam Pharma down 11% [Aug 7, 15]
Among the Technology Review fifty smartest companies: Illumina ($5M SBIR plus acquired firms), Alnylam ($600K SBIR), DNAnexus (one SBIR). The other quadrillion SBIR winners haven't been as smart as the best. To make the list, a company must have truly innovative technology and a business model that is both practical and ambitious, with the result that it has set the agenda in its field over the past 12 months. [technologyreview.com, Jun 29]
Trial results released suggest the lead drug by Alnylam Pharmaceuticals for a rare neurodegenerative disease continues to stop nerve damage after a year, confirming earlier results. [Don Seiffert, Boston Business Journal, Apr 21, 15]
Alnylam Pharmaceuticals raised $450 million this week in a stock offering, adding to an already sizeable $880 million war chest of cash. [Ben Fidler, xconomy.com, Jan 23, 15]
Isis Pharma and Alnylam Pharmaceuticals renewed their decade-old partnership to develop RNA-based drugs. ... In addition, Isis announced a collaboration with Janssen Biotech to develop drugs for autoimmune diseases of the gut, with an eye to making them orally available, something Isis hasn't done before. [Bradley Fikes, utsandiego.com, Jan 12, 15]
Alynylam Pharma down 10% [Dec 23, 14]
Alnylam Pharma up 19% [Oct 13, 14]
Inspired by the discovery, another group of researchers—including the former thesis supervisor of one of the Nobel laureates—founded Alnylam Pharmaceuticals ($600K SBIR in 2006) in 2002. Their goal: fight diseases like familial amyloid polyneuropathy, or FAP, by using RNAi to eliminate bad proteins. ... now Alnylam is testing a drug to treat FAP in advanced human trials ... This could be just the beginning for RNAi. Alnylam has more than 11 drugs, including ones for hemophilia, hepatitis B, and even high cholesterol, in its development pipeline, and has three in human trials —progress that led the pharmaceutical company Sanofi to make a $700 million investment in the company last winter. [Kevin Bullis, technologyreview.com, Sep 14, 14]
Alnylam Pharma up 10% [May 1, 14]
Alnylam Pharma down 12% [Apr 10, 14]
Alnylam Pharma up 41% after the drug developer said it will receive a $700 million investment from the Genzyme unit of French pharmaceutical giant Sanofi as part of an expanded collaboration. ..... also announced that it will pay another pharmaceutical giant, Merck and Co., $175 million upfront to buy its Sirna Therapeutics unit. [AP, Jan 13, 14]
Alnylam Pharmaceuticals specializing in RNAi gene technology, said it has earned a $7 million milestone payment from Genzyme for its work on patisiran, a potential treatment for a rare disease called ATTR. [Chris Reidy, Boston Globe, Nov 25, 13]
Alnylam Pharma up 11% [Oct 10, 13]
Alynlam Pharma< up 10% [Sep 23, 13]
Alnylam Pharma up 13% [Jul 12, 13]
Alnylam Pharma up 16% [Jul 11, 13] reported positive trial results for one of its experimental RNA interference drugs. [Investors Business Daily, Jul 11]
Alnylam Pharma up 10% [Jan 16, 13]
Alnylam Pharmaceuticals said that it has restructured its relationship with Tekmira Pharmaceuticals Corp. of Canada with a new licensing agreement; it added that the two companies have resolved all litigation between them in a settlement agreement. [Chris Reidy, Boston Globe, Nov 13, 12]
Alnylam Pharmaceuticals and Genzyme said that they have formed an exclusive alliance to develop and commercialize RNAi therapeutics for the treatment of transthyretin-mediated amyloidosis, or ATTR, in Japan and other Asia-Pacific countries.[Boston Globe, Oct 22, 12]
Alnylam Pharmaceuticals inked a10-year strategic alliance with Monsanto to develop biotech products for the farming industry. Alnylam will receive $29.2 million upfront as well as potential royalties and milestone payments, in exchange for giving Monsanto exclusive worldwide rights to its RNAi-based technology for agricultural use. [Erin Kutz, xconomy.com, Aug 29, 12]
Alnylam Pharmaceuticals said that it has earned a development milestone payment from GlaxoSmithKline totaling $3.2 million. ... related to progress in the companies’ collaboration on the use of VaxiRNA technology for the production of GSK influenza vaccine. [DC Denison, Boston Globe, Jul 30, 12]
Alnylam Pharma up 53% [Jul 16, 12] the developer of a treatment for a rare genetic disorder, rose the most ever after the drug showed promise in an early clinical trial. ... its experimental drug for TTR-mediated amyloidosis reduced levels of the protein that causes the disease by as much as 94 percent in 17 healthy volunteers. [Bloomberg]
Alnylam Pharmaceuticals said that it received special regulatory incentives for a drug designed to treat a potentially fatal neurodegenerative disease.[Mass High Tech, Jun 19, 12]
Alnylam Pharmaceuticalsset a price of $10.75 per share for its stock offering announced Monday, and is looking to raise around $73.5 million. [Mass High Tech, Feb 20, 12]
Alnylam Pharmaceuticalssaid it plans to cut its workforce by 33 percent, or 61 jobs, as part of a “strategic corporate restructuring†plan. One goal of the plan is to save about $20 million in 2012 cash operating expenses. All the company’s employees work in Cambridge. Alnylam said it is looking to align its resources as it accelerates development of promising drug candidates in its pipeline, including one for hemophilia [Chris Reidy, Boston Globe, Jan 20, 12]
Alnylam Pharma up 15% [Feb 18, 11]
Alnylam Pharmaceuticalsunveiled a goal to have five drug candidates in the late stages of clinical development by 2015. [Boston Globe, Jan 6, 11]
Alnylam Pharmaceuticals developing drugs based on RNA interference, said it intends to reduce its workforce by 25 percent to 30 percent as it looks to save about $25 million in 2011 cash operating expenses. [Boston Globe, Sep 24, 10]
Alnylam Pharmaceuticals said that three European countries have cleared it for early-stage clinical testing of a potential treatment for a hereditary disease caused by a genetic mutation. [Boston Globe, Jun 29, 10]
Short Interest. Synaptics has shorts amounting to 43% of its float. Alnylam Pharma has short interest of 38 days of average volume. [Wall Street Journal, Mar 25]
Companies to Watch in personalized medicine. Affymetrix, Life Tech, Illumina, Helicos Biosciences, Metabolon. Among the fifty most innovative: A123 Systems, American Superconductor, Alnylam, Illumina, iRobot, Novomer, BIND Biosciences. [MIT Tech Review, M/A10]
DIY Pharma. At a time when major drug makers are consolidating and may be less willing to buy fledgling companies, biotechs have to make it on their own and bring drugs to market themselves. Industry leaders warned that the old model of forming a biotech company, shepherding a drug through development and years of clinical trials, and then selling the company to a pharmaceutical buyer may be played out. Success will now require a survival mentality and a focus on remaining independent, said Barry Greene, president of Cambridge biotech Alnylam Pharmaceuticals Inc. [Robert Weisman, Boston Globe, Oct 7, 09]
Alnylam Pharmaceuticals and Regulus Therapeutics (no SBIR) said that they have been awarded a US patent that covers some of their intellectual property related to microRNAs, a field thought to be ripe for developing new drugs. [Boston Globe, Aug 11, 09]
Alnylam Pharmaceuticals said today it extended a long-standing contract with Novartis focusing on developing drugs using RNAi, or gene silencing, technology. This marks the second extension by Novartis, as well as the fifth and final year of the contract. [Boston Globe, Jul 17]
Alnylam Pharma up 11% [Mar 10, 09]
Two local life sciences companies are teaming up to work on a collaboration to commercialize some RNAi therapeutics that could potentially yield one of the companies just over $100 million in up-front and milestone payments. Cubist Pharmaceuticals and Alnylam Pharmaceuticals announced that they have formed a strategic collaboration to develop and commercialize Alnylam's ALN-RSV program; the RSV-specific RNAi therapeutic program includes ALN-RSV01, which is currently in Phase II clinical development for the treatment of respiratory syncytial virus infection in adult lung transplant patients, the two companies said in a press release. [Boston Globe, Jan 9, 09]
Alnylam Pharmaceuticals (Cambridge, MA; $600K SBIR) granted Shanghai GenePharma a non-exclusive world-wide license to manufacture and provide RNAi research products and services under the Kreutzer-Limmer patent family. [company website, Mar 20, 08] The nearly $1B market cap barely moved.
Alnylam Pharmaceuticals (Cambridge, MA; no SBIR) said it was part of a research team awarded a new $3.8 million grant from the Michael J. Fox Foundation to further develop an RNAi therapeutic for the treatment of Parkinson's disease.... seeks to develop novel technologies based on RNA interference, or RNAi, a naturally occurring mechanism within cells for selectively silencing and regulating specific genes; since many diseases are caused by the inappropriate activity of specific cells, the ability to silence genes selectively through RNAi has great potential, researchers think. [Chris Reidy, Boston Globe, Jan 7, 07]
Alpenglow Biosciences (Seattle, WA; $1.3M SBIR) landed a $1.6 million grant to help develop artificial intelligence-enabled microscopy using its 3D technology. [Rick Morgan, Seattle Inno, Aug 1, 2023]
Montgomery County [MD, a competitor for America's richest county] will dole out $500,000 to investors in 10 life sciences companies through its coveted biotech tax credit, a fifth of which will go to backers of diagnostics company DioGenix (Gaithersburg, MD; no SBIR) ... piggybacks on the $3.5 million in tax credits from the state to those same 46 investors. The incentives are tied to a total $7 million in private biotech investments in the county last year. Also receiving the credits are backers of 20/20 GeneSystems (Rockville, MD; $4.6M SBIR, incl one of $3.3M), Alper Biotech LLC, American Gene Technologies International Inc., BeneVir Biopharm Inc., ConverGene LLC, Creatv MicroTech (Potomac, MD; $11.6M SBIR)., Rafagen Inc., Sequella (Rockville, MD; $10.3M SBIR). and SynAm Vaccine. [Bill Flook,Washington Business Journal, Feb 28, 14]
Alphabet Energy (Oakland, CA; $300K SBIR) plans to begin selling a new type of material that can turn heat into electricity. Unlike previous thermoelectrics, as such materials are known, it is abundant, cheap, and nontoxic. ... AB's solution is tetrahedrite: an abundant, naturally occurring mineral that also happens to be more efficient on average than existing thermoelectric materials. .... tetrahedrite has promise because it doesn’t require the expensive up-front manufacturing that other materials require. [Suzanne Jacobs, technologyreview.com, Jul 15] No news on why it had not been discovered before.
AlphaCore Pharma, (Ann Arbor, MI; $1.5M SBIR) biotech company working on a drug to treat atherosclerosis, announced that it has been acquired by MedImmune, the biologics division of the Delaware-based British pharmaceutical giant AstraZeneca. The terms of the deal were not disclosed. [Sarah Schmid, xconomy.com, Apr 5, 13]
AlphaMed (Acton, MA; six Phase 1 SBIRs) reports it has received a $750,000 grant from the National Cancer Institute to advance its experimental treatment for deadly skin cancer. ... The two-person firm hopes to find development partners and raise $5 million to $10 million in a Series A round of venture capital this year .....the company's founders: Richard F. Testa, formerly of Thermo Electron Corp., Digital Equipment Corp., and General Electric Co.; Herbert A. Moore, formerly of DuPont Merck Pharmaceuticals Co., Hoffman la Roche Inc., and Tracerlab Inc. [Mass High Tech, May 7, 08]
In response to losing a lawsuit, Alphatec Holdings (Carlsbad, CA; no SBIR) said it has delayed its fourth quarter and fiscal year 2013 earnings results until March 17. The company is the parent of Alphatec Spine, a medical device maker. OrthoTec (no SBIR), which had sued Alphatec subsidiary Surgiview for breach of contract, won a verdict of about $48 million in the jury trial. The verdict was announced Feb. 11 in Superior Court of Los Angeles County. The total amount, including interest, totals $73 million, OrthoTec said. [Bradley Fikes, utsandiego.com, Feb 24]
animal vaccine producer Harrisvaccines (Ames, IA; $400K SBIR, founded 2005) recently acquired by Merck as part of its animal health division, launched by then ISU professor Hank Harris and his postdoc Matt Erdman, who identified and sought to develop a vaccine from a wild strain of the devastating porcine reproductive and respiratory syndrome virus (PRRS). They teamed up with AlphaVax (Raleigh, NC: no SBIR), a human vaccine company, to apply its proprietary alphavirus-based technology to veterinary medicine for the first time. ... Since the initial PRRS vaccine, Harrisvaccines has produced the first pig vaccines on the market for swine flu and porcine epidemic diarrhea virus, as well as bird vaccines following the 2015 outbreak of avian flu that plagued the state’s chicken flocks [Jenny Rood, the-scientist.com, Aug 1, 16]
AlphaVax (RTP, NC; no SBIR) got three-year $3.6M NIH contract to advance its development of adjuvant technologies, which are agents used to enhance the effects of other agents used in vaccines. In February, the company raised $12.7M in a preferred stock offering to begin clinical trials relating to herpes and influenza. [Raleigh News & Observer, Jul 12]
Oncothyreon down 17% [Apr 19, 14] said a test of its lung cancer drug in Japan "did not meet its primary endpoint of an improvement in overall survival, and no treatment effect was seen." The study of 178 patients in Japan of patients with Stage III non-small cell lung cancer by Merck of Germany of tecemotide, compared with a placebo [Ben Miller, Puget Sound Business Journal, Aug 19, 14] also has acquired Alpine Biosciences (Seattle, WA; no SBIR) [for about $27 million in stock] developing protocells, a technology platform designed to deliver therapeutic agents. [Ashley Stewart, Puget Sound Business Journal, Aug 11, 14]
Oncothyreon has acquired another local firm, Alpine Biosciences (Seattle, WA; no SBIR) for about $27 million in stock. Alpine Biosciences, an early stage company that has not advanced any drugs into clinical trials [Seattle Times, Aug 11, 14]
Alpine Data Labs (San Francisco, CA; no SBIR) raised $16 million in a Series B round of funding for its big data analytics technology, which is used by customers including Sony, Nike and Barclays. .... works with customers who have invested in Hadoop, an open-source software framework for processing large data sets. [John Sailors, San Francisco Business Times, Nov 25, 13]
Alpine Immune Sciences (Seattle, WA; no SBIR), a leading clinical-stage immunotherapy company focused on developing innovative treatments for cancer and autoimmune/inflammatory diseases, and AbbVie, a research-based global biopharmaceutical company, announced an exclusive worldwide option and license agreement for ALPN-101, a first-in-class dual CD28/ICOS costimulation antagonist. ... Alpine will receive an upfront payment of $60 million, and will also be eligible to receive up to an aggregate of $805 million for exercise of the option and success-based development, regulatory and commercial milestones. In addition, Alpine is eligible to receive tiered royalties on net sales of ALPN-101 [joint press release, Jun 18, 20]
Alpine Immune Sciences (Seattle, WA; no SBIR) up 135% [Jun 18, 20], a leading clinical-stage immunotherapy company focused on developing innovative treatments for cancer and autoimmune/inflammatory diseases, and AbbVie announced an exclusive worldwide option and license agreement for ALPN-101, a first-in-class dual CD28/ICOS costimulation antagonist. [joint press release, Jun 18, 20]
Alpine Immune Sciences up 24% [Aug 16, 19] reported quarterly financial results
Alpine Immune down 15% [Feb 8, 19]
Alpine Immune Sciences (Seattle, WA; no SBIR) a leading immunotherapy company dedicated to developing innovative treatments for patients suffering from cancer and autoimmune/inflammatory diseases, announced it has entered into a definitive securities purchase of common stock expected to result in gross proceeds of $25 million [company press release, Jan 16, 19]
Alpine Immune Sciencesdown 11% [Aug 17, 18]
Alpine Immune Sciences up 13% [May 18, 18]
Alpine Immune Sciences (Seattle WA; no SBIR, 11 employees, market cap $140M) up 10% [Dec 8, 17] a leading immunotherapy company focused on developing treatments for autoimmune/inflammatory diseases and cancer, announced [positive] results of a preclinical study of novel immuno-oncology molecules derived from the company's variant immunoglobulin (Ig) domain (vIgD) platform [company press release, Dec 6, 17]
Alpine Immune Sciences (Seattle, WA; no SBIR, founded 2015, 15 employees) up 19% [Sep 22, 17] a leading immunotherapy company focused on developing treatments for autoimmune/inflammatory diseases and cancer, announced a planned poster presentation highlighting recent data from a preclinical study evaluating dual ICOS/CD28 antagonists generated by the Company's vlgD(TM) platform [comapny press release, Sep 20, 17] absorbed Nivalis by merger in Apr 2017. ... led by former Dendreon CEO Mitchell Gold netted $48 million in Series A funding [press release Jun 1, 16]
Alpine Immune Sciences (Seattle, WA; no SBIR), made its market debut [IPO] by merging with another biotech, Nivalis Therapeutics (Boulder, CO; no SBIR), which was rich in cash but had poor prospects after a drug trial failed last fall. ... Alpine, which describes itself as a developer of proprietary, protein-based immunotherapies to potentially treat cancers and inflammatory diseases, says it aims to apply for permission to begin its first clinical trial in the second half of 2018 [Seattle Times, Jul 25, 17]
Nivalis Therapeutics (formerly N30 Pharmaceuticals, Boulder, CO; no SBIR, founded 2007) and Alpine Immune Sciences (Seattle, WA; no SBIR, founded 2015, 30+ employees), a privately-held biotechnology company developing novel therapies using its next-generation immune system modulation platform, jointly announced they have entered into a definitive merger agreement under which Alpine will merge with a wholly-owned subsidiary of Nivalis in an all-stock transaction. The merger will result in a combined company with a novel protein-based discovery platform focused on inflammation and immuno-oncology. [Yahoo Business Wire, Apr 18, 17]
Alpine Immune Sciences (Seattle, WA; founded 2015, under 20 employees) announced the closing of its $48million Series A financing round. .... developing a next‐ generation immune system modulation platform [company press release, Jun 13, 16]
Young immunotherapy biotech company Alpine Immune Sciences (Seattle, WA; founded Jan 2015) landed its first collaboration deal [as it] announced that it is teaming up with California-based immunotherapy biotech Kite Pharma (Santa Monica, CA; no SBIR) to discover and develop immunotherapy treatments for cancer. ... raised about $2.6 million earlier this year. [Annie Zak, Puget Sound Business Journal, Oct 27, 15]
Alpine Immune Sciences ; no SBIR, four employees) formed in January and led by former Dendreon CEO Mitch Gold, just raised another $1.3 million financing round. ... develops immunotherapy treatments for cancer and autoimmune diseases. [Annie Zak, Puget Sound Business Journal, May 14, 15]
Alseres Pharmaceuticals (Hopkinton, MA; no SBIR) focused on the development of therapeutic and diagnostic products for disorders in the central nervous system, announced $1 million financing. [Boston Globe, Nov 20, 08]
Fifty
Nifty
Techno-Innovators as
judged by Technology
Review
magazine [Apr 12]. In the company of investment magnets like Facebook
and Google are a few companies and ideas that would be fit for a
realistic SBIR program intent on seeding technically uncertain
innovation with a future if it can be shown to
work.
Alta Devices (no
SBIR) high-efficiency
gallium arsenide–based
solar cells provide a way to lower the cost of solar power.
Can economically produce robust cells that use only small amounts of
the expensive semiconductor.
Integrated Diagnostics (Baltimore, MD; $1M
SBIR) By
reducing the cost of diagnostic tests,
it has allowed the monitoring of more disease markers.
Its synthetic antibodies replace more expensive antibodies widely used
in diagnostics.
Suntech (no
SBIR) Has developed a
low-cost way
of making better silicon solar cells.
Its new panels are more efficient because they reflect less light and
use thinner electrodes that block less
light. Sakti3 (no
SBIR) Its
high-energy batteries,
which will first appear in consumer devices, could make electric cars
cheaper and improve their range.
Making batteries without the flammable liquid found in conventional
electric-car batteries means they can store more energy.
LanzaTech (no
SBIR) Makes fuel and
chemicals from the carbon
monoxide produced by processes such as steelmaking.
Genetically engineered organisms turn the gas into ethanol and other
useful chemicals.
First Solar
(Toledo,
OH; $750K SBIR) It is
reducing the
cost of utility-Âscale
photovoltaic installations.
constrains costs with vertical integration of everything from plant
construction to the manufacture of high-efficiency cadmium telluride
cells.
Wildcat Discovery
(no SBIR) Has
used high-speed methods to find
materials that improve the performance of batteries. Identified
a pair of materials that could increase energy density by 25 percent in
batteries for cars and portable electronics.
Siluria
(no SBIR) Its
catalytic process is able to convert
cheap and abundant natural gas into ethylene, a commodity chemical used
to make plastic.
Developed a family of catalysts that
selectively cause methane to react to form ethylene.
Organovo
(San
Diego, CA; $260K SBIR) Its
three-dimensional artificial tissue
structures can be used for drug testing and are likely to find
therapeutic applications. A printing process methodically
deposits
layers of cells and gel material to build up new
tissues.
Cellular Dynamics
International
(Madison, WI; $500K SBIR) Using human iPS cells in drug
screening
could accelerate the development of new therapies.
Its new product derived from iPS cells is meant for use in vascular
targeted drug discovery, tissue regeneration, and life science
research.
Foundation Medicine (no SBIR) Its new diagnostics exploit a
growing
understanding of the molecular basis of cancer.
It has developed a comprehensive cancer diagnostic test and is
partnering with pharmaceutical companies to use the test in drug
development.
Alta Devices, (Santa Clara, CA; no SBIR), whose founders include leading researchers from Caltech and the University of California, Berkeley, is developing a way to make photovoltaic cells using films of gallium arsenide that are only a micrometer thick. Gallium arsenide, which is widely used as an ingredient in lasers and other photonic devices, has great optical properties but is too expensive for most solar cells. The new technology, however, uses so little of the material that its price is no longer prohibitive. Alta Devices has spent the last several years perfecting the production process; it has begun a pilot line to make the photovoltaic materials next year and hopes to start commercial production in 2013. [David Rotman, Technology Review, J/F12]
Altair Therapeutics, a spinoff from Isis Pharmaceuticals, has shut down operations after the startup’s only drug candidate failed in a mid-stage clinical trial against asthma [signonsandiego.com, Feb 3, 11]
AltAir Fuels, (Seattle, WA startup), said it has entered into agreements with [14] airlines to negotiate the purchase of jet fuel and diesel derived from the camelina plant, a weed related to mustard that produces seeds with a high oil content. ... the company aims to build a new facility within the Tesoro refinery in Anacortes and begin operating in 2012. He said the company expects Tesoro to become an investor in AltAir. ... The camelina oil will be sourced from Montana-based Sustainable Oils, which has camelina-research expertise and production contracts with farmers. [Cristi Heim, Seattle Times, Dec 16, 09] SBIR history unknowable until SBA repairs its often crippled website.
Invertix (McLean, VA; $1M SBIR) and Near Infinity (no SBIR) are now operating as Altamira Technologies. ..... announced it was teaming up with Ball Aerospace & Technologies to go after one of four prime contractor spots on an eight-year, $960 million deal to support the National Air and Space Intelligence Center at Wright-Patterson Air Force Base. [Joe Cogliano, Dayton Business Journal, Jun 19, 13]
Nature Prices Extraction.AltaRock (Seattle, WA; no SBIR) stopped its California geothermal project after earthquakes in Switzerland from similar extraction of heat from geologically active rocks. In addition to a $6 million grant from the Energy Department, AltaRock had attracted some $30 million in venture capital from high-profile investors ... AltaRock has also received some $25 million in federal money for a project in Oregon [James Glanz, Wall Street Journal, Dec 11, 09]
Private companies to watch on electricity as picked by MIT Tech Review (Sep/Oct09): Nanosolar ($1.7M SBIR) founded 2002, raised $400M; A123 Systems IPO Sep 24; Brightsource Energy; Tendril; 1366 Technologies; Deepwater Wind; Solyndra; Silver Spring Networks; AltaRock; Stirling Energy Systems.
FLIR Systems announced that it has acquired Altavian (Gainesville, FL; no SBIR, founded 2011) manufacturer of small unmanned aerial systems (sUAS) for defense and public safety customers. Altavian’s airframes integrate multiple sensors, including FLIR thermal technology, to provide users with decision support and intelligence, surveillance, and reconnaissance (ISR) capability. [FLIR press release, Dec 2, 20]
San Diego County
companies that
raised the largest amount of venture capital in the fourth quarter of
2015
Sapphire Energy
($200K SBIR)
$91 million; Effector
Therapeutics: $40 million; MD Revolution:
$22.45 million;
AltheaDX:
$20.1 million; Elcelyx
Therapeutics: $20
million; Amplyx
Pharmaceuticals:
$20 million; Astute
Medical:
$20 million; Glysens
($6.8M SBIR): $20 million; Crinetics
Pharmaceuticals ($200K SBIR): $18
million; Enlibrium:
$15 million Source:
MoneyTree Survey by
PricewaterhouseCoopers and the NVCA with data from Thomson Reuters
[xconomy.com]
Hercules Technology Growth Capital Inc. has closed loan commitments of $52 million to three new portfolio companies Althea Technologies (San Diego, CA; $400K SBIR), Calera (no SBIR) (CEO Brent Constantz picked by CNBC as one of fifteen leading innovators), and an unnamed company. [San Francisco Business Times, Aug 5, 10]
Altimmune up 50% [Mar 7, 19]
Altimmune up 16% [Jan 22, 19]
Altimmune up 21% [Oct 16, 18]
Altimmune down 32% [Oct 5, 18] announced it has entered into a purchase agreement with several institutional investors for the [$25M] of common units [company press release, Oct 8, 18]
Altimmune up 54% [Oct 5, 18]
Altimmune up 13% [Oct 1, 18]
Altimmune (Gaithersburd, MD; no SBIR) down 50% [Sep 28, 18] announced the pricing of an underwritten public offering of common units and pre-funded units ... at $5 per unit, to raise $12M [company press release, Sep 28, 18]
Altimmune down 28% [Sep 27, 18]
Altimmune down 47% [Sep 24, 18] announced that the Biomedical Advanced Research and Development Authority (BARDA) is modifying its existing contract with Altimmune by adding $2.5 million to the $21.6 million base contract ($24.1 million total for the modified base contract) and extending the performance period through November 2019. ... also announced it has entered into purchase agreements at a public offering price of $17.02 per share, for expected gross proceeds of approximately $4.9 million [company press releases, Sep 24, 18]
Altimmune up 59% [Sep 20, 18]
Altimmune (Gaithersburg, MD; no SBIR) up 285% [Sep 19, 18] completed a 1:30 reverse split of its common shares last week
Altimmune (Gaithersburg, MD; no SBIR) biotech faces threat of stock delisting for stock falling below one dollar. [Vandana Sinha, Washington Business Journal, May 18, 18]
Altimmune (Gaithersburg, MD; no SBIR), a clinical-stage immunotherapeutics company, today announced it has closed its offering of approximately 15,656 shares of Series B convertible preferred stock and warrants. The Company received approximately $13.0 million in net proceeds [company press release, Aug 21, 17] also announced that it plans to expand into a new headquarters to accommodate its recent acquisition of Pharmathene [Tina Reed, Washington Business Journal, Aug 23, 17]
Altimmune
(Gaithersburg, MD;
SBIR) was awarded a
five-year
federal contract worth up to $120.2 million for the development of its
nasal spray anthrax vaccine candidate. [Tina Reed,
Washington
Business Journal, Aug 10, 16] first step is $14M reported earlier.
The U.S. Biomedical Advanced Research and Development Authority awarded $14.3 million to finance a drug trial of Altimmune (formerly Vaxin (Birmingham, AL, Gaithersburg, MD; $2.4M SBIR, founded 1997)'s anthrax vaccine candidate, NasoShield. ... could also receive $105.9 million for additional pretrial, clinical and production development. [Washington Business Journal, Aug 10, 16]
Altis Biosystems (Chapel Hill, NC; $1.2M SBIR) stem-cell technology startup, has raised a $3.1M round .... Altis' stem-cell platform was created at UNC-Chapel Hill following a NIH research award to develop a microfluidic organ-on-a-chip to mimic the human colon. [ATLinno, Jul 29, 20]
Hing C. Wong founded Altor (Miramar FL; $1.5M SBIR) in 2002 as a spin-off from Sunol Molecular (Miramar FL; $0.5M SBIR) which seeded the company with $4M. Top venture funds then invested $6M. The company’s proprietary technology, which it calls its “STAR†platform, has been in development for a decade. [Allan Maurer, Tech Journal South, Nov 9]
Altra (Los Angeles CA), a biofuel company, said it received $50 M from a group of private investors including venture capitalist Vinod Khosla, a founder of Sun Microsystems. Altra, founded in 2004 as Malibu Capital Partners Inc., acquires and develops projects using renewable energy, including ethanol and biodiesel. [LA Times, Apr 6]
Altura Medical (Menlo Park, CA; no SBIR), a venture-backed stent graft developer, has been acquired by Lombard Medical (Irvine, CA; no SBIR) in a deal valued at up to $50.5 million. ... Altura's low-profile endovascular stent graft technology is aimed at the treatment of abdominal aneurysms. Lombard plans to launch the device in Europe early next year and to recruit for a U.S. clinical study later in 2016. [Cromwell Schubarth, Silicon Valley Business Journal, Jul 30, 15]
Altus Pharmaceuticalsthe former Waltham drug maker that filed for Chapter 7 bankruptcy in November and has since ceased operations, has had its intellectual property portfolio and protein formulation assets picked up by San Diego biotech Althea Technologies[Mass High Tech, May 4, 10]
At least five Massachusetts biotechs Dynogen Pharmaceuticals , Epix Pharmaceuticals, Oscient Pharmaceuticals, Biopure and Altus have more or less ceased operations since the stock market meltdown in September 2008. [Julie Donnelly, Mass High Tech, Mar 5, 10]
Nasdaq said it will delist Altus Pharmaceuticals [AP, Dec 16, 09]
Altus Pharmaceuticals (Waltham, MA; no SBIR) filed for bankruptcy. ... had been developing a human growth hormone that would have been injected to treat diseases [Boston Globe, Nov 12, 09]
Three years after Altus Pharmaceuticals went public and raised $105 million in a single day, the Cambridge biotechnology company is running out of money, and its stock, which once traded for more than $25 a share, closed at 40 cents yesterday. [Scott Kirsner, Boston Globe, May 9, 09]
Shares of Altus Pharmaceuticals plunged to an all-time low Tuesday as Wall Street reacted negatively to preliminary results from a late stage trial of its Trizytek enzymes. [Boston Globe, Aug 13,08]
Altus Pharmaceuticals up 11% after reporting top-line results from a Phase 1 clinical trial of ALTU-237 in healthy adult volunteers. [Jun 5, 08]
Altus Pharma up 11% [May 22, 08]
Altus Pharmaceuticals up 10% [Mar 18, 08]
Altus Pharmaceuticals up 15% [Feb 4, 08]
Altus Pharmaceuticals bought back a human growth hormone formulation it had licensed to a California biotech [Genentech] almost exactly one year ago ... reported a net loss of $55.7 M on $5.1 M in revenue for 2006. [Mass High Tech, Dec 20, 07] The return was disastrous news for the stock which tumbled 44%.
Altus Pharmaceuticals up 10% [Nov 13, 07]
Altus Pharmaceuticals up 10% [Aug 16,07]
ALung Technologies raises $5M [Patty Tascarella, Pittsburgh Business Times, Jan 9, 19]
ALung Technologies (Pittsburgh, PA; no SBIR, founded 1997 as a spin-out of U Pittsburgh), the leading provider of low-flow extracorporeal carbon dioxide removal (ECCO2R) technologies for treating patients with acute respiratory failure, announced the closing of a $36 million Series C financing ... will support a planned US-based pivotal trial for FDA approval of the company’s Hemolung Respiratory Assist System (RAS), a minimally invasive artificial lung device which removes carbon dioxide independently of the lungs through a process called Respiratory Dialysis®. [company press release, Apr 11, 17]
ALung Technologies (Pittsburgh PA; no SBIR) raised $12M for clinical trials. [Patty Tascarella, Pittsburgh Business Times, Feb 19, 16] the leading provider of low-flow extracorporeal carbon dioxide removal (ECCO2R) technologies for treating patients with acute respiratory failure . [company website]
ALung Technologies (Pittsburgh, PA; no SBIR)'s product was successfully used in an emergency at Texas hospital, only the fourth time the device was used in the United States. ... shipped its Hemolung Respiratory Assist System to Memorial Hermann Heart & Vascular Institute in Houston for a young patient who was suffering severe breathing problems. A hospital physician decided that Alung's device offered the best chance for the patient, whose condition improved after treatment. ... uses advanced technology to support the removal of carbon dioxide in the lung and delivering oxygen into the bloodstream. [Kris B. Mamula, Pittsburgh Business Times, Oct 8, 15]
Innovation Works and the Pittsburgh Life Sciences Greenhouse have spent the past decade as a tag-team source for fledgling companies — ideas even — to find the financial support needed to grow into viable, productive and profitable companies. .... Looking at the 2001-2005 period, firms funded by the two groups during this period include Aethon (no SBIR), Vivisimo ($700K SBIR), ALung Technologies (no SBIR), Plextronics ($300K SBIR), Inc., RedZone Robotics ($1.6M SBIR) and Thorley Industries (no SBIR) (4moms). Other than Vivisimo, which was bought by IBM in 2012, all of those companies are core firms in the portfolios of local venture capital firms [Ethan Lott, Pittsburgh Business Times, Jul 8, 13]
ALung Technologies (Pittsburgh, PA; no SBIR) said it has raised $2.5 million from its investors. ... to fund clinical trials in India and Germany scheduled to begin in late 2009, and support working capital needs. The investors are private individuals or angels and were not identified. ... commercializing artificial lung devices for the treatment of acute and chronic respiratory disorders. [Pittsburgh Business Journal, Oct 6, 09]
Alveolus Bio (Birmingham, AL; no prior SBIR) awarded a [$2.5M Fast Track NIH SBIR] grant toward its research on chronic obstructive pulmonary disease. [Laurel Thrailkill, Alabama Inno, February 16, 2023]
Alvine Pharmaceuticals (San Carlos, CA; no SBIR) lined up its first Big Pharma partnership, inking a [$70M] deal with AbbVie (a recent spinoff of Abbott Labs) around its experimental celiac disease drug. [Ron Leuty, San Francisco Business Times, Jul 20, 13]
ALX Oncology (Ireland and Burlingame, CA; no SBIR), a clinical-stage immuno-oncology company developing therapies toblock the CD47 checkpoint mechanism, announced the closing of a $105 million Series C equity financing ... will support the expansion ofthe clinical development of ALX148, a next generation CD47 myeloid checkpoint inhibitor,incombination with anti-cancer therapeutics,intoadditional solid tumorandhematologicindication [company press release, Feb 12, 20]
Alycone Lifesciences (Lowell, MA; no SBIR) that optimizes molecular therapy for the brain, raised $2.2M in a $3M funding round, according to an SEC filing. [Sri Kalyanaraman, Boston Inno, Jul 3, 19]
Alzeca Biosciences (Houston, TX; no SBIR, founded 2011) an early-stage healthcare diagnostic company focused on developing novel MRI-based targeted imaging agents for the early diagnosis of Alzheimer’s disease and other neurodegenerative disorders, announced today that it has closed an $11 million Series A financing. [company press release, Aug 17, 17]
Alzeca (Houston, TX; no SBIR, founded 2011) developing an imaging agent to help doctors detect Alzheimer’s disease at its earliest stages, announced Thursday it has raised $11 million in a Series A round of funding. .... has developed an imaging agent that it says can, when used with an MRI, detect the presence of abnormal brain proteins associated with Alzheimer’s disease and other causes of dementia, including chronic traumatic encephalopathy (CTE). [Angela Shah, xconomy.com, Aug 18, 17]
.gov to the rescue. After two failures to go public, Alzheon (Framingham, MA; no SBIR) is moving forward with a phase 3 study of its lead Alzheimer’s disease program thanks to a $47 million grant from the National Institutes of Health’s National Institute on Aging (NIA). [Amirah Al Idrus, Fierce Biotech, Aug 20, 20]
Alzheon (Framingham, MA; no SBIR, founded 2013) is turning to the public markets to finance a new round of testing for its experimental Alzheimer’s disease drug. .... set a preliminary $80 million target for its [IPO] ... Alzheon’s drug, ALZ-801, is a reworked version of tramiprosate, a drug that was meant to block the formation of clumps of beta-amyloid protein that accumulate in the brains of Alzheimer’s patients. But under Montreal-based Neurochem, the drug failed in clinical trials. [Frank Vinluan, xconomy.com, Mar 17, 18] total funding $37M [crunchbase.com]